

1 SIRI & GLIMSTAD LLP
2 Aaron Siri (Pro Hac Vice To Be Filed)
3 Email: aaron@sirillp.com
4 Elizabeth A. Brehm (Pro Hac Vice To Be Filed)
5 Email: ebrehm@sirillp.com
6 200 Park Avenue
7 Seventeenth Floor
8 New York, NY 10166
9 Telephone: 212-532-1091
10 Facsimile: 646-417-5967

11 Caroline Tucker (SBN 261377)
12 Email: ctucker@sirillp.com
13 700 S. Flower Street, Suite 1000
14 Los Angeles, CA 90017
15 Telephone 213-376-3739
16 Facsimile 646-417-5967

17 CHRIS WIEST ATTORNEY AT LAW, PLLC
18 Chris Wiest (Pro Hac Vice To Be Filed)
19 Email: chris@cwiestlaw.com
20 25 Town Center Blvd, STE 104
21 Crestview Hills, KY 41017
22 Telephone: 513-257-1895
23 Facsimile: 859-495-0803

24 Attorneys for Plaintiff
25 AARON KHERIATY, M.D.

26 **UNITED STATES DISTRICT COURT**
27 **CENTRAL DISTRICT OF CALIFORNIA**
28 **SOUTHERN DIVISION**

AARON KHERIATY, M.D.,

Plaintiff,

v.

Case No. 8:21-cv-01367 JVS (KESx)

**PLAINTIFF'S
MEMORANDUM OF LAW
IN SUPPORT OF**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA, a corporation, et al.,

Defendants.

**MOTION FOR
PRELIMINARY
INJUNCTION**

Date: September 27, 2021
Time: 1:30 pm
Place: Courtroom 10C
Judge: Hon. James V. Selna

TABLE OF CONTENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PRELIMINARY STATEMENT 1

FACTS 4

I. THE PLAINTIFF HAD COVID-19 4

II. COVID-19 IN CALIFORNIA AND FAILED RESTRICTIVE MEASURES..... 5

**III. PLAINTIFF HAS A LOWER RISK OF BECOMING RE-INFECTED
AND TRANSMITTING THE VIRUS THAN VACCINATED
INDIVIDUALS 6**

A. Infection with COVID-19 Virus Provides Robust Long-Term Immunity 6

B. Natural Immunity is Superior to Vaccine Immunity 7

 i. Natural Immunity – Great Than 99% Effective 7

 ii. Vaccine Immunity – Far Less than 99% Effective 8

 iii. COVID-19 Vaccines Do Not Prevent Infection and Transmission 11

**IV. COVID-19 VACCINES ARE NOT RISK-FREE AND THE RISK IS
GREATER FOR THE PREVIOUSLY INFECTED 12**

A. Vaccinating Naturally Immune Individuals Presents an Increased Risk 12

B. The Covid-19 Vaccines Present Certain Risks for Everyone 12

V. THE MANDATE IMPLEMENTED BY UC..... 13

ARGUMENT 15

**I. PLAINTIFF IS LIKELY TO SUCCEED ON THE MERITS OF HIS
CLAIM BECAUSE DEFENDANTS’ RESTRICTIONS VIOLATE HIS
CONSTITUTIONAL RIGHTS 15**

A. Plaintiff’s Right to Equal Protection of the Laws Has Been Violated 15

 i. Naturally Immune Individuals are Similarly Situated to
 Vaccinated Individuals..... 16

 ii. The Court Should Apply Strict Scrutiny Because the Mandate
 Implicates Plaintiff’s Fundamental Liberty Interest in Bodily
 Integrity..... 17

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

iii. The Mandate Cannot Satisfy Strict Scrutiny Analysis Because It Does Not Satisfy a Compelling Government Interest When Applied to Naturally Immune Individuals 18

iv. The Mandate Cannot Satisfy Strict Scrutiny Analysis Because It is Not Narrowly Tailored..... 18

v. The Mandate, Which Conditions Employment on the Invasion of Bodily Integrity, Triggers the Unconstitutional Conditions Doctrine..... 19

vi. The Mandate Does Not Pass Rational Basis 19

B. Plaintiff’s Fundamental Liberty Right to Bodily Integrity Has Been Violated..... 20

C. Plaintiff’s Fundamental Liberty Right to Informational Privacy Has Been Violated 22

II. PLAINTIFF IS SUFFERING AND WILL SUFFER IRREPARABLE HARM, THE BALANCE OF THE EQUITIES TIP IN HIS FAVOR, AND THE PUBLIC INTEREST WEIGHS IN FAVOR OF A PRELIMINARY INJUNCTION 23

CONCLUSION 24

TABLE OF AUTHORITIES

Cases

Agency for Int’l Dev. v. Alliance for Open Soc’y Int’l, Inc., 570 U.S. 205
(2013)..... 19

Am. Trucking Ass’ns v. City of Los Angeles, 559 F.3d 1046 (9th Cir. 2012)
..... 23

Benson v. Terhune, 304 F.3d 874 (9th Cir. 2002) 21

County of Santa Cruz v. Ashcroft, 279 F. Supp. 2d 1192 (N.D. Cal. Aug.
28, 2003)..... 17

Cruzan v. Dir., Mo. Dept. of Health, 497 U.S. 261 (1990)..... 17, 21

Doe v. Att’y Gen., 941 F.2d 780 (9th Cir. 1991) 23

Galvan v Duffie, 807 Fed. App’x 696 (9th Cir 2020)..... 17, 21

Golinsky v. United States Office of Pers. Mgmt., 824 F. Supp. 2d
(N.D.Cal. Feb. 22, 2012)..... 16

In re Crawford, 194 F.3d 954 (9th Cir. 1999)..... 22, 23

Keyishian v. Board of Regents of Univ. of State of N. Y., 385 U.S. 589
(1967)..... 19

L.A. Mem’l Coliseum Comm’n v. NFL, 634 F.2d 1197 9th Cir. 1980)..... 15

Lazy Y Ranch LTD v. Behrens, 546 F.3d 580 (9th Cir. 2008)..... 16

Lockary v Kayfetz, 917 F.2d 1150 (9th Cir 1990) 19

Monterey Mech. Co. v. Wilson, 125 F.3d 702 (9th Cir. 1997) 23

Nelson v. Nat’l Aero. & Space Admin., 530 F.3d 865 (9th Cir. 2008),
rev’d on other grounds, 131 S. Ct. 746 (2011) 22

Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 126 (9th Cir.
1998)..... 22

Perry v. Sindermann, 408 U.S. 593 (1972) 19

Reno v. Flores, 507 U.S. 292 (1993)..... 21

1 *Romer v. Evans*, 517 U.S. 620 (1996) 20
2 *Sable Commc’ns of Cal., Inc. v. FCC*, 492 U.S. 115 (1989)..... 18
3 *Sanchez v City of Fresno*, 914 F. Supp. 2d 1079 (E.D. Cal. 2012)..... 16, 17
4 *Saulsberry v. Maricopa Cnty.*, 151 F. Supp. 2d 1109 (D. Ariz. 2001) 17
5 *U.S. v. Playboy Entm’t Grp.*, 529 U.S. 803 (2000) 18
6 *Wash v. Glucksberg*, 521 U.S. 702 (1997) 17, 20
7 *Washington v. Harper*, 494 U.S. 210 (1990)..... 17
8 *Whitlow v. Cal. Dep’t of Educ.*, 203 F. Supp. 3d 1079 (S.D. Cal. 2016)..... 21

9
10 **Constitutional Provisions**

11
12 U.S. CONST. amend. XIV § 1 21
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1
2 Plaintiff AARON KHERIATY, M.D., by and through his attorneys, respectfully
3 submits this memorandum of law in support of his motion for preliminary injunction
4 against Defendants, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, and
5 MICHAEL V. DRAKE, in his official capacity as President of the University of
6 California (collectively, “**Defendants**”).

7 **I. PRELIMINARY STATEMENT**

8 As confirmed by recent data and studies, the Director of the Centers for Disease
9 Control and Prevention (“**CDC**”) recently explained that individuals vaccinated for
10 COVID-19, while having less symptoms, can still become infected with and transmit the
11 virus, and that the amount of virus in those individuals’ noses is the same as the
12 unvaccinated who have COVID-19. In contrast, those that have had COVID-19, upon
13 reexposure to the virus, have neutralizing immunity, that not only prevents symptoms but
14 also reinfection and transmission.

15 The Plaintiff, Aaron Kheriaty, M.D., Professor of Psychiatry and Human Behavior
16 at the University of California Irvine School of Medicine (the “**Plaintiff**”), who has had
17 COVID-19 and hence is immune to this virus, brings this action because the University
18 of California Irving (“**UCI**”) will soon refuse to allow him back on campus, while
19 permitting those with vaccine immunity back on campus and is thereby violating his
20 liberty interests and treating him differently from other similarly situated individuals who
21 are permitted back on campus. The Equal Protection Clause of the Fourteenth
22 Amendment to the U.S. Constitution requires a state to treat an individual in the same
23 manner as others in similar conditions and circumstances, and Plaintiff has at least as
24 good immunity to COVID-19 as his vaccinated peers but yet will be excluded from
25 campus.

26 Over the eons of human development, our bodies have created a remarkable
27 immune system capable of protecting us against a wide variety of pathogenic viruses.

1 This system includes an enormously diverse repertoire of cells with a nearly unlimited
2 capacity to recognize and ‘adapt’ to previously unseen viruses. Rather than having to re-
3 create the same immunological response every time a virus attacks the body, our immune
4 systems have an innate form of memory which prevents reinfection with the same virus.
5 This memory system creates T cells and memory B-cells which in the future are capable
6 of making antibodies to all antigens of a given virus thereby providing previously infected
7 individuals with neutralizing immunity to a previously encountered virus (“**naturally**
8 **immune individuals**”).

9 While different vaccines for COVID-19 work in different ways, they are all
10 designed to create immunity to a portion of the virus (specifically, the spike protein),
11 without creating too many side effects, in the hope that this partial immunity to a portion
12 of the virus will confer neutralizing immunity to the entire virus when encountered by
13 the vaccinated individual. Despite humanity’s best efforts at mimicking the immune
14 system’s protection, the immunity generated after infection with a virus, including
15 SARS-CoV-2 (the virus which causes the disease COVID-19, hereinafter the “**virus**” or
16 the “**COVID-19 virus**”), creates a more robust and durable form of immunity to a virus
17 than any vaccine can create.

18 The University of California (“**UC**”) recently enacted a policy to “facilitate the
19 protection of the health and safety of the University community” by ensuring that
20 individuals who return to campus have immunity to the virus that causes COVID-19 (the
21 “**Mandate**”). *See* Declaration of Plaintiff Aaron Kheriaty (hereinafter, “**A.K. Dec.**”) ¶ 3.
22 However, to reach this goal, UC decided that only vaccinated individuals will be
23 permitted on a UC campus, ignoring those who have natural immunity to the virus. In
24 enacting this policy, the University is treating naturally immune individuals differently
25 from individuals whose immunity was created by one of the COVID-19 vaccines.

26 Plaintiff was infected with the virus in July 2020 and had COVID-19. In fighting
27 off the virus, his body created a robust immunity to every antigen on the COVID-19 virus,
28

1 not just the spike protein of the virus as happens with the COVID-19 vaccines.
2 Nevertheless, UCI has told Plaintiff that he cannot return to campus unless he receives a
3 COVID-19 vaccine. Thus, the school is treating him differently by refusing to re-admit
4 him to campus when other individuals who are considered immune to the virus are being
5 admitted back simply because their immunity was created by a vaccine. This policy is
6 illogical and cannot withstand strict scrutiny or even a rational basis test because naturally
7 immune individuals, like Plaintiff, have at least as good or better immunity to the virus
8 that causes COVID-19 than do individuals who are vaccinated.

9 In the more than 19 months that the world has been transfixed by the COVID-19
10 pandemic, evidence shows that the reinfection rate after natural infection is less than 1%,
11 and there are no documented cases of reinfection and transmission to others by naturally
12 immune individuals. In contrast, COVID-19 vaccination in the optimal setting of a
13 clinical trial has, at best, an estimated 67% to 95% efficacy (depending on the COVID-
14 19 vaccine and the variant of the virus) and the vaccine manufacturers, public health
15 agencies, and the Biden administration have made clear that booster doses will be needed,
16 due to waning immunity created by the vaccines. Likewise, CDC studies are replete
17 with reports of so-called “breakthrough cases” where fully vaccinated individuals are
18 infected and, in those cases, the amount of virus in those individuals’ noses is the same
19 as the unvaccinated who have COVID-19. This has led to the CDC’s revised guidelines
20 recommending a return to masks for those who have been vaccinated and experts to
21 conclude that “vaccination is now about personal protection” because “herd immunity is
22 not relevant as we are seeing plenty of evidence of repeat and breakthrough infections.”¹

23 As described more fully herein, UCI’s refusal to readmit Plaintiff to campus unless
24 he receives a vaccine is an equal protection violation. The right of individuals to their
25 bodily integrity, which includes a right to refuse medical treatment, has long been
26

27 ¹ See <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html>; see
28 also <https://www.washingtonpost.com/health/2021/07/29/cdc-mask-guidance/>.

1 recognized as one of the fundamental liberty rights afforded under due process. By
2 forcing Plaintiff to receive a vaccine he does not want or need, and that may cause him
3 harm, in order to be treated equally as other individuals who are also immune, UCI’s
4 Mandate implicates Plaintiff’s substantive due process rights, and the Court should
5 analyze his equal protection claim under the strict scrutiny analysis, i.e., whether the
6 Mandate is both satisfying a compelling government need and is implemented by the
7 least restrictive means. Defendants cannot satisfy either of these prongs. Even though a
8 government entity may have a compelling government interest in preventing the spread
9 of COVID-19, that interest is not furthered by compelling Plaintiff to be vaccinated to
10 satisfy this interest because he is already immune and, unlike the vaccinated, if exposed
11 to the virus, has neutralizing immunity. By failing to acknowledge that “naturally”
12 immune individuals are unlikely to spread the virus, and certainly far less likely than the
13 vaccinated, the Mandate is not narrowly tailored.

14 Nor can the Mandate satisfy rational basis analysis. Because Plaintiff is already
15 immune and less likely to infect other individuals than are people who have been
16 vaccinated, requiring him to be vaccinated in order to return to campus is irrational. In
17 addition, by targeting people who have had the virus but remain unvaccinated, the
18 Mandate unfairly singles out one unpopular group for disparate treatment.

19 For these reasons, more fully explained below, Plaintiff seeks a preliminary
20 injunction enjoining Defendants from enforcing the Mandate against him or any other
21 “naturally” immune individual.

22 **FACTS**

23 **I. THE PLAINTIFF HAD COVID-19**

24 Plaintiff is a professor of Psychiatry and Human Behavior at the UCI School of
25 Medicine and the director of the Medical Ethics Program at UCI Health. *See* A.K. Dec.
26 ¶ 7. Plaintiff’s residency training was at UCI from 2003-2007. *Id.* ¶ 6. In 2007, Plaintiff
27 was hired by UCI as a Health Sciences Assistant Clinical Professor. *Id.* Plaintiff was
28

1 promoted to Health Sciences Associate Clinical Professor in 2013 and to Health Sciences
2 Clinical Professor in 2019 and holds this position currently. *Id.* ¶ 6-7.

3 Plaintiff contracted the COVID-19 virus in July 2020, which was confirmed by
4 PCR testing, and he experienced many of the common symptoms associated with
5 COVID-19, including loss of taste and smell. *Id.* ¶ 2. Plaintiff fully recovered. *Id.*

6 **II. COVID-19 IN CALIFORNIA AND FAILED RESTRICTIVE MEASURES**

7 The first confirmed case of the COVID-19 virus in California was on January 22,
8 2020.² Governor Gavin Newsom (“**Newsom**”) instituted aggressive stay at home orders
9 in California on March 19, 2020, when there were approximately 900 cases within the
10 state.³ Despite the aggressive stay at home orders, the virus continued to spread.

11 The CDC has explained that even with protective measures as instituted in
12 California, “most of the U.S. population will be exposed to this virus [SARS-CoV-2].”⁴
13 The CDC estimates that, through May 2021, approximately 49% of those aged 18 to 49
14 years have been infected with SARS-CoV-2 despite lockdowns. *See* Declaration of
15 Joseph Ladopo, MD, PhD; John Patrick Whelan MD, PhD; Lazlo Boros, MD; Carole
16 Browner PhD, MPH; Aditi Bhargava, PhD; and Gabriel Vorobiof, Bachelor of Medicine
17 and Bachelor of Surgery (hereinafter, “**UC Faculty Dec.**”) ¶ 3.

18 UC is a public university intended to serve the residents of California and is open
19 to students from around the world. It currently has more than 280,000 students and
20 more than 227,000 faculty and staff. *Id.* ¶ 2. UC is telling those that are immune from
21 prior infection that unless they get vaccinated that they need not bother leaving their
22 homes since they will be excluded from campus.

23 If Defendants instituted the Mandate with the goal of having a student body and
24

25 ² *See* <https://www.latimes.com/world-nation/story/2020-08-21/surprising-tale-first-la-covid-19-case>.

26 ³ *See* <https://www.politico.com/states/f/?id=00000170-f5a4-d209-af70-fdae4c930000>; *see also* <https://www.ksla.com/2020/03/20/california-becomes-first-state-order-lockdown/>.

27 ⁴ https://stacks.cdc.gov/view/cdc/86068/cdc_86068_DS1.pdf.

1 faculty that is immune to the COVID-19 virus, it would have exempted from the Mandate
2 those who are already immune due to having had COVID-19. Failure to do so means
3 that Defendants’ Mandate is not about immunity, it is only about vaccination status.

4 **III. PLAINTIFF HAS A LOWER RISK OF BECOMING INFECTED AND**
5 **TRANSMITTING THE VIRUS THAN VACCINATED INDIVIDUALS**

6 Peer reviewed studies on COVID-19 demonstrate the durability of natural
7 immunity following COVID-19 infection. A.K. Dec. ¶¶ 12-14. CDC and FDA data also
8 shows that natural immunity has proved far more than 99% effective while vaccine
9 immunity is at best between 67% and 95% effective, depending on the vaccine, and this
10 is under the previous ideal conditions of a clinical trial. UC Faculty Dec. ¶ 14. Moreover,
11 unlike those vaccinated for COVID-19 who can still become infected and have the same
12 amount of virus in their nose as those unvaccinated and infected with COVID-19, there
13 has never been a single documented case of a naturally immune individual becoming re-
14 infected with and transmitting the virus to anyone.

15 **A. Infection with COVID-19 Virus Provides Long-Term Immunity**

16 The human body knows how to develop immunity to new viruses. The adaptive
17 immune system consists of an enormously diverse repertoire of B cells—precursors of
18 antibody-secreting plasma cells—and T cells with a nearly unlimited capacity to
19 recognize and ‘adapt’ to previously unseen pathogens. UC Faculty Dec. ¶ 5.

20 As explained by Dr. Ryan Cole, a Mayo Clinic-trained pathologist, “Yes, our
21 antibody levels drop over time, however, scientifically, the memory B cells that make
22 antibodies have been proven to be present in our lymph nodes and bone marrow.” A.K.
23 Dec. ¶ 13. Dr. Cole further explains, “They are primed and ready to produce a broad
24 array of antibodies upon...exposure. It would be physiologically, energetically
25 impossible to maintain high antibody levels to all the pathogens we are constantly
26 exposed to, and we would look like the ‘swollen Stay-Puft marshmallow man’ of lymph
27 nodes, constantly, if the immune system were required to do that.” *Id.*

1 In line with Dr. Cole’s explanation, numerous immunologic studies of individuals
2 that have had the COVID-19 virus demonstrate that they developed sustained, broad and
3 durable immunity, and robust B cell and T cell memory to the virus which protect them
4 from reinfection. UC Faculty Dec. ¶¶ 5, 7-8. In other words, “natural” immunity to the
5 COVID-19 virus continues to be present and effective even after antibody levels,
6 detectable by lab tests, wane over time. *Id.* Similarly, in a study of monkeys that were
7 deliberately re-exposed to the COVID-19 virus after having COVID-19, *none* of them
8 were re-infected. *Id.* ¶ 18.

9 Reflecting these findings, the immunity produced by the closely-related virus,
10 SARS-CoV-1, is lifelong. Declaration of Peter A McCullough, MD, MPH (hereinafter
11 “**McCullough Dec.**”) ¶ 14. As explained by an infectious-disease physician and professor
12 at the UC: “Natural immunity after COVID-19 infection is likely lifelong, extrapolating
13 from data on other coronaviruses that cause severe illness, SARS and MERS.”⁵

14 **B. Natural Immunity is Superior to Vaccine Immunity**

15 *i. Natural Immunity – Great Than 99% Effective*

16 The hunt for re-infections has been a nationwide effort and out of the estimated
17 120.2 million individuals in the United States who have been infected with SARS-CoV-
18 2 as of May 2021,⁶ there is not a single documented case of an individual being re-
19 infected with the virus and transmitting it to another person. UC Faculty Dec. ¶ 11, 12,
20 14, 2; McCullough Dec. ¶ 17.

21 A five-month study looking at reinfection rates in employees of the Cleveland
22 Clinic Health System previously infected with the COVID-19 virus found that not one of
23 the 1,359 previously infected subjects who remained unvaccinated was reinfected with
24 the virus despite a high background rate of COVID-19 in the hospital. UC Faculty Dec ¶
25 11. Irish researchers recently published a review of 11 cohort studies with over 600,000
26

27 ⁵ <https://www.wsj.com/articles/herd-immunity-is-near-despite-faucis-denial-11616624554>.

28 ⁶ See <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.

1 total recovered COVID-19 patients (not all of whom were well defined and may have
2 had suspected COVID-19) who were followed up with over 10 months. *Id.* They found
3 the reinfection rate to be 0.27% “with no study reporting an increase in the risk of
4 reinfection over time.” *Id.* ¶ 13. Based on this data, the researchers were able to assert
5 that “naturally acquired SARS-CoV-2 immunity does not wane for at least 10 months
6 post-infection.” *Id.* Moreover, this study also did not document a single case of
7 reinfection that then resulted in transmission to another person.

8 Given that the current number of confirmed cases worldwide is approximately 200
9 million,⁷ if reinfection was possible in even one percent of individuals, the world would
10 have observed 2 million second and third cases with many requiring hospitalization and
11 coming to clinical attention. *Id.* ¶ 12; McCullough Dec. ¶ 17. No such large volume of
12 reinfection cases has come to clinical attention in any region of the world. *Id.*

13 ***ii. Vaccine Immunity – Far Less than 99% Effective***

14 In contrast to greater than 99% efficacy from natural immunity, the efficacy from
15 vaccine immunity in a clinical trial setting is admittedly no greater than between 67%
16 and 95%, depending on the COVID-19 vaccine. The Pfizer vaccine had initially, at best,
17 efficacy of 95%,⁸ the Moderna has efficacy of 94.5%,⁹ and the J&J vaccine has efficacy
18 of approximately 67%,¹⁰ and that was under previous ideal conditions in a clinical trial,
19 against the original wild-type variant of the virus. The COVID-19 vaccines have had
20 considerably less efficacy in the real world. UC Faculty Dec. ¶ 14. But even assuming
21 the optimal clinical trial efficacy numbers, this is still far less than the efficacy from
22 having had the COVID-19 virus, which is over 99%. *Id.* ¶ 14.

23 Vaccines, by design, attempt to emulate the immunity created by a natural
24 infection. Nonetheless, they have never achieved the same level of protection afforded

25 _____
26 ⁷ See <https://covid19.who.int/>.

27 ⁸ See <https://www.fda.gov/media/144416/download>.

28 ⁹ See <https://www.fda.gov/media/144673/download>.

¹⁰ See <https://www.fda.gov/media/146338/download>.

1 by natural infection from a virus. Every single vaccine for a virus confers an inferior
2 immunity to having had the actual virus. Even the best vaccines do not confer immunity
3 to all recipients.¹¹ In those who do obtain some immunity from vaccination, the
4 temporary immunity created by any vaccine typically wanes over time. Hence, the
5 warning in the Mandate that COVID-19 boosters will be needed.¹² This has been
6 confirmed by the pharmaceutical companies selling the COVID-19 vaccines and the CDC
7 has echoed the likely need for boosters of the COVID-19 vaccines, as discussed at its
8 advisory committee meeting on June 23, 2021.¹³

9 Reflecting the fact that infection-induced immunity to this virus is much deeper
10 and broader than vaccine immunity (*see* UC Faculty Dec. at 16), in an outbreak of
11 COVID-19 among gold mine workers in French Guiana, 60% of the fully vaccinated gold
12 mine workers were infected while none of the individuals with a prior COVID-19
13 infection were infected. *Id.* ¶ 11. Studies analyzing the entire population of Israel has
14 found that those with prior natural infection had a higher rate of protection from infection,
15 hospitalization, and severe illness than those that had immunity from the COVID-19
16 vaccine. *Id.* Another report from Israel found a sixfold rate of COVID-19 infection
17 among the vaccinated versus the naturally immune:

18 With a total of 835,792 Israelis known to have recovered from
19 the virus, the 72 instances of reinfection amount to 0.0086% of
20 people who were already infected with COVID. By contrast,

21
22 ¹¹ Pfizer Recipient Fact Sheet at <https://www.fda.gov/media/144414/download> (“The
23 COVID-19 Vaccine may not protect everyone.”); Moderna Recipient Fact Sheet at
24 <https://www.fda.gov/media/144638/download> (same); J&J Recipient Fact Sheet at
25 <https://www.fda.gov/media/146305/download> (same).

26 ¹² <https://policy.ucop.edu/doc/5000695/SARS-Cov-2> at FAQ No. 4 which states,
27 “Infectious disease experts anticipate that annual or more frequent boosters will be
28 necessary and receipt of boosters will be required.”

¹³ *See* <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/06-COVID-Oliver-508.pdf>; *see also, e.g.,* <https://www.nytimes.com/2021/04/16/world/pfizer-vaccine-booster.html>.

1 Israelis who were vaccinated were 6.72 times more likely to get
2 infected after the shot than after natural infection.

3 *Id.* Reflecting this reality, internal official UCI emails reflect that there is a sufficiently
4 alarming number of vaccinated individuals acquiring symptomatic COVID-19 such that
5 it necessitated notice to the entire UCI School of Medicine about this issue, while no such
6 notice has been necessary for naturally immune individuals:

- 7 • On July 17, 2021, UCI informed faculty and residents, “[t]here has been a
8 substantial increase in the number of breakthrough infections [*i.e.*, infections in
9 fully vaccinated individuals] among our UCI health care workers, including
10 residents and fellows.” A.K. Dec. ¶ 19.
- 11 • On July 22, 2021, UCI Health’s CEO advised that “[t]he COVID-19 delta variant
12 is now responsible for the majority (75%) of UC cases, including several
13 breakthrough vaccine cases.” *Id.*
- 14 • On July 27, 2021 UCI explained that “due to continued and increasing concerns
15 about the spread of COVID-19, even among vaccinated individuals, we will not
16 be returning to the classrooms as had been expected for the past several months.”
17 *Id.*

18 In contrast, there has been no such notice of increasing cases among those who have
19 recovered from COVID-19. *Id.*

20 What is happening at UCI is similarly being seen nationwide as the number of
21 cases of COVID-19 in fully vaccinated individuals is rising precipitously. That number
22 was growing so rapidly and burdening resources to such an extent that the CDC changed
23 its reporting criteria to only report breakthrough cases resulting in hospitalization or
24 death. UC Faculty. Dec. ¶ 9.

25 But simply taking the FDA and CDC data at face value, the reality is that natural
26 infection provides for greater than 99% protection while vaccine immunity provides for,
27 at best, between 67% and 95% protection.

1 *iii. COVID-19 Vaccines Do Not Prevent Infection and Transmission*

2 Natural immunity confers an additional benefit over vaccine immunity. Natural
3 immunity will prevent a virus from being able to replicate and shed in the naturally
4 immune individual. UC Faculty Dec. ¶ 17. In contrast, COVID-19 vaccines appear to
5 reduce symptoms in some but still permit the vaccinees to become infected with and
6 transmit the virus. *Id.*

7 In animal studies, the COVID-19 vaccine candidates could *not* fully block viral
8 infection and replication in the nose of monkeys upon viral challenge. UC Faculty Dec.
9 ¶ 18. In contrast, natural COVID-19 infection of monkeys completely prevented further
10 re-infection at any site tested—by nasal, throat, and anal swabs. *Id.*

11 Viral carriage by the vaccinated is reflected in the recent outbreak in Barnstable
12 County, Massachusetts, which has a 69% vaccination coverage rate among its eligible
13 residents. *Id.* ¶ 19. A recent CDC investigation found that 74% of those infected in the
14 outbreak were fully vaccinated for COVID-19 and, even more alarming, the vaccinated
15 had on average more virus in their nose than the unvaccinated that were infected. *Id.* The
16 study reported zero cases of infection among those that previously had COVID-19.

17 This forced the Director of the CDC, Rochelle Walensky, to admit on CNN that
18 individuals vaccinated for COVID-19, while having less symptoms, can still become
19 infected with and transmit the virus. *Id.* ¶ 20. Dr. Walensky admitted that “**what [the**
20 **COVID-19 vaccines] can’t do anymore is prevent transmission.**” After this
21 admission, Dr. Walensky was asked by Wolf Blitzer: “you get covid, you’re fully
22 vaccinated, but you are totally asymptomatic, you can still pass on the virus to someone
23 else, is that right?” and Dr. Walensky answers “**that is exactly right.**” *Id.*

24 Defendants will nonetheless only allow individuals that have been vaccinated back
25 on campus, despite the unequivocal data that proves that the COVID-19 vaccines cannot
26 and do not prevent infection and transmission. On the other hand, Defendants will *not*
27 allow back on campus “naturally” immune individuals who, upon reexposure to the virus,
28

1 have neutralizing immunity, that not only prevents symptoms but also reinfection and
2 transmission. McCullough Dec. ¶¶ 13-20. As explained by a professor at Johns Hopkins
3 School of Medicine, the failure to lift restrictions on naturally immune individuals is “one
4 of the biggest failures of our current medical leadership.”¹⁴

5 **IV. COVID-19 VACCINES ARE NOT RISK-FREE AND THE RISK IS** 6 **GREATER FOR THE PREVIOUSLY INFECTED**

7 There are legitimate safety concerns regarding the current COVID-19 vaccines,
8 and heightened concerns when vaccinating naturally immune individuals.

9 **A. Vaccinating “Naturally” Immune Individuals Presents an Increased Risk**

10 Studies have found that naturally immune individuals have significantly higher
11 rates of adverse reactions after a COVID-19 vaccine. Raw, *et al.* reported that among
12 974 individuals vaccinated for COVID-19, the vaccinated COVID-19 recovered patients
13 had higher rates of vaccine reactions. UC Faculty Dec. ¶ 23. Mathioudakis, *et al.* found
14 the same result in a study of 2,002 individuals. *Id.* Krammer, *et al.* found the same result
15 in a study of 231 individuals, concluding that, “[v]accine recipients with preexisting
16 immunity experience systemic side effects with a significantly higher frequency than
17 antibody naïve vaccines.” *Id.*

18 **B. The COVID-19 Vaccines Present Certain Risks for Everyone**

19 There are also risks to receiving COVID-19 vaccines irrespective of prior
20 infection. The primary system for tracking adverse vaccine events in the United States
21 is the CDC’s Vaccine Adverse Events Reporting System (“VAERS”). A.K. Dec. ¶ 22.
22 A three-year federal government funded study by Harvard researchers tracking 715,000
23 patients found that “fewer than 1% of vaccine adverse events are reported.” *Id.* ¶ 25.

24 Reports of serious adverse events from COVID-19 vaccines are similarly
25 underreported to VAERS. *Id.* For example, according to the CDC, “Anaphylaxis after
26

27 ¹⁴ <https://summit.news/2021/05/26/johns-hopkins-prof-half-of-americans-have-natural-immunity-dismissing-it-is-biggest-failure-of-medical-leadership/>.
28

1 COVID-19 vaccination is **rare** and occurred in approximately **2 to 5 people per million**
2 vaccinated in the United States based on events reported to VAERS.” *Id.* This is in stark
3 contrast to a recent study at Mass General Brigham that assessed anaphylaxis in a clinical
4 setting after the administration of COVID-19 vaccines and found “severe reactions
5 consistent with anaphylaxis occurred at a rate of **2.47 per 10,000 vaccinations.**” *Id.* This
6 is equivalent to 50 to 120 times more cases than what VAERS and the CDC are reporting.
7 And this is for a serious, potentially life-threatening, adverse event that occurs almost
8 immediately after vaccination and which vaccine providers are repeatedly advised to
9 watch for and report. UC Faculty Dec. ¶ 25.

10 If anaphylaxis is being underreported, the level of underreporting for serious
11 adverse events that do not occur immediately after vaccination or are not easily identified
12 is likely far greater. For example, on June 23, 2021, the CDC reported the alarming
13 numbers of reported myocarditis and pericarditis cases occurring after COVID-19
14 vaccination. UC Faculty Dec. ¶ 26. The long-term effects of myocarditis are not fully
15 understood but can be very serious. *Id.* Cases of thrombocytopenia have also occurred
16 after COVID-19 vaccination, as well as serious and sometimes fatal blood clots. *Id.*
17 These and numerous other serious adverse events that are recognized but the true rate of
18 these serious adverse events is most certainly underreported.¹⁵

19 Even if the risks from the COVID-19 vaccines are truly small, there is no reason
20 to expose someone to *any* risk when they are already immune. UC Faculty Dec. ¶ 22.

21 **V. THE MANDATE IMPLEMENTED BY UC**

22 On July 15, 2021, the UC system released its final COVID-19 Vaccination
23 Program Policy.¹⁶ Since that time, it has systemically enforced the policy. The stated

24 ¹⁵ The spike protein from COVID-19 vaccines enters the bloodstream and can be found
25 in almost all vital organs. <https://tinyurl.com/2zbbnwjp>. A viral immunologist stated:
26 “We thought the spike protein was a great target antigen, we never knew the spike protein
27 itself was a toxin... So by vaccinating people we are inadvertently inoculating them with
28 a toxin.” <https://tinyurl.com/329ybktb>.

¹⁶ See <https://policy.ucop.edu/doc/5000695/SARS-Cov-2>.

1 purpose of the policy “is to facilitate protection of the health and safety of the University
2 community” by requiring the UC community to “be fully vaccinated against COVID-19
3 before physically accessing the University’s Locations and Programs.”

4 The Mandate is clear that it is a permanent policy and that “compliance will require
5 repeat vaccinations or boosters on an annual or recurring basis.”¹⁷ The Frequently Asked
6 Questions section of the Mandate specifically addresses “naturally” immune individuals:

7 *I was recently diagnosed with COVID-19, and/or I had an*
8 *antibody test that shows that I have natural immunity. Does*
9 *this support a Medical Exemption? You may be eligible for a*
10 *temporary Medical Exemption (and, therefore, a temporary*
11 *Exception), for up to 90 days after your diagnosis and certain*
12 *treatments. According to the US Food and Drug*
13 *Administration, however, “a positive result from an antibody*
14 *test does not mean you have a specific amount of immunity or*
15 *protection from SARS-CoV-2 infection ... Currently*
16 *authorized SARS-CoV-2 antibody tests are not validated to*
17 *evaluate specific immunity or protection from SARS-CoV-2*
18 *infection.” For this reason, individuals who have been*
19 *diagnosed with COVID-19 or had an antibody test are not*
20 *permanently exempt from vaccination.*¹⁸

21 As discussed above, the immunity achieved following natural infection does not expire
22 after 90 days and is, almost certainly, lifelong. UC has not shared any data to show that
23 immunity on day 89 following diagnosis differs from immunity on day 91 following
24 diagnosis. Plaintiff recovered from COVID-19 over one year ago and would not be
25 entitled to this temporary naturally immune exemption even though his immunity is
26

27 ¹⁷ *Id.* at pages 4 and 10 of 14.

28 ¹⁸ *Id.* at page 11 of 14, ¶ 9 (“**temporary naturally immune exemption**”).

1 superior to an individual who was vaccinated 1 day or 91 days ago.

2 Plaintiff, and his fellow students and faculty that are “naturally” immune, will
3 suffer great detriment if prevented from returning to campus. Plaintiff is frustrated and
4 negatively impacted by the prospect of being forced to choose between an invasion of his
5 bodily integrity and his employment at UCI. A.K. Dec. ¶¶ 4, 39. Plaintiff merely wants
6 to be treated the same as those deemed immune through vaccination. Instead, he is being
7 required, under threat of exclusion from UC, to violate his bodily integrity with an
8 injection of a product that presents risks but no benefit to him or others similarly situated.

9 ARGUMENT

10 It lacks rational basis, let alone a compelling reason, to allow vaccinated
11 individuals to attend or work at UC in person when their immunity is less effective at
12 preventing infection and spread of COVID-19 than those that have had the virus.

13 The issuance of preliminary injunctive relief rests upon consideration of four
14 factors: [1] the likelihood of the plaintiffs’ success on the merits; [2] the threat of
15 irreparable harm to the plaintiffs if the injunction is not imposed; [3] the relative balance
16 of this harm to the plaintiffs and the harm to the defendants if the injunction is imposed;
17 and [4] the public interest. *L.A. Mem’l Coliseum Comm’n v. NFL*, 634 F.2d 1197, 1200-
18 01 (9th Cir. 1980).

19 I. PLAINTIFF IS LIKELY TO SUCCEED ON THE MERITS BECAUSE 20 DEFENDANTS’ RULE VIOLATE HIS CONSTITUTIONAL RIGHTS

21 A. Plaintiff’s Right to Equal Protection of the Laws Has Been Violated

22 Plaintiff is immune to SARS-CoV-2. Therefore, Plaintiff is at least as equally
23 situated as those who are fully vaccinated with a COVID-19 vaccine, yet Defendants
24 deny Plaintiff equal treatment and seek to burden Plaintiff with an unnecessary violation
25 of bodily integrity to which Plaintiff does not consent in order to be allowed to continue
26 to work at UCI. Defendants’ denial of Plaintiff’s constitutional rights in this manner
27
28

1 cannot be justified under a strict scrutiny analysis.

2 When analyzing an equal protection violation, courts apply a two-part analysis.
3 First, they identify the defendants' classification of groups. *See Lazy Y Ranch LTD v.*
4 *Behrens*, 546 F.3d 580, 589 (9th Cir. 2008). Essentially, the question is whether the
5 policy is applied in a discriminatory manner or imposes different burdens on different
6 groups of people. Next, the court should identify the level of scrutiny. *See Golinsky v.*
7 *U.S. Office of Pers. Mgmt.*, 824 F. Supp. 2d (N.D.Cal. Feb. 22, 2012). If the classification
8 implicates a fundamental right, the court applies a heightened level of scrutiny. *See*
9 *Sanchez v. City of Fresno*, 914 F. Supp. 2d 1079, 1111 (E.D. Cal. 2012). Under strict
10 scrutiny, the government must show the highest need for such restrictions combined with
11 the least restrictive methods of achieving that need. *Id.* at 1108.

12 ***i. Naturally Immune Individuals are Similarly Situated to Vaccinated Individuals***

13 The Mandate's express purpose is to protect members of the UCI community from
14 COVID-19. A.K. Dec. ¶3. Defendants seek to achieve this by ensuring that only people
15 who theoretically have immunity to the virus return to campus. *Id.* Both individuals with
16 natural immunity, like Plaintiff, and individuals who are vaccinated are alike in that they
17 have immunity to the virus that causes COVID-19. UC Faculty Dec. ¶¶ 5-16. Naturally
18 immune individuals have at least as good, and in fact superior, immunity when compared
19 to vaccinated individuals. *See, e.g., McCullough Dec. ¶¶ 13-20.*

20 Nevertheless, the Mandate fails to treat these two groups of immune individuals
21 similarly. Individuals who have vaccine-created immunity will be permitted to return to
22 campus.¹⁹ However, with the exception of the temporary naturally immune exception,
23 individuals who have natural immunity will not be allowed to return to campus.²⁰

24
25
26
27 ¹⁹ *See* <https://policy.ucop.edu/doc/5000695/SARS-Cov-2>.

28 ²⁰ *Id.* at 11.

1 ***ii. The Court Should Apply Strict Scrutiny Because the Mandate Implicates***
2 ***Plaintiff's Fundamental Liberty Interest in Bodily Integrity***

3 “The Fourteenth Amendment’s due process clause ‘provides heightened protection
4 against government interference with certain fundamental rights and liberty
5 interests.’” *Sanchez*, 914 F. Supp. 2d at 1100-01 (quoting *Wash. v. Glucksberg*, 521 U.S.
6 702, 720 (1997)). It is well established that these fundamental liberty interests include
7 the right to bodily integrity. *See Cty. of Santa Cruz v. Ashcroft*, 279 F. Supp. 2d 1192
8 (N.D. Cal. Aug. 28, 2003) (“The analysis in *Cruzan*, in which the Supreme Court
9 presumed the existence of a constitutionally protected liberty interest in refusing
10 unwanted medical treatment, was based on a long line of earlier cases recognizing such
11 a right. The fundamental right to maintain bodily integrity protects against unjustified
12 invasions of one’s body by the state.”). “This notion of bodily integrity has been
13 embodied in the requirement that informed consent is generally required for medical
14 treatment.” *Cruzan v. Dir., Mo. Dept. of Health*, 497 U.S. 261, 277-78 (1990). This
15 means that the right to bodily integrity includes the concept that a “competent person has
16 a constitutionally protected liberty interest in refusing unwanted medical treatment.” *Id.*;
17 *Wash. v. Harper*, 494 U.S. 210 (1990); *see also Galvan v Duffie*, 807 Fed. App’x 696,
18 697 (9th Cir. 2020) (quoting *Cruzan*).

19 Here, the Mandate unquestionably impinges this right to refuse unwanted medical
20 treatments. UCI is telling Plaintiff that to return to campus, and thereby be treated equally
21 with other individuals who are immune to COVID-19, he must submit to receive a
22 vaccine, which is a medical treatment he does not want to receive. Because the Mandate
23 impinges a fundamental liberty right by forcing a choice on Plaintiff, it must be analyzed
24 under strict scrutiny. *Sanchez*, 914 F. Supp. 2d at 1108, 1111 (holding that a city’s
25 demolition of homeless shelters as temperatures approached freezing could implicate the
26 fundamental right to life/bodily integrity and thus form the basis for strict scrutiny of the
27 equal protection claim); *Saulsberry v. Maricopa Cty.*, 151 F. Supp. 2d 1109, 1118 (D.
28

1 Ariz. 2001) (“A competent person has a constitutionally protected liberty interest to
2 refuse unwanted medical treatment.”).

3 **iii. The Mandate Cannot Satisfy Strict Scrutiny Because It Does Not Satisfy a**
4 **Compelling Government Interest As Applied to Naturally Immune Individuals**

5 While Defendants may be able to claim that there is a compelling need to limit
6 transmission of SARS-CoV-2, as applied to Plaintiff, that interest is not in any way
7 furthered by compelling him to be vaccinated. Plaintiff is already immune to the virus.
8 See Section III.a., *supra*. That immunity is superior to the immunity created by vaccines.
9 See Section III.b., *supra*. Therefore, Plaintiff and other naturally immune individuals are
10 at less risk than the vaccinated of transmitting the virus. See Section III, *supra*. Under
11 such circumstances, Defendants’ need to prevent transmission cannot trump Plaintiff’s
12 fundamental right to bodily integrity and to willingly consent to any medical procedure.

13 Further, as applied to Plaintiff, the Mandate is arbitrary, oppressive, and irrational.
14 The Mandate it is not just a response to a temporary emergency where deference may be
15 given to the government—it is a permanent policy with no end date.²¹

16 **iv. The Mandate Cannot Satisfy Strict Scrutiny As It is Not Narrowly Tailored**

17 The Supreme Court explained that any restriction implicating a fundamental right
18 “must be narrowly tailored to promote a compelling Government interest.” *U.S. v.*
19 *Playboy Entm’t Grp.*, 529 U.S. 803, 813 (2000). “If a less restrictive alternative would
20 serve the Government’s purpose, the legislature must use that alternative.” *Id.*; see also
21 *Sable Commc’ns of Cal. v. FCC*, 492 U.S. 115, 126 (1989).

22 Defendants’ Mandate is not narrowly tailored because it does not exempt naturally
23 immune individuals whose immunity to SARS-CoV-2 is at least as good as, and in fact
24 better than, the fully vaccinated. There are numerous ways to achieve the asserted
25 interest, including, without limitation, providing the same exemptions for the naturally
26 immune as for the vaccinated. Defendants cannot prove that naturally immune

27 _____
28 ²¹ See <https://policy.ucop.edu/doc/5000695/SARS-Cov-2> (“This is a permanent policy.”)

1 individuals have any higher risk of reinfection and transmission of SARS-CoV-2 when
2 compared to the fully vaccinated and, hence, the Mandate violates Plaintiff’s
3 constitutional rights to equal protection and bodily autonomy. The Mandate is overbroad
4 as to Plaintiff and others that are naturally immune.

5 **v. *The Mandate, Which Conditions Employment on the Invasion of Bodily***
6 ***Integrity, Triggers the Unconstitutional Conditions Doctrine***

7 It is possible that Defendants may raise issues related to rights as employers. But
8 government cannot condition benefits, or employment, on forgoing fundamental rights,
9 which triggers the unconstitutional conditions doctrine. *Perry v. Sindermann*, 408 U.S.
10 593, 597 (1972); *Agency for Int’l Dev. v. Alliance for Open Soc’y Int’l, Inc.*, 570 U.S.
11 205 (2013); *Keyishian v. Bd. of Regents*, 385 U.S. 589 (1967).

12 **vi. *The Mandate Does Not Pass Rational Basis***

13 Even if the Court were to assume that the Mandate does not implicate the
14 fundamental right to bodily integrity, which the Mandate does implicate, then it should
15 still be struck down under a rational basis analysis. “[W]hen a [government] policy
16 distinguishes one group of persons from another,” but does not implicate a fundamental
17 interest or a protected class, “that distinction must be rationally related to a legitimate
18 governmental purpose.” *Sanchez*, 914 F. Supp. 2d at 1108. “However, the rational
19 relation test will not sustain conduct by state officials that is malicious, irrational or
20 plainly arbitrary.” *Lockary v Kayfetz*, 917 F.2d 1150, 1155 (9th Cir. 1990). In *Lockary*,
21 for example, the plaintiffs were denied water hookups for their new buildings supposedly
22 because of a water shortage and, while a need to control water due to a shortage is a
23 legitimate governmental purpose, the Ninth Circuit found that plaintiffs presented
24 evidence that the water shortage may not have actually existed. *Id.* If there was no water
25 shortage then, even under a rational basis evaluation, the city’s refusal to provide new
26 hookups “may have been arbitrary or even malicious conduct prohibited by due process
27
28

1 and equal protection.” *Id.*

2 The situation here is similar to that in *Lockary*. With the Mandate, UCI seeks to
3 ensure that individuals on its campuses will increase public health by having immunity
4 to the virus that causes COVID-19. However, the need to preclude Plaintiff and other
5 naturally immune individuals from campus is irrational because those individuals are at
6 least as immune to the virus than are people who have been vaccinated. *See* Section III,
7 *supra*. Therefore, even on a rational basis evaluation, the distinction made by Defendants
8 between people with natural immunity and vaccine immunity is irrational.

9 Alternatively, if Defendants are aware of the natural immunity possessed by
10 Plaintiff, but still chose to make the distinction simply because they preferred to favor
11 vaccinated people, that decision too cannot pass a rational basis test. Defendants’ refusal
12 to exempt naturally immune individuals shows that the Mandate is not about wanting an
13 immune student body and faculty, it is only about having a vaccinated student body and
14 faculty. Similar to the LGBTQ in *Romer v. Evans*,²² people who are not vaccinated are
15 an unpopular group at the moment, and a desire to harm them is prejudice as purpose and
16 not legitimate. A purpose to discriminate against the unvaccinated (a politically
17 unpopular group), but who are naturally immune and no more likely to transmit the virus
18 than vaccinated individuals, cannot constitute a legitimate governmental interest. The
19 Mandate, therefore, cannot satisfy rational basis review and is unconstitutional.

20 **B. Plaintiff’s Fundamental Right to Bodily Integrity Has Been Violated**

21 “The Fourteenth Amendment’s due process clause ‘provides heightened protection
22 against government interference with certain fundamental rights and liberty
23 interests.’” *Sanchez*, 914 F. Supp. 2d at 1100-01 (quoting *Glucksberg*, 521 U.S. at 720).

24
25
26 _____
27 ²² *Romer v. Evans*, 517 U.S. 620, 634 (1996) (“If the constitutional conception of ‘equal
28 protection of the laws’ means anything, it must at the very least mean that a bare . . . desire
to harm a politically unpopular group cannot constitute a *legitimate* governmental interest.”).

1 As discussed *supra*, Plaintiff’s constitutional right to bodily integrity is impinged by the
2 Mandate. *See* Section I.A.ii.

3 It is well established that individuals have a fundamental liberty interest in and
4 right to bodily integrity and informed consent. *See Benson v. Terhune*, 304 F.3d 874, 884
5 (9th Cir. 2002) (“The due process clause of the Fourteenth Amendment substantively
6 protects a person’s rights to be free from unjustified intrusions to the body.”). “This
7 notion of bodily integrity has been embodied in the requirement that informed consent is
8 generally required for medical treatment.” *Cruzan*, 497 U.S. at 277-78. *See also Benson*,
9 304 F.3d at 884 (a person has a right “to refuse unwanted medical treatment and to receive
10 sufficient information to exercise these rights intelligently”). This means that the right
11 to bodily integrity includes the concept that a “competent person has a constitutionally
12 protected liberty interest in refusing unwanted medical treatment.” *Galvan*, 807 Fed.
13 App’x at 697 (quoting *Cruzan*, 497 U.S. at 277-78).

14 Defendants lack a compelling interest to impinge on Plaintiff’s fundamental rights.
15 The United States Constitution guarantees that state governments shall not “deprive any
16 person of life, liberty, or property without due process of law,” U.S. CONST. amend.
17 XIV § 1, and “forbids the government to infringe certain ‘fundamental’ liberty interests
18 *at all*, no matter what process is provided, unless the infringement is narrowly tailored to
19 serve a compelling state interest.” *Reno v. Flores*, 507 U.S. 292, 301-02 (1993).

20 As explained above, Plaintiff has constitutional and fundamental liberty interests
21 in bodily integrity and informed consent, and the substantive due process rights to liberty
22 and to life. Thus, Defendants must prove that the Mandate serves a compelling state
23 interest and is narrowly tailored to that interest.

24 Defendants cannot show that the Mandate serves a compelling state interest. *See*
25 Section I.A.3. While prior court decisions have found that a compelling state interest to
26 control the spread of infection from person-to-person can trump certain constitutional
27 rights in certain situations, *see generally Whitlow v. Cal. Dep’t of Educ.*, 203 F. Supp. 3d
28

1 1079, 1089 (S.D. Cal. 2016), this interest is non-existent with respect to the COVID-19
2 vaccine since this vaccine does not prevent vaccinated individuals from becoming infected
3 and transmitting COVID-19. *See supra*, Section I.B.iii.

4 Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, has
5 explained: “Herd immunity is not a possibility because [the Delta variant] still infects
6 vaccinated individuals.”²³ The vaccinated, when infected, can transmit the virus to
7 others, and are more likely to do so because they have less symptoms and hence are more
8 likely to interact with others not knowing they are contagious. *See supra*, Section I.B.iii.
9 On the other hand, those who have had the COVID-19 virus and recovered have not been
10 shown to become re-infected and transmit the virus to others. *See, e.g.*, McCullough Dec.
11 ¶¶ 16-17; UC Faculty Dec. ¶¶ 11-18. Therefore, there is no compelling interest in
12 requiring the COVID-19 vaccine among the naturally immune.

13 Hence, excluding individuals from the UC locations as a means to compel such
14 individuals to receive an injection of a COVID-19 vaccine does not pass strict scrutiny.
15 There is not even a rational basis to exclude the unvaccinated, recovered individuals from
16 UC since vaccinated individuals are *at least* as likely to spread COVID-19 and, in reality,
17 are more likely. *See* Section I.A.v.

18 **C. Plaintiff’s Fundamental Right to Informational Privacy Has Been Violated**

19 As a condition of employment, Defendants are compelling the disclosure of
20 sensitive medical information: vaccination status. The Ninth Circuit has repeatedly
21 acknowledged that the Constitution protects an “individual interest in avoiding disclosure
22 of personal matters.” *In re Crawford*, 194 F.3d 954, 958 (9th Cir. 1999). “This interest
23 covers a wide range of personal matters, including ... medical information.” *Nelson v.*

24
25 ²³ <https://twitter.com/Channel4News/status/1425086490002997248>. Professor Pollard
26 also stated that, “And what I suspect the virus will throw up next is a variant which is
27 perhaps even better at transmitting in vaccinated populations. And so that’s even **more**
28 **of a reason not to be making a vaccine program around herd immunity...**” (emphasis
added).

1 *Nat'l Aero. & Space Admin.*, 530 F.3d 865, 877-78 (9th Cir. 2008), *rev'd on other*
2 *grounds*, 131 S. Ct. 746 (2011). *See also Norman-Bloodsaw v. Lawrence Berkeley Lab.*,
3 135 F.3d 1260, 1269 (9th Cir. 1998) (“The constitutionally protected privacy interest in
4 avoiding disclosure of personal matters clearly encompasses medical information and its
5 confidentiality.”). If the government’s actions compel disclosure of private information,
6 it “has the burden of showing that its use of the information would advance a legitimate
7 state interest and that its actions are narrowly tailored to meet the legitimate interest.”
8 *Crawford*, 194 F.3d at 959 (internal quotation marks omitted). We must “balance the
9 government’s interest in having or using the information against the individual’s interest
10 in denying access,” weighing, among other things, “the type of [information] requested,
11 ... the potential for harm in any subsequent nonconsensual disclosure, ... the adequacy of
12 safeguards to prevent unauthorized disclosure, the degree of need for access, and whether
13 there is an express statutory mandate, articulated public policy, or other recognizable
14 public interest militating towards access.” *Doe v. Att’y Gen.*, 941 F.2d 780, 796-97 (9th
15 Cir. 1991).

16 There is no narrow tailoring, much less legitimate interest, in applying the
17 disclosure of vaccination status to the naturally immune. And, certainly, the Defendants
18 could meet all of their interests by requiring disclosure of either vaccination status or
19 natural immunity, demonstrating a lack of narrow tailoring.

20 **II. PLAINTIFF IS SUFFERING AND WILL SUFFER IRREPARABLE HARM,**
21 **THE BALANCE OF THE EQUITIES TIP IN HIS FAVOR, AND THE PUBLIC**
22 **INTEREST WEIGHS IN FAVOR OF A PRELIMINARY INJUNCTION**

23 Plaintiff will continue to suffer irreparable harm if the preliminary injunction
24 requested herein is not granted. It has long been established that the loss of constitutional
25 freedoms constitute irreparable harm. *Am. Trucking Ass’ns v. L.A.*, 559 F.3d 1046, 1059
26 (9th Cir. 2012); *Monterey Mech. Co. v. Wilson*, 125 F.3d 702, 715 (9th Cir. 1997).
27 Moreover, without a preliminary injunction preserving the status quo, Plaintiff will suffer
28

1 an impending loss of employment and of his professional reputation. Indeed, “the loss
2 of one’s job does not carry merely monetary consequences; it carries emotional damages
3 and stress, which cannot be compensated by mere back payment of wages.” *Nelson*, 530
4 F.3d at 877-78.

5 If Plaintiff is not permitted on campus as a result of this mandate, his practice and
6 roles at UC will be drastically and adversely affected, including in the following ways:

- 7 a. He will not be able to attend in-person meetings with his team or with
8 patients and families in the hospital and so his role as ethics committee chair
9 and director of the ethics consult service will be impacted;
- 10 b. He will not be able to hold Monday and Tuesday afternoon Resident Clinic;
- 11 c. He will not be able to see his own patients from his practice as his faculty
12 practice is located at the Department of Psychiatry clinic;
- 13 d. He will not be able to do his Resident in-person teaching;
- 14 e. He will not be able to do on-site ethics consultations in the hospital; and
- 15 f. He will not be able to teach the Ethics and Behavioral Science course for
16 first and second-year medical students. A.K. Dec. ¶4.

17 The balance of the equities also tips in Plaintiff’s favor. Among other reasons
18 discussed *supra* at Section III, while the COVID-19 vaccine, depending on brand, at best
19 under the optimal setting of a clinical trial has between 67% and 95% efficacy, and that
20 protection wanes over time, Plaintiff poses virtually no risk to others.

21 Finally, the public interest always weighs in favor of the vindication of
22 constitutional rights. *See Melendres v. Arpaio*, 695 F.3d 990 (9th Cir. 2012). Treating
23 naturally immune individuals differently from the fully vaccinated, when both have
24 immunity, by demanding Plaintiff violate his right bodily integrity presents only a risk of
25 harm and is unconstitutional.

26 CONCLUSION

27 For the foregoing reasons, Plaintiff respectfully requests the court issue a
28

1 preliminary injunction enjoining and prohibiting Defendants enforcing the Mandate as to
2 naturally immune individuals.

3
4 Dated: August 23, 2021

5 SIRI & GLIMSTAD LLP

6 By: /s/ Caroline Tucker

7 Aaron Siri (Pro Hac Vice to be filed)

8 Elizabeth Brehm (Pro Hac Vice to be filed)

9 Caroline Tucker

10 CHRIS WIEST ATTORNEY AT LAW, PLLC

11 Chris Wiest (Pro Hac Vice to be Filed)

12 Attorneys for Plaintiff

13 AARON KHERIATY, M.D.

1 SIRI & GLIMSTAD LLP
2 CAROLINE TUCKER (SBN 261377)
3 ctucker@sirillp.com
4 700 S. Flower Street, Suite 1000
5 Los Angeles, CA 90017
6 Telephone 213-376-3739
7 Facsimile 646-417-5967

8 SIRI & GLIMSTAD LLP
9 Aaron Siri (Pro Hac Vice To Be Filed)
10 Email: aaron@sirillp.com
11 Elizabeth A. Brehm (Pro Hac Vice To Be Filed)
12 Email: ebrehm@sirillp.com
13 200 Park Avenue
14 Seventeenth Floor
15 New York, NY 10166
16 Telephone: 212-532-1091
17 Facsimile: 646-417-5967

18 CHRIS WIEST ATTORNEY AT LAW, PLLC
19 Chris Wiest (Pro Hac Vice To Be Filed)
20 Email: chris@cwiestlaw.com
21 25 Town Center Blvd, STE 104
22 Crestview Hills, KY 41017
23 Telephone: 513-257-1895
24 Facsimile: 859-495-0803

25 Attorneys for Plaintiff
26 AARON KHERIATY

27 **UNITED STATES DISTRICT COURT**
28 **CENTRAL DISTRICT OF CALIFORNIA**
SOUTHERN DIVISION

AARON KHERIATY M.D.,

Plaintiff,

v.

Case No. 8:21-cv-01367 JVS (KESx)

**DECLARATION OF UNIVERSITY
OF CALIFORNIA FACULTY IN
SUPPORT OF PLAINTIFF'S**

1 THE REGENTS OF THE UNIVERSITY
2 OF CALIFORNIA, a Corporation, and
3 MICHAEL V. DRAKE, in his official
4 capacity as President of the UNIVERSITY
OF CALIFORNIA,

5 Defendants.

**MOTION FOR PRELIMINARY
INJUNCTION**

Date: September 27, 2021

Time: 1:30 pm

Place: Courtroom 10C

Judge: Hon. James V. Selna

7
8 We, the undersigned, declare as follows:

9 1. We are adults of sound mind and make this declaration voluntarily, based
10 upon our own personal knowledge, education, and experience.

11
12 2. The University of California (“UC”) is a public university intended to serve
13 the residents of California and is open to students from around the world. It currently has
14 more than 280,000 students and more than 227,000 faculty and staff.¹ We are a group
15 of UC faculty writing regarding vaccination for individuals who have recovered from
16 COVID-19 (the “**naturally immune**”). True and correct copies of our CVs are attached
17 to this declaration as **Exhibit A**. Extensive scientific data demonstrates that naturally
18 immune individuals have robust immunity as a result of having been exposed to the
19 SARS-CoV-2 virus and may suffer *worse* adverse effects after vaccination than
20 individuals not previously exposed to the virus.

21 3. The evidence shows the infection caused by the SARS-CoV-2 virus in
22 humans produces durable immunity, and that natural immunity induced by the virus is at
23

24
25
26
27 ¹ <https://www.universityofcalifornia.edu/uc-system>.

1 least comparable to vaccine-induced immunity. We base these opinions on careful
2 reviews of published and preprint medical literature. The Centers for Disease Control and
3 Prevention (“CDC”) estimates that approximately 115 million persons in the U.S. (35%
4 of the population) were infected with SARS-CoV-2 by April 2021.² The CDC also
5 estimates that approximately forty nine percent of those aged eighteen to forty-nine years
6 have been infected with SARS-CoV-2.³ The California Department of Public Health
7 estimates that as of June 2021, 85.9% of adults age 18 and older in California have
8 antibodies to SARS-CoV-2.⁴

11 4. Our declaration addresses three areas:

- 13 A. The strength of natural immunity appearing subsequent to a SARS-CoV-
14 2 infection.
- 16 B. Whether the Covid-19 vaccine can prevent infection and transmission of
17 SARS-CoV-2.
- 19 C. Concerns about the growing number of reported serious harms after
20 receiving the Covid-19 vaccine.

24 _____
25 ² <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.

26 ³ *Ibid.*

27 ⁴ [https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Sero-prevalence-
28 COVID-19-Data.aspx](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Sero-prevalence-COVID-19-Data.aspx).

1 **A. Natural Immunity**

2 5. The human body knows how to develop immunity to new viruses. The
3
4 adaptive immune system consists of an enormously diverse repertoire of B cells
5 (precursors of antibody-secreting plasma cells) and T cells with a nearly unlimited
6 capacity to recognize and ‘adapt’ to previously unseen pathogens.

7
8 6. University of California policy currently indicates that individuals recently
9 diagnosed with COVID-19 “may be eligible for a temporary Medical Exemption (and,
10 therefore, a temporary Exception), for up to 90 days after your diagnosis and certain
11 treatments.” However, as a matter of factual evidence, more is known about the
12 durability of natural immunity than the durability of immunity from the Covid-19
13 vaccines, due to the novelty of the vaccines. Data (please see the cited research studies
14 below) indicate that natural immunity is more durable than immunity from the Covid-19
15 vaccines. The 90-day temporary Medical Exemption is therefore not supported by
16 scientific data and underestimates the durability of natural immunity.
17
18

19
20 7. The robust natural immunity that develops after SARS-CoV-2 infection
21 derives from multiple sources, including antibodies to the nucleocapsid and to the spike
22 protein, T-helper cells, B-cells, natural killer cells, and innate immunity. Immunologic
23 studies using human subjects who have had SARS-CoV-2 demonstrate that they
24
25
26
27
28

1 developed sustained immunity⁵ which protect from reinfection⁶ and robust T-cell
2 memory⁷ to the virus. This means that the adaptive immune system, after being
3 successfully engaged in the immune response to SARS-CoV-2, will be capable of
4 recognizing SARS-CoV-2 in the future.

6 8. As such, it is a more extensive host defense system than the limited array of
7 antibodies to the spike protein generated by COVID-19 vaccines. The natural immunity
8 produced by the closely related SARS-CoV-1 has been documented to last for years.⁸

9 This is evident from numerous studies, including:

- 10
11
12 a. A study from researchers at the La Jolla Institute for Immunology found
13 that that the immune systems of those who recovered from COVID-19
14 had durable memories of the virus up to eight months after infection.⁹

15
16
17
18
19
20 ⁵ <https://pubmed.ncbi.nlm.nih.gov/32743600/>;
21 <https://www.medrxiv.org/content/10.1101/2020.07.21.20159178v1>.

22 ⁶ <https://www.nih.gov/news-events/nih-research-matters/sars-cov-2-antibodies-protect-reinfection>.

23 ⁷ <https://pubmed.ncbi.nlm.nih.gov/32979941/>.

24 ⁸ <https://www.nature.com/articles/s41586-020-2550-z>;
25 <https://www.cidrap.umn.edu/news-perspective/2008/08/researchers-find-long-lived-immunity-1918-pandemic-virus>.

26 ⁹ <https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19>.

- 1 b. A study from researchers at Washington University School of Medicine
2 which found that “SARS-CoV-2 infection induces a robust antigen-
3 specific, long-lived humoral immune response in humans.”¹⁰
4
- 5 c. A study from researchers at Emory University and Fred Hutchinson
6 Cancer Research Center which found that recovered COVID-19 patients
7 mount broad, durable immunity after infection, and that “[t]he durable
8 antibody responses in the COVID-19 recovery period are further
9 substantiated by the ongoing rise in both the spike and RBD memory B
10 cell responses after over 3–5 months before entering a plateau phase over
11 6–8 months. Persistence of RBD memory B cells has been noted.”¹¹
12
- 13 d. A different group of researchers at Aarhus University Hospital in
14 Denmark studied the immune response following SARS-CoV-2
15 infections in 203 recovered patients. The patients’ disease severity
16 ranged from mild to serious cases that required hospitalization. The
17 authors found that the vast majority of recovered individuals had
18 detectable, functional SARS-CoV2 spike-specific adaptive immune
19 responses, despite diverse disease severities, making vaccination post-
20 COVID-19 for any of them redundant.¹²
21
22
23
24

25 ¹⁰ <https://www.nature.com/articles/s41586-021-03647-4>.

26 ¹¹ <https://doi.org/10.1016/j.xcrm.2021.100354>.

27 ¹² [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(21\)00203-6/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00203-6/fulltext)

1 e. The most recent study of T-cell immunity six months after infection
2 demonstrated that every single person tested showed “robust T cell
3 responses to SARS-CoV-2 virus peptides [six months after primary
4 infection] in all participants” which included those with “asymptomatic
5 or mild/moderate COVID-19 infection.”¹³
6

7
8 9. The Pfizer vaccine had initially, at best, efficacy of 95%,¹⁴ the Moderna
9 vaccine had efficacy of 94.5%,¹⁵ and the J&J vaccine efficacy was approximately 67%,¹⁶
10 and that was under the ideal conditions in a clinical trial, against the original wild-type
11 variant of the virus. The COVID-19 vaccines have had considerably less efficacy in the
12 real world which has been the case based on the data to date.¹⁷ Hence, there have been
13 many thousands of reported “breakthrough” cases of COVID-19 subsequent to
14 vaccination. Most such cases are alleged to arise from variant strains of the virus that the
15 original vaccine was not designed to neutralize. The number of breakthrough cases
16 among the vaccinated was growing so rapidly and burdening resources to such an extent
17
18
19

20
21 xt.

22 ¹³ <https://www.uk-cic.org/news/cellular-immunity-sars-cov-2-found-six-months-non-hospitalised-individuals>.

23 ¹⁴ <https://www.fda.gov/media/144416/download>.

24 ¹⁵ <https://www.fda.gov/media/144673/download>.

25 ¹⁶ <https://www.fda.gov/media/146338/download>.

26 ¹⁷ https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w;
27 <https://www.nejm.org/doi/10.1056/NEJMoa2108891>; https://wwwnc.cdc.gov/eid/article/27/10/21-1427_article.

1 that the CDC changed its reporting criteria to only report breakthrough cases to
2 breakthrough cases resulting in hospitalization or death.¹⁸ In contrast, the more varied
3 and evolving resources of the native immune system of COVID-19 survivors have proven
4 effective at neutralizing such variants.¹⁹

6 10. After a natural SARS-CoV-2 infection, even in cases where antibody
7 responses have not met the threshold for being “reactive” in the approximately 100
8 commercial assays, the evidence is clear that cellular based immunity is present. This
9 evidence reflects that clinical infection alone, without either antibody or cellular based
10 testing afterwards, is sufficient to identify an individual who is either no longer
11 susceptible or minimally susceptible to COVID-19, similar to the vaccines.²⁰

14 11. Importantly, in such individuals who have had natural SARS-CoV-2
15 infections, the evidence reflects that they are less likely to again acquire, carry, and
16 transmit the virus to another individual when compared to those vaccinated for this
17 virus.²¹ This is evident from numerous studies, including:

- 20 a. A new Israeli study of over 6 million participants found that natural
21 immunity from SARS-CoV-2 infection was better than vaccination
22 immunity in reducing risk of COVID-19 reinfection, hospitalization, and
23

24 ¹⁸ *Ibid.*

25 ¹⁹ <https://www.cdc.gov/mmwr/volumes/70/wr/mm7021e3.htm>.

26 ²⁰ <https://pubmed.ncbi.nlm.nih.gov/33058753/>.

27 ²¹ <https://pubmed.ncbi.nlm.nih.gov/33184509/>.

1 severe illness. Vaccination was highly effective, with overall estimated
2 efficacy for documented infection of 92.8%, hospitalization 94.2% and
3 severe illness 94.4%. Similarly, the overall estimated level of protection
4 from prior SARS-CoV-2 infection for documented infection was 94.8%,
5 hospitalization 94.1%, and severe illness 96.4%.²² As the study explains,
6 “both the BNT162b2 vaccine and prior SARS-CoV-2 infection are
7 effective against both subsequent SARS-CoV-2 infection and other
8 COVID-19–related outcomes.”²³

- 9
10
11
12 b. Another study from Israel found that the vaccinated had 6.72 times the
13 rate of infection as compared to those that had had COVID-19:

14 With a total of 835,792 Israelis known to have
15 recovered from the virus, the 72 instances of
16 reinfection amount to 0.0086% of people who
17 were already infected with COVID.
18

19
20
21 By contrast, Israelis who were vaccinated were
22 6.72 times more likely to get infected after the
23 shot than after natural infection.²⁴
24

25
26 ²² <https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1>.

27 ²³ *Ibid.*

28 ²⁴ <https://www.theblaze.com/op-ed/horowitz-israeli-government-data-shows-natural->

- 1 c. The Cleveland Clinic recently released an investigation evaluating the
2 value of COVID-19 vaccination in persons previously infected with the
3 SARS-CoV-2 virus. All employees of the Cleveland Clinic’s Ohio
4 facility on December 16, 2020, the day their COVID-19 vaccination
5 program began, were included (n=52,238). Any individual testing
6 positive for SARS-CoV-2 at least 42 days earlier was considered
7 *previously infected*. The investigators measured cumulative incidence of
8 SARS-CoV-2 infection over the next five months. They found that **none**
9 **of the 1,359 previously infected who remained unvaccinated**
10 **contracted SARS-CoV-2 over the course of the research despite a**
11 **high background rate of COVID-19 in the hospital.** The authors
12 concluded that “individuals who have had SARS-CoV-2 infection are
13 unlikely to benefit from COVID-19 vaccination.”²⁵
14
15 d. A similarly conducted study led by a researcher at University of
16 California Los Angeles found that there was no difference in the infection
17 incidence between vaccinated individuals and individuals with previous
18 infection.²⁶
19
20
21
22
23
24

25 [immunity-from-infection-much-stronger-than-vaccine-induced-immunity#toggle-gdpr.](#)

26 ²⁵ <https://doi.org/10.1101/2021.06.01.21258176>.

27 ²⁶ <https://www.medrxiv.org/content/10.1101/2021.07.03.21259976v2.full-text>.

1 e. An outbreak of SARS-CoV-2 caused by the Gamma variant infected
2 24/44 (55%) employees of a gold mine in French Guiana. The attack rate
3 was 15/25 (60.0%) in fully vaccinated miners, 6/15 (40.0%) in those
4 partially vaccinated or with a history of COVID-19 (none of the partially
5 vaccinated with a history of COVID-19 were positive), and 3/4 (75%) in
6 those not vaccinated. The attack rate was 0/6 among persons with a
7 previous history of COVID-19 versus 63.2% among those with no
8 previous history.²⁷

9 f. Israel is currently having a new outbreak of COVID-19 cases and the
10 “Health Ministry data ... showed that fully vaccinated individuals were
11 responsible for most new cases and most of those hospitalized in
12 moderate condition or worse.”²⁸

13 12. Given the current number of estimated COVID-19 worldwide cases of
14 approximately 204 million,²⁹ if reinfection occurred in only 1% of individuals, the world
15 would have observed 2.04 million second and third cases, with many coming to clinical
16 attention and/or requiring hospitalization. In fact, no such large volume of recurrent cases
17 has been observed in any world region. In the 19 months since the COVID-19 virus first
18
19
20
21
22
23

24 ²⁷ https://wwwnc.cdc.gov/eid/article/27/10/21-1427_article.

25 ²⁸ <https://www.timesofisrael.com/over-5000-new-coronavirus-cases-confirmed-monday-as-new-limits-mulled/>.

26 ²⁹ <https://covid19.who.int/>.

1 appeared in the United States, doctors and scientists have not identified any naturally
2 immune individual that was re-infected with and transmitted this virus to anyone.

3
4 13. Irish researchers recently published a review of eleven cohort studies with
5 over 600,000 total recovered COVID patients, not all of whom were well defined and
6 may have had suspected COVID-19 with positive serologies later on who were followed
7 up with over ten months. They found the reinfection rate to be 0.27% “with no study
8 reporting an increase in the risk of reinfection over time.”³⁰ Based on this data, the
9 researchers were able to assert that “naturally acquired SARS-CoV-2 immunity does not
10 wane for at least 10 months post-infection.”³¹ The study also did not identify any case of
11 reinfection of SARS-CoV-2 that resulted in further transmission of the virus.
12
13

14 14. Based on this data, prior infection with SARS-CoV-2 appears to provide
15 greater than 99% efficacy from reinfection, which is far greater protection than the
16 efficacy from vaccine immunity which, in an optimal clinical trial setting, provided no
17 greater than between 67% and 95% efficacy, depending on the COVID-19 vaccine. The
18 Pfizer vaccine was reported to have, at best, efficacy of 95%,³² the Moderna vaccine
19 94.5%,³³ and the J&J vaccine 67%,³⁴ under the previous ideal conditions in a clinical
20
21
22

23 ³⁰ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209951/pdf/RMV-9999-e2260.pdf>.

24 ³¹ *Ibid.*

25 ³² <https://www.fda.gov/media/144416/download>.

26 ³³ <https://www.fda.gov/media/144673/download>.

27 ³⁴ <https://www.fda.gov/media/146338/download>.

1 trial, against the original wild-type variant of the virus. But even assuming the optimal
2 clinical trial efficacy numbers, this is still far less than the efficacy from having had the
3 COVID-19 virus, which, based on all the available data, is over 99% effective in
4 preventing reinfection. *Id.* ¶ 14.

6 15. This finding is not surprising given that vaccines, by design, attempt to
7 emulate the immunity created by a natural infection. Nonetheless, they never achieve the
8 same level of protection afforded by natural infection from a virus. They universally
9 confer inferior immunity to having had the actual virus and even the best vaccines do not
10 confer immunity to all recipients. In those who do obtain some immunity from
11 vaccination, the immunity created typically wanes over time.

14 16. A recent article aptly explained why infection-induced immunity to SARS-
15 CoV-2 is much deeper and broader than vaccine immunity:

17 A natural infection induces hundreds upon hundreds of
18 antibodies against all proteins of the virus, including the
19 envelope, the membrane, the nucleocapsid, and the
20 spike...Dozens upon dozens of these antibodies neutralize the
21 virus when encountered again. Additionally, because of the
22 immune system exposure to these numerous proteins
23 (epitomes), our T cells mount a robust memory, as well. Our T
24 cells are the ‘marines’ of the immune system and the first line

1 of defense against pathogens. T cell memory to those infected
2 with SARSCOV1 is at 17 years and running still....

3
4 In vaccine-induced immunity...we mount an antibody
5 response to only the spike and its constituent proteins ... [and]
6 this produces much fewer neutralizing antibodies, and as the
7 virus preferentially mutates at the spike, these proteins are
8 shaped differently and antibodies can no longer ‘lock and key’
9 bind to these new shapes.
10
11

12
13 **B. Covid-19 Vaccinated Individuals Can Still Become Infected and Transmit the**
14 **Virus**

15 17. Natural immunity confers an additional benefit over vaccine immunity.
16 Natural immunity will prevent a virus from being able to replicate and shed in the
17 naturally immune individual. In contrast, COVID-19 vaccines appear to reduce
18 symptoms in some but still permit the vaccinees to become infected with and transmit the
19 virus.³⁵

20
21 18. In animal studies, the COVID-19 vaccine candidates could *not* fully block
22 viral infection and replication in the nose of monkeys upon viral challenge.³⁶ In contrast,
23
24

25 ³⁵ <https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html>
26 (“There is some evidence that vaccination may make illness less severe for those who are
27 vaccinated and still get sick.”).

28 ³⁶ <https://www.nejm.org/doi/full/10.1056/NEJMoa2024671>; <https://pubmed.ncbi.nlm.nih.gov/36811111/>

1 the SARS-CoV-2 infection of monkeys completely prevented further re-infection at any
2 site tested – by nasal, throat, and anal swabs.³⁷

3
4 19. Viral carriage by the vaccinated is reflected in the recent outbreak in
5 Barnstable County, Massachusetts, which has a 69% vaccination coverage rate amount
6 its eligible residents.³⁸ A recent CDC investigation found that 74% of those infected in
7 the outbreak were fully vaccinated for COVID-19 and, even more alarming, the
8 vaccinated had on average more virus in their nose than the unvaccinated that were
9 infected. The study reported zero cases of infection among those that previously had
10 COVID-19.
11

12
13 20. This forced the Director of the CDC, Rochelle Walensky, to admit that
14 individuals vaccinated for COVID-19, while having less symptoms, can still become
15 infected with and transmit the virus.³⁹ Dr. Walensky admitted that “**what [the COVID-
16 19 vaccines] can’t do anymore is prevent transmission.**”⁴⁰ After this admission, Wolf
17 Blitzer asked Dr. Walensky if “you get covid, you’re fully vaccinated, but you are totally
18
19
20
21
22

23 [nih.gov/32511340](https://www.nih.gov/32511340).

24 ³⁷ <https://pubmed.ncbi.nlm.nih.gov/32616673/>.

25 ³⁸ <https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm>.

26 ³⁹ <https://twitter.com/CNNSitRoom/status/1423422301882748929>.

27 ⁴⁰ <https://twitter.com/CNNSitRoom/status/1423422301882748929>.

1 asymptomatic, you can still pass on the virus to someone else, is that right?” and Dr.
2 Walensky answers “**that is exactly right.**”⁴¹

3
4 21. While COVID-19 vaccinees can be asymptomatic carriers and spreaders of
5 SARS-CoV-2, based on all available data to date, the naturally immune have a near zero
6 risk of becoming reinfected with and transmitting SARS-CoV-2.

7
8 **C. Concerns About Harms Associated with the Vaccine**

9 22. The COVID-19 vaccine is not without risk, particularly for those previously
10 infected with SARS-CoV-2. It violates medical ethics to expose someone to this risk
11 when they have robust, durable immunity that actually neutralizes SARS-CoV-2 upon
12 exposure.

13
14 23. Studies have found that naturally immune individuals have significantly
15 higher rates of adverse reactions when receiving the COVID-19 vaccine. For example,
16 Raw et al. reported that among 974 individuals vaccinated for COVID-19, the vaccinated
17 COVID-19 recovered patients had higher rates of vaccine reactions.⁴² Mathioudakis et
18 al. found the same result in a study of 2,002 individuals vaccinated for COVID-19.⁴³
19
20
21 Krammer et al. found the same result in a study of 231 volunteers vaccinated for COVID-
22

23
24
25 ⁴¹ <https://twitter.com/CNNSitRoom/status/1423422301882748929>.

26 ⁴² <https://www.medrxiv.org/content/10.1101/2021.04.15.21252192v1>.

27 ⁴³ <https://www.mdpi.com/2075-1729/11/3/249>.

1 19, concluding that, “Vaccine recipients with preexisting immunity experience systemic
2 side effects with a significantly higher frequency than antibody naïve vaccines.”⁴⁴

3
4 24. The primary system for tracking adverse events after vaccination in the
5 United States is the Vaccine Adverse Events Reporting System (VAERS) to which
6 “fewer than 1% of vaccine adverse events are reported.”⁴⁵

7
8 25. Reports of serious adverse events from COVID-19 vaccines are apparently
9 similarly underreported to VAERS. *Id.* For example, according to the CDC,
10 “Anaphylaxis after COVID-19 vaccination is **rare** and occurred in approximately **2 to 5**
11 **people per million** vaccinated in the United States based on events reported to
12 VAERS.”⁴⁶ However, a recent study at Mass General Brigham that assessed anaphylaxis
13 in a clinical setting after COVID-19 vaccination found “severe reactions consistent with
14 anaphylaxis occurred at a rate of **2.47 per 10,000 vaccinations.**”⁴⁷ This is equivalent to
15 50 to 120 times more cases than what VAERS and the CDC are reporting for a serious,
16 potentially life-threatening, adverse event that occurs almost immediately after
17 vaccination and which medical providers are advised they must watch for and report.

18
19
20
21
22
23 _____
24 ⁴⁴ <https://doi.org/10.1101/2021.01.29.21250653>.

25 ⁴⁵ <https://healthit.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>.

26 ⁴⁶ <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>.

27 ⁴⁷ <https://jamanetwork.com/journals/jama/fullarticle/2777417>.

1 26. If anaphylaxis is being underreported, the level of underreporting for serious
2 adverse events that do not occur immediately after vaccination or are not easily identified
3 is likely far greater. For example, on June 23, 2021, the CDC reported the alarming
4 numbers of reported myocarditis and pericarditis cases occurring after COVID-19
5 vaccination.⁴⁸ The long-term effects of myocarditis are not fully understood but can be
6 very serious. Cases of thrombocytopenia have also occurred after COVID-19
7 vaccination, as well as serious and sometimes fatal blood clots.⁴⁹ These and numerous
8 other serious adverse events are being recognized but the true rate of these serious adverse
9 events is most certainly underreported.⁵⁰

13
14 ⁴⁸ <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf> at page 27.

15 ⁴⁹ <https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine>.

17 ⁵⁰ Research shows that the coronavirus spike protein from COVID-19 vaccines enters the
18 bloodstream and can be found throughout the body in almost all vital organs.
19 <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075>. This
20 would help explain the high rate of reported blood clots, heart disease, brain damage and
21 reproductive issues. Dr. Byram Bridle, a viral immunologist and associate professor at
22 the University of Guelph, Ontario, recently stated: “We made a big mistake. We didn’t
23 realize it until now... We thought the spike protein was a great target antigen, we never
24 knew the spike protein itself was a toxin and was a pathogenic protein. So by vaccinating
25 people we are inadvertently inoculating them with a toxin.” <https://omny.fm/shows/on-point-with-alex-pierson/new-peer-reviewed-study-on-covid-19-vaccines-sugge>. Recent
26 data from Japan – data not required by the U.S. – reflects that lipid nano particles from
27 the vaccine encapsulating the spike protein mRNA are being deposited into vital organs
28 after vaccination. Of concern are the data related to lipid nano particles depositing into
the adrenal glands, bone marrow, liver, ovaries, brain, and spleen and increasing in
quantity over time post-vaccination. <https://www.icandecide.org/wp-content/uploads/2021/06/Translation-of-Japanese-data.pdf> at 16-17.

1 27. Studies reflect that the SARS-CoV-2 spike protein from COVID-19
2 vaccines enters the bloodstream and can be found throughout the body in almost all vital
3 organs.⁵¹ This accords with recent data from Japan – data not required by the U.S. –
4 which reflects that lipid nano particles from the vaccine encapsulating the spike protein are
5 being deposited into vital organs after vaccination, including the adrenal glands, bone
6 marrow, liver, ovaries, brain, and spleen and increasing in quantity over time post-
7 vaccination.⁵² This may explain the high rate of reported blood clots, heart disease, and
8 other serious issues from the COVID-19 vaccine.
9

10
11 28. In a paper published by Bruno, et al. the authors pose urgent questions on
12 COVID-19 vaccine safety, highlighting the high number of reported serious adverse
13 events to this vaccine and the short comings of the clinical trials including exclusion of
14 those with prior SARS-CoV-2 infection.⁵³ Vaccinating the naturally immune can lead to
15 serious injury or death by causing antigen specific tissue inflammation in any tissues
16 harboring viral antigens.
17

18
19 29. The ethical issue with exposing the naturally immune is compounded by the
20 fact that the data on the safety and pharmacokinetic profiles of the spike protein have not
21
22

23
24 ⁵¹ <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075>.

25 ⁵² [https://www.lifesitenews.com/wp-content/uploads/2021/06/Pfizer-bio-distribution-
26 confidential-document-translated-to-english.pdf](https://www.lifesitenews.com/wp-content/uploads/2021/06/Pfizer-bio-distribution-confidential-document-translated-to-english.pdf) at 16-17.

27 ⁵³ [https://jeffreydachmd.com/wp-content/uploads/2021/05/Peter-A-Mccullough-.SARS-
28 -CoV2-mass-vaccination-Urgent-questions-on-vaccine-safety.pdf](https://jeffreydachmd.com/wp-content/uploads/2021/05/Peter-A-Mccullough-.SARS-CoV2-mass-vaccination-Urgent-questions-on-vaccine-safety.pdf).

1 been made available to the scientific community. In particular:

2 a. All COVID-19 vaccines produce SARS-CoV-2 spike protein in-situ.

3
4 Therefore, the safety profile of spike protein itself (i.e., in the absence of virus) must be
5 thoroughly understood, and this is not currently the case.

6 b. Evidence of systemic circulation of the spike protein or its components after
7 vaccination has been reported.⁵⁴ In fact, all studies we are aware of to date raise concerns
8 about the safety of spike protein,^{55 56 57 58 59 60 61 62 63 64 65 66 67} and that the concentration
9 of circulatory spikes is correlated with disease severity in COVID-19 patients.⁶⁸
10

11 c. Additional potential COVID-19 vaccine safety concerns have been
12
13

14 ⁵⁴ <http://dx.doi.org/10.1093/cid/ciab465>.

15 ⁵⁵ <http://dx.doi.org/10.1038/nm1267>.

16 ⁵⁶ <http://dx.doi.org/10.1128/JVI.02560-09>.

17 ⁵⁷ <http://dx.doi.org/10.1371/journal.ppat.1009128>.

18 ⁵⁸ <http://dx.doi.org/10.1186/s13045-020-00954-7>.

19 ⁵⁹ <https://www.mdpi.com/2673-527X/1/1/4>.

20 ⁶⁰ <http://dx.doi.org/10.1016/j.ejim.2021.04.019>.

21 ⁶¹ <http://dx.doi.org/10.1165/rcmb.2020-0544OC>.

22 ⁶² <http://dx.doi.org/10.1038/s41593-020-00771-8>.

23 ⁶³ <http://dx.doi.org/10.1016/j.bbrc.2021.03.100>.

24 ⁶⁴ <http://dx.doi.org/10.1161/CIRCRESAHA.121.318902>.

25 ⁶⁵ <http://dx.doi.org/10.1073/pnas.2105968118>.

26 ⁶⁶ <http://dx.doi.org/10.1016/j.vph.2020.106823>.

27 ⁶⁷ <http://dx.doi.org/10.3390/vaccines9010036>.

28 ⁶⁸ <http://dx.doi.org/10.1093/clinchem/hvaa213>.

1 identified, including risks that may vary by age and sex. Additional concerns may be
2 identified in the future.^{69 70 71}

3
4 30. A thorough investigation of serious adverse events captured by
5 pharmacovigilance systems in the U.S. has not yet been reported and the systems in the
6 U.S. have limitations. In Israel, for example, myocarditis was estimated to occur in 1 in
7 3000 to 1 in 6000 men ages 16 to 24 who received the Pfizer/BioNTech, or between 5
8 and 25 times the background rate.⁷² However, this excess risk was not detected by the
9 CDC for several months.

10
11 31. Because previously infected individuals are already immune to SARS-CoV-
12 2, the risks they face from COVID-19 vaccination, even if minimal, exceeds the benefit
13 of receiving the vaccine.

14
15 32. Based on our communications with other University of California
16 physicians and researchers, it is our understanding that many agree that mandating
17 vaccination for individuals who have recovered from COVID-19 is unlikely to yield a
18 health benefit, but they are reluctant to express this publicly due to concerns about
19 employment security, academic promotion, or other repercussions.

20
21
22
23 _____
24 ⁶⁹ <http://dx.doi.org/10.3390/biology10030238>.

25 ⁷⁰ <http://dx.doi.org/10.1016/j.mehy.2020.110009>.


26 ⁷¹ <http://dx.doi.org/10.1016/j.tranon.2020.100814>.

27 ⁷² <https://www.sciencemag.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination>.

1 33. Based on the foregoing, we conclude that those who have been infected with
2 SARS-CoV-2 are at least as protected as those vaccinated for COVID-19, are less likely
3 to spread SARS-CoV-2 to others, and will be exposed to the potential harm from this
4 vaccine without a counterbalancing benefit because they are already immune to the virus.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct this 14 day of August, 2021, at Los Angeles CA.



Joseph Ladapo, MD, PhD
Center for HIV Identification, Prevention, and Treatment Services, UCLA; Associate Professor with Tenure, Division of General Internal Medicine/Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA


1 I declare under penalty of perjury under the laws of the United States of America that the
2 foregoing is true and correct this 17th day of August, 2021, at Los Angeles,
3 CA
4 _____
5

6
7 
8

9 John Patrick Whelan, MD, PhD

10 Clinical Associate Professor of Molecular
11 Microbiology & Immunology, Keck/USC;
12 Clinical Associate Professor of Pediatrics,
13 David Geffen School of Medicine, UCLA
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


1 I declare under penalty of perjury under the laws of the United States of America that
2 the foregoing is true and correct this 14 day of August, 2021, at
3 Szolnok, HUNGARY
4

5
6 
7

8 Laszlo G. Boros, MD
9 Recently Retired Adjunct Professor of Pediatrics,
10 Endocrinology and Metabolism, UCLA
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 I declare under penalty of perjury under the laws of the United States of America that
2 the foregoing is true and correct this _____ day of August, 2021, at
3

4 _____

5
6 

7
8 Carole Browner, PhD, MPH

9 Distinguished Research Professor, Professor

10 Emerita, Departments of Psychiatry,

11 Anthropology, and Gender Studies, UCLA
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 I declare under penalty of perjury under the laws of the United States of America that the
2 foregoing is true and correct this _____ day of August, 2021, at _____,

3
4 _____.



5 Dated: ___8/18/21_____

6 Aditi Bhargava, PhD
7 Professor Emerita, Department of Ob-Gyn,
8 Center for Reproductive Sciences, UCSF


9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

I declare under penalty of perjury under the laws of the United States of America that
the foregoing is true and correct this _____ day of August, 2021, at

_____.

Dated: 8/13/21



Gabriel Vorobiof
Health Sciences Associate Clinical Professor of
Medicine, Division of Cardiology and the
Department of Molecular & Medical
Pharmacology, UCLA

Exhibit A

Joseph A. Ladapo, M.D., Ph.D.
Curriculum Vitae

BUSINESS INFORMATION

Business Address: UCLA Department of Medicine
Division of General Internal Medicine and
Health Services Research (GIM/HSR)
1100 Glendon Ave., Suite 850
Los Angeles, CA 90024

Business Phone: (310) 794-2728

Email: jladapo@mednet.ucla.edu

URLs: <https://www.uclahealth.org/joseph-ladapo>
<http://pophealth.med.nyu.edu/faculty/ladapj01>

EDUCATION

1996-2000	B.A.	WAKE FOREST UNIVERSITY Chemistry, <i>Magna cum laude</i>
2000-2008	M.D.	HARVARD MEDICAL SCHOOL New Pathway program
2003-2004		HARVARD UNIVERSITY JOHN F. KENNEDY SCHOOL OF GOVERNMENT Spent one year in Master in Public Policy program before transferring to Ph.D. Program in Health Policy
2004-2008	Ph.D.	HARVARD UNIVERSITY Health Policy, Decision Sciences concentration
2006 Jul -2007 Jun		HARVARD MEDICAL SCHOOL/HARVARD PILGRIM HEALTH CARE Helmut Schumann Fellowship, Ambulatory Medicine
2008 Jun -2011 Jun		BETH ISRAEL DEACONESS MEDICAL CENTER Residency in Internal Medicine

LICENSURE

2011-2016	New York, Medical License (Number 262408-1)
2016-present	California, Medical License (Number 144374)

BOARD CERTIFICATION:

2011-present	Board Certification, American Board of Internal Medicine
--------------	--

PROFESSIONAL EXPERIENCE:

Present Positions:

- 2020 Jun-present **Core Scientist.** Center for HIV Identification, Prevention, and Treatment Services (CHIPTS), UCLA, Los Angeles, CA
- 2020 May-present **Associate Professor with Tenure.** Division of General Internal Medicine/Health Services Research (GIM/HSR), Department of Medicine (DOM), David Geffen School of Medicine at UCLA (DGSOM), Los Angeles, CA
- 2016 Jul-2020 April **Associate Professor-in-Residence.** Division of General Internal Medicine/Health Services Research (GIM/HSR), Department of Medicine (DOM), David Geffen School of Medicine at UCLA (DGSOM), Los Angeles, CA
- 2016 Jul-present **Adjunct Assistant Professor.** Department of Population Health and Medicine, New York University School of Medicine

Past Positions:

- 2012 Nov - 2014 Jan **Staff Fellow.** Food and Drug Administration, Center for Devices and Radiological Health, Bethesda, MD
- 2011 Jun - 2016 Jun **Assistant Professor.** Population Health and Medicine, New York University School of Medicine
- 2011 Jun - 2016 Jun **Assistant Attending,** Medicine, Tisch Hospital, New York, NY
- 2011 Jun - 2016 Jun **Assistant Attending.** Medicine, Bellevue Hospital, New York, NY

PROFESSIONAL ACTIVITIES:

University-Based Committee Service and Activities:

- 2019-2020 **Member.** Faculty Search Committee, Division of General Internal Medicine/Health Services Research (GIM/HSR), Department of Medicine, David Geffen School of Medicine at UCLA
- 2021 Jul - 2022 Jun **Member.** UCLA South General Institutional Review Board (SGIRB)

Committee Service (non UCLA/non UCLA-affiliated):

- 2001-2002,
2004-2005 **Member.** Committee on Admission of Students, Harvard Medical School, Boston, MA
- 2005 Jun-2011 Jul **Tutor** for pre-medical students. Cabot House Pre-Med Committee, Harvard University, Cambridge, MA

2015-2016 **Member.** Secondary Prevention Guidelines Committee, New York University School of Medicine

Professional Associations and Scholarly Societies:

2007, 2011-present **Member.** Society for Medical Decision Making
2013-present **Member.** AcademyHealth
2014-present **Member.** American College of Physicians
2015-present **Member.** American Heart Association
2016-present **Member.** Society of General Internal Medicine

Editorial Services to Scholarly Publications (Reviewer):

2009-present American Heart Journal (AHJ), Reviewer
2009-present Annals of Internal Medicine (AIM)
2009-present Circulation
2009-present Health Affairs
2009-present JAMA
2009-present JAMA Internal Medicine
2009-present JAMA Ophthalmology
2009-present JAMA Pediatrics
2009-present Journal of American College of Cardiology (JACC)
2009-present Journal of American Heart Association JAHA
2009-present Journal of General Internal Medicine (JGIM)
2009-present Pediatrics
2009-present PLoS ONE
2009-present Radiology
2009-present Value in Health
2017-present British Journal of Ophthalmology
2018-present American Heart Journal (AHJ), Editorial Board Member
2020 Journal of the American Society of Nephrology

Consulting Activities:

2008 Jun – 2019 Dec **Research Consultant.** S2 Statistical Solutions, Inc., Cincinnati, OH
2010 Jun – 2019 Dec **Research Consultant.** CardioDx, Inc., Palo Alto, CA

2019 **Research Consultant.** The Medicines Company, Parsippany, NJ
2020 Jun-present **Senior Advisor,** Gallup, Inc. GALLUP®

Community Service: None

HONORS AND AWARDS

1996-2000 Guy T. Carswell Scholarship, Wake Forest University
2004-2005 National Library of Medicine Training Grant
2005 Academy of Achievement International Achievement Summit Attendee
2005 National Science Foundation Graduate Research Fellowship Honorable Mention
2005 Graduate Society Summer Fellowship, Harvard University
2005-2006 Agency for Healthcare Research and Quality Training Grant
2007 Helmut Schumann Fellow in the Department of Ambulatory Care and Prevention at Harvard Medical School and Harvard Pilgrim Health Care, Deferred until 2007
2007 Harvard Medical School through the MD/Ph.D. Social Sciences Track and the Medical Sciences Training Program (MSTP), Second cycle funding
2010 Daniel E. Ford Award in Health Services and Outcomes Research, John Hopkins University
2012 Harvard Medical School Class of 2012 Resident Teaching Award
2013-2019 National Institute of Health Loan Repayment Award (National Heart, Lung, and Blood Institute)
2014 Annals' Junior Investigator Recognition Award
2014–2019 Amos Scholar, Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED

2008 Co-Investigator
NIMHD (R24 MD001648-08)
“A Community-Academic Partnership to Address Disparities in Obesity among Youth: Students for Nutrition and Exercise (SNaX)”
*01/01/08–12/31/15 Total Award: \$1,149,674
PI: M. Schuster
*Dr. Ladapo participated on the grant from 01/01/12 to 12/31/12.
The study aims to evaluate the effectiveness of a community-based participatory research intervention for middle school students, SNaX, in promoting peer advocacy of healthy eating and school cafeteria changes to reduce obesity.

- 2009-2013 Co-Investigator
 AHRQ (R24 MD001648-08)
“Comparative Effectiveness of ACE Inhibitors for African Americans”
 *09/30/11–07/31/13 Total Award: \$1,185,673
 PI: G. Ogedegbe
 *Dr. Ladapo participated on the grant from 01/01/12 to 12/31/12.
 This study aims to examine potential racial differences in the effectiveness, safety and adverse effects of ACE inhibitors.
- 2010-2012 Paid Consultant
 NHLBI (RC2 HL101663)
“Comparison of Depression Interventions after Acute Coronary Syndromes (CODIACS)”
 08/01/10–07/31/12 Total Award: \$2,197,126
 PI: K. Davidson
 Multicenter, randomized, controlled trial of a patient preference-based, stepped care protocol for persistent depressive symptoms after acute coronary syndrome.
- 2010-2013 Co-Investigator
 NCCDPHP (1U48DP002671-01)
“NYU Prevention Research Center: Comparative Effectiveness Research”
 07/14/10–07/13/13 Total Award: \$3,287,881
 PI: R. Braithwaite
 The aim of the study is to leverage resources and conduct a multi-factorial community -based CER study in urban black communities to reduce hypertension and colorectal cancer disparities.
- 2010-2014 Co-Investigator
 NHLBI (5U01HL105229-04)
“Effectiveness of smoking-cessation interventions for urban hospital patients”
 09/20/10–12/31/14 Total Award: \$5,109,906
 PI: S. Sherman
 Comparing the effectiveness and cost effectiveness of an enhanced inpatient intervention for all smokers plus one of two post-discharge cessation options among a diverse population of psychiatric and medical/surgical patients at two urban hospitals.
- 2012-2018 Co-Investigator
 NCI (4R01CA162035-05)
“Implementing Tobacco Use Treatment Guidelines in Dental Public Health Clinics”
 04/01/12–08/31/18 Total Award: \$3,623,498
 PIs: D. Shelley and J. Ostroff

This study will test models of care that have promise to increase adoption and implementation of tobacco cessation clinical practice guideline into routine dental practice, an essential step toward achieving national health objectives and for ultimately reducing tobacco-related health disparities in the United States.

2013-2016 Co-Investigator
NHLBI (5R01HL117323-03)
“Incorporation of a hypertension working group into the Jackson Heart Study”
06/15/13–06/30/16
PI: P. Muntner

The proposed study will identify novel risk factors for hypertension and potential approaches to improve hypertension control rates and reduce blood pressure related complications among African Americans.

2013-2018 Co-Investigator
NHLBI (5R01HL114924-03)
“Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes”
08/01/13–07/31/18 Total Award: \$2,448,552
PI: K. Davidson

This RCT will evaluate the quality-adjusted life year benefits and health care costs of implementing the American Heart Association’s guideline for screening and treatment of depression in adults with acute coronary syndrome.

2013-2019 Principal Investigator
NIH/NHLBI (1K23HL116787-05)
“Patient-centered Approaches to Diagnosing Coronary Heart Disease”
08/01/13–07/31/19 Total Award: \$348,564

The aim of this study is to develop patient-centered approaches to diagnosing coronary heart disease that improve diagnostic accuracy, reduce unnecessary testing and radiation exposure, and incorporate the impact of false-positive stress test results on patients’ anxiety, perception of illness, and quality of life.

2014-2015 Co-Investigator
PCORI: CDRN (1306-03961)
“New York City Clinical Data Research Network”
05/15/14–10/16/15
PI: R. Kaushal

The New York City Clinical Data Research Network (NYC-CDRN) will bring together 7 health systems and a total of 22 organizations from across New York City to prepare a comprehensive data infrastructure for comparative effectiveness research covering up to 6 million patients

- 2015-2019 Principal Investigator
AMFDP/ RWJF (72426)
“A Randomized Comparative Effectiveness Trial of Financial Incentives versus Usual Care for Smokers Hospitalized in the Veterans Affairs Hospital System”
01/01/15–12/31/19 Total Award: \$286,954
- The aim of this study is to determine the feasibility and acceptability of financial incentives to promote smoking cessation, and compare the impact of two approaches for smoking cessation in smokers hospitalized in the Veterans Affairs Hospital System. We will also estimate the short-term and long-term return on investment of using financial incentives to promote smoking cessation.
- 2017-2021 Principal Investigator
NIH (7R01MD011544-02)
“Financial Incentive Strategies for Weight Loss in Obese Patients Living in Socioeconomically Disadvantaged Neighborhoods”
02/13/17–06/30/21 Total Award: \$3,455,054
- This randomized study will enroll patients with obesity living in neighborhoods with a high concentration of low socioeconomic status households and compare the impact of financial incentives for weight loss on sustained weight loss, use of evidenced-based therapy, and quality of life; we will also determine the intervention's short-term and long-term return on investment.
- 2018-2022 Principal Investigator
NIH/NHLBI (U01HL142104-03)
“Behavioral Economics and Implementation Research to Reduce Cardiovascular Risk in HIV-infected Adults”
06/01/18–05/31/22 Total Award: \$2,771,584
- This study will evaluate the effectiveness and acceptability of a multi-level, multi-component intervention to increase evidence-based prescribing of statins to people living with HIV at increased risk of cardiovascular disease.
- 2018-2021 Co-Investigator
NIH/NIA (R011AG059815)
“Pragmatic Trial of an Electronic Health Record/Behavioral Economics Intervention to Reduce Pre-operative Testing for Cataract Surgery”
09/01/18–06/30/21 Total Award: \$1,970,305
PI: C. Sarkisian
- This study is an interdisciplinary electronic health record (EHR)-based intervention that applies behavioral economics approaches (i.e., “nudges”) to reduce pre-op testing for cataract surgery in a real-world clinical setting. Using a pragmatic randomized trial that will be implemented at UCLA Health, we will

measure changes in the percentage of patients undergoing pre-op testing (labs, EKG, CXR) and other secondary patient, physician and system level outcomes.

2018-2020

Pilot Principal Investigator

Resource Centers for Minority Aging Research (RCMAR) (P30AG021684)

“Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III”

09/15/18–06/30/20 Total Award: \$ 31,500

Project PI: C. Mangione

To create a program that will contribute to the reduction in health disparities for African American & Latino elders by training & mentoring minority faculty who will advance their careers by conducting research on minority elders.

2019-2023

Principal Investigator

NIH/NHLBI (1R01DA045688-01A1)

“Financial Incentives for Smoking Cessation Treatment II”

02/15/19–03/31/23

Co-PI: S. Sherman

This randomized study is enrolling high-risk, hospitalized smokers and comparing the impact of three financial incentive/behavioral economic approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life; an economic evaluation of the strategies will also be performed.

2019-2023

Principal Investigator

NIH/NIDA (1R01DA045688-02)

“Financial Incentive Strategies for Smoking Cessation in High-Risk, Hospitalized Patients”

02/15/19–12/31/23 Total Award: \$3,374,192

Co-PI: S. Sherman

This three-arm randomized trial aims to significantly advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers in Los Angeles and New York. We will compare the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life as well as the short and long-term return on investment of using goal-directed and outcome-based financial incentives to promote smoking cessation.

2020

Principal Investigator

NIH (R01DA045688-02S1)

“Financial Incentives to Help People with Cognitive Impairment Quit Smoking”

01/01/20–12/31/20 Total Award: \$383,718

Co-PI: S. Sherman

The aim of this study are to adapt standard FIESTA II interventions for patients with dementia who are current smokers and evaluate the effectiveness of the dementia-specific smoking cessation interventions vs. usual care.

2020-2023 Principal Investigator
NIH (UG3HL154302-01)
“Multi-ethnic Multi-level Strategies and Behavioral Economics to Eliminate Hypertension Disparities in LA County”
09/01/20–08/31/23 Total Award: \$2,717,988
Co-PI: A. Brown

Using the Exploration, Preparation, Implementation, Sustainment (EPIS) framework, which describes the multi-stage, multi-level process of implementing evidence-based practices (EBPs) in public service systems, this project proposes multi-level interventions for hypertension control. EPIS provides a comprehensive, organized list of relevant factors to consider at each level, like other frameworks (e.g., CFIR), but organizes the factors within stages that will guide our implementation process from initial exploration through long-term sustainment. This project will expand by also explicitly incorporating factors that contribute to and maintain racial/ethnic CVD disparities and will complete EPIS Exploration/Preparation stages in the UG3 and Implementation/ Sustainment stages in the UG4.

LECTURES AND PRESENTATIONS

1. 2013 Oct **Presenter.** What’s Changed in the Assessment of CAD post-COURAGE, BARI-2D, FAME-2 and FREEDOM? via teleconference. ACC Webinar, October 15, 2013
2. 2014 Mar **Presenter.** Challenges in Appropriate Testing and Evaluation of Patients with Suspected Heart Disease. Grand Rounds, Department of Medicine, Hackensack University Medical Center, Hackensack, NJ, March 11, 2014
3. 2014 Sep **Presenter.** Reducing the Population Health Burden of Cardiovascular Disease, Jefferson School of Population Health Forum, 2014; Presentation 85; Philadelphia, PA, September 10, 2014, Audience: Physicians and hospital administrators
Podcast available at:
http://jdc.jefferson.edu/hpforum/85/http://library.jefferson.edu/videos/jsph/health_policy_forum/pophealthforum091014.mp3
4. 2014 Nov **Presenter.** Challenges in Diagnosis of Coronary Artery Disease and Novel Methods for Improving Diagnosis, National Association of Managed Care Physicians, Fall Managed Care Forum; Las Vegas, NV, November 14, 2014

5. 2015 Sep **Presenter.** Quality Pitfalls and Challenges in the Evaluation of Patients for Heart Disease, U.S. Group Reinsurance ROSE Conference; Bloomington, MN.
6. 2019 Jan **Presenter.** Gene-expression Test for Diagnosing Obstructive Coronary Artery Disease. Precision Medicine World Conference, Silicon Valley, CA, January 22, 2019, Audience: physicians, basic scientists, biotech engineers
7. 2019 Dec **Presenter.** Influenza: Epidemiology, Treatment, and Vaccination. Presented at: West Hills Hospital & Medical Center (WHHMC), West Hills, CA, December 06, 2019. Audience: WHHMC Department of Medicine Multi-specialty physicians
8. 2020 Dec **Presenter.** Behavioral Economics and Implementation Research to Reduce Cardiovascular Risk in HIV-Infected Adult. Presented at: NHLBI Workshop on the Integration of Behavioral Economics into Implementation Research (BEIR) to Address Heart, Lung, Blood and Sleep (HLBS) Conditions (Virtual presentation), October 29, 2020. Audience: NHLBI Participants and Workshop Invitees
9. 2021 Apr **Presenter.** The HIV Example and Lessons for Psoriasis and Psoriatic Arthritis. Presented at: NHLBI Virtual Stakeholder Meeting: Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins (Virtual presentation), April 09, 2021. Audience: NHLBI Participants and Stakeholders

Abstract (not in print) Presentations:

1. **Ladapo JA**, Shaffer JA, Fang Y, Uhler LM, Ye S, Davidson KW. Cost-effectiveness of Enhanced Depression Care for Patients with Acute Coronary Syndrome and Depressive Symptoms: Results of the COPES Randomized Controlled Trial. Presented at: SMDM Annual North American Meeting; October 17, 2012; Phoenix, AZ. Abstract available in: SMDM Conference Proceedings <https://smdm.confex.com/smdm/2012az/webprogram/Paper6921.html>. Poster Presentation.
2. Nrupen A. Bhavsar NA, Ravenell JE, Ogedegbe G, Jason A. Roy JA, Braithwaite RS, **Ladapo JA**. Projected Cost-Effectiveness of a Barbershop-Based Intervention to Reduce Hypertension in Black Men. Presented at: SMDM Annual North American Meeting; October 17, 2012; Phoenix, AZ. Abstract available in: SMDM Conference Proceedings <https://smdm.confex.com/smdm/2012az/webprogram/Paper7296.html>. Poster Presentation.
3. **Ladapo JA**, Blecker S, Elashoff MR, Federspiel JJ, Vieira DL, Sharma G, Monane M, Rosenberg S, Phelps CE, Douglas PS. Referral Bias in the Diagnostic Performance of Exercise Testing with Imaging for Coronary Artery Disease. Presented at: SMDM Annual North American Meeting; October 18, 2012; Phoenix, AZ. Abstract available in: SMDM

Conference Proceedings.

<https://smdm.confex.com/smdm/2012az/webprogram/Paper7052.html>. Oral Presentation.

4. Phelps CE, Douglas PS, O'Sullivan AK, Deflin M, Leahy K, Elashoff MR, Monane M, and **Ladapo J**. Cost Effectiveness of a Gene Expression Score and Myocardial Perfusion Imaging for Diagnosis of Coronary Artery Disease. Presented at: SMDM Annual North American Meeting; October 19, 2012; Phoenix, AZ. Abstract available in: SMDM Conference Proceedings.
<https://smdm.confex.com/smdm/2012az/webprogram/Paper7215.html>. Poster Presentation.
5. **Ladapo JA**, Lyons-Hartnet H, Yau M, Rich P, Newton, D, Bruce-Mensah K, Johnson A, Ping Y, Stemkowski S, Monane M. The Clinical Utility of Novel Genomic-Based Test on Medical Decision Making for the Evaluation of Obstructive Coronary Artery Disease in the Ambulatory Care Setting. Presented at: SMDM Annual North American Meeting; October 21, 2013; Baltimore, MD. Abstract available in: SMDM Conference Proceedings.
<https://smdm.confex.com/smdm/2013md/webprogram/Paper7824.html>. Poster Presentation.
6. **Ladapo JA**. Physician Decision-Making and Trends in Use of Cardiac Stress Testing to Diagnose Coronary Heart Disease in the United States. Presented at: SMDM Annual North American Meeting; Baltimore, MD; October 21, 2013. Abstract available in: SMDM Conference Proceedings.
<https://smdm.confex.com/smdm/2013md/webprogram/Paper7918.html>. Oral Presentation.
7. **Ladapo JA**, Rodwin BA, Braithwaite RS, Pandya A, Riles TS, Rockman CB, Berger JS. Adherence to Preventive Practices and Projected Population Impact of Health System Interventions for Coronary Heart Disease. Presented at: SMDM Annual North American Meeting; October 22, 2013; Baltimore, MD. Abstract available in: SMDM Conference Proceedings <https://smdm.confex.com/smdm/2013md/webprogram/Paper7752.html>. Oral Presentation.
8. **Ladapo J**, Lyons H, Yau M, Rich P, Newton D, BruceMensah K, Johnson A, Zhou Y, Stemkowski S, Monane M. The Clinical Utility of a Novel Genomic-Based, Gene Expression Test to Evaluate Elderly Patients ≥ 65 Years Old Presenting with Symptoms of Suspected Obstructive Coronary Artery Disease in the Ambulatory Care Setting: Subgroup Results from the REGISTRY I Trial (Investigation of a Novel Gene Expression Test for the Diagnosis of Obstructive CAD on Physician's Practice Pattern). Presented at: Gerontological Society of America (GSA); November 20-24, 2013; New Orleans, LA. Poster Presentation.
9. **Ladapo JA**, Sharp D, Maniet B, Ross L, Blanchard J, Monane M. Use of a Personalized Medicine, Gene Expression Score Influenced Decision Making around Referral to Cardiology among Female Patients Presenting to Primary Care with Symptoms Suggestive of Obstructive Coronary Artery Disease. Presented at: SMDM Annual North American Meeting; October 22, 2014; Miami, FL. Abstract available in: SMDM Conference Proceedings. <https://smdm.confex.com/smdm/2014fl/webprogram/Paper8488.html> Poster Presentation.
10. **Ladapo JA**. Physician Decision Making and Trends in the Use of Cardiac Stress Testing in the United States. American College of Physicians (ACP) Internal Medicine Meeting; April 28-May 02, 2015; Boston, MA. Oral Presentation.

11. **Ladapo J**, Pitcavage JM, Pfeifer JM, Lee IA, Runge JM, Williams BA. Patient Beliefs and Preferences Do Not Explain Variation in Subsequent Testing after Initial Evaluation for Ischemic Heart Disease. SMDM Annual North American Meeting; October 20, 2015; St. Louis, MO. Abstract available at: SMDM Conference Proceedings. <https://smdm.confex.com/smdm/2015mo/webprogram/Paper9128.html>. Oral Presentation.

TEACHING ACTIVITIES

Teaching Activities (UCLA or UCLA-affiliated):

Clinical Teaching

- 2016 Jul-present **Hospitalist**. Ward Attending: Inpatient Internal Medicine, Course #: IM101 (Attending, 5 times per year), Ronald Reagan-UCLA Med. Ctr., Audience: Residents, Fellows and Medical Students
- 2019 Apr-Jun **Preceptor**. Longitudinal, Course # MD001, DGSOM at UCLA, Spring, 2019. Audience: 3rd year medical students
- 2019 Oct-Dec **Preceptor**. Longitudinal, Course # MD001, DGSOM at UCLA, Fall, 2019. Audience: 3rd year medical students

Mentoring

- 2016 Sep-Present **Medical Student Mentor**. Mentee: Cassandra DeWitt, DGSOM at UCLA
Project: *“Differences in Cardiovascular Care among Patients with and without HIV”*
- 2017 Aug-Present **Medical Student Mentor**. Mentee: Alexander Chen, DGSOM at UCLA
Project: *“Physician Prescribing of Opioids to Patients at Increased Risk of Overdose from Benzodiazepine Use in the United States”*
- 2019 Jan-Present **Medical Student Mentor**. Mentee: Zekun Feng, DGSOM at UCLA
Project: *“Differences in Cardiovascular Care between Adults with and without Opioid Prescriptions in the United States”*
- 2019 Mar-Present **Medical Student Mentor**. Mentee: Dominic Williams, DGSOM at UCLA
Project: *“Differences in Cardiovascular Care between Adults with and without Opioid Prescriptions in the United States”*
- 2020 May-Present **Medical Student Mentor**. Mentee: Jasmeet Dhaliwal, 2020 UCLA CTSI Summer Fellowship Program, DGSOM at UCLA
Project: *“Undertreatment of Hypertension in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis”*

Lectures and Other Teaching Activities

- 2016 Mar **Presenter**. Preventing Cardiovascular Disease: Pathways through Diagnostic Testing, Clinical Guidelines, and Patient Decision

- Making, GIM/HSR Seminar Series, DGSOM, Los Angeles, CA, March 10, 2016, Audience: UCLA Faculty/Fellows
- 2018 Jan **Presenter.** Can Behavioral Economics Improve Health? Department of Grand Rounds, VA Greater Los Angeles Healthcare System, Los Angeles, CA, January 24, 2018, Audience: VA Attending Physicians, Residents and Medical Students
- 2019 Jun **Presenter.** Reducing Cardiovascular Risk among People Living with HIV: The INcreasing Statin Prescribing in HIV Behavioral Economics REsearch (INSPIRE) Randomized Trial). Grand Rounds, UCLA CFAR/AIDS Institute, Los Angeles, CA, June 07, 2019, Audience: CARE Center Community Advisory Board
- 2019 Oct **Presenter.** INcreasing Statin Prescribing in HIV Behavioral Economics Research (INSPIRE). UCLA Center for Clinical AIDS Research and Education (CARE), Los Angeles, CA, October 15, 2019, Audience: CARE Center Community Advisory Board
- 2021 May **Presenter.** Preventing Cardiovascular Disease: Pathways through Diagnostic Testing, Clinical Guidelines, and Patient Decision Making, GIM/HSR Seminar Series, DGSOM, Los Angeles, CA, May 14, 2021, Audience: UCLA Faculty/Fellows/Staff

Teaching Activities (non UCLA or UCLA-affiliated):

Clinical Teaching

- 2011 Jun - 2016 Jun **Assistant Attending Physician** in Medicine, Tisch Hospital, New York, NY
- 2011 Jun - 2016 Jun **Assistant Attending Physician** in Medicine, Bellevue Hospital, New York, NY

Mentoring

- 2012 Oct - 2015 Feb **Medical Student Mentor.** Mentee: Benjamin Rodwin, MD, New York University School of Medicine/Columbia University College of Physicians and Surgeons
 Project: *“Scientific Publications on Firearms in Youth before and after Congressional Action Prohibiting Federal Research Funding”*
- 2014 Feb-Present **Doctoral Research Mentor.** Mentee: Elizabeth Stevens, MPH, New York University College of Global Public Health
 Project(s):
 ○ *“Use of Pre-Operative Testing and Physicians’ Response to Professional Society Guidance”*

- “*Cost and Cost-Effectiveness of Students for Nutrition and Exercise (SnaX)*”
- “*Quality of Health Economic Evaluations for a Major Cardiovascular Disease Practice Guideline*”

2014 Jul -2016 Aug **Medical Student Mentor.** Mentee: Michael O’Donnell, MD, New York University School of Medicine/Yale University School of Medicine
Project(s): “*Appropriate Use of Cardiac Stress Testing with Imaging*”

2014 Jul-Present **Medical Student Mentor.** Mentee: Saahil Jumkhawala, Tufts University School of Medicine
Project: “*Preferences for Financial Incentive Design among Hospitalized Patients Interested in Quitting Smoking*”

2014 Oct – 2015 May **Medical Student Mentor.** Mentee: Daniel Farrell, MD, New York University School of Medicine/ Columbia University College of Physicians and Surgeons
Project: “*Quality of Health Economic Evaluations for a Major Cardiovascular Disease Practice Guideline*”

2016 Apr-Present **Medical Student Mentor.** Mentee: Andrew White, SUNY Downstate College of Medicine
Project: “*Association between Financial Distress and Smoking Cessation Outcomes among Hospitalized Patients Receiving Financial Incentives for Smoking Cessation*”

Other Teaching Activities

1998 **Teaching Fellow.** Introduction to Organic Chemistry, Wake Forest University, Winston-Salem, NC

2005 **Teaching Fellow.** Health Economics and Policy, Harvard University, Cambridge, MA

2005 **Teaching Fellow.** Decision Analysis in Clinical Research, Harvard School of Public Health, Boston, MA

2005 Jun - 2011 Jul **Tutor** for pre-medical students. Cabot House Pre-Med Committee, Harvard University, Cambridge, MA

2006 **Teaching Fellow.** Decision Analysis Methods in Public Health and Medicine, Harvard School of Public Health, Boston, MA

2007 **Teaching Fellow.** Introduction to Health Care Policy, Harvard University, Cambridge, MA

2008 **Teaching Fellow.** The Economics of Health Care Policy, Harvard

Kennedy School of Government, Cambridge, MA

2013 Jun - 2014 Jul

Co-Director. Decision Analytic Research Methods, New York University School of Medicine, New York, NY

2014 Mar

Presenter. *Challenges in Appropriate Testing and Evaluation of Patients with Suspected Heart Disease.* Grand Rounds, Department of Medicine, Hackensack University Medical Center, Hackensack, NJ, March 11, 2014

Joseph A. Ladapo
PUBLICATIONS/BIBLIOGRAPHY

RESEARCH PAPERS

RESEARCH PAPERS (PEER-REVIEWED):

A. RESEARCH PAPERS – PEER REVIEWED:

1. Sobol RW, Watson DE, Nakamura J, Yakes FM, Hou E, Horton JK, **Ladapo J**, Van Houten B, Swenberg JA, Tindall KR, Samson LD, Wilson SH. Mutations Associated with Base Excision Repair Deficiency and Methylation-Induced Genotoxic Stress. *Proc Natl Acad Sci*. 2002 May 14;99(10):6860-5. doi: 10.1073/pnas.092662499. PMID: PMC124494.
2. **Ladapo JA**, Neumann PJ, Keren R, Prosser LA. Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Pediatric Health Interventions. *Pharmacoeconomics*. 2007 Oct;25(10):817-28. doi: 10.2165/00019053-200725100-00002.
3. **Ladapo JA**, Hoffmann U, Bamberg F, Nagurney JT, Cutler DM, Weinstein MC, Gazelle, GS. Cost-Effectiveness of Coronary MDCT in the Triage of Patients with Acute Chest Pain. *Am J Roentgenol*. 2008 Aug;191(2):455-63. doi: 10.2214/AJR.07.3611.
4. Prosser LA, **Ladapo JA**, Rusinak D, Waisbren SL. Parental Tolerance for False-Positive Newborn Screening Results. *Arch Pediatr Adolesc Med*. 2008 Sep;162(9):870-6. doi: 10.1001/archpediatrics.2008.1.
5. Warren L, **Ladapo JA**, Borah B, Gunnarsson CL. Open Abdominal Versus Laparoscopic and Vaginal Hysterectomy: Analysis of a Large US Payer Measuring Quality & Cost of Care. *J Minim Invasive Gynecol*. 2009 Sep-Oct;16(5):581-8. doi: 10.1016/j.jmig.2009.06.018.
6. **Ladapo JA**, Horwitz JR, Weinstein MC, Gazelle GS, Cutler DM. Adoption and Spread of New Imaging Technology: A Case Study. *Health Aff (Millwood)*. 2009 Nov-Dec;28(6):w1122-32. doi: 10.1377/hlthaff.28.6.w1122.
7. **Ladapo JA**, Jaffer FA, Hoffmann U, Thomson CC, Bamberg F, Dec W et al. Clinical Outcomes and Cost-Effectiveness of Coronary Computed Tomography Angiography in the Evaluation of Patients with Chest Pain. *J Am Coll Cardiol*. 2009 Dec 15;54(25):2409-22. doi: 10.1016/j.jacc.2009.10.012.
8. Fullum TM, **Ladapo JA**, Borah BJ, Gunnarsson CL. Comparison of the Clinical and Economic Outcomes between Open and Minimally Invasive Appendectomy and Colectomy: Evidence from a Large Commercial Payer Database. *Surg Endosc*. 2010 Apr;24(4):845-53. doi: 10.1007/s00464-009-0675-0. PMID: PMC2846276.
9. Pilz G, Patel PA, Fell U, **Ladapo JA**, Rizzo JA, Fang H, et al. Adenosine-Stress Cardiac Magnetic Resonance Imaging in Suspected Coronary Artery Disease: A Net Cost Analysis and Reimbursement Implications. *Int J Cardiovasc Imaging*. 2011 Jan;27(1):113-21. doi: 10.1007/s10554-010-9645-9. PMID: PMC3035783.

10. **Ladapo JA**, Jaffer FA, Weinstein MC, Froelicher ES. Projected Cost-Effectiveness of Smoking Cessation Interventions in Patients Hospitalized with Myocardial Infarction. *Arch Intern Med*. 2011 Jan 10;171(1):39-45. doi: 10.1001/archinternmed.2010.479.
11. Goehler A, Ollendorf DA, Jaeger M, **Ladapo J**, Neumann T, Gazelle GS, et al. A Simulation Model of Clinical and Economic Outcomes of Cardiac CT Triage of Patients with Acute Chest Pain in the Emergency Department. *Am J Roentgenol*. 2011 Apr;196(4):853-61. doi: 10.2214/AJR.10.4962.
12. **Ladapo JA**, David G, Gunnarsson CL, Hao S, White S, et al. Healthcare Utilization and Expenditures in Patients with Atrial Fibrillation Treated with Catheter Ablation. *J Cardiovasc Electrophysiol*. 2012 Jan;23(1):1-8. doi: 10.1111/j.1540-8167.2011.02130.x.
13. **Ladapo JA**, Kymes SM, Ladapo JA, Nwosu VC, Pasquale LR. Projected Clinical Outcomes of Glaucoma Screening in African American Individuals. *Arch Ophthalmol*. 2012 Mar;130(3):365-72. doi: 10.1001/archophthalmol.2011.1224.
14. Reynolds MR, Gunnarsson CL, Hunter TD, **Ladapo JA**, March JL, Zhang M, Hao SC. Health Outcomes with Catheter Ablation or Antiarrhythmic Drug Therapy in Atrial Fibrillation: Results of a Propensity-Matched Analysis. *Circ Cardiovasc Qual Outcomes*. 2012 Mar 1;5(2):171-81. doi: 10.1161/CIRCOUTCOMES.111.963108.
15. Lee J, Kothari R, **Ladapo JA**, Scott DJ, Celi LA. Interrogating a Clinical Database to Study Treatment of Hypotension in the Critically Ill. *BMJ Open*. 2012 Jun 8;2(3). pii: e000916. doi: 10.1136/bmjopen-2012-000916. PMID: PMC3371576.
16. Gunnarsson C, Chen J, Rizzo JA, **Ladapo JA**, Naim A, Lofland JH. The Direct Healthcare Insurer and Out-of-Pocket Expenditures of Psoriasis: Evidence from a United States National Survey. *J Dermatolog Treat*. 2012 Aug;23(4):240-54. doi: 10.3109/09546634.2010.550911.
17. Hao SC, Hunter TD, Gunnarsson C, March JL, White SA, **Ladapo JA**, Reynolds MR. Acute Safety Outcomes in Younger and Older Patients with Atrial Fibrillation Treated with Catheter Ablation. *J Interv Card Electrophysiol*. 2012 Nov;35(2):173-82. doi: 10.1007/s10840-012-9690-5.
18. **Ladapo JA**, Shaffer JA, Fan Y, Ye S, Davidson KW. Cost-Effectiveness of Enhanced Depression Care after Acute Coronary Syndrome: Results from the Coronary Psychosocial Evaluation Studies Randomized Controlled Trial. *Arch Intern Med*. 2012 Nov 26;172(21):1682-4. doi: 10.1001/archinternmed.2012.4448. PMID: PMC3657548.
19. Gunnarsson C, Chen J, Rizzo JA, **Ladapo JA**, Lofland JH. Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey. *Dig Dis Sci*. 2012 Dec;57(12):3080-91. doi: 10.1007/s10620-012-2289-y.
20. Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, **Ladapo JA**. Genetic Testing in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Cost-Effectiveness Analysis. *J Thromb Haemost*. 2013 Jan;11(1):81-91. doi: 10.1111/jth.12059.
21. Gunnarsson C, Chen J, Rizzo JA, **Ladapo JA**, Naim A, Lofland JH. The Employee Absenteeism Costs of Inflammatory Bowel Disease: Evidence from US National Survey Data. *J Occup Environ Med*. 2013 Apr;55(4):393-401. doi: 10.1097/JOM.0b013e31827cba48.

22. Thomas GS, Voros S, McPherson JA, Lansky AJ, Winn ME, Bateman TM, Elashoff MR, Lieu HD, Johnson AM, Daniels SE, **Ladapo JA**, Phelps CE, Douglas PS, Rosenberg S. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Non-Diabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. *Circ Cardiovasc Genet*. 2013 Apr;6(2):154-62. doi: 10.1161/CIRCGENETICS.112.964015.
23. Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, Dornelas E, Duer-Hefele J, Frasure-Smith N, Freedland KE, Haas DC, Jaffe AS, **Ladapo JA**, Lesperance F, Medina V, Newman JD, Osorio GA, Parsons F, Schwartz JE, Shaffer JA, Shapiro PA, Sheps DS, Vaccarino V, Whang W, Ye S. Centralized, Stepped, Patient Preference-Based Treatment for Patients with Post-Acute Coronary Syndrome Depression: CODIACS Vanguard Randomized Controlled Trial. *JAMA Intern Med*. 2013 Jun 10;173(11):997-1004. doi: 10.1001/jamainternmed.2013.915. PMID: PMC3681929.
24. **Ladapo JA**, Rodwin BA, Ryan AM, Trasande L, Blustein J. Scientific Publications on Firearms in Youth before and after Congressional Action Prohibiting Federal Research Funding. *JAMA*. 2013 Aug 7;310(5):532-4. doi: 10.1001/jama.2013.119355.
25. **Ladapo JA**, Elliott MN, Bogart LM, Kanouse DE, Vestal KD, Klein DJ, Ratner JA, Schuster MA. Cost of Talking Parents, Healthy Teens: A Worksite-Based Intervention to Promote Parent-Adolescent Sexual Health Communication. *J Adolesc Health*. 2013 Nov;53(5):595-601. doi: 10.1016/j.jadohealth.2012.11.015. PMID: PMC4538929.
26. **Ladapo JA**, Blecker S, Elashoff MR, Federspiel JJ, Vieira DL, Sharma G, Monane M, Rosenberg S, Phelps CE, Douglas PS BA. Clinical Implications of Referral Bias in the Diagnostic Performance of Exercise Testing for Coronary Artery Disease. *J Am Heart Assoc*. 2013 Dec 13;2(6):e000505. doi: 10.1161/JAHA.113.000505. PMID: PMC3886773.
27. Phelps CE, O'Sullivan AK, **Ladapo JA**, Weinstein MC, Leahy K, Douglas PS. Cost Effectiveness of a Gene Expression Score and Myocardial Perfusion Imaging for Diagnosis of Coronary Artery Disease. *Am Heart J*. 2014 May;167(5):697-706.e2. doi: 10.1016/j.ahj.2014.02.005.
28. Cole H, Schoenthaler A, Braithwaite RS, **Ladapo J**, Mentor S, Uyei J, Trinh-Shevrin C. Community-Based Settings and Sampling Strategies: Implications for Reducing Racial Health Disparities among Black Men, New York City, 2010-2013. *Prev Chronic Dis*. 2014 Jun 19;11:E105. doi: 10.5888/pcd11.140083. PMID: PMC4068114.
29. **Ladapo JA**, Elliott MN, Kanouse DE, Tortolero SR, Windle M, Cuccaro PM, Davies SL, Schuster MA. Tobacco Use and Smoking Intentions among U.S. Fifth-Grade Students. *J Adolesc Health*. 2014 Sep;55(3):445-51. doi: 10.1016/j.jadohealth.2014.03.008. PMID: PMC4143448.
30. Hochheiser LI, Juusola JL, Monane M, **Ladapo JA**. Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease. *Popul Health Manag*. 2014 Oct;17(5):287-96. doi: 10.1089/pop.2013.0096. PMID: PMC4162448.
31. Ye S, Shaffer JA, Rieckmann N, Schwartz JE, Kronish IM, **Ladapo JA**, Whang W, Burg MM, Davidson KW. Long-Term Outcomes of Enhanced Depression Treatment in

- Patients with Acute Coronary Syndromes. *Am J Med*. 2014 Oct;127(10):1012-6. doi: 10.1016/j.amjmed.2014.05.004. PMID: PMC4198457.
32. **Ladapo JA**, Blecker S, Douglas PS. Physician Decision Making and Trends in the Use of Cardiac Stress Testing in the United States: An Analysis of Repeated Cross-Sectional Data. *Ann Intern Med*. 2014 Oct 7;161(7):482-90. doi: 10.7326/M14-0296. PMID: PMC4335355.
 33. Blecker S, **Ladapo JA**, Doran KM, Goldfeld KS, Katz S. Emergency Department Visits for Heart Failure and Subsequent Hospitalization or Observation Unit Admission. *Am Heart J*. 2014 Dec;168(6):901-8.e1. doi: 10.1016/j.ahj.2014.08.002. PMID: PMC4254520.
 34. Williams BA, **Ladapo JA**, Merhige ME. External Validation of Models for Estimating Pretest Probability of Coronary Artery Disease among Individuals Undergoing Myocardial Perfusion Imaging. *Int J Cardiol*. 2015 Mar 1;182:534-40. doi: 10.1016/j.ijcard.2015.01.015.
 35. Clarke JL, **Ladapo JA**, Monane M, Lansky A, Skoufalos A, Nash DB. The Diagnosis of CAD in Women: Addressing the Unmet Need—a Report from the National Expert Roundtable Meeting. *Popul Health Manag*. 2015 Apr;18(2):86-92. doi: 10.1089/pop.2015.0006. PMID: PMC4410448.
 36. Gunnarsson C, Chen J, Rizzo JA, **Ladapo JA**, Naim A, Lofland JH. The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence from US National Survey Data. *J Occup Environ Med*. 2015 Jun; 57(6):635-42. doi: 10.1097/JOM.0000000000000461.
 37. **Ladapo JA**, Lyons H, Yau M, Rich P, Newton D, Bruce K, Johnson A, Zhou Y, Stemkowski S, Monane M. Enhanced Assessment of Chest Pain and Related Symptoms in the Primary Care Setting through the Use of a Novel Personalized Medicine Genomic Test: Results from a Prospective Registry Study. *Am J Med Qual*. 2015 Jul-Aug;30(4):345-52. doi: 10.1177/1062860614532517.
 38. Sigmund AE, Stevens ER, Blitz J, **Ladapo JA**. Use of Pre-Operative Testing and Physicians' Response to Professional Society Guidance. *JAMA Intern Med*. 2015 Aug;175(8):1352-9. doi: 10.1001/jamainternmed.2015.2081. PMID: PMC4526021.
 39. **Ladapo JA**, Goldfeld KS, Douglas PS. Projected Morbidity and Mortality from Missed Diagnoses of Coronary Artery Disease in the United States. *Int J Cardiol*. 2015 Sep 15;195:250-2. doi: 10.1016/j.ijcard.2015.05.033. PMID: PMC4526023.
 40. **Ladapo JA**, Herman L, Weiner BH, Rhees B, Castle L, Monane M, McPherson JA. Use of A Blood Test Incorporating Age, Sex, and Gene Expression Influences Medical Decision-Making in the Evaluation of Women Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease: Summary Results from Two Ambulatory Care Studies in Primary Care. *Menopause*. 2015 Nov;22(11):1224-30. doi: 10.1097/GME.0000000000000443.
 41. **Ladapo JA**, Blecker S, Douglas PS. Appropriateness of Cardiac Stress Test Use among Primary Care Physicians and Cardiologists in the United States. *Int J Cardiol*. 2016 Jan 15;203:584-6. doi: 10.1016/j.ijcard.2015.10.238. PMID: PMC4688169.
 42. **Ladapo JA**, Bogart LM, Klein DJ, Cowgill BO, Uyeda K, Binkle DG, Stevens ER, Schuster MA. Cost and Cost-Effectiveness of Students for Nutrition and Exercise

- (SNaX). *Acad Pediatr*. 2016 Apr;16(3):247-53. doi: 10.1016/j.acap.2015.07.009. PMID: PMC4808504.
43. **Ladapo JA**, Turakhia MP, Ryan MP, Mollenkopf SA, Reynolds MR. Health Care Utilization and Expenditures Associated with Remote Monitoring in Patients with Implantable Cardiac Devices. *Am J of Cardiol*. 2016 May 1;117(9):1455-62. doi: 10.1016/j.amjcard.2016.02.015.
 44. Blecker S, Gavin NP, Park H, **Ladapo JA**, Katz SD. Observation Units as Substitutes for Hospitalization or Home Discharge. *Ann Emerg Med*. 2016 Jun;67(6):706-713.e2. doi: 10.1016/j.annemergmed.2015.10.025. PMID: PMC4976781.
 45. Juusola JL, Quisel TR, Foschini L, **Ladapo JA**. The Impact of an Online Crowdsourcing Diagnostic Tool on Healthcare Utilization: A Novel Approach to Retrospective Claims Analysis. *J Med Internet Res*. 2016 Jun 1;18(6):e127. doi: 10.2196/jmir.5644. PMID: PMC4909973.
 46. **Ladapo JA**, Blecker S, O'Donnell M, Jumkhawala SA, Douglas PS. Appropriate Use of Cardiac Stress Testing with Imaging: A Systematic Review and Meta-Analysis. *PLoS One*. 2016 Aug 18;11(8):e0161153. doi: 10.1371/journal.pone.0161153. PMID: PMC4990235.
 47. Sherman SE, Link AR, Rogers ES, Krebs P, **Ladapo JA**, Shelley DR, Fang Y, Wang B, Grossman E. Smoking-Cessation Interventions for Urban Hospital Patients: A Randomized Comparative Effectiveness Trial. *Am J Prev Med*. 2016 Oct;51(4):566-77. doi: 10.1016/j.amepre.2016.06.023. PMID: PMC5089173.
 48. **Ladapo JA**, Hoffmann U, Lee KL, Coles A, Huang M, Mark DB, Dolor RJ, Pelberg RA, Budoff M, Sigurdsson G, Severance HW, Douglas PS. Changes in Medical Therapy and Lifestyle after Anatomical or Functional Testing for Coronary Artery Disease. *J Am Heart Assoc*. 2016 Oct 12;5(10). pii: e003807. doi: 10.1161/jaha.116.003807. PMID: PMC5121482.
 49. **Ladapo JA**, Elliott MN, Kanouse DE, Schwebel DC, Toomey SL, Mrug S, Cuccaro PM, Tortolero SR, Schuster MA. Firearm Ownership and Acquisition among Parents with Risk Factors for Self-Harm or Other Violence. *Acad Pediatr*. 2016 Nov-Dec;16(8):742-749. doi: 10.1016/j.acap.2016.05.145. PMID: PMC5077672.
 50. Crotty DJ, Chen XJ, Scipione MR, Dubrovskaya Y, Louie E, **Ladapo JA**, Papadopoulos J. Allergic Reactions in Hospitalized Patients with a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem. *J Pharm Pract*. 2017 Feb;30(1):42-48. doi: 10.1177/0897190015587254.
 51. Diaz KM, Booth JN 3rd, Seals SR, Abdalla M, Dubbert PM, Sims M, **Ladapo JA**, Redmond N, Muntner P, Shimbo D. Physical Activity and Incident Hypertension in African Americans: The Jackson Heart Study. *Hypertension*. 2017 Mar;69(3):421-427. doi: 10.1161/HYPERTENSIONAHA.116.08398. PMID: PMC5302780.
 52. **Ladapo JA**, Budoff M, Sharp D, Zapien M, Huang L, Maniet B, Herman L, Monane M. Clinical Utility of a Precision Medicine Test Evaluating Outpatients with Suspected Obstructive Coronary Artery Disease. *Am J Med*. 2017 Apr;130(4):482.e11-482.e17. doi: 10.1016/j.amjmed.2016.11.021.

53. Berger JS and **Ladapo JA**. Underuse of Prevention and Lifestyle Counseling in Patients with Peripheral Artery Disease. *J Am Coll Cardiol*. 2017 May 9;69(18):2293-2300. doi: 10.1016/j.jacc.2017.02.064. PMID: PMC5497594.
54. Ajam AA, Nguyen XV, Kelly RA, **Ladapo JA**, Lang EV. Effects of Interpersonal Skills Training on MRI Operations in a Saturated Market: A Randomized Trial. *J Am Coll Radiol*. 2017 Jul;14(7):963-970. doi: 10.1016/j.jacr.2017.03.015. PMID: PMC5604243.
55. **Ladapo JA**, Coles A, Dolor RJ, Mark DB, Cooper L, Lee KL, Goldberg J, Shapiro MD, Hoffmann U, Douglas PS. Quantifying Sociodemographic and Income Disparities in Medical Therapy and Lifestyle among Symptomatic Patients with Suspected Coronary Artery Disease: a Cross-Sectional Study in North America. *BMJ Open*. 2017 Sep 29;7(9):e016364. doi: 10.1136/bmjopen-2017-016364. PMID: PMC5640109.
56. **Ladapo JA**, Chokshi DA. Changes in Cardiovascular Care Provision after the Affordable Care Act. *Am J Manag Care*. 2017 Nov;23(11):e366-e373.
57. **Ladapo JA**, Richards AK, DeWitt CM, Harawa NT, Shoptaw S, Cunningham WE, Mafi JN. Disparities in the Quality of Cardiovascular Care between HIV-Infected Versus HIV-Uninfected Adults in the United States: A Cross-Sectional Study. *J Am Heart Assoc*. 2017 Nov 14;6(11). pii: e007107. doi: 10.1161/JAHA.117.007107. PMID: PMC5721786.
58. **Ladapo JA**, Budoff MJ, Sharp D, Kuo JZ, Huang L, Maniet B, Herman L, Monane M. Utility of a Precision Medicine Test in Elderly Adults with Symptoms Suggestive of Coronary Artery Disease. *J Am Geriatr Soc*. *J Am Geriatr Soc*. 2018 Feb;66(2):309-315. doi: 10.1111/jgs.15215.
59. Chang JI, Chokshi D, **Ladapo J**. Coordination across Ambulatory Care: A Comparison of Referrals and Health Information Exchange across Convenient and Traditional Settings. *J Ambul Care Manage*. 2018 Apr/Jun;41(2):128-137. doi: 10.1097/JAC.0000000000000227.
60. Robbins R, Seixas A, Jean-Louis G, Parthasarathy S, Rapoport DM, Ogedegbe G, **Ladapo JA**. National Patterns of Physician Management of Sleep Apnea and Treatment among Patients with Hypertension. *PLoS One*. 2018 May 23;13(5):e0196981. doi: 10.1371/journal.pone.0196981. PMID: PMC5965818.
61. **Ladapo JA**, Laroche MR, Chen A, Villalon MM, Vassar S, Huang DY, Mafi JN. Physician Prescribing of Opioids to Patients at Increased Risk of Overdose from Benzodiazepine Use in the United States. *JAMA Psychiatry*. 2018 Jun 1;75(6):623-630. doi: 10.1001/jamapsychiatry.2018.0544. PMID: PMC6137520.
62. **Ladapo JA**, Budoff MJ, Azarmina P, Sharp D, Baker A, Maniet B, Herman L, Monane M. Economic Outcomes of a Precision Medicine Blood Test to Assess Obstructive Coronary Artery Disease: Results from the PRESET Registry. *Managed Care*. 2018 Jun;27(6):34-40.
63. Stevens ER, Farrell D, Jumkhawala SA, **Ladapo JA**. Quality of Health Economic Evaluations for the ACC/AHA Stable Ischemic Heart Disease Practice Guideline: A Systematic Review. *Am Heart J*. 2018 Oct;204:17-33. doi: 10.1016/j.ahj.2018.06.013.
64. French KM, Gonzalez SZ, Sherman SE, Link AR, Malik S, Tseng CH, Jumkhawala SA, Tejada B, White A, **Ladapo JA**. Financial Incentives for Smoking Treatment: protocol

- of the FIESTA trial and FIESTA Oral Microbiome Substudy. *Trials*. 2018 Nov 21; 19(1):646. doi: 10.1186/s13063-018-3003-y. PMID: PMC6249787.
65. **Ladapo JA**, Spritzer CE, Nguyen XV, Pool J, Lang E. Economics of MRI Operations after Implementation of Interpersonal Skills Training. *J Am Coll Radiol*. 2018 Dec;15(12):1775-1783. doi: 10.1016/j.jacr.2018.01.017. PMID: PMC6129443.
66. Snow SC, Fonarow GC, **Ladapo JA**, Washington DL, Hoggatt KJ, Ziaecian B. National Rate of Tobacco and Substance Use Disorders among Hospitalized Heart Failure Patients. *Am J Med*. 2019 Apr;132(4):478-488.e4. doi: 10.1016/j.amjmed.2018.11.038. PMID: PMC6615901.
67. Jay M, Orstad SL, Wali S, Wylie-Rosett J, Tseng CH, Sweat V, Wittleder S, Shu SB, Goldstein NJ, **Ladapo JA**. Goal-directed Versus Outcome-Based Financial Incentives for Weight Loss among Low-Income Patients with Obesity: Rationale and Design of the Financial Incentives foR Weight Reduction (FIREWoRk) Randomised Controlled Trial. *BMJ Open*. 2019 Apr 8;9(4):e025278. doi: 10.1136/bmjopen-2018-025278. PMID: PMC6500238.
68. Gul B, Lansky A, Budoff MJ, Sharp D, Maniet B, Herman L, Kuo JZ, Huang L, Monane M, **Ladapo JA**. The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. *J Womens Health (Larchmt)*. 2019 May;28(5):728-35. doi: 10.1089/jwh.2018.7203. PMID: PMC6537117.
69. **Ladapo J**, Pfeifer J, Pitcavage J, Williams B, Choy-Shan, A. Quantifying Sex Differences in Cardiovascular Care among Patients Evaluated for Suspected Ischemic Heart Disease. *J Womens Health (Larchmt)*. 2019 May;28(5):698-704. doi: 10.1089/jwh.2018.7018. PMID: PMC6537115.
70. Newman JD, Berger JS, **Ladapo JA**. Underuse of Medications and Lifestyle Counseling to Prevent Cardiovascular Disease in Patients with Diabetes. *Diabetes Care*. 2019 May;42(5):e75-e76. doi: 10.2337/dc18-1554. PMID: PMC6489102.
71. Mafi JN, Godoy-Travieso P, Wei E, Anders M, Amaya R, Carrillo CA, Berry JL, Sarff L, Daskivich L, Vangala S, **Ladapo J**, Keeler E, Damberg CL, Sarkisian C. Evaluation of an Intervention to Reduce Low-Value Preoperative Care for Patients Undergoing Cataract Surgery at a Safety-Net Health System. *JAMA Intern Med*. 2019 May 1;179(5):648-57. doi: 10.1001/jamainternmed.2018.8358. PMID: PMC6503569.
72. Moise N, Davidson KW, Cheung YKK, Clarke GN, Dolor RJ, Duer-Hefeje J, **Ladapo JA**, Margolis KL, St Onge T, Parsons F, Retuerto J, Schmit KM, Thanataveerat A, Kronish IM. Rationale, Design, and Baseline Data for A Multicenter Randomized Clinical Trial Comparing Depression Screening Strategies after Acute Coronary Syndrome: The Comparison of Depression Identification after Acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. *Contemp Clin Trials*. 2019 Sep;84:105826. doi: 10.1016/j.cct.2019.105826.
73. **Ladapo JA**, Tseng CH, Sherman SE. Financial Incentives for Smoking Cessation in Hospitalized Patients: A Randomized Clinical Trial. *Am J Med*. 2020 Jun;133(6):741-749. doi: 10.1016/j.amjmed.2019.12.025. PMID: PMC7293955 (available on 2021-06-01).

74. Thornton PL, Kumanyika SK, Gregg EW, Araneta MR, Baskin ML, Chin MH, Crespo CJ, de Groot M, Garcia DO, Haire-Joshu D, Heisler M, Hill-Briggs F, **Ladapo JA**, Lindberg NM, Manson SM, Marrero DG, Peek ME, Shields AE, Tate DF, Mangione CM. New Research Directions on Disparities in Obesity and Type 2 Diabetes. *Ann N Y Acad Sci.* 2020 Feb;1461(1):5-24. doi: 10.1111/nyas.14270. PMID: PMC7159314.
75. Takada S, Ober AJ, Currier, JS, Goldstein NJ, Horwich TB, Mittman, BS, Shu SB, Tseng CH, Vijayan T, Wali S, Cunningham WE, **Ladapo JA**. Reducing Cardiovascular Risk among People Living with HIV: Rationale and Design of the Increasing Statin Prescribing in HIV Behavioral Economics Research (Inspire) Randomized Controlled Trial. *Prog Cardiovasc Dis.* Mar-Apr 2020;63(2):109-117. doi: 10.1016/j.pcad.2020.02.012.
76. Gamble-George JC, Longenecker CT, Weibel AR, Au DH, Brown AF, Bosworth H, Crothers K, Cunningham WE, Fiscella KA, Hamilton AB, Helfrich CD, **Ladapo JA**, Luque A, Tobin JN14, Wyatt GE. ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (The PRECluDE) Consortium: Combatting Chronic Disease Comorbidities in HIV Populations through Implementation Research. *Prog Cardiovasc Dis.* 2020 Mar-Apr 2020;63(2):79-91. doi: 10.1016/j.pcad.2020.03.006. PMID: PMC7237329.
77. Feng Z, Williams D, **Ladapo JA**. Differences in Cardiovascular Care between Adults with and without Opioid Prescriptions in the United States. *J Am Heart Assoc.* 2020 Jun 2;9(11):e015961. doi: 10.1161/JAHA.120.015961. PMID: PMC7429007.
78. DeWitt CM, Ponce RB, Bry H, Wali S, Sedlander E, **Ladapo JA**. Patient-Reported Reasons for Not Using Primary Prevention Statin Therapy. *J Clin Med.* 2020 Oct 18;9(10):3337. doi.org/10.3390/jcm9103337. PMID: PMC7603153.
79. McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, Berkowitz RL, Berry AC, Borody TJ, Brewer JH, Brufsky AM, Clarke T, Derwand R, Eck A, Eck J, Eisner RA, Fareed GC, Farella A, Fonseca SNS, Geyer CE Jr, Gonnering RS, Graves KE, Gross KBV, Hazan S, Held KS, Hight HT, Immanuel S, Jacobs MM, **Ladapo JA**, Lee LH, Littell J, Lozano I, Mangat HS, Marble B, McKinnon JE, Merritt LD, Orient JM, Oskoui R, Pompan DC, Procter BC, Prodromos C, Rajter JC, Rajter JJ, Ram CVS, Rios SS, Risch HA, Robb MJA, Rutherford M, Scholz M, Singleton MM, Tumlin JA, Tyson BM, Urso RG, Victory K, Vliet EL, Wax CM, Wolkoff AG, Wooll V, Zelenko V. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). *Rev Cardiovasc Med.* 2020 Dec 30;21(4):517-530. doi:10.31083/j.rcm.2020.04.264.
80. ***Ladapo JA**, Davidson KW, Moise N, Chen A, Clarke GN, Dolor RJ, Margolis KL, Thanataveerat A, Kronish IM. Economic Outcomes of Depression Screening after Acute Coronary Syndromes: The CODIACS-QoL Randomized Clinical Trial. *Gen Hosp Psychiatry.* 2021 Apr 3;71:47-54. doi: 10.1016/j.genhosppsy.2021.04.001. Online ahead of print.
81. *Oronce CIA, Fendick AM, **Ladapo JA**, Sarkisian, Mafi, JN. The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007-2016. *J Gen Intern Med.* 2021 Apr 14;1-8. doi: 10.1007/s11606-021-06784-8. Online ahead of print. PMID: PMC8045442

B. RESEARCH PAPERS – PEER REVIEWED (IN PRESS): None

C. RESEARCH PAPERS – PEER REVIEWED (SUBMITTED): None

RESEARCH PAPERS (NON-PEER-REVIEWED):

D. RESEARCH PAPERS - NON PEER-REVIEWED: None

E. RESEARCH PAPERS - NON PEER-REVIEWED (IN PRESS): None

F. RESEARCH PAPERS - NON PEER-REVIEWED (SUBMITTED): None

CASE REPORTS None

CASE REPORTS (IN PRESS) None

CHAPTERS None

CHAPTERS (IN PRESS) None

BOOKS

1. **Ladapo JA**. Cost-Effectiveness Analysis in Atherosclerosis. New York, NY: NYU Langone Medical Center. Version 1.1 E-book Available on iPad, iPhone and Mac.; 2016 Oct 28. 27 p.

BOOKS (IN PRESS): None

LETTERS TO THE EDITOR/ACADEMIC EDITORIALS

1. **Ladapo JA**, Douglas PS. Evaluation for Coronary Artery Disease and Medicare Spending. *JAMA*. 2012 Mar 7;307(9):911; author reply 912. doi: 10.1001/jama.307.9.911-a.
2. **Ladapo JA**, Ogedegbe G. Do Black Patients with Chronic Kidney Disease Benefit Equally from all Blood Pressure Lowering Agents? *BMJ*. 2014 Jan 15;348:g142. doi: 10.1136/bmj.g142. PMID: PMC4688567.
3. **Ladapo JA**, Goldfeld KS. Statistical Uncertainty in 10-Year Framingham Risk of Coronary Heart Disease and Cardiovascular Disease. *J Am Coll Cardiol*. 2014 Feb 4;63(4):377-8. doi: 10.1016/j.jacc.2013.07.108.
4. **Ladapo JA**, Fang Y, Davidson KW, Braithwaite RS. Open Access to Economic Outcome Data Will Help to Bridge the Gap between Clinical Trials and Clinical Guidelines. *BMJ*. 2015 Jun 8;350:h3091. doi: 10.1136/bmj.h3091. PMID: PMC4707513.
5. **Ladapo JA**, Treatment of Patients with Stable Ischemic Heart Disease. *JAMA*. 2016 May 3; 315(17):1905. doi:10.1001/jama.2016.0683.

6. Blecker S, Gavin NP, Park H, **Ladapo JA**. [In reply--Refers to: Suri P and Baugh C.] Observation Units as Substitutes for Hospitalization or Home Discharge. *Ann Emerg Med*. 2016 Jun;67(6):792-793. doi: 10.1016/j.annemergmed.2016.01.044.
7. **Ladapo JA**, Prochaska JJ. Paying Smokers to Quit: Does It Work? Should We Do It? *J Am Coll Cardiol*. 2016 Aug 23;68(8):786-8. doi: 10.1016/j.jacc.2016.04.067. PMID: PMC5108450.
8. **Ladapo JA**. Strengths and Limitations of Using Cost Evaluations to Inform Cardiovascular Care. *JACC Cardiovasc Interv*. 2017 Feb 27;10(4):352-354. doi: 10.1016/j.jcin.2016.12.011.
9. **Ladapo JA**, Turakhia MP, Ryan MP, Mollenkopf SA, Reynolds MR. [In reply--Refers to: Raymakers AJN, Lynd LD] Inclusion Criteria May Significantly Bias Study Results. *The Am J Cardiol*, 2017 Aug;120(3):e25. doi: 10.1016/j.amjcard.2016.07.002.
10. **Ladapo JA**, Pfeifer J, Choy-Shan A, Pitcavage JM, Williams BA. Association of Patient Beliefs and Preference with Subsequent Testing after Initial Evaluation for Ischemic Heart Disease. *JACC: Cardiovascular Imaging*. 2017 Sep;10(9):1076-1078. doi: 10.1016/j.jcmg.2016.09.015. PMID: PMC5537034.
11. **Ladapo JA**. Capsule Commentary on Silvestri et al., Impact of Cost Display on Ordering Patterns for Hospital Laboratory and Imaging Services. *J Gen Intern Med*. 2018 Aug;33(8):1383. doi: 10.1007/s11606-018-4516-5. PMID: PMC6082188.

REVIEWS

1. Rodwin BA, Spruill TM, **Ladapo JA**. Economics of Psychosocial Factors in Patients with Cardiovascular Disease. *Prog Cardiovasc Dis*. 2013 May-Jun;55(6):563-73. doi: 10.1016/j.pcad.2013.03.006.

EDITORIALS

1. **Ladapo J**, "What Should Be Covered, People or Procedures?" *Harvard WebWeekly*, April 2005, <http://webweekly.hms.harvard.edu/archive/2005/4_25/student_scene.html> (10 May 2005)
2. **Ladapo J**, "Weighing In on the CDC's Latest Obesity Study," *Harvard WebWeekly*, May 2005, <http://webweekly.hms.harvard.edu/archive/2005/5_23/student_scene.html> (01 August 2005)
3. **Ladapo J**, "Let Consumers Drive Progress in Health Care Quality," *Harvard Focus*, June 2005, <http://focus.hms.harvard.edu/2005/Jun10_2005/forum.shtml> (19 July 2005)
4. **Ladapo J**, "The Mixed Bag of Medical Malpractice," *Harvard Focus*, July 2005, <http://focus.hms.harvard.edu/2005/Jul15_2005/forum.shtml> (04 August 2005)
5. **Ladapo J**, "A Tulane Hospital Trainee Weathers Hurricane Katrina," *Harvard WebWeekly*, October 2005, <http://webweekly.hms.harvard.edu/archive/2005/10_3/student_scene.html> (10 October 2005)
6. **Ladapo J**, "Field Hospitals Bring Hope after South Asian Quake," *Harvard WebWeekly*, November 2005, <http://webweekly.hms.harvard.edu/archive/2005/11_14/student_scene.html> (3 December 2005)
7. **Ladapo J**, "Medicare Drug Benefit Tests Health Care Marketplace," *Harvard Focus*, January 2006, <<http://focus.hms.harvard.edu/2006/012706/forum.shtml>> (18 February 2006)

8. **Ladapo J**, “Conventional Medicine Faces the Alternative,” *Harvard Focus*, March 2006, <<http://focus.hms.harvard.edu/2006/032406/forum.shtml>> (12 April 2006)
9. **Ladapo J**, “Waging the Postwar Battle for Mental Health,” *Harvard Focus*, May 2006, <<http://focus.hms.harvard.edu/2006/051906/forum.shtml>> (03 June 2006)
10. **Ladapo J**, “Grave New World: Gene-doping in Sports,” *Harvard WebWeekly*, August 2006, < http://webweekly.hms.harvard.edu/archive/2006/0807/student_scene.html> (07 August 2006)
11. **Ladapo J**, “Diversity Strategies Change, Goal Remains to Improve Patient Care,” *Harvard Focus*, October 2006, <<http://focus.hms.harvard.edu/2006/101306/forum.shtml>> (8 February 2007)
12. **Ladapo J**, “New CT May Separate Low- from High-risk Chest Pain Patients,” *Harvard WebWeekly*, November 2006, <http://webweekly.hms.harvard.edu/archive/2006/1113/student_scene.html> (08 February 2007)
13. **Ladapo J**, “City Can Take the Heat, Gets into the Kitchen to Ban Trans Fats,” *Harvard WebWeekly*, December 2006, <http://webweekly.hms.harvard.edu/archive/2006/1225/student_scene.html> (8 February 2007)
14. **Ladapo J**, “Un-Match Day: Some Grads Pursue Alternatives to Medicine,” *Harvard Focus*, February 2007, <<http://focus.hms.harvard.edu/2007/022307/forum.shtml>> (09 June 2007)
15. **Ladapo J**, “Sixty Years and Still Ticking,” *Harvard WebWeekly*, March 2007, <http://webweekly.hms.harvard.edu/archive/2007/0326/student_scene.html> (09 June 2007)
16. **Ladapo J**, “Bone Marrow Donation: What It Means,” *Harvard Focus*, May 2007, <<http://focus.hms.harvard.edu/2007/050407/forum.shtml>> (09 June 2007)
17. **Ladapo J**, “New Yardstick Measures Value of Health Care Technologies,” *Harvard WebWeekly*, May 2007, <http://webweekly.hms.harvard.edu/archive/2007/0521/student_scene.html#Sanders> (09 June 2007)
18. **Ladapo J**, “Archives Project Documents Women’s Achievements in Medicine,” *Harvard Focus*, July 2007, <<http://focus.hms.harvard.edu/2007/071307/forum.shtml>> (10 September 2007)
19. **Ladapo J**, “Resident Work Hours: The Debate Won’t Rest,” *Harvard Focus*, October 2007, <<http://focus.hms.harvard.edu/2007/101207/forum.shtml>> (24 November 2007)
20. **Ladapo J**, “Is More Always Better? Evaluating Health Care Technology,” *Harvard WebWeekly*, November 2007, <http://webweekly.hms.harvard.edu/archive/2007/1112/student_scene.html> (16 December 2007)
21. **Ladapo J**, “Broadening the Safety Net for Child Health,” *Harvard WebWeekly*, December 2007, <http://webweekly.hms.harvard.edu/archive/2007/1224/student_scene.html> (3 January 2008)
22. **Ladapo J**, “Will Anyone Pay for Cardiac CTA?” *Harvard WebWeekly*, January 2008, <http://webweekly.hms.harvard.edu/archive/2008/0128/student_scene.html> (23 February 2008)

23. **Ladapo J**, “Primaries Heat Up Health Coverage Debate,” *Harvard Focus*, February 2008, <<http://focus.hms.harvard.edu/2008/022208/forum.shtml>> (23 February 2008)
24. **Ladapo J**, “What’s Debt Got to Do with It?,” *Harvard Focus*, May 2008, <<http://focus.hms.harvard.edu/2008/050208/forum.shtml>> (20 March 2009)
25. **Ladapo J**, “Keeping Patients First,” *Harvard Focus*, June 2008, <<http://focus.hms.harvard.edu/2008/060608/forum.shtml>> (20 March 2009)
26. **Ladapo J**, “A Pitfall of Sharing Care Decisions with Patients,” *Harvard Focus*, July 2008, <<http://focus.hms.harvard.edu/2008/071108/forum.shtml>> (20 March 2009)
27. **Ladapo J**, “Aligning Patient Care with Patient Needs,” *Harvard Focus*, October 2008, <<http://focus.hms.harvard.edu/2008/101008/forum.shtml>> (20 March 2009)
28. **Ladapo J**, “A Question Arises in Care of Heart Patients” *Harvard WebWeekly*, December 2008, <http://webweekly.hms.harvard.edu/archive/2008/1222/student_scene.html> (20 March 2009)
29. **Ladapo J**, “Caring for the Patient, Caring About the Family,” *Harvard Focus*, February 2009, <<http://focus.hms.harvard.edu/2009/022009/forum.shtml>> (20 March 2009)
30. **Ladapo J**, “Wired for Patient Care” *Harvard WebWeekly*, April 2009, <http://webweekly.hms.harvard.edu/archive/2009/041009/perspective_ladapo.html> (08 May 2009)
31. **Ladapo J**, “Better Value Care Requires Physicians to Know Cost” *Harvard WebWeekly*, May 2009, <http://webweekly.hms.harvard.edu/archive/2009/042809/perspective_ladapo.html> (08 May 2009)
32. **Ladapo J**, “Smoking Cessation Counseling: Too Effective to Ignore” *Harvard Focus*, July 2009, <<http://focus.hms.harvard.edu/2009/071009/forum.shtml>> (28 July 2009)
33. **Ladapo J**, “Hybrid Studies Pick Up Speed” *Harvard Focus*, January 2010, <<http://focus.hms.harvard.edu/2010/010810/forum.shtml>> (22 January 2010)
34. **Ladapo J**, “When Patient Status Conflicts with Patient Goals” *Harvard Focus*, April 2010, <<http://archives.focus.hms.harvard.edu/2010/042310/forum.shtml>> (4 May 2010)
35. **Ladapo J**, “The Doctor’s Art” *Harvard Focus*, July 2010, <<http://www.focushms.com/?p=91>> (22 August 2010)
36. **Ladapo J**, “Engaging Patients in End-of-Life Care” *Harvard Focus*, December 2010, <<http://www.focushms.com/forum/engaging-patients-in-end-of-life-care/>> (18 March 2011)
37. **Ladapo J**, “When the Patient Is the Teacher” *Harvard Focus*, May 2011, <<http://www.focushms.com/features/when-the-patient-is-the-teacher/>> (29 July 2011)
38. **Ladapo J**, “After Residency, a New Outlook” *Harvard Focus*, October 2011, <<http://www.focushms.com/forum/after-residency-a-new-outlook/>> (20 December 2011)
39. **Ladapo J**, “Why Patients Should Worry about a Normal Cardiac Stress Test” *News & Observer*, November 6, 2015, <<http://www.newsobserver.com/opinion/oped/article43489080.html>> (30 November 2015)
40. **Ladapo J**, “As a Doctor, I Thought I Knew How to Treat My Patients: Then My Wife Ended Up in the Hospital.” *Washington Post*, January 25, 2016, <<http://wpo.st/CWQ61>> (16 February 2016)

41. **Ladapo J**, Ravenell J, “Doctors’ Duty to Young Black Men.” *New York Daily News*, July 24, 2016, <<http://www.nydailynews.com/opinion/ladapo-ravenell-doctors-duty-young-black-men-article-1.2722119>>.
42. **Ladapo JA**. The Only Response to Trump-Era Hate. *New York Daily News*, November 16, 2016. <<http://www.nydailynews.com/opinion/joseph-ladapo-response-trump-era-hate-article-1.2875977>>
43. **Ladapo JA**. A Prescription for Empathy. *San Francisco Chronicle*, March 09, 2017. <<http://www.sfchronicle.com/opinion/openforum/article/A-prescription-for-empathy-10990864.php#comments>>
44. **Ladapo JA**. Coronavirus Pandemic: We Were Caught Unprepared. It Is Too Late for Shutdowns To Save Us. *USA Today*, March 24, 2020. <<https://www.usatoday.com/story/opinion/2020/03/24/coronavirus-shutdowns-worth-public-health-system-unprepared-column/2898324001/>>
45. **Ladapo JA**. Lockdowns Won’t Stop the Spread. *Wall Street Journal*, April 09, 2020. <<https://www.wsj.com/articles/lockdowns-wont-stop-the-spread-11586474560>>
46. **Ladapo JA**. The Looming Civil-Liberties Battle. *Wall Street Journal*, April 29, 2020. <<https://www.wsj.com/articles/the-looming-civil-liberties-battle-11588198523>>
47. **Ladapo JA**. The Crucial Reopening Question. *Wall Street Journal*, May 21, 2020. <<https://www.wsj.com/articles/the-crucial-reopening-question-11590100302>>
48. **Ladapo JA**. The Coronavirus Credibility Gap. *Wall Street Journal*, July 01, 2020. <<https://www.wsj.com/articles/the-coronavirus-credibility-gap-11593645643?mod=searchresults&page=1&pos=1>>
49. **Ladapo JA**. Fear and Loathing in Covid America. *Wall Street Journal*, August 03, 2020. <<https://www.wsj.com/articles/fear-and-loathing-in-covid-america-11596470084>>
50. **Ladapo JA**. How to Live with Covid, Not for It. *Wall Street Journal*, September 16, 2020. <<https://www.wsj.com/articles/how-to-live-with-covid-not-for-it-11600271921>>
51. **Ladapo JA** and Risch HA. Let’s All Be Honest about Hydroxychloroquine: Evidence Is More Positive than Many in the Medical Community Admit. *New York Daily News*, October 18, 2020. <<https://www.nydailynews.com/opinion/ny-oped-lets-all-be-honest-about-hydroxychloroquine-20201013-5j5q4i23qvufzos4jh7ztc3usa-story.html>>
52. **Ladapo JA**. Masks Are a Distraction From the Pandemic Reality. *Wall Street Journal*, October 29, 2020. <<https://www.wsj.com/articles/masks-are-a-distraction-from-the-pandemic-reality-11603927026>>
53. **Ladapo JA**. Too Much Caution Is Killing Covid Patients. *Wall Street Journal*, November 24, 2020. <<https://www.wsj.com/articles/too-much-caution-is-killing-covid-patients-11606238928>>
54. **Ladapo JA**. The Universal Vaccination’ Chimera. *Wall Street Journal*, February 04, 2021. <<https://www.wsj.com/articles/the-universal-vaccination-chimera-11612466130>>
55. **Ladapo JA**. An American Epidemic of ‘Covid Mania’. *Wall Street Journal*, April 19, 2021. <<https://www.wsj.com/articles/an-american-epidemic-of-covid-mania-11618871457>>

PAPERS IN PREPARATION (RESEARCH COMPLETED) None

ABSTRACTS/POSTER PRESENTATIONS

1. Elashoff M, **Ladapo JA**, Herman CE, Douglas PS. Myocardial Perfusion Imaging Has Markedly Lower Sensitivity after Accounting for Verification Bias. Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; May 9-11, 2012; Atlanta, GA. Abstract available at: *Circ Cardiovasc Qual Outcomes*. 2012;5:A259. http://circoutcomes.ahajournals.org/content/5/Suppl_1/A259.abstract?sid=3ff8cf1d-07b3-4ecb-8dab-a2fc3acbafcb. Poster Presentation.
2. **Ladapo JA**, Seare JG, Iorga SR, Buzinec PN, Monane M. Marked Variability in the Patterns of Care and Health Outcomes among Patients Evaluated for Suspected Obstructive Coronary Artery Disease: Results from a Healthcare Claims Database Study of 12,129 Patients. Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; May 17, 2013; Baltimore, MD. Abstract available in: *Circ Cardiovasc Qual Outcomes*. 2013;6:A348. http://circoutcomes.ahajournals.org/content/6/Suppl_1/A348?cited-by=yes&legid=circvq;6/Suppl_1/A348. Poster Presentation.
3. **Ladapo JA**, Lyons H, Yau M, Rich P, Newton D, Bruce-Mensah K, Johnson A, Yunping Zhou Y, Stephen Stemkowski S, Monane M. The Clinical Utility of Novel Genomic-Based, Gene Expression Test in a Registry Study of Women Evaluated for Symptoms Suggestive of Obstructive Coronary Artery Disease in the Ambulatory Care Setting. Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; October 10, 2013; Dallas, TX. Abstract available in: 2013 NAMS Conference Proceedings: 2013:P-61;p.60-61. <http://www.menopause.org/docs/default-source/agm/scientific-poster-abstracts.pdf>. Poster Presentation.
4. McPherson J, Phelps C, Yay M, Juusola J, Monane M, **Ladapo J**. Use of a Personalized Medicine, Blood-Based Gene Expression Score Was Associated with Lower Diagnostic Testing Costs in Women Presenting to Cardiologists with Symptoms Suggestive of Obstructive Coronary Artery Disease: An Economic Analysis of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) Trial. Presented at: The North American Menopause Society (NAMS) Annual Meeting; October 10, 2013; Dallas, TX. Abstract available in: 2013 NAMS Conference Proceedings: 2013: S-1;p.1. <http://www.menopause.org/docs/default-source/agm/scientific-poster-abstracts.pdf>. Oral Presentation.
5. **Ladapo JA**, Rodwin BA, Braithwaite RS, Pandya A, Riles TS, Rockman CB, Berger JS. Physician Decision-Making and Trends in Use of Cardiac Stress Testing to Diagnose Coronary Heart Disease in the United States. Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; November 18, 2013; Dallas, TX. Abstract available in: *Circ*. 2013;128(Suppl 22):A15561, http://circ.ahajournals.org/content/128/Suppl_22/A15561. Poster Presentation.
6. **Ladapo JA**, Blecker S, Douglas PS. No Evidence of Racial/Ethnic Disparities in the Noninvasive Evaluation of Patients for Coronary Heart Disease in the United States. Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; November 19, 2013; Dallas, TX. Abstract available in: *Circ*.

2013;128:A15581, http://circ.ahajournals.org/content/128/Suppl_22/A15581. Poster Presentation.

7. **Ladapo JA**, Blecker S, Douglas P. Trends in Inappropriate Use of Cardiac Stress Testing with Imaging among Primary Care Physicians and Cardiologists in the United States. Presented at: American College of Cardiology (ACC) Annual Scientific Session & Expo; March 30, 2014; Washington, DC. Abstract available in: *J Am Coll Cardiol*. 2014 Apr 01;63(12, S):A1294. doi:10.1016/S0735-1097(14)61294-8. http://www.onlinejacc.org/content/accj/63/12_Supplement/A1294.full.pdf. Oral Presentation.
8. **Ladapo JA**, Sharp D, Maniet B, Ross L, Blanchard J, Monane M, McPherson J. The Use of a Personalized Medicine, Blood-based Gene Expression Score in a Community-Based Cardiovascular Registry Enrolling Patients Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease: Interim Results from the PRESET Registry (A Registry to Evaluate Patterns of Care Associated with the Use of Corus® CAD in Real World Clinical Care Settings). Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; June 2-4, 2014; Baltimore, MD. Abstract available in: *Circ Cardiovasc Qual Outcomes*. 2014;7:A167. http://circoutcomes.ahajournals.org/content/7/Suppl_1/A167.abstract?sid=cf35a209-0b01-4756-9868-06426c1fe23a. Poster Presentation.
9. **Ladapo JA**, Herman L, Weiner BH, Rhees B, Castle L, McPherson J. The Use of a Gene Expression Score Was Associated with Improved Medical Decision Making in the Evaluation of Women Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease: Summary Results from Two Ambulatory Care Studies in Primary Care. Presented at: American College of Cardiology (ACC) Annual Scientific Session & Expo; March 15, 2015; San Diego, CA. Abstract available at: <http://www.cardioidx.com/assets/Abstracts/2015-ACC-Ladapo-LEN-150031.pdf>. Poster Presentation.
10. **Ladapo JA**, Budoff M, Ross L, Huang L, Sharp D, Maniet B, Monane M, Pokrywka GS, Wright RF. Primary Endpoint Results from a Community-Based Registry Evaluating the Use of a Blood-Based Age/Sex/Gene Expression Test in Patients Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease: the PRESET Registry (A Registry to Evaluate Patterns of Care Associated with the Use of Corus® CAD in Real World Clinical Care Settings). Presented at: American Heart Association Scientific Session Quality of Care and Outcomes Research Meeting; April 29-May 01, 2015; Baltimore, MD. Presentation did not occur, as the conference was canceled. Abstract available in: *Circ Cardiovasc Qual Outcomes*. 2015;8:A142. http://circoutcomes.ahajournals.org/content/8/Suppl_2/A142. Poster Presentation.
11. Pokrywka G, **Ladapo JA**, Wright R, McLaughlin P, Maniet B, Sharp D, Ross L, Huan L, Mark Monane M, Budoff M. The Clinical Utility of a Blood Test Incorporating Age, Sex, and Gene Expression in the Evaluation of Women Presenting with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease in a Large Primary Care Registry (PRESET): Subgroup Analysis of the Primary Efficacy Endpoint. Presented at: The North American Menopause Society (NAMS) Annual Meeting; October 01, 2015; Las Vegas, NV. Abstract available in: 2015 NAMS Conference Proceedings: 2015:p-91;p.73

<http://www.menopause.org/docs/default-source/agm/nams-2015-scientific-poster-abstracts.pdf> Poster Presentation.

12. **Ladapo JA**, Udo Hoffmann U, Lee KL, Coles A, Huang M, Mark DB, Dolor RL, Pelberg RA, Budoff M, Sigurdsson G, Severance HW, Douglas PS. Changes in Medical Therapy and Lifestyle After Anatomical Versus Functional Testing for Coronary Artery Disease: The PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain). Presented at: American Heart Association; November 10, 2015; Orlando, FL. Abstract available in: *Circ.* 2015;132:A14051.
http://circ.ahajournals.org/content/132/Suppl_3/A14051. Oral Presentation.
13. **Ladapo JA**, Chokshi DA. Changes in Physicians' Provision of Preventive Cardiovascular Care after the Affordable Care Act. Presented at: American Heart Association; November 13, 2016; New Orleans, LA. Abstract available in: *Circ.* 2016;
http://circ.ahajournals.org/content/134/Suppl_1. Oral Presentation.
14. **Ladapo JA**, Chokshi DA. Comparative Effectiveness of a Precision Medicine Blood Test versus Cardiac Stress Testing or Coronary Computed Tomography Angiography Among Patients with Suspected Obstructive Coronary Artery Disease. Accepted for presentation at: American Heart Association; November 11, 2018; Chicago, IL.

MEDIA

1. **Ladapo JA**. Interview with Stan Bunger, KCBS News Radio, May 25, 2020. Discussion regarding op-ed "The Crucial Reopening Question" *WSJ*. May 21, 2020. Available at: <https://kcbsradio.radio.com/media/audio-channel/what-will-employers-do-if-customers-or-employees-test-positive-for-coronavirus>
2. **Ladapo JA**. Interview on YouTube, McCombs School of Business Salem Center for Policy, June 18, 2020. Discussion regarding op-ed "The Crucial Reopening Question" *WSJ*. May 21, 2020. Available at: <https://www.youtube.com/watch?v=wSCKtx6WrPM>
3. **Ladapo JA**. Interview on YouTube, McCombs School of Business Salem Center for Policy, June 18, 2020. Discussion regarding op-ed "The Crucial Reopening Question" *WSJ*. May 21, 2020. Available at: <https://www.youtube.com/watch?v=wSCKtx6WrPM>
4. **Ladapo JA**. Interview with Quin McCarthy, Salem Radio Network: "Chicago's Morning Answer and The Dan Profit Show", July 07, 2020. Discussion regarding op-ed "The Coronavirus Credibility Gap" *WSJ*. July 01, 2020.
5. **Ladapo JA**. Interview on KTLA5, Coronavirus Weekly with Christina Pascucci, July 10, 2020. Discussion regarding op-ed "The Coronavirus Credibility Gap" *WSJ*. July 01, 2020. Available at: <https://ktla.com/podcasts/coronavirus-daily/ep-57-the-coronavirus-credibility-gap-coronavirus-weekly-podcast/>
6. **Ladapo JA**. Interview on KPCC Radio: "Airtalk with Larry Mantle", July 14, 2020. Discussion regarding op-ed "The Coronavirus Credibility Gap" *WSJ*. July 01, 2020. Available at: <https://www.scpr.org/programs/airtalk/2020/07/14/65809/gov-newsom-orders-statewide-reclosures-as-cases-co/>

7. **Ladapo JA**. Interview on YouTube channel program: “Coffee with Cornelius Christian”, July 17, 2020. Discussion regarding op-ed “The Coronavirus Credibility Gap” *WSJ*. July 01, 2020. Available at: <https://www.youtube.com/watch?v=OmBhEX75oo4>
8. **Ladapo JA**. Interview on AM870 Radio: “Dennis Prager Show”, October 29, 2020. Discussion regarding *WSJ* op-ed “Masks Are a Distraction from the Pandemic Reality” October 29, 2020
Segment 1: Masks Are a Distraction from the Pandemic Reality
Available at: <https://dennisprager.com/video/dr-ladapo-masks-are-a-distraction-from-the-pandemic-reality/>
Segment 2: This is NOT a Sustainable Strategy
Available at: <https://dennisprager.com/video/dr-ladapo-this-is-not-a-sustainable-strategy/>
9. **Ladapo JA**. Interview on KUSI News: “Good Morning San Diego”, October 30, 2020. Discussion regarding *WSJ* op-ed “Masks Are a Distraction from the Pandemic Reality” October 29, 2020. Available at: <https://www.kusi.com/dr-joseph-ladapo-op-ed-masks-are-a-distraction-from-the-pandemic-reality/>

Curriculum Vitae
John Patrick Whelan MD PhD

Office Address: UCLA Pediatrics, 10833 Le Conte Ave., Rm 12-430, Los Angeles CA 90095
Phone: 310-206-1826
Email: pwhelan@mednet.ucla.edu

Education:

College: Harvard University, Cambridge MA

A.B. Biochemistry; Skiddy von Stade Prize at commencement.

Medical/Graduate School: Baylor College of Medicine, Houston TX, *PhD 1992; MD 1993*

Thesis: Primary activation of human CD4+ T lymphocytes: regulation of phosphatidylinositol signaling by PKC-dependent cellular crosstalk.

Post-doctoral Training:

Internship: Scripps Green Hospital, La Jolla CA, 1993 - 1994

Residency: Scripps Green Hospital, La Jolla CA, 1994 – 1996

Fellowship: Rheumatology, Brigham & Women's Hospital, Boston MA, 1996 - 1999

AIDS-Oncology Fellow, Massachusetts General Hospital, Boston MA, 1998 – 2000

Faculty Appointments:

1999 – 2011. Instructor in Pediatrics, Harvard Medical School

2011 – 2013. Asst Professor of Pediatrics, Keck School of Medicine of USC

2018 – 2020. Asst Clinical Professor of Pediatrics, David Geffen School of Medicine

2012 – present. Lecturer in Pediatrics, Harvard Medical School

2016 – present. Clinical Asst Prof of Molecular Microbiology & Immunology, Keck/USC

2020 – present. Assoc Clinical Professor of Pediatrics, David Geffen School of Medicine

Appointments at Hospitals/Affiliated Institutions:

Pediatric Rheumatologist, Ronald Reagan UCLA Medical Center/Mattel Children's Hospital

Associate Physician, Massachusetts General Hospital

Major Administrative Leadership Positions:

Local:

2005 – 2009 Member, Human Studies IRB, Partners Healthcare

2009 – 2015. Harvard Catalyst Clinical Research Center (HCCRC) Review Committee

2012 – present. Academic Advisory Board, Institute for Advanced Catholic Studies at USC.

Regional:

1984 – present. Physicians for Social Responsibility (past chapter president)

1989 – present. Physicians for Human Rights (past chapter president)

2018 - 2019. *President* of the Los Angeles Pediatric Society; current Board of Directors

National:

Past President and member of the Board of Directors, Catholic Democrats, a 60,000 member national advocacy group involved in Catholic bioethics (2004 – present).

Board of Directors, National Catholic Reporter (2006 – 2012).

Session chair, ACR Annual Mtg (2007, 2012, 2013, 2014), Degos Disease & Related Vasculopathies Study Group.

Session chair and presenter, ACR Annual Mtg (2020), Covid Vasculopathy

International:

Organizer and Moderator, Degos Disease International Scientific Meeting, Boston, 9 Nov 2007.

Co-organizer, NIH Degos Disease International Scientific Symp, Bethesda MD, 27 Apr 2018.

Professional Societies:

1984 – present. Physicians for Social Responsibility (past chapter president)

1986 – present. American Association for the Advancement of Science

1989 – present. Physicians for Human Rights (past chapter president)

1996 – present. American College of Rheumatology

2015 – 2021. Board of Directors, Los Angeles Pediatric Society

Editorial Activities:

Founding co-editor, *Pediatric Rheumatology Online Journal*

Reviewer: New Engl J Med, Orphanet, Harvard Catalyst, Pediatric Rheumatology, Arthritis Care & Research, Amer J Transplantation.

Honors and Prizes:

1978 Valedictorian, Loyola High School, Los Angeles

1978 1st place, Bank of America Math & Science Scholars for Southern California

1982 Skiddy von Stade Prize at Harvard Commencement

1990 Outstanding Lab Instructor of the Basic Science Curriculum, BCM class of 1993

1992 Alumni Recognition Award at graduation, Baylor College of Medicine

1992 Admissions Committee Award, Baylor College of Medicine

1992 Outstanding Lab Instructor of the Basic Science Curriculum, BCM class of 1995

1994 NIH Research Recognition Awards for Clinical Trainees, Bethesda MD

1995 Charles & Virginia Feld Award for Humanism in Medicine, Scripps Green Hospital

2011 Certificate of Excellence in Tutoring (Teaching Award), Harvard Medical School

2014 and 2012 Nominee for the Gleitsman Citizen Activist Award, Center for Public Leadership, Kennedy School of Government, Harvard University

2020 "Premier Problem Based Learning Tutor," UCLA Basic Science Curriculum

Teaching and Training:

2018 – present. DGSOM Problem-Based Learning instructor.

2012 – present. Keck USC School of Medicine, immunodeficiency lectures, Foundations of Medical Sciences course

2013 – present. Keck USC School of Medicine, lecturer in graduate immunology course INTD522 ("Infectious Diseases, Host Defense and Immunological Abnormalities")

1998 – present. MGH clinical lectures in rheumatology to House Staff; consultative service one wk/month

2005 – 2013. MGH Continuing Medical Education course faculty in Pediatrics

2000 – 2011. Tutorial leader, Introduction to Microbiology and Immunology course at HMS

1997 – present. Non-resident tutor in medicine, Lowell House, Harvard University. Advising pre-medical students and writing house letters of recommendation.

1997 – 2010. Annual autumn seminar in Lowell House at Harvard University entitled, “Scientific and ethical frontiers in medicine and science,” attended by 15 undergraduates one night weekly for four terms.

1996 – 1999. Conference and consultative interaction with the resident teams at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center while on the clinical service.

1996 – 1999. HMS Introduction to Clinical Medicine Course, training sophomore medical students in the musculoskeletal exam; lectures at the Mass College of Pharmacy.

Report of Regional, National, and International Invited Teaching and Presentations:

1. UCLA Rheumatology Grand Rounds, “Non-vasculitic Vasculopathies,” 19 Feb 2021
2. UCLA Rheumatology Grand Rounds, “Reverse genetics: Is it possible to catch RA from one’s children?” 22 Feb 2019
3. UCLA Rheumatology Grand Rounds, “PANDAS syndrome,” 30 Nov 2018
4. UCLA Pediatrics Grand Rounds, “Viral Arthritis,” 7 Sep 2018
5. Los Angeles Pediatric Society Annual Meeting, Keynote Speaker, 25 Sep 2016
6. Keck/USC Rheumatology Fellowship Seminar, “Rheumatoid Vasculitis,” 10 Jun 2016
7. American College of Rheumatology, Degos Study Group (Boston) 17 Nov 2014
8. Carney Hospital Grand Rounds (affiliated with Tufts School of Medicine). “Immunodeficiency, Infection, and Mental Health.” (Dorchester MA) 5 Feb 2014
9. MERSI Symposium on Child Uveitis. “Eye disease in idiopathic juvenile arthritis.” (Cambridge MA) 29 Sept 2012
10. Harvard Genetics Course. “Rheumatic disease and pregnancy.” 22 Apr 2012
11. USC Health Policy Institute. “How will the Affordable Care Act impact unintended pregnancy in the US?” 17 Apr 2012
12. Health Law and Bioethics Society, USC Gould School of Law. “Does expanding healthcare coverage increase abortion?” Jan 2012
13. MGH General Pediatrics Course. “When zebras limp: uncommon causes of leg pain in children.” Dec 2011
14. Alexion Conference on Degos, NYC. “A Pediatric Perspective on Degos Disease,” May 2011
15. BWH Center for Bioethics. “Religious Perspectives on Embryonic Stem Cell Research,” May 2011 (moderator)
16. Childrens Hospital Los Angeles. “Degos Disease and Related Vasculopathies,” Nov 2010
17. MGH Pediatric Grand Rounds. “New Research on Anti-nuclear and other Autoantibody Production,” Sept 2010
18. NCR Washington DC Conference. “A Catholic Bioethics Perspective on Health Insurance Reform,” May 2010
19. MGH Rheumatology Grand Rounds. “Stickler Syndrome-associated Musculoskeletal Disease,” May 2010
20. Albany Medical College. “Parallels between Degos Disease and Henoch-Schoenlein Purpura,” April 2010
21. NY Hosp for Special Surgery. “Perspectives on Pediatric Degos Disease,” March 2010
22. BWH Center for Bioethics. “Stem Cell Research, IVF and the Culture Wars: Medical Ethics and the Catholic Voice,” 3/11/2009

Current Licensure:

Massachusetts medical license 150043

California medical license A53446

ABIM Board Certification

Rheumatology (2011 - 2021)
Internal Medicine (2011 - 2021)

Bibliography

Primary Reference:

1. Whelan P. Letter to the Food and Drug Administration. *J Biol Physics Chem* 2021;21:10-11
2. Sharma S, Brennan B, Naden R, Whelan P. A case of Degos disease in pregnancy. *Obstetric Medicine* 2016. *Epub* 6/2/2016.
3. Shapiro L, Whelan P, Magro C. Case 18-2014: A man with a rash, myalgia, and weakness. *N Engl J Med*. 2014;371(14):1361.
4. Gaffney EM, Kmiec DW, Whelan JP. *America Undecided* (Los Angeles: Amazon Press, 2012), 243 pages. Medicolegal and bioethical analysis of the political opposition to the 2010 Affordable Care Act: a collaboration by two former law school deans and a bioethicist.
5. Hill CA, Maturo S, Gallagher TQ, Whelan P, Pasternack MS, Hartnick CJ, Kieff DA. Clinical Problem Solving: Pathology Quiz Case 2. *Archives of Otorhinolaryngology, Head & Neck Surgery*. 2012;138(3):317-319.
6. Whelan P. Abortion Rates and Universal Health Care. *New Eng J Med* 2010;362(13)e45.
7. Whelan JP and A Zembowicz. CPC: A 22-Month-old boy with the rapid growth of firm subcutaneous nodules. *N Eng J Med* 2006: 354:2697-2704.
8. Whelan P. Link between rheumatoid arthritis and cancer. *Z Rheumatol*. 2006;65:497-504.
9. Whelan JP, N Reilly, DT Scadden. KSHV-associated primary effusion lymphomas display a characteristic chemokine receptor expression pattern and respond chemotactically to components present in the effusion. *Blood* 2000;96:21a.
10. Whelan JP, Shearer WT, Gilliam EB, Hardy KJ. A protein kinase C-activating phorbol ester accelerates the T cell antigen receptor-stimulated phosphatidylinositol cycle in normal human CD4+ T cells. *J.Immunol*. 1992;148:2872- 2878.
11. Gilliam EB, Schulam PG, Whelan JP, Rosenblatt HM, Shearer WT. Phorbol ester plus calcium ionophore induces release of arachidonic acid from membrane phospholipids of a human B cell line. *Cell. Immunol*. 1991;136:41-49.

Reviews:

1. Whelan P. Clinical manifestations and diagnosis of rheumatoid vasculitis. Up-to-Date in Rheumatology. 2021;29.1. www.uptodate.com
2. Whelan P. Epidemiology and pathogenesis of rheumatoid vasculitis. Up-to-Date in Rheumatology. 2021;29.1. www.uptodate.com
3. Whelan P. Treatment of rheumatoid vasculitis. Up-to-Date in Rheumatology. 2021;29.1. www.uptodate.com
4. Whelan P. Toevd-19 in Children. *LA Ped Society Newsletter*. 2021;8(1)
5. Whelan P. The Vaping Pandemic. *LA Ped Society Newsletter*. 2019;6(1)
6. Whelan P. Zika Virus Infection. *LA Ped Society Newsletter*. 2016;3(1)
7. Whelan P. When not to worry about Henoch-Schoenlein Purpura. *Los Angeles Pediatric Society*. 2014;1(1)
8. Whelan JP. New developments in the basic biology of Henoch-Schönlein purpura. *Pedi. Rheum. Online J*. 2003;1(1).
<http://www.pedrheumonlinejournal.org/issues1/Basic%20Biology.html>
9. Whelan JP and DT Scadden. New developments in the etiopathogenesis and treatment of HIV-related Kaposi's sarcoma. *Clin. Dermatol*. 2000;18(4):469-477.

10. Whelan JP. Rheumatoid arthritis: a new perspective on an old ailment. *Res. Report* 1998;3:80-86.

Book Chapters:

1. Whelan P, A rheumatologist's perspective on childhood uveitis, In: *Childhood Uveitis*, C. Stephen Foster *et al.*, eds. Manchester VT: Shires Press, 2011; chapter 7.
2. Whelan JP and DT Scadden. Cancer in the Immunosuppressed Patient, In: *Oncology: An Evidence-Based Approach*, Chang, Ganz, *et al.*, eds., Springer-Verlag New York, 2006; chapter 96.
3. Whelan JP and DT Scadden. Lymphoma and abnormalities of the immune system. In: *Non-Hodgkin's Lymphomas*, Mauch PM, Armitage JO, Harris NL, Coiffier B Dalla-Favera R, eds., 1st ed. Baltimore: Williams & Wilkins, 2004; chapter 45.
4. Whelan JP, Cannon CL. Hypersensitivity. In: *Immunology, Infection, and Immunity: An Introductory Text*. Pier GB, Lyczak JB, Wetzler LM, eds. 2004:chapter 25.
5. Whelan JP, Gilliam EB, Shearer WT. Characterization of phosphatidylinositol and phosphatidylcholine metabolism in human lymphocytes. In: Hughes MR, *et al.*, eds. *Molecular Endocrinology and Hormone Action*. Houston: Biological Associates, Inc., 1993:chapter 5.

László Géza Boros, MD

+36.20.396.0533 (HU); <https://www.laszlogboros.com>

Electronic correspondence: contact@laszlogboros.com; boros.laszlo@protonmail.com



Appointments

<u>Title</u>	<u>Affiliation</u>	<u>Dates of Appointment</u>
Chief Scientist	<i>Deutenomics Science Institute and SIDMAP, LLC., Culver city, CA, USA</i>	<i>August 2004 - present</i>
Professor	<i>Departments of Pediatrics, Endocrinology & Metabolism, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>July 2020 – June 2021 (step III) July 2017 – June 2020 (step II) July 2014 – June 2017 (step I)</i>
Investigator	<i>UCLA Clinical and Translational Science Institute (CTSI), Los Angeles, CA, USA</i>	<i>July 2011 – June 2020</i>
Investigator	<i>The Lundquist Institute for Biomedical Innovations at the Harbor-UCLA Medical Center, Torrance, CA, USA</i>	<i>January 2006 – June 2020</i>
Associate Professor	<i>Departments of Endocrinology & Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>July 2004 – June 2014</i>
Co-Director	<i>BioMedical Mass Spectroscopy Research Laboratory, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA</i>	<i>December 1998 – Apr 2004</i>
Assistant Professor	<i>Departments of Endocrinology & Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>September 1998 – June 2004</i>
Research Scientist	<i>Division of General Surgery, The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>May 1996 – Aug 1998</i>
Medical Student Research Advisor	<i>The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>January 1995 – Aug 1998</i>
Research Associate 2- B/H, Postdoctoral Researcher	<i>Division of General Surgery, The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>June 1990 - May 1996</i>
Visiting Scholar	<i>Essen University Medical School Department of Internal Medicine, Essen, Germany</i>	<i>January 1989 – May 1990</i>
Postgraduate Research Fellow	<i>Hungarian Academy of Sciences, Budapest, Hungary</i>	<i>September 1987 – Dec 1989</i>



Education

<u>School & Location</u>	<u>Degrees</u>	<u>Attendance</u>	<u>Field of Study</u>
Miklós Bercsényi High School Törökszentmiklós, Hungary	High School Diploma	1976 – 1980	Biology, Physics
Albert Szent-Györgyi School of Medicine Szeged, Hungary, EU	<u>Doctor of Medicine (M.D.)</u>	1981 – 1987	Medicine

Certifications

Unrestricted License to Practice Medicine in Hungary and the European Union, Hungarian Board of Medical Examiners, [17/1987 O.E. Szeged, Hungary](#)

United States Medical Licensing Examination (USMLE – ID-0-519-920-3) - [Basic Medical Sciences](#) (1995)

Professional Memberships & Awards

Three-year domestic research fellowship award of the Hungarian Academy of Sciences (1987)
 C. Williams Hall Outstanding Publication Award - Academy of Surgical Research of the USA (1997)
 American Society for Leukocyte Biology (ASLA; 1992-1995)
 American Association for Cancer Research (AACR; 1998-2012; Membership No: 70054)
 American Pancreatic Association (APA; 1998-present)
 The American Physiological Society (APS; 1998-2010; Membership No: 31927)
 Richard E. Weitzman Memorial Research Award – University of California, Los Angeles, CA, USA, June 2001
 American Gastroenterological Association (AGA; 2002-2007; Membership No: 902797)
 Excellence in Clinical Research Award – GCRC at Harbor-UCLA Medical Center, September 2004
 Metabolomics Society (2004-present; Membership No: 04942012)
 Géza Hetényi Memorial Membership Award of the Hungarian Gastroenterological Society (2007)
 Public Health Impact Investigator Award of the United States Food and Drug Administration (2011)
 President - USA West Coast Hungarian Scientist Club (2014)
 Science Award the county of Jász-Nagykun-Szolnok – Hungary, European Union (2014)
 Best Publication Award - Metabolomics Society & Springer Nature – San Francisco, CA, USA (2015)
 External Member – Hungarian Academy of Sciences – Medical Sciences (V. - 3839/1/2015/HTMT)
 Regional Member Scientists' Club Szeged – Hungarian Academy of Sciences (2018)
 Twenty Years' [Service Award](#) from the Los Angeles Biomedical Research Institute (LABIOMED) (2019)
 President – Scientific Translators of Ancient Literature - Hungary, European Union (2019-present)

Consulting & Scientific Expert Work

Central Research Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, VIII. Szigony street 43, Hungary - Consultant and Collaborator, Carcinogenesis and Metabolic Profiling 1996 - 2003.

Hermanies, Major, Castelli & Goodman (Cincinnati, OH). Medical Expert Consultant; Parsley vs. Terminix - Pesticide (Isofenphos) Poisoning and Chronic Myeloid Leukemia (case evaluation), 1997 – 2002.

Goodson & Mullins, LTD (Cincinnati, OH). Medical Expert Consultant and Witness; Parsley vs. Terminix (legal arbitration, public) 2002 – 2003. Parsley v. Terminix International Co., No. C-3-97-394, 1998 U.S. Dist. LEXIS 22891 (S.D. Ohio Sept. 15, 1998). Additional reference: Contracting with tortfeasors: Mandatory arbitration clauses and personal injury claims. Elizabeth G. Thornburg, Professor of Law, Southern Methodist University, Dedman School of Law (page 259-260).



<https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1323&context=lcp>

Biomedicina Research & Development, Inc. (Budapest, Hungary) – Consultant, Tumor Growth Inhibitory Metabolic Effects of Fermented Wheat Germ, 1999 – 2008.

GenPath Pharmaceuticals, Inc. (Cambridge, Massachusetts, USA) – Scientific Advisor and Consultant, 2004 - 2005.

Aveo Pharmaceuticals, Inc. (Cambridge, Massachusetts, USA) – Scientific Advisor and Consultant, 2005 - 2006.

Patrick Swayze's diagnosis with pancreatic cancer medical condition and prognosis coverage (Los Angeles, CA, USA) – Medical Respondent - Access-Hollywood, Entertainment Tonight, E-news! March 6 – 2008

<https://www.accessonline.com/articles/friends-celebrities-offer-support-for-patrick-swayze-62739>

Cornerstone Pharmaceuticals, Inc. (Cranbury, NJ) – Consultant, April 2010 – 2011.

United States Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR) (Jefferson, Arkansas) – Consultant and Advisor, April 2010 – 2019.

Center for Chemical Biology, Stanford University, Stanford Research Institute International (SRI), Ravenswood Avenue, Menlo Park CA 94025 USA – Advisor/Consultant, January 2013 – 2018.

Pacific West Law Group, LLP - Oxygen treatment and deuterium depletion in integrative medicine, Mill Valley CA 94941 USA – Medical Expert Consultant, December 2018 – 2019.

Richard Jaffe, Esquire and Children's Health Defense, Robert F. Kennedy Jr. - <https://childrenshealthdefense.org/> - Sacramento, New York City, Houston USA – Scientist Expert Consultant, 2020.

The Guy Foundation, Invited Panel Scientist, 2020 Autumn Series virtual lectures (on Zoom), 2020.

Patents

Methods and compositions for detecting immune system activation. United States Patent Application number WO2013142303 A1; Application number PCT/US2013/031879; Publication date Sep 26, 2013; Filing date Mar 15, 2013; Priority date Mar 19, 2012

Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof. United States of America Patent Application US20040259816 A1; Application number US 10/824,597; Publication date Dec 23, 2004; Filing date Apr 15, 2004; Priority date Oct 1, 2002

Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof. United States Patent Application number PCT/US2005/011741; Publication date Oct 27, 2005; Filing date Apr 7, 2005; Priority date Apr 15, 2004


Analyzing non-toxic stable labeled glucose isotope formation via mass spectrometry/nuclear magnetic resonance. United States of America Patent Application number US 10/192,744; Publication date Sep 25, 2003; Filing date Jul 9, 2002; Priority date Mar 22, 2002

Using an isotope such as a stable (13C) isotope for labeling a metabolome to examine mechanisms of cellular substrate flow modification in response to various drugs, which can improve the drug discovery and testing processes. United States Patent Application number US 10/192,743; Publication date Sep 25, 2003; Filing date Jul 9, 2002; Priority date Mar 22, 2002



Publication Statistics (Google Scholar)

	All	Since 2016
Citations	7955	3024
h-index	51	28
i10-index	100	65



<https://scholar.google.com/citations?user=ThtG5CUAAAAJ&hl=en&oi=ao>

Editorial work

Scientific Reports (ISSN 2045-2322) [Member of the Editorial Board](#) (2019 - present) – Publisher: Nature

Molecules (ISSN 1420-3049) [Member of the Editorial Board](#) (2019 - present) - Publisher: MDPI

Medicine® (ISSN: 0025-7974) Editor (2016 – present) - Publisher: Wolters Kluwer; (Frequency: Weekly)

Metabolomics (ISSN 1573-3890) Editor & Reviewer (2005 – present)

Pancreas (ISSN 1536-4828) Associate Editor & Reviewer (1999 – present)

Session Chair Assignments

Pharmaceutical & Disease State Applications in Drug Development. Advances in Metabolic Profiling, London, United Kingdom, Nov 1-2, 2005.

Surgical Treatment of Pancreatic Cancer. 41st Meeting of the European Pancreatic Club (APC), Szeged, Hungary, July 3, 2009.



Second Scientific Session, 1st International Symposium on Deuterium Depletion, Budapest, Hungary, May 14, 2010.

Second Scientific Session, 2nd International Symposium on Deuterium Depletion, Budapest, Hungary, May 17-18, 2012. Co-chairman Professor Richard J. Robins, University of Nantes.

Biochemical Aspects and Mechanism of Action of Deuterium Depletion Session, 3rd International Symposium on Deuterium Depletion, Budapest, Hungary, May 08, 2015. Co-chair: Dr. Gabor Somlyai, HYD, LLC.

European Society for Isotope Research (ESIR), Methods & Instrumental Techniques Session, Zadar, Croatia, September 23, 2015. Co-chair: S. Halas, Mass Spectrometry Laboratory, Institute of Physics, Marie Curie-Sklodowska University, Lublin, Poland.

Third Scientific Session, 4th International Symposium on Deuterium Depletion, Budapest, Hungary, October 18, 2019.

Research, Academic & Teaching Committees

MASS SPECTROMETRY ANALYSIS PLANNING COMMITTEE – THE LUNDQUIST INSTITUTE OF BIOMEDICAL INNOVATION AT THE HARBOR-UCLA MEDICAL CENTER, TORRANCE, CA (2000-2020)

UCLA SPECIAL PROGRAM OF RESEARCH EXCELLENCE (SPORE) IN PANCREATIC CANCER - DEVELOPMENTAL RESEARCH PROGRAM COMMITTEE (2002-2008)

UCLA – UCSD (SAN DIEGO) CENTER GRANT FOR PANCREATIC CANCER PRELIMINARY/FEASIBILITY GRANTS COMMITTEE - DEVELOPMENTAL RESEARCH PROGRAM COMMITTEE (2002-2005)

METABOLOMICS (ISSN 1573-3890) (SUPERVISING MEMBER - ELECTION COMMITTEE, 2012)

HIRSHBERG FOUNDATION FOR PANCREATIC CANCER RESEARCH SCIENTIFIC ADVISORY BOARD (2003 – 2016)

HIRSHBERG FOUNDATION FOR PANCREATIC CANCER RESEARCH SEED GRANTS PANEL (REVIEWER, 2003 – 2015)

WEITZMAN RESEARCH AWARD SELECTION COMMITTEE – HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE FACULTY SOCIETY (2003-20015)

MEMBER - PRESIDENTIAL SUBCOMMITTEE - HUNGARIAN SCIENCE ABROAD - HUNGARIAN ACADEMY OF SCIENCES – SECTION OF MEDICAL SCIENCES (V.) - (2014-2017)

UCLA PEDIATRICS EXECUTIVE DEPARTMENT CHAIR FIVE-YEAR ADMINISTRATIVE REVIEW COMMITTEE – REVIEWER (2015)

ASSOCIATION OF AMERICAN MEDICAL COLLEGES' (AAMC) FACULTY FORWARD ENGAGEMENT PANEL – SELECTED FACULTY SURVEYOR (2016)

AMERICAN COLLEGE FOR ADVANCEMENT IN MEDICINE (ACAM) – EDUCATION COMMITTEE – MEMBER (2016-2019)

¹³CIGNATURE ²HEALTH METABOLIC CLINIC – SANTA MONICA, CA - CHIEF SCIENTIFIC ADVISOR (2016-2019)



Peer Reviewed Publications

1. Pap, A., **Boros, L.G.** Alcohol-induced chronic pancreatitis in rats after temporary occlusion of the biliopancreatic ducts with Ethibloc. *Pancreas* 4: 249-255, 1989.
2. Pap, A., **Boros, L.G.**, Hajnal, F. Essential role of cholecystokinin in pancreatic regeneration after 60% distal resection in rats. *Pancreas* 6: 412-418, 1991.
3. **Boros, L.G.**, Lepow, C., Ruland, F., Flancbaum, L.J., Townsend, M.C. CD-ROM source data uploaded to the operating and storage devices of an IBM 3090 mainframe through a PC terminal. *Computer Methods & Programs Biomedicine* 38: 77-89, 1992.
4. **Boros, L.G.**, Damico, J., Flancbaum, L.J., Townsend, M.C., Beckley, P.D., Jones, S.D. An automated computer method utilizing Procomm Plus and DataEase (4.2) PC - and SAS (6.06) mainframe software for isolated, perfused guinea pig heart studies. *Computer Methods & Programs Biomedicine* 39: 271-284, 1993.
5. Oberyszyn, T.M., Sabourin, C.L., Bijur, G.N., Oberyszyn, A.S., **Boros, L.G.**, Robertson, F.M. Interleukin-1 β gene expression and localization of interleukin-1 β protein during tumor promotion. *Molecular Carcinogenesis* 7: 238-248, 1993.
6. Robertson, F.M., Bijur, G.N., Oberyszyn, A.S., Pellegrini, A., **Boros, L.G.**, Sabourin, C.L., Oberyszyn, T.M. Granulocyte-macrophage colony stimulating factor gene expression and function during tumor promotion. *Carcinogenesis* 15: 1017-1029, 1994.
7. Choban, P.S., McKnight, T., Flancbaum, L.J., Sabourin, C.L., Bijur, G.N., **Boros, L.G.**, Marley, J., Burge, J.C., Robertson, F.M. Characterization of a murine model of acute lung injury (ALI): a prominent role for interleukin-1. *Journal of Investigative Surgery* 9: 95-109, 1994.
8. Robertson, F.M., Pellegrini, A.E., Ross, M.S., Oberyszyn, A.S., **Boros, L.G.**, Bijur, G.N., Sabourin, C.L., Oberyszyn, T.M. Interleukin-1 β gene expression during wound healing. *Wound Repair & Regeneration* 3: 473-84, 1995.
9. Fisher, W.E., **Boros, L.G.**, O'Dorisio, T., O'Dorisio, S., Schirmer, W.J. The influence of diabetes on the growth of pancreatic cancer. *Surgical Forum* 45: 151-152, 1994.
10. Fisher, W.E., **Boros, L.G.**, Tamaddon, K.A., O'Dorisio, S.M., O'Dorisio, T.M., Schirmer, W.J. Somatostatin-receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo. *Surgical Forum* 16: 138-140, 1995.
11. Fisher, W.E., **Boros, L.G.**, Schirmer, W.J. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. *Surgery* 118: 453-457, 1995.
12. Fisher, W.E., **Boros, L.G.**, Tamaddon, K.A., O'Dorisio, T.M., O'Dorisio, S.M., Schirmer, W.J. GI hormonal changes in diabetes influence pancreatic cancer growth. *Journal of Surgical Research* 58: 754-758, 1995.
13. Fisher, W.E., **Boros, L.G.**, Schirmer, W.J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. *Journal of Surgical Research* 63: 310-313, 1996.
14. Fisher, W.E., Muscarella, P., **Boros, L.G.**, Schirmer, W.J. Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the Syrian hamster and nude mouse. *Surgery* 123: 315-320, 1998.



15. Melvin, W.S., **Boros, L.G.**, Muscarella, P., Brandes, J.L., Johnson, J.A., Fisher, W.E., Schirmer, W.J., Ellison, E.C. Dehydroepiandrosterone-sulfate inhibits pancreatic cancer cell proliferation *in vitro* and *in vivo*. *Surgery* 121: 392-397, 1996.
16. **Boros, L.G.**, Puigjaner, J., Cascante, M., Lee, P., Brandes, J.L., Bassilian, S., Yusuf, F.I., Williams, R.D., Muscarella, P., Melvin, W.S., Schirmer, W.J. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and cancer cell proliferation. *Cancer Research* 57: 4242-4248, 1997.
17. Fisher, W.E., Doran, T.A., Muscarella, P., **Boros, L.G.**, Ellison, E.C., Schirmer, W.J. Somatostatin receptor subtype 1-5 gene expression in human pancreatic cancer. *Journal of the National Cancer Institute* 90: 322-324, 1998.
18. **Boros, L.G.**, Lee, P., Brandes, J.L., Cascante, M., Muscarella, P., Schirmer, W.J., Melvin, W.S. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? *Medical Hypotheses* 50: 55-59, 1998.
19. **Boros, L.G.**, Brandes, J.L., Yusuf, F.I., Cascante, M., Williams, R.D., Schirmer, W.J. Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin. A possible mechanism of antitumor action. *Medical Hypotheses* 50: 501-506, 1998.
20. **Boros, L.G.**, Brandes, J.L., Lee, P., Cascante, M., Puigjaner, J., Revesz, E., Bray, T.M., Schirmer, W.J., Melvin, W.S. Thiamin supplementation to cancer patients: A double edged sword. *Anticancer Research* 18: 595-602, 1998.
21. **Boros, L.G.**, Williams, R.D. Chronic isofenphos poisoning: case report of agnogenic myeloid metaplasia with a rapid progression into acute myeloid leukemia. *Leukemia Research* 22: 849-851, 1998.
22. Lee P., **Boros, L.G.**, Puigjaner, J., Bassilian, S., Lim, S., Cascante, M. Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-¹³C₂]glucose. *American Journal of Physiology [Endocrinology & Metabolism]* 274: E843-E851, 1998.
23. Muscarella, P., **Boros, L.G.**, Fisher, W.E., Rink, C., Melvin, W.S. Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice. *Journal of Surgical Research* 79: 154-157, 1998.
24. Fisher, W.E., Muscarella, P., **Boros, L.G.**, Schirmer, W.J. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. *International Journal of Pancreatology* 24: 169-80, 1998.
25. Rais, B., Comin, B., Puigjaner, J., Brandes, J.L., Creppy, E., Saboureau, D., Ennamany, R., Lee, W-N.P., **Boros, L.G.**, Cascante, M. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. *FEBS Letters* 456: 113-19, 1999.
26. Cascante, M., Centelles, J.J., Veech, R.L., Lee, W-N.P., **Boros, L.G.**, The role of thiamine (vitamin-B₁) and transketolase in tumor cell proliferation. *Nutrition & Cancer* 36: 150-154, 2000.
27. **Boros, L.G.**, Torday, J.S., Lim, S., Bassilian, S., Cascante, M., Lee, W-N.P. TGF- β_1 promotes glucose carbon incorporation into nucleic acid ribose through the non-oxidative pentose cycle in lung epithelial carcinoma cells. *Cancer Research* 60: 1183-1195, 2000.
28. **Boros, L.G.**, Lim, S., Bassilian, S., Lee, W-N.P. Genistein inhibits non-oxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. *Pancreas* 22: 1-7, 2000.
29. Lee, W-N.P., Bassilian, S., Lim, S., **Boros, L.G.** Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. *American Journal of Physiology [Endocrinology & Metabolism]* 279: E425-E432, 2000.



30. **Boros, L.G.** Population thiamine status and varying cancer rates between Western, Asian and African countries. *Anticancer Research* 20: 2245-8, 2000.
31. **Boros, L.G.**, Lapis, K., Szende, B., Tomoskozi-Farkas, R., Balogh, A., Boren, J., Marin, S., Cascante, M., Hidvegi, M. Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells. *Pancreas* 23: 141-147, 2001.
32. **Boros, L.G.**, Williams, R.D. Isofenphos induced metabolic changes in K562 myeloid blast cells. *Leukemia Research* 25: 883-890, 2001.
33. Comín-Anduix, B., Boren, J., Martinez, S., Moro, C., Centelles, J.J., Trebukhina, R., Petushok, N., Lee, W-N.P., **Boros, L.G.**, Cascante, M. The effect of thiamine supplementation on tumor proliferation: A metabolic control analysis study. *European Journal of Biochemistry* 268: 4177-82, 2001.
34. Boren, J., Cascante, M., Marin, S., Comín-Anduix, B., Centelles, J.J., Lim, S., Bassilian, S., Ahmed, S., Lee W-N.P., **Boros, L.G.** Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow towards nucleic acid and fatty acid synthesis in myeloid tumor cells. *Journal of Biological Chemistry* 276: 37747-37753, 2001.
35. **Boros, L.G.**, Lee, W-N.P., Go, V.L.W. A metabolic hypothesis of cell growth and death in pancreatic cancer. *Pancreas* 24: 26-33, 2002.
36. Bassilian, S., Ahmed, S., Lim, S.K., **Boros, L.G.**, Mao, C.S., Lee, W-N.P. Loss of regulation of lipogenesis in the Zucker diabetic rat. II. Changes in stearate and oleate synthesis. *American Journal of Physiology Endocrinology & Metabolism* 282: E507-13, 2002.
37. **Boros, L.G.**, Cascante, M., Lee, W-N.P. Metabolic Profiling of Cell Growth and Death in Cancer: applications in drug discovery. *Drug Discovery Today* 7: 364-372, 2002.
38. Cascante, M., **Boros, L.G.**, Comin, B., Atauri, P., Centelles, J.J., Lee, W-N.P. Metabolic control analysis in drug discovery and disease. *Nature Biotechnology* 20: 243-249, 2002.
39. **Boros, L.G.**, Lee, W-N.P., Cascante, M. Imatinib and chronic-phase leukemias. *New England Journal of Medicine* 347: 67-68, 2002.
40. **Boros, L.G.**, Torday, J.S., Lee W-N.P., Rehan, V.H. Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung fibroblasts. *Molecular Genetics & Metabolism* 77: 230-236, 2002.
41. Comín-Anduix, B., **Boros, L.G.**, Marin, S., Boren, J.A., Callol-Massot, C., Centelles, J.J., Torres, L., Agell, N., Bassilian, S., Cascante, M.S. Fermented wheat germ extract inhibits enzymes of glucose metabolism and induces apoptosis through the activation of poly(ADP-ribose) polymerase in Jurkat T-cell leukemia tumor cultures. *Journal of Biological Chemistry* 277: 46408-464014, 2002.
42. Bulotta, A., Hui, H., Anastasi, E., Bertolotto, C., **Boros, L.G.**, Di Mario, U., Perfetti, R. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. *Journal of Molecular Endocrinology* 29: 347-60, 2002.
43. Guo, T.B., **Boros, L.G.**, Chan, K.C., Hikim, A.P., Hudson, A.P., Swerdloff, R.S., Mitchell, A.P., Salameh, W.A. Spermatogenic expression of RNA-binding motif protein 7, a protein that interacts with splicing factors. *Journal of Andrology* 24: 204-214, 2003.
44. Bulotta, A., Perfetti, R., Hui, H., **Boros, L. G.** Glucagon-like peptide-1 stimulates glucose derived *de novo* fatty acid synthesis and chain elongation during cell differentiation. *Journal of Lipid Research* 44: 1559-1564, 2003.



45. Boren, J., Lee, W.N., Bassilian, S., Centelles, J.J., Lim, S., Ahmed, S., **Boros, L.G.**, Cascante, M. The stable isotope-based dynamic metabolic profile of butyrate induced HT29 cell differentiation. *Journal of Biological Chemistry* 278: 28395-28402, 2003.
46. **Boros, L.G.**, Steinkamp, M.P., Fleming, J.C., Lee, W-N.P., Cascante, M., Neufeld, E.J. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA): mechanism for the syndrome. *Blood* 102: 3556-3562, 2003.
47. **Boros, L.G.**, Brackett, D.J., Harrigan, G.G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). *Current Cancer Drug Targets* 3: 445-453, 2003.
48. Marin, S., Chiang, K, Bassilian, S., Lee, W-N.P., **Boros, L.G.**, Fernández-Novell, J.M., Centelles, J.J., Medrano, A., Rodriguez-Gil, J.E., Cascante, M. Metabolic strategy of boar spermatozoa revealed by a metabolomic characterization. *FEBS Letters* 554: 342-346, 2003.
49. Marin, S., Lee, W.N., Bassilian, S., Lim, S., **Boros, L.G.**, Centelles, J.J., Fernandez-Novell, J.M., Guinovart, J.J., Cascante, M. Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-¹³C₂]-glucose. *Biochemical Journal* 381: 287-294, 2004.
50. Williams, R.D., **Boros, L.G.**, Kolanko, C.J., Jackman, S.M., Eggers, T.R. Chromosomal aberrations in human lymphocytes exposed to the anticholinesterase pesticide isofenphos with mechanisms of leukemogenesis. *Leukemia Research* 28: 947-958, 2004.
51. Lee, W.N., Guo, P., Lim, S., Bassilian, S., Lee, S.T., Boren, J., Cascante, M., Go, V.L., **Boros, L.G.** Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. *British Journal of Cancer* 91: 2094-2100, 2004.
52. **Boros, L.G.**, Serkova, N.J., Cascante, M., Lee, W.N. Use of metabolic pathway flux information in targeted cancer drug design. *Drug Discovery Today Therapeutic Strategies* 1: 435-443, 2004.
53. Harrigan, G.G., Brackett, D.J., **Boros, L.G.** Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. *Mini Reviews in Medicinal Chemistry* 5: 13-20, 2005.
54. Eibl, G., Takata, Y., **Boros, L.G.**, Liu, J., Okada, Y., Reber, H.A., Hines, O.J. Growth Stimulation of COX-2-Negative Pancreatic Cancer by a Selective COX-2 Inhibitor. *Cancer Research* 65: 982-990, 2005.
55. Balog, A., Gyulai, Z., **Boros, L.G.**, Farkas, G., Takacs, T., Lonovics, J., Mandi, Y. Polymorphism of the TNF-alpha, HSP70-2, and CD14 genes increases susceptibility to severe acute pancreatitis. *Pancreas* 30:e46-e50, 2005.
56. Vizan, P., **Boros, L.G.**, Figueras, A., Capella, G., Mangués, R., Bassilian, S., Lim, S., Lee, W-N.P., Cascante, M. K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. *Cancer Res.* 65: 5512-5, 2005.
57. **Boros, L.G.**, Nichelatti, M., Shoenfeld, Y. Fermented Wheat Germ Extract (Avemar) in the Treatment of Cancer and Autoimmune Diseases. *Ann N Y Acad Sci.* 1051: 529-542, 2005. DOI: 10.1196/annals.1361.097
58. **Boros, L.G.**, Nichelatti, M., Shoenfeld, Y. Fermentiertes Weizenkeimextrakt (Avemar) bei der Behandlung von Krebs- und Autoimmunerkrankungen. *Ann N Y Acad Sci (GER).* 1051: 529-542, 2005.



59. Serkova, N., **Boros, L.G.** Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. *Am J Pharmacogenomics* 5: 293-302, 2005.
60. **Boros, L.G.**, Lerner, M.R., Morgan, D.L., Taylor, S.L., Smith, B.J., Postier, R.G., Brackett, D.J. [1,2-¹³C₂]-D-glucose profiles of the serum, liver, pancreas and DMBA-induced pancreatic tumors of rats. *Pancreas* 31: 337-43, 2005.
61. Maguire, G., Lee, W-N.P., Manheim, D., **Boros, L.G.** SIDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. *Expert Opin Drug Discov* 1: 351-359, 2006.
62. Rehan, V.K., Wang, Y., Sugano, S., Santos, J., Patel, S., Sakurai, R., **Boros, L.G.**, Lee, W.P., Torday, J.S. In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism. *Am J Physiol Lung Cell Mol Physiol.* 292: 323-333, 2007.
63. Centelles, J.J., Ramos-Montoya, A., Lim, S., Bassilian, S., **Boros, L.G.**, Marín, S., Cascante, M., Lee, W-N.P. Metabolic profile and quantification of deoxyribose synthesis pathways in HepG2 cells. *Metabolomics* 3: 105-111, 2007.
64. Huang, J., Gabrielsen, J.S., Cooksey, R.C., Luo, B., **Boros, L.G.**, Jones, D.L., Jouihan, H.A., Soesanto, Y., Knecht, L., Hazel, M.W., Kushner, J.P., McClain, D.A. Increased glucose disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. *Journal of Biological Chemistry* 282: 37501-37507, 2007.
65. **Boros, L.G.**, Boros, T.F. Use of metabolic pathway flux information in anticancer drug design. *Ernst Schering Found Symp Proc.* 4:189-203, 2007.
66. Harrigan, G.G, Maguire, G., **Boros, L.G.** Metabolomics in Alcohol Research and Drug Development. *Alcohol Res Health* 31(1):: 26-35, 2008.
67. Vazquez, A., Beg, Q.K., de Menezes, M.A., Ernst, J., Bar-Joseph, Z., Barabasi, A.L., **Boros, L.G.**, Oltvai, Z.N. Impact of the solvent capacity constraint on E. coli metabolism. *BMC Syst Biol.* 2: 7, 2008.
68. **Boros, L.G.**, Deng, Q., Pandol, S.J., Tsukamoto, H., Go, V-L.W., Lee, W-N.P. Ethanol Diversely Alters Palmitate, Stearate, and Oleate Metabolism in the Liver and Pancreas of Rats Using the Deuterium Oxide Single Tracer. *Pancreas* 38:e47-e52, 2009.
69. Kominsky, D.J., Klawitter, J., Brown, J.L., **Boros, L.G.**, Melo, J.V., Eckhardt, S.G., Serkova, N.J. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. *Clinical Cancer Research* 15: 3442-50, 2009.
70. Hui, H., Huang, D., McArthur, D., Nissen, N., **Boros, L.G.**, Heaney, A.P. Direct spectrophotometric determination of serum fructose in pancreatic cancer patients. *Pancreas* 38:706-12, 2009.
71. Beger, R.D., Hansen, D.K., Schnackenberg, L.K., Cross, B.M., Fatollahi, J.J., Lagunero, F.T., Sarnyai, Z., **Boros, L.G.** Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice. *Metabolomics.* 5(3):336-345, 2009.
72. Espinoza, D.O., **Boros, L.G.**, Crunkhorn, S., Gami, H., Patti, M.E. Dual modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1alpha and -1beta in cultured myotubes. *FASEB J.* 24(4): 1003-1014, 2010.
73. Liu, H., Huang, D., McArthur, D.L., **Boros, L.G.**, Nissen, N., Heaney, A.P. Fructose Induces Transketolase Flux to Promote Pancreatic Cancer Growth. *Cancer Research* 70(15): 6368-6376, 2010.



74. Huang, D., Dhawan, T., Young, S., Yong, W.H., Boros, L.G., Heaney, A.P. Fructose impairs glucose-induced hepatic triglyceride synthesis. *Lipids Health Dis.* 10(1):20, 2011. - designated as 'Highly accessed'
75. Gu, W., Lloyd, D.J., Chinookswong, N., Komorowski, R., Sivits, G., Graham, M., Winters, K.A., Yan, H., **Boros, L.G.**, Lindberg, R.A., Veniant, M.M. Pharmacological targeting of glucagon and GLP-1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. *J Pharmacol Exp Ther* 338: 70-81, 2011.
76. Sonko, B.J., Schmitt, T.C., Guo, L., Shi, Q., **Boros, L.G.**, Leakey, J.E., Beger, R.D.. Assessment of usnic acid toxicity in rat primary hepatocytes using 13C isotopomer distribution analysis of lactate, glutamate and glucose. *Food Chem Toxicol* 49(11): 2968-2974, 2011.
77. Bhalla K., Hwang B.J., Dewi R.E., Ou L., Twaddel W., Fang H.B., Vafai S.B., Vazquez F., Puigserver P., **Boros, L.G.**, Girnun G.D.. PGC1 α promotes tumor growth by inducing gene expression programs supporting lipogenesis. *Cancer Res* 71(21): 6888-6898, 2011.
78. **Boros L.G.**, Huang, D., Heaney, A.P. Fructose Drives Glucose via Direct Oxidation and Promotes Palmitate/Oleate Co-Release from Hepg2 Cells: Relevance with the Randle Cycle. *Metabolomics: Open Access* 2: 107, 2012. doi: 10.4172/2153- 0769.1000107
79. Huang, J., Simcox, J., Mitchell, T.J., Jones, D., Cox, J., Luo, B., Cooksey, R.C., **Boros, L.G.**, McClain, D.A.. Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice. *FASEB J* 27: 2845-2854, 2013. doi: 10.1096/fj.12-216929
80. Singh, A., Happel, C., Manna, S.K., Acquah-Mensah, G., Carratero, J., Kumar, S., Nasipuri, P., Krausz, W.K., Wakabayashi, N., Dewi, L., **Boros, L.G.**, Gonzalez, F.J., Gabrielson, E., Wong, K.K., Girnun, G., Biswal, S. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. *Journal of Clinical Investigation* 123(7): 2921–2934, 2013. doi: 10.1172/JCI66353
81. Yang, Y., Lane, A.N., Ricketts, C.J., Sourbier, C., Wei, M-H., Shuch, B., Pike, L., Wu, M., Rouault, T.A., **Boros, L.G.**, Fan, T.W.-M., Linehan, W.M. Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. *PLoS ONE* 8(8): e72179, 2013. doi: 10.1371/journal.pone.0072179
82. Tedeschi P.M., Markert E.K., Gounder M., Lin H., Dvorzhinski D., Dolfi S.C., Chan L.L., Qiu J., DiPaola R.S., Hirshfield K.M., **Boros L.G.**, Bertino J.R., Oltvai Z.N., Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. *Cell Death and Disease* 4: e877, 2013. doi: 10.1038/cddis.2013.393
83. Jenkins, Y., Sun, T.-Q., Markovtsov, V., Li, W., Nguyen, H., Foretz, M., Li, Y., Pan, A., Uy, G., Gross, L., Baltgalvis, K., Yung, S.L., Gururaja, T., Kinoshita, T., Owyang, A., Smith, I.J., McCaughey, M., White, K., Godinez, G., Alcantara, R., Choy, C., Ren, H., Basile, R., Sweeny, D.J., Xu, X., Issakani, S.D., Carroll, D.C., Goff, D.A., Shaw, S.J., Singh, R., **Boros, L.G.**, Laplante, M.-A., Marcotte, B., Kohen, R., Viollet, B., Marette, A., Payan, D.G., Kinsella, T.M., Hitoshi, Y. AMPK Activation through Mitochondrial Regulation Results in Increased Substrate Oxidation and Improved Metabolic Parameters in Models of Diabetes. *PLoS ONE* 8(12): e81870, 2013. doi:10.1371/journal.pone.0081870
84. Lamonte, G., Tang, X., Chen, J.L., Wu, J., Ding, C.K., Keenan, M.M., Sangokoya, C., Kung, H.N., Ilkayeva, O., Boros, L.G., Newgard, C.B., Chi, J.T. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. *Cancer and Metabolism* 1(1): 23, 2013. doi: 10.1186/2049-3002-1-23 (Highly Accessed)



85. Cantoria, M.J., **Boros, L.G.**, Meuillet, M.J. Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. *Metabolomics* 10: 91-104, 2014. doi: 10.1007/s11306-013-0555-4 - Best Publication Award - Metabolomics Society & Springer – San Francisco, CA, USA, July 02, 2015
86. Laderoute, K.R., Calaoagan, J.M., Chao, W.-r., Dinh, D., Denko, N., Duellman, S., Kalra, J., Liu, X., Papandreou, I., Sambucetti, L., **Boros, L.G.** 5'-AMP-Activated Protein Kinase (AMPK) Supports the Growth of Aggressive Experimental Human Breast Cancer Tumors. *Journal of Biological Chemistry* 289: 22850-64, 2014. PMID: 24993821 doi: 10.1074/jbc.M114.576371.
87. Reitman, Z.J., Duncan, C.G., Poteet, E., Winters, A., Yan, L.J., Gooden, D.M., Spasojevic, I., **Boros, L.G.**, Yang, S.H., Yan, H. Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and D-2-hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. *Journal of Biological Chemistry* 289: 23318-28, 2014. PMID: 24986863 doi: 10.1074/jbc.M114.575183.
88. Varma, V., **Boros, L.G.**, Nolen, G.T., Chang, C-W., Wabitsch, M., Beger, R.D., Kaput, J. Metabolic fate of fructose in human adipocytes: A targeted ¹³C tracer fate association study. *Metabolomics* 11(3): 529-544, 2015. doi: 10.1007/s11306-014-0716-0
89. Glick, G.D., Rossignol, R., Lyssiotis, C.A., Wahl, D., Lesch, C., Sanchez, B., Liu, X., Hao, L.Y., Taylor, C., Hurd, A., Ferrara, J.L., Tkachev, V., Byersdorfer, C., **Boros, L.G.**, Opipari, A.W. Targeting increased anaplerotic metabolism of pathogenic T cells to treat immune disease. *Journal of Pharmacology & Experimental Therapeutics* 351: 298-307, 2014. PMID: 25125579 doi: 10.1124/jpet.114.218099.
90. Buescher, J.M., Antoniewicz, M.R., **Boros, L.G.**, Brugess, S., Brunengraber, H., Clish, C.B., DeBerardinis, R.J., Feron, O., Frezza, C., Ghesquiere, B., Gottlieb, E., Hiller, K., Jones, R.G., Kamphorst, J.J., Kibbey, R.G., Kimmelman, A.C., Locasale, J.W., Lunt, S.Y., Maddocks, O., Malloy, C., Metallo, C.M., Meuillet, E.J., Munger, J., Nöh, K., Rabinowitz, J.D., Ralser, M., Sauer, U., Stephanopoulos, G., St-Pierre, J., Tennant, D.A., Wittmann, C., Vander Heiden, M.G., Vazquez, A., Voudsen, K., Young, J.D., Zamboni, N., Fendt, S-M. A roadmap for interpreting 13C metabolite labeling patterns from cells. *Current Opinion in Biotechnology* 34C: 189-201, 2015. doi: 10.1016/j.copbio.2015.02.003
91. **Boros, L.G.**, Somlyai, G. Compartmentalized NADPH Synthesis, Intramolecular Deuterium Disequilibrium and Water Pools of Mammalian Cells. *Molecular Cell* 55: 253–263, 2014. [http://www.cell.com/molecular-cell/comments/S1097-2765\(14\)00402-X](http://www.cell.com/molecular-cell/comments/S1097-2765(14)00402-X)
92. Varma, V., **Boros, L.G.**, Nolen, G. T., Chang, C-W., Wabitsch, M, Beger, R.D., Kaput, J. Fructose alters intermediary metabolism of glucose in human adipocytes and diverts glucose to serine oxidation in the one-carbon cycle energy producing pathway. *Metabolites* 5(2): 364-385, 2015. doi: 10.3390/metabo5020364
93. Montal, E. D., Dewi, R., Bhalla, K., Ou, L., Hwang, B.J., Ropell, A. E., Gordon, C., Liu, W-J., DeBerardinis, R. J., Sudderth, J., Twaddell, W., **Boros, L. G.**, Shroyer, K. R., Duraisamy, S., Drapkin, R., Powers, R. S., Rohde, J. M., Boxer, M. B., Wong, K-K., Girnun, G. D. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. *Molecular Cell* 60(Nov 19): 1-13. doi: 10.1016/j.molcel.2015.09.025
94. **Boros, L.G.**, D'Agostino, D.P., Katz, H.E., Roth, J.P., Meuillet, E.J., Somlyai, G. Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle. *Medical Hypotheses* 87: 69-74, 2016. doi: 10.1016/j.mehy.2015.11.016
95. **Boros, L.G.**, Somlyai, G., Collins, T.Q., Patel, H., Beger, R.D. Serine Oxidation via Glycine Cleavage (SOGC) Continues its Emergence as a Hallmark of Defective Mitochondria. *Cell Metabolism* 23: 635–648, 2016. <https://goo.gl/vTHaCO>



96. **Boros, L.G.**, Collins, T.Q., Somlyai, G. What to eat or what not to eat - that is still the question. *Neuro-Oncology* 19(4): 595-596, 2017. doi: 10.1093/neuonc/now284
97. Somlyai, G., Collins, T.Q., Meuillet, E.J., Hitendra, P., D'Agostino, D.P., **Boros, L.G.** Structural homologies between Phenformin, Lipitor and Gleevec aim the same metabolic oncotarget in leukemia and melanoma. *Oncotarget* 8: 50187-50192, 2017. doi: 10.18632/oncotarget.16238
98. Edderkaoui, M., Chheda, C., Soufi, B., Zayou, F., Hu, R., Ramanujan, V.K., Pan, X., **Boros, L.G.**, Tajbakhsh, J., Madhav, A., Bhowmick, N., Wang, Q., Lewis, M., Tuli, R., Habtezion, A., Murali, R., Pandol, S.J. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. *Gastroenterology* 155: 1985–1998, 2018. doi: 10.1053/j.gastro.2018.08.028
99. Joyner, M.J., **Boros, L.G.**, Fink G. Biological Reductionism versus Redundancy in a Degenerate World. *Perspectives in Biology and Medicine* 61(4): 517-526, 2018. doi: 10.1353/pbm.2018.00612018
100. **Boros, L.G.**, Collins, T.Q., Boros, E.A., Lantos, F., Somlyai, G. Deuterium and metabolic water matter – what this means biochemically and clinically. *Science Advances* 4(8): eaat7314, 2018. DOI: 10.1126/sciadv.aat7314 - <https://advances.sciencemag.org/content/4/8/eaat7314/tab-e-letters>
101. **Boros, L.G.**, Krüger, T.P.J., Letoha, T., Tuszyński, J.A., Dorfsman, P.D. Lech, J.C. To stabilize or not to stabilize RNA - that is still the question. *Science Advances* 7(24): eabf1771, 2021. DOI: 10.1126/sciadv.abf1771 - <https://advances.sciencemag.org/content/7/24/eabf1771/tab-e-letters>

Book Contributions

- Boros, L.G.**, Singer, M.V. Animal models of chronic pancreatitis. A critical review of experimental studies. *In: Pancreatitis. New data and geographical distribution.* Eds. H. Sarles, CD Johnson, JF Saunier. Chapter 7, pages: 67-82. *Arnette Blackwell, Paris, France 1991.*
- Robertson, F.M., Bijur, G.N., Oberyszyn, A.S., Nill, M.R., **Boros, L.G.**, Spencer, W.J., Sabourin, C.L., Oberyszyn, T.M. Interleukin-1 β in murine multistage carcinogenesis. *In: Skin Cancer: Mechanisms and Human Relevance.* Eds. Hasan Mukhtar. Chapter 20, pages: 255-272. *CRC Press, Boca Raton, Ann Arbor, London, Tokyo 1995.*
- Singer, M.V., **Boros, L.G.**, Mayr, C. Experimentelle Modelle der chronischen Pankreatitis. *In: Erkrankungen des exokrinen Pankreas.* Eds. Mössner, J., Adler, G., Fölsch, U.R., Singer, M.V., eds.. Jena, Stuttgart: Gustav Fischer, 1995: 303-312.
- Cascante, M., Comin, B., Raïs, B., Boren, J., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Application of metabolic control analysis to the design of a new strategy for cancer therapy. *In: Technological and Medical Implications of Metabolic Control Analysis.* Eds. Cornish-Bowden, A. and Cardenas, M.L. Kluwer Academic Publishers, The Netherlands, 1999: 173-180.
- Boros, L.G.**, Cascante, M., Lee, W-N.P. Stable Isotope-Based Dynamic Metabolic Profiling in Disease and Health. *In: Metabolite Profiling: Its Role in Biomarker Discovery and Gene Function Analysis.* Eds. Harrigan, G.G. and Goodacre, R.; Kluwer Academic Publishers, United States of America, 2003 pp. 141-169.
- Boros, L.G.**, Lee, W-N.P. Metabolic Network Characteristics in Cell Growth and Death in Cancer. *In: Nutritional Oncology, Second Edition,* Eds. Heber, Blackburn, Go, & Milner; Elsevier, United States of America, 2006 pp. 57-68.



7. **Boros, L.G.**, Lee, W-N.P. Targeted Drug Design and Metabolic Pathway Flux. In: *Metabolome Analyses: Strategies for Systems Biology*. Eds. Vaidyanathan, S., Harrigan, G.G. and Goodacre, R.; Springer, Boston, United States of America, 2005 pp. 323-337.
8. Cascante, M., **Boros, L.G.**, Boren J.A. Modeling of Regulation of Glycolysis and Overall Energy Metabolism Under a Systems Biology Approach. In: *Handbook of Neurochemistry & Molecular Neurobiology 3rd, Brain Energetics, Integration of Molecular and Cellular Processes*; Eds. Gibson & Diemel; Part 8, 2006 pp. 861-875.
9. Sarnyai, Z., **Boros, L.G.** Modeling Networks of Glycolysis, Overall Energy Metabolism and Drug Metabolism under a Systems Biology Approach. In: *Annual Reports in Medicinal Chemistry*, Chapter 20, Volume 43, 2008 pp. 329–349.
10. Cantoria, M.J., Patel, H., **Boros, L.G.**, Meuillet, E.J. Metformin and Pancreatic Cancer Metabolism. *Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment* (In). Dr. Kelly McCall (Ed.), ISBN: 978-953-51-1375-1, InTech, DOI: 10.5772/57432. Available from: <http://www.intechopen.com/books/pancreatic-cancer-insights-into-molecular-mechanisms-and-novel-approaches-to-early-detection-and-treatment/metformin-and-pancreatic-cancer-metabolism>
11. **Boros L.G.**, Beger R.D., Meuillet E.J., Colca J.R., Szalma S., Thompson P.A., Dux L, Farkas Gy. Jr., Somlyai G. Targeted ¹³C-labeled tracer fate associations for drug efficacy testing in cancer. In: *Tumor Cell Metabolism – Pathways, Regulation & Biology*, Eds. Shoshan, M. (Karolinska Institute, Stockholm, Sweden) & Mazurek, S.L. (Justus-Liebig-University, Giessen, Germany), Chapter 15 pages 349-372, 2014. ISBN 978-3-7091-1823-8 ISBN 978-3-7091-1824-5 (eBook) DOI 10.1007/978-3-7091-1824-5 Publisher Springer Vienna; Copyright Holder: Springer-Verlag Wien

Abstracts

1. **Boros, L.G.**, Pap, A, Berger, Z. Chronic pancreatitis-like lesions provoked by duct occlusion with Ethibloc in rats can be maintained by alcohol administration. Presented at the European Pancreatic Club, Manchester, England, September, 1985.
2. **Boros, L.G.**, Pap, A. Recovery of the pancreatic enzyme content in Ethibloc induced obstructive pancreatitis can be inhibited by alcohol administration. Presented at the European Pancreatic Club, Nijmegen, The Netherlands, September, 1986.
3. **Boros, L.G.**, Hajnal, F., Pap, A., Takats, T., Nagy, I. Pancreatic insufficiency and atrophy provoked by intraductal oleic acid can be progressed by alcohol and regenerated by cholecystokinin octapeptide (CCK 8). Presented at the European Pancreatic Club, Marseille, France, September, 1987.
4. **Boros, L.G.**, Berger, Z., Pap, A., Takats, T., Nagy, I. CCK-8 accelerates, the CCK antagonist CR-1409 inhibits pancreatic regeneration after resection in rat. Presented at the European Pancreatic Club, Budapest, Hungary, August, 1988.
5. **Boros, L.G.**, Pap, A., Takats, T., Nagy, I. Alcohol inhibits the regeneration after pancreatic resection in rats. Presented at the European Pancreatic Club, Budapest, Hungary, August, 1988.
6. **Boros, L.G.**, Oberyszyn, T.M., Sabourin, C.L., Bijur, G.N., Oberyszyn, A.E., Robertson, F.M. Cytokines regulating neutrophil migration during cutaneous inflammation. Presented at the Association of Leukocyte Biology, Charlestown, NC, USA, December, 1992.
7. **Boros, L.G.**, Muscarella P., Brandes, J.L., Johnson J.A., Schirmer, W.J., Ellison, E.C., Melvin, W.S. The effect of BZA-5B, a farnesyl protein transferase inhibitor, on the growth of human pancreatic cancer. Presented at the American Gastroenterological Society, Washington, DC, USA, May, 1996.



8. Muscarella P., **Boros, L.G.**, Brandes, J.L., Johnson J.A., Melvin, W.S., Schirmer, W.J., Ellison, E.C. Dehydroepiandrosterone-sulfate inhibits pancreatic cancer cell proliferation in vitro and in vivo. Presented at the American Gastroenterological Society, Washington, DC, USA, May, 1996.
9. **Boros, L.G.**, Muscarella P., Brandes, J.L., Johnson J.A., Melvin, W.S., Schirmer, W.J., Ellison, E.C. Orally administered dehydroepiandrosterone inhibits the growth of subcutaneously injected pancreatic cancer cells in nude mice. Presented at the American Gastroenterological Society, San Francisco, CA, USA, May, 1997.
10. **Boros, L.G.**, Puigjaner, J., Rais, B., Comin, B., Lee, P., Melvin, W.S., Schirmer, W.J., Cascante, M. Oxythiamine and dehydroepiandrosterone inhibit the non-oxidative synthesis of ribose and cancer cell proliferation. Presented at the American Gastroenterological Society, San Francisco, CA, USA, May, 1997.
11. Rais, B., Comin, B., **Boros, L.G.**, Lee, P., Melvin, W.S., Schirmer, W.J., Cascante, M. Inhibition of Ehrlich's ascites tumor cell proliferation by pentose cycle inhibitors is associated with an arrest in the G0-G1 cell cycle phases. Presented at the The First Annual Meeting on Experimental Therapeutics of Human Cancer, Frederick, Maryland, USA, June, 1998.
12. Guenther, D.A., Huang, E., Ikramuddin S., **Boros, L.G.**, Melvin, W.S. Natural killer cell activity is not different following laparoscopy compared to open surgery. Presented at the Society of American Gastrointestinal and Endoscopic Surgeons, San Antonio, Texas, USA, March, 1999.
13. Cascante, M., Comin, B., Boren, J., Moro, C., Martinez, S., Centelles, J.J., LeeW-N.P., and **Boros, L.G.** Plenary lecture: Inhibition of tumor ribose-phosphate synthesis: Anew strategy to control tumor proliferation. Presented at the ComBio99. Australian Society for Biochemistry and Molecular Biology, Sidney, Australia, September, 1999.
14. Cascante, M., Comin, B., Raïs, B., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Application of metabolic control analysis to the design of a new strategy for cancer therapy. Presented at the MCA 99 NATO Advanced Research Workshop on Technological and Medical Implications of Metabolic Control Analysis, Visegrad, Hungary, July, 1999.
15. **Boros, L.G.**, Comin, B., Boren, J., Martinez, S., Moro, C., Centelles, J.J., Lee, W.N.P., and M. Cascante. Over-expression of transketolase: a mechanism by which thiamine supplementation promotes cancer growth. Presented at the American Association for Cancer Research, San Francisco, CA, USA, April, 2000.
16. **Boros, L.G.**, Torday, J.S., Lim, S., Bassilian, S., Cascante, M., and Lee, W.N.P. TGF- β increases nucleic acid ribose synthesis through the non-oxidative pentose cycle in lung carcinoma cells. Presented at the American Association for Cancer Research, San Francisco, CA, USA, April, 2000.
17. Lee, W-N.P., Bassilian, S., Lim, S., **Boros, L.G.** 2-Deoxyglucose inhibits both the oxidative and non-oxidative branches of the pentose cycle. Presented at the Federation of American Societies for Experimental Biology, San Diego, CA, USA, April, 2000.
18. Steinkamp, M.P., Fleming, J.C., **Boros, L.G.**, Neufeld, E.J. Thiamine depletion in thiamine-responsive megaloblastic anemia (TRMA) mutant fibroblasts leads to a reduction in non-oxidative ribose synthesis. Presented at the American Society for Biochemistry and Molecular Biology and The American Society for Pharmacology and Experimental Therapeutics (ASBMB/ASPE), 2000.
19. Comin, B., Boren, J., Moro, S., Martinez, S., Lee, W-N.P., **Boros, L.G.**, Centelles, J.J., Cascante, M. New antitumoral drugs based on ribose-phosphate synthesis tested by metabolic control analysis. Presented at the 18th International Congress of Biochemistry and Molecular Biology, Birmingham, UK, July, 2000.



20. Boren, J., Comin, B., Centelles, J.J., Moro, S., Martinez, S., Le, W-N.P., **Boros, L.G.**, Cascante, M. Modeling metabolic networks for the search of new targets in cancer therapy. Presented at the Biochemical Systems Theory (SYMBIOSYS), Puerto de la Cruz, Tenerife, Canary Islands, Spain, September, 2000.
21. **Boros, L.G.**, Lee, W-N.P., Hidvegi, M., Go, V.L.W. Metabolic effects of fermented wheat germ extract with anti-tumor properties in cultured MIA pancreatic adenocarcinoma cells. Presented at the Combined Meeting of the International Association of Pancreatology and the American Pancreatic Association, Chicago, Illinois, USA, November, 2000.
22. **Boros, L.G.**, Lee, W-N.P., Go, V.L.W. Metabolic targets of tumor growth inhibitory signals in MIA pancreatic adenocarcinoma cells: a metabolic hypothesis of cellular signaling pathways. Presented at the Combined Meeting of the International Association of Pancreatology and the American Pancreatic Association, Chicago, Illinois, November, 2000.
23. Lee, W-N.P., Mao, C.S, Bassilian, S., **Boros, L.G.** Plasma fatty acid production and the role of de novo lipogenesis in energy transport. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.
24. **Boros, L.G.**, Lee, W-N.P., Williams, R.D. Isofenphos organophosphate pesticide induces metabolic changes of the invasive phenotype in K562 myeloid blast cells. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.
25. **Boros, L.G.**, Boren, A.J., Marin, S., Cascante, M., Lim, S., Bassilian, S., Ahmed, S., Lee, W-N.P. STI571 decreases glucose derived nucleic acid synthesis but increases direct glucose oxidation in K562 myeloid blast cells. Presented at the American Association for Cancer Research, New Orleans, LA, USA, March, 2001.
26. Lee, W-N.P., Lim, S., Bassilian, S., Ahmed S., Mao, C.S., **Boros, L.G.** Glucose metabolic changes in HepG2 cells induced by the phosphorylase inhibitor CP-329,626. Presented at the Federation of American Societies for Experimental Biology, Orlando, Florida, USA, March 31-April 4, 2001.
27. Lee, W-N.P., Martinez, S., Lim, S., Bassilian, S., Ahmed, S., Boren, J., Mao, C., **Boros, L.G.**, Cascante, M. Diverse metabolic changes of glucosamine induced insulin resistance in HepG2 cells. Presented at the International Conference of Pediatric Endocrinology Montreal 2001, Montreal, Canada, Sept, 2001.
28. Rehan, V., Feng, S., Rehan, Y.H., Lee, W-N.P., Torday, J.S., **Boros, L.G.** Evidence for metabolic phenotype changes during trans-differentiation of pulmonary lipofibroblasts to myofibroblasts in response to hyperoxia. Presented at the Pediatric Academic Societies Annual Meeting, Baltimore, MD, April-May, 2001.
29. Lee, W-N.P., Martinez, S., Lim, S., Bassilian, S., Ahmed, S., Boren, J., Mao, C., **Boros, L.G.**, Cascante, M. Diverse Metabolic Changes of Glucosamine Induced Insulin Resistance in HEPG2 Cells. Presented at the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology (LWPES/ESPE) 6th Joint Meeting, Montreal, Canada, July, 2001.
30. **Boros, L.G.**, Syed, A.S., Bassilian S., Lim, S., Lee, W-N.P. Lack of proliferative and metabolic response in MIA pancreatic adenocarcinoma cell cultures to STI571 (Gleevec). Presented at the American Pancreatic Association, Chicago, Illinois, November, 2001.
31. Bulotta, A., Perfetti, R., Hui, H., **Boros, L.G.** Differentiation of cultured ARIP carcinoma cells is mediated via glucose intermediary metabolic changes in response to Glucagon-like peptide 1 (GLP-1) treatment. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2001.



32. **Boros, L.G.**, Go, V.L., Lee, W-N.P. Metabolic Profiling of Cell Growth and Death in Cancer. Presented at the Cambridge Healthtech Institute's Premier Conference on Metabolic Profiling: Pathways to Discovery (keynote address), Sheraton Chapel Hill Hotel, Chapel Hill, North Carolina, December 4, 2001.
33. **Boros, L.G.**, Bassilian S., Lim, S., Lee, W-N.P. STI571 (Gleevec) inhibits de novo palmitate but does not affect nucleic acid synthesis in MIA pancreatic adenocarcinoma cells. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.
34. Tucker, C., **Boros, L.G.**, Patel, S.M., Santos, J., Reddy, S.G., Lee, W-N.P., Torday, J.S., Rehan, V.K.. Dihydroxycholecalciferol (Vitamin D₃) affects lipid metabolism differentially in pulmonary alveolar type II cells and fibroblasts. Presented to the Pediatric Academic Societies' Annual Meeting, Baltimore, MD, May, 2002.
35. Cascante, M., Comin, B., Raïs, B., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Metabolic control theory and stable isotope based metabolic profiling. Presented at the EMBIO Meeting, Barcelona, Spain, June, 2002.
36. Cascante, M., Comin, B., Atauri, P., Ramos, A., Vizán, P., **Boros, L.G.**, Centelles, J.J., Mazurek, S., Eigenbrodt, E., Frederiks, W.M., Lee, W-N.P., Boren, J. Modeling metabolic networks in drug discovery and disease. Presented at the European Science Foundation (ESF) Meeting, Granada, June, 2002.
37. **Boros, L.G.**, Go, V.L.W., Lee, W-N.P. Stable isotope-based metabolic profiling in pancreatic cancer: applications in biomarker discovery and gene function analysis. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2002.
38. **Boros, L.G.**, Deng, Q., Pandol, S.J., Tsukamoto, H., Go, V.L.W., Lee, W-N.P. Ethanol induced tissue specific lipotoxicity in the liver and pancreas. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2002.
39. **Boros, L.G.**, Harrigan, G.G. Stable isotope-based metabolic profiling: applications in biomarker discovery & gene function testing. Presented at the Cambridge Healthtech Institute's Second Conference on Metabolic Profiling, Sheraton Chapel Hill Hotel, Chapel Hill, North Carolina, December 4, 2002.
40. Tucker, C., **Boros, L.G.**, Santos, J., Bassilian, S., Torday, J.S., Lee, W-N. P., Rehan, V. Differential proliferative and metabolic effects of vitamin D3 on near-term fetal rat lung fibroblasts and type II cells. Presented at the American Federation for Medical Research Western Regional Meeting Neonatology Session, Carmel, CA, February, 2003.
41. Ramos-Montoya, A. **Boros, L.G.**, Bassilian, S., Lim, S., Lee, W-N.P., Cascante, M. Pentose and purine synthetic pathway inhibitors do not have synergistic effect on colon carcinoma cell growth. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2003.
42. Bulotta, A., Perfetti, R., Hui, H., **Boros, L.G.** Glucagon-like peptide-1 regulates insulin release via glucose derived de novo fatty acid synthesis and chain elongation in pancreatic carcinoma cells. Presented at the American Diabetes Association Meeting Metabolism III Session, Chicago, IL, March, 2003.
43. Tucker, C., **Boros, L.G.**, Santos, J., Torday, J.S., Rehan, V. Differential proliferative and metabolic effects of vitamin-D3 on near-term fetal rat lung fibroblasts and type II cells. Presented at the Pediatric Academic Societies' Annual Meeting in Seattle, Cardiopulmonary Development Session, Washington, May 3-6, 2003.
44. Lee, W-N.P., **Boros, L.G.**, Mao, C.S. Tracer approaches to determining glyconeogenesis. Presented at the American Society for Parenteral and Enteral Nutrition Meeting, Nutrition Week, San Antonio, TX, January, 2003.
45. **Boros, L.G.** Metabolic profiling using stable isotope tracer technology GC/MS. Presented at the 20th Annual Conference on Metabolic Profiling: Biomarker Discovery, Drug Efficacy and Fundamental Biochemistry, Asilomar, CA, October 15-18, 2004.



46. **Boros, L.G.**, Lerner, M., Morgan, D., Taylor, S., Postier, R., Brackett, D. Different positional accumulation of [1,2-¹³C₂]glucose into RNA ribose of DMBA-induced pancreatic tumors, pancreas and liver. Presented at the American Pancreatic Association, Chicago, Illinois, November 4-5, 2004.
47. Guo, P., Bassilian, S., Lim, S., Lee, W.-N.P., **Boros, L.G.** Doxorubicin induces Mia PaCa-2 cell apoptosis by increasing GSK-3 β expression, β -catenin degradation and by limiting DNA/RNA ribose synthesis in the pentose cycle. Presented at the American Pancreatic Association, Chicago, Illinois, November 4-5, 2004.
48. Miljus, J., Melo, J.V., **Boros, L.G.**, Anderson, N., Talpaz, M., Leibfritz, D., Eckhardt, S.G., Serkova, N. Metabolic profile of imatinib resistance in chronic myeloid leukemia cells. Presented at the 46th American Society of Hematology Meeting in San Diego, CA, December 4-7, 2004.
49. **Boros, L.G.** CASE STUDY: Single metabolic mechanism of Gleevec resistance regardless of the genetic makeup of leukemia cells. Presented at the 5th Annual Metabolic Profiling: Pathways in Discovery Meeting, Lake Buena Vista, FL, December 13-14, 2004.
50. **Boros, L.G.**, Lee, W-N.P. Predicting clinical resistance to Gleevec treatment by in vitro applied stable isotope-based dynamic metabolic profiling (SIDMAP). Presented at the 2005 FDA Science Forum, Washington, DC, April 27-28, 2005.
51. Sahai, I., M. Montefusco, C.M., Fleming, J.C., **Boros, L.G.**, Tartaglini, E., Chick, G., Neufeld, E.J. Role of Defective High-Affinity Thiamine Transporter slc19a2 in Marrow from a Mouse Model of Thiamine-Responsive Anemia Syndrome: Evidence for Defective Deoxyribose and Heme Synthesis. Presented at the 47th American Society of Hematology, San Diego, CA, December 3-6, 2005. [link](#)
52. Sugano, S., **Boros, L.G.**, Wang, Y., Santos, J., Lee, W-P., Torday, J.S., Rehan, V.K. Maternal nicotine exposure: lung alveolar type II cell proliferation, differentiation and metabolic profile. Presented at the Western Society for Pediatric Research (WSPR), Carmel, CA, February 3, 2006. (WINNER OF THE WSPR LOWELL GLASGOW STUDENT RESEARCH AWARD).
53. Erkkila, K., Liu, P.Y., Lee, P.W-N., **Boros, L.G.**, Ferrini, M., Sinha Hikim, A.P., Wang, C., Lue, Y.H., Swerdloff, R.S.. XXY mice exhibit altered palmitate and stearate metabolism in the brain. Presented at the Annual Meeting of the Endocrine Society (ENDO), Boston, MA, June 24-27, 2006.
54. **Boros, L.G.**, Kochegarov, A., Szigeti, I., Lee, S.T., Jancso, G., Jákli, G., Somlyai, G. Deuterium depleted water alters glucose-derived fatty acid and cholesterol synthesis of tumor cells. Presented at the Annual International Meeting of the Metabolomics Society, Boston, MA, June 25-29, 2006.
55. Beger, R.D., Hansen, D.K., Schnackenberg, L.K., Fatollahi, J.J., **Boros, L.G.** Decreased glycogen and RNA ribose synthesis and turnover from [U-¹³C₆]-D-glucose is an early metabolic marker of valproic acid toxicity on the liver in mice. 3rd Annual Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.
56. **Boros, L.G.**, Szigeti, I. Szabo, G. Sarnyai, Z. Delayed uptake of [U-¹³C₆]-D-glucose and abnormal ¹³C isotopomer production after acute and chronic antipsychotic treatment in mice. Presented at the Annual International Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.
57. Vizan, P., **Boros, L.G.**, Peiris, M., Figueras, A., Capella, G., Mangués, R., Lee, W-N.P., Selivanov., Cascante, M. K-ras codon-specific mutations produce distinctive metabolic phenotypes in mice fibroblasts. Presented at the Annual International Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.



58. Harris, D.M., Li, L., Fatollahi, J.J., Lagunero, F.T., Cross, B.M., Go, V.L.W., **Boros, L.G.** Luteolin inhibits proliferation and de novo fatty acid synthesis in pancreatic cancer cells. Presented at the American Association for Cancer Research, San Diego, CA, USA, April, 2008.
59. Sonko, B.J., Guo, L., Schmitt, T., Leakey, J., **Boros, L.G.**, Beger, R. In Vitro Usnic Acid Concentration/Time Dependency Toxicity Evaluation. Models and Mechanisms of Hepatotoxicity, Society of Toxicology, Salt Lake City, Utah, USA, March 7-11, 2009.
60. Sonko, B.J., Schmitt, T.M., **Boros, L.G.**, Sakar, S., Syed, A., Beger, R. Effect of Chronic MPTP Administration on Glycolysis and TCA cycle Pathways in Mouse Model of Parkinson's Disease. Twenty-sixth International Neurotoxicological Conference, Portland, Oregon, USA, June 5-10, 2010.
61. Varma, V., Nolen, G.T., **Boros L.G.**, Kaput, J. Fructose Metabolism and Its Influence on Glucose Metabolism in Human Adipocytes. 70th - Integrated Physiology Session, American Diabetes Association, Orlando, Florida, June 25-29, 2010.
62. Bolin, D., Ahmad, M., Banner, B., **Boros, L.G.**, Cai, J., Gillespie, P., Goodnow, P., Gubler, M.L., Hamilton, M.M., Hayden, S., Huang, K.S., Liu, X., Lou J.P., Mark D., McDermott L., Perrotta A., Qian Y., Ren Y., Rondinone C., Rowan K., Spence C., Tilley J., Sergi J., Thakkar K., Yi L., Yun W., Xiang Q., Zhang X., Conde-Knape C., Olivier A.R. A Novel Approach for the Treatment of Type 2 Diabetes (T2D): Characterization of a Potent, Orally Active, Small Molecule Glycogen Synthase Activator. 70th Scientific Sessions – Insulin Action and Metabolism, American Diabetes Association, Orlando, Florida, June 25-29, 2010.
63. Varma, V., Nolen, G.T., **Boros, L.G.**, Kaput, J. Fructose Alters Glucose Metabolism of Human Adipocytes. 1st Annual Foods Program Science and Research Conference, Food and Drug Administration, White Oak Campus, Silver Spring, Maryland, June 21-22, 2011.
64. Varma, V., Nolen, G.T., **Boros, L.G.**, Kaput, J. Fructose is a Potent Lipogenic Macronutrient in Human Adipocytes. Joint meeting on Diabetes and Obesity – ‘Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms’ (J8) AND ‘Genetic & Molecular Basis of Obesity and Body Weight Regulation’ (J7) at Santa Fe, NM, January 29-February 3, 2012.
65. Cantoria, M.J., **Boros, L.G.**, Meuillet, M.J.. Metformin Inhibits the TCA Cycle and Fatty Acid Synthesis in MIAPaCa-2 Pancreatic Cancer Cells. International Association of Pancreatology and the American Pancreatic Association Joint Meeting, Miami, FL, October 31, November 02, 2012 (PII-60)
66. Yang, Y., Lane, A., Ricketts, C., Wei, M.H., Pike, L., Wu, M., Rouault, T.A., **Boros, L.G.**, Fan, T., Linehan, M. (C063) Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma (HLRCC). Presented at the 9th American Associations for Cancer Research and Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Preclinical Models, Maui, Hawaii, February 21-25, 2013.
67. **Boros, L.G.**, Serkova, N.J., Laderoute, K.R., Linehan, W.M., Meuillet, M.J.. Stable ¹³C Isotope Enriched Metabolome (Isotopolome) Wide Associations (IWAS) Improve System Wide Association Studies (SWAS) for Phenotype and Drug Research. World Biotechnology Congress, Medical Biotechnology, Boston, MA, June 3-6, 2013.
68. **Boros, L.G.**, Lee, W-N.P. Cross-labeled ¹³C-stearate fate detection in the [1,2-¹³C₂]-d-glucose derived isotopolome improves system wide associations when compared with external; [U-¹³C₁₈]-stearate incubation in rosiglitazone treated HEPG₂ Cells. 9th Annual Conference of the Metabolomics Society, SECC, Glasgow, Scotland, July 1-4, 2013.



69. Cantoria, M.J., **Boros, L.G.**, Patel, H., Han, H., Ignatenko, N. Meuillet, M.J. Metformin-induced metabolic changes are k-ras-dependent in animal models of pancreatic cancer. Presented at the American Association for Cancer Research, San Diego, CA, April 8, 2014.
70. **Boros, L.G.**, Meuillet, M.J., Somlyai, I., Jancsó, G., Jákli, G., Krempels, K., Puskás, L.G., Nagy, I.L., Molnár, M., Laderoute, K.L., Thompson, P.A., Somlyai, G. Fumarate hydratase and deuterium depletion control oncogenesis via NADPH-dependent reductive synthesis: mitochondrial matrix water, DNA deuteration and epigenetic events. Presented at the American Association for Cancer Research, San Diego, CA, April 8, 2014.
71. Weston, R., Rodier, J., Coffey, S., Glickenhau, A., **Boros, L.G.**, MacDonald, M.E., Carroll, J.B. Investigating Hepatic Dysfunction In The Httq111/+ Mouse With A Perturbagen-based Primary Hepatocyte System. *J Neurol Neurosurg Psychiatry* 85: A19-A20, 2014. doi:10.1136/jnnp-2014-309032.58
72. **Boros, L.G.** Targeted ¹³C Tracer Fate Association Studies for Clinical Isobolomics. Presented at SciX 2014, the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS), Reno, Lake Tahoe, NV, USA, September 30, 2014.
73. Vijayalakshmi, V., **Boros, L.G.**, Nolen, G.T., Beger, R.D., Kaput, J. Fructose diverts glucose to glycerol and serine oxidation in the one-carbon cycle energy producing pathway of human adipocytes. Diabetes and Metabolic Dysfunction, Mitochondria, Metabolism and Heart Failure, Keystone Symposium at the Santa Fe Community Convention Center, Santa Fe, NM, USA, January 27 – February 1, 2015.
74. **Boros, L.G.** Biochemical interpretations of ²H/¹H ratio contrast magnetic resonance spectroscopy: tissue phenotyping by mitochondrial matrix (metabolic ¹H²O) and cytoplasmic (²H¹HO) water ratios in cells. 3rd International Congress on Deuterium Depletion, Budapest, Hungary, EU, May 07, 2015 – 13th Presentation (23 minutes) LASZLO G. BOROS - <http://www.deuteriumdepletion.com/2015program.php>
75. **Boros, L.G.**, Katz, H.E., Roth, J.P., Somlyai, G. Gluconeogenesis and the pentose cycle impact deuterium depleted water efficacy in anticancer therapeutics. 3rd International Congress on Deuterium Depletion, Budapest, Hungary, EU, May 08, 2015 – 4th Presentation (52 minutes) LASZLO G. BOROS - <http://www.deuteriumdepletion.com/2015program.php>
76. Blanco, F.F., Zarei, M., Brody, J.R., **Boros, L.G.**, Winter, J.M. The RNA binding protein, HuR, regulates pancreatic cancer cell metabolism. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1191. doi:10.1158/1538-7445.AM2015-1191 - <http://goo.gl/L0UszO>
77. **Boros, L.G.**, Somlyai, G. Deuterium and Hydrogen Ratios Determine Proton Spin-Lattice T1-Weighted Magnetic Resonance Images: Clinical Applications in Cancer. European Society for Isotope Research, ESIR Isotope Workshop XIII September 20 – 24, pp: 92-93, 2015, Zadar, Croatia. Eds: Krajcar Bronić, I., Horvatinčić, N., Obelić, B., Publisher: Ruđer Bošković Institute, Zagreb, Croatia, 2015; ISBN 978-953-7941-08-6 - <http://esir2015.irb.hr/Programme/Deuterium-and-hydrogen-ratios-determine-proton-spin-lattice-T1-weighted-Magnetic-Resonance-Images-Clinical-applications-in-cancer>
78. **Boros, L.G.**, Patel, H., Somlyai, G. The oncoisotopic effect of deuterium and carbon-dependent oncoisotope depletion in processed carbohydrates by ketogenic mitochondrial substrate oxidation. 1st Annual Conference on Nutritional Ketosis and Metabolic Therapeutics, Tampa Bay, Florida, January 28-30, 2016
79. Zarei, M., Blanco, FF., **Boros, L.G.**, Yeo, C.J., Brody, J.R., Winter, J.M. Post-transcriptional regulation of IDH1 by the RNA-binding protein HuR is important for pancreatic cancer cell survival under nutrient deprivation. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B41. - <http://goo.gl/ZUo51p>



80. **Boros, L.G.**, Nutritional ketosis improves nanomechanics for ATP synthase and TCA cycle turnover via aspartate mediated proton transfer in mitochondria. 2nd Annual Conference on Nutritional Ketosis and Metabolic Therapeutics, Tampa Bay, Florida, February 1-4, 2017.
81. Somlyai, G., Molnár, M., Somlyai, I., Fórizs, I., Czuppon, G., **Boros, L.G.** Hydrogen/deuterium ratio is a key regulator of energy production and cell proliferation – submolecular dimensions of drug development. 3rd International Conference on Clinical Sciences Drug Discovery, Reston, Virginia, USA, November 9-11, 2017.
82. Yee, J.K., Lu, Q., Lim, S., Han, G., Desai, M., **Boros, L.G.**, Ma, L. Flavonoids in the treatment of non-alcoholic fatty liver disease: a tracer-based cell culture study. Pediatrics Endocrine Society (PES) Annual Meeting, Fort Worth, Texas, USA, April 24-27, 2020.

Invited Presentations, Keynotes & Teaching

1. Distribution of stable ¹³C labels in structural macromolecules of pancreatic adenocarcinoma cells from [1,2-¹³C₂]glucose: The application of mass spectrometry to cancer cell metabolism. Central Research Institute of Experimental Medicine of the Hungarian Academy of Sciences and the Hungarian Gastroenterological Society Research Section Seminars, Invited Speaker, Budapest, Hungary, June, 1997
2. Ribose synthesis in tumor cells: A new target for anti-tumor therapy. Faculty and Student Research Conference, Department of Human Nutrition, The Ohio State University, Columbus, OH, USA, October, 1997
3. Thiamine and the tumor proliferation process; ribose synthesis through transketolase. Abbott-Ross Laboratories Research Seminar, Invited Speaker, Columbus, OH, USA, May 1997
4. Inhibition of tumor proliferation through the synthesis of RNA ribose. Pathology 850(b): Seminars in Pathology - Continuing Medical Education Program, The Ohio State University, Columbus, OH, USA, April, 1997
5. Inhibition of tumor cell proliferation through the synthesis of nucleic acid ribose: a new approach to tumor therapy. University of Barcelona department of Biochemistry Research Seminar, Barcelona, Catalonia, Spain, November, 1998
6. Gas Chromatography/Mass Spectrometry Chemical Analysis, Summer Student Advisor. Harbor-UCLA Research and Education Institute, Torrance, CA, USA, June-July, 1999.
7. Carbon ¹³C mass isotope studies in cancer cell glucose metabolism: a practical application in tumor cell metabolic response to transforming growth factor-beta (TGF- β_2) treatment. Schebo-Tech presentation, Giessen, Germany, August, 1999
8. The role of thiamine (vitamin B₁) in the proliferation of tumor cells: clinical consequences. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, January 6, 1999
9. Transforming growth factor-beta (TGF-beta 2) induces non-oxidative glucose metabolic changes in tumor cells: an explanation for hypoxia resistance in tumors. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 22, 1999
10. Thiamine-responsive megaloblastic anemia and the role of vitamin B₁ in nucleic acid synthesis. Nutrition Research Seminars UCLA School of Medicine, Department of Nutrition, Los Angeles, CA, USA, January 31, 2000



11. Impaired non-oxidative nucleic acid ribose synthesis in thiamine responsive megaloblastic anemia. Endocrine Clinical Conference, UCLA School of Medicine, Department of Endocrinology. Torrance, CA, USA, March 15, 2000
12. Characterization of tumor cell metabolism with stable glucose isotopes and GC/MS in response to growth modifying agents. Sala de Graus, Facultat de Biologia. University of Barcelona, Barcelona, Spain, May 19, 2000
13. Metabolic phenotypic changes in pancreatic adenocarcinoma cells after fermented wheat germ extract (Aveamar) treatment. UCLA School of Medicine, Center for Human Nutrition research seminars, Los Angeles, CA, USA, July 21, 2000
14. Methods of determining the metabolic phenotype of mammalian cells. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, December 12, 2000
15. Metabolic adaptation to promoters and inhibitors of human cell transformation. University of California Irvine, Division of Endocrinology, Diabetes and Metabolism, Faculty Science Seminar, Irvine, CA, USA, January 24, 2001
16. Metabolic markers of the lipofibroblast-myofibroblast trans-differentiation process in premature rat lung. UCLA School of Medicine, Center for Human Nutrition seminar presentation, Los Angeles, CA, USA, January 26, 2001
17. Metabolic characteristics of lipofibroblast-myofibroblast trans-differentiation in premature rat lung. UCLA School of Medicine, Department of Pediatrics research seminar, Los Angeles, CA, USA, February 15, 2001
18. Metabolic pathology of lipofibroblast-myofibroblast trans-differentiation. Harbor-UCLA Medical Center, Department of Pathology Grand Rounds, Torrance, CA, USA, February 16, 2001
19. Treatment of chronic myeloid leukemia with Bcr-Abl tyrosine kinase inhibitor Gleevec: the metabolic consequences. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, July 11, 2001
20. Basics of mass spectrometry and proteomics analyses. Introduction to Biomedical Research and Experimental Techniques. Fellow/Faculty Continued Education Program, University of California Research and Education Institute, Torrance, CA, USA, August 29, 2001
21. Metabolic Adaptation of Mammalian Cells to Growth Modifying Signals. Weitzman memorial research award acceptance lecture 2001, Faculty Society of Harbor-UCLA, Torrance, CA, USA, September 13, 2001
22. Stable isotope labeling of proliferation-related macromolecules using [1,2-¹³C₂]glucose: the effect of growth modifying signals. Cedar Sinai Medical Center Research Conference, Los Angeles, CA, September 14, 2001
23. STI571 (Gleevec) and leukemia cell proliferation. Leukemia Research Group and Task Force Meeting, UCLA School of Medicine, Department of Internal Medicine Division of Hematology, Los Angeles, CA, October 1, 2001
24. Metabolic adaptive changes in chronic myeloid leukemia cells in response to STI571 (Gleevec) treatment. Endocrine/Metabolism Research Seminar Series, Cedar Sinai Medical Center, Los Angeles, CA, USA, October 5, 2001
25. Pancreatic and leukemia tumor growth-control through metabolic pathway-linked signal transduction pathways: the lesson learned with STI571. UCLA School of Medicine, Center for Human Nutrition Research Seminar, Los Angeles, CA, USA, October 19, 2001
26. ThermoQest Finnegan LCQ Classic, Duo, Deca and triple quadrupole (TSQ) basic instrument operations. Atmospheric pressure ionization (API) and ion trap theory. Harbor-UCLA Research and Education Institute, laboratory course, Torrance, CA, USA, December 11-12, 2002



27. Opposite metabolic adaptive changes in tumor genesis and tumor growth control in leukemia tumor cells. Sala de Graus, Facultat de Biologia. University of Barcelona, Barcelona, Spain, USA, December 18, 2001
28. Metabolic effects of ethanol injury in the liver and pancreas: tissue specific differences in fatty acid synthesis. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, January 9, 2002
29. Tissue specific lipotoxicity in the liver and pancreas after ethanol administration in rats. UCLA School of Medicine, Center for Human Nutrition Research Seminar, Los Angeles, CA, USA, January 25, 2002
30. Tumor cell metabolism and novel treatment modalities: Bcr-Abl tyrosine kinase inhibitor Gleevec. Endocrine and Metabolism Clinical Research Conference, City of Hope National Medical Center, Duarte, CA, USA, February 6, 2002
31. Molecules with memory: the stable isotope labeled metabolome in biomedical research. GC/MS research presentation, Visiting Professor Grand Rounds Part II, Torrance, CA, USA, March 5, 2002
32. Tracing pathways in dynamic metabolic profiling and their utilization in the drug discovery process. GC/MS research presentation, Visiting Professor Grand Rounds Part IV, Torrance, CA, USA, March 5, 2002
33. Metabolic profiles of tumor cells in response to novel anti-proliferative treatment modalities. Waters Metabolomics Technology Forum, Waters Corporation, Milford, MA, USA, March 26 & 27, 2002
34. Metabolic profiling of metabolic diseases with unknown mechanisms: how to make silent genes to talk. Harvard School of Medicine, Department of Hematology Research Seminar, Boston, MA, USA, March 27, 2002
35. Glucagon like peptide-1 (GLP-1) induced metabolic adaptation of pancreatic epithelial cells to differentiation and insulin release. Endocrine/Metabolism Research Seminar Series, Cedar Sinai Medical Center, Los Angeles, CA, USA, May 17, 2002
36. Glucagon like peptide-1 (GLP-1) induces differentiation and insulin release of pancreatic epithelial cells: Potential use for the treatment of type 2 diabetes mellitus. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, June 12, 2002
37. Ethanol-induced tissue specific lipotoxicity in the liver and pancreas: a new application of the stable isotope-based metabolic profiling technology. Research Seminar, University of Southern California (USC), Los Angeles, CA, USA, July 8, 2002
38. Stable isotope-based dynamic metabolic profiling for industrial drug target screening, drug efficacy testing and new drug development. Research Seminar, Pharmacia, Saint Louis, MO, USA, August 12, 2002
39. Utilization of ¹³C labeled stable glucose isotopomers in the industrial drug testing process. Research Seminar, Sigma-Aldrich-Isotech, Miamisburg, OH, USA, August 13, 2002
40. Use of asparagine as a substitute for glutamine in cell cultures: effects on glucose metabolism. University of California School of Medicine Harbor-UCLA Research and Education Institute Summer Fellow Education Program Presentation, Torrance, CA, USA, August 14, 2002
41. Introduction to mass spectrometry for biomedical research and experimental techniques. Fellow/Faculty Continued Education Program, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 5, 2002



42. Metabolic profiling with stable isotopes and GC/MS. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 21, 2002
43. Differential effects of vitamin D₃ on premature lung cells. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 22, 2002
44. Application of metabolic profiling in cancer drug discovery: Gleevec. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, September 23, 2002
45. Diagnostic applications of stable isotope tracers and their prognostic value in drug sensitivity testing of human tumor cells. Oncotech, Tustin, CA, USA, December 10, 2002
46. Adrenal cortical carcinoma: mass spectral analysis of plasma steroid profile (case presentation). Harbor-UCLA Medical Center, Department of Endocrinology Grand Rounds, Torrance, CA, USA, January 03, 2003
47. Stable isotopes in metabolic profiling of pancreatic tumor cell physiology: tracer designs, applications and data analysis/presentation methods. Pancreatic SPORE grant meeting research seminar, UCLA School of Medicine, Department of Surgery, Los Angeles, CA, January 9, 2003
48. Drug target discovery and drug testing through metabolic profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC) Poster Presentation Session, Los Angeles, CA, USA, March 11, 2003
49. Drug target discovery and drug testing through metabolic profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC) Poster Presentation Session, Los Angeles, CA, USA, March 11, 2003
50. Improving Drug Target Discovery And Drug Effectiveness For The Industry Through Metabolic Profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC), Los Angeles, CA, USA, March 13, 2003
51. Vitamin-D₃ for the treatment of lung fibrosis. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, April 23, 2003
52. Early diagnosis of pancreatic cancer using serum metabolome GC/MS analysis and [1,2-¹³C₂]glucose as the tracer. Cambridge Isotope Laboratories, Andover, MA, July 2, 2003
53. Stable Isotope-Based Metabolic Profiling (SIDMAP) of human cancer. Utah Venture Associate presentation, Harbor-UCLA Medical Center, Torrance, CA, August 15, 2003
54. Glucagon-like peptide-1 stimulates glucose derived *de novo* fatty acid synthesis and insulin production during beta cell differentiation. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 17, 2003
55. Metabolic pathways regulating cell cycle and apoptosis. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, October 7, 2003
56. Biomarkers of tumor cell proliferation and apoptosis revealed by metabolomics. International Society for Analytical and Molecular Morphology, Santa Fe, NM, October 14, 2003



57. Glucagon-like peptide-1 regulates *de novo* fatty acid synthesis and insulin release of beta cells. Endocrine & Metabolism Clinical Research Conference, City of Hope National Medical Center, Duarte, CA, USA, October 29, 2003
58. Rottlerin in the treatment of pancreatic cancer. Department of Veterans Affairs - Greater Los Angeles Hospital, Los Angeles, CA, January 14, 2004
59. Unique metabolic characteristics of IBC cells aiding diagnosis and treatment. Inflammatory Breast Cancer Research Foundation - Activist Meeting, Washington DC, MD, April 30, 2004.
60. Metabolic Profiles Associated with Aggressive Inflammatory Breast Cancer Cell Growth: exploring new avenues of diagnosis and treatment. Inflammatory Breast Cancer Research Foundation - Board Meeting, Washington DC, MD, April 30, 2004
61. Organ Specific Metabolic Abnormalities in Thiamine Responsive Megaloblastic Anemia and Diabetes in Children. Harbor-UCLA Medical Center, Department of Pediatrics Grand Rounds, Torrance, CA, USA, July 29, 2004
62. Unlocking Thiamine Responsive Megaloblastic Anemia: an unknown disease entity of the past. General Clinical Research Center Excellence in Clinical Research Award for 2003; award acceptance lecture, Torrance, CA, USA, September 21, 2004
63. Time of Flight Mass Spectrometry: from science to clinic. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, October 5, 2004
64. Clinical Trials in a Test Tube: Understanding the Powers of Stable Isotope-based Dynamic Metabolic Profiling (SIDMAP) in Drug Discovery. Eight Annual Functional Genomics Meeting, Cambridge Healthtech Institute, Boston, MA, November 9, 2004
65. Understanding Glivec-induced metabolic network changes as markers of response in cancer. Oncology Research Management Board, Novartis Pharmaceuticals, Basel, Switzerland, March 22, 2005
66. Targeted drugs and the tracer labeled metabolome of tumor cells: how to predict resistance and develop intervention strategies. University of Utah, Department of Biochemistry Research Seminar, Salt Lake City, UT, April 18, 2005
67. Understanding drug resistance and failure using stable isotope-based dynamic metabolic profiling (SIDMAP). 62nd Annual Meeting of the Korean Society for Biochemistry & Molecular Biology, Cellular Metabolism and Metabolomics Seminar Lecture, Seoul, Korea, May 19, 2005
68. Predicting clinical resistance to targeted therapies using stable isotope-based dynamic metabolic profiling (SIDMAP). Korean Institute of Science and Technology Research Seminar, Seoul, Korea, May 19, 2005
69. Applications of stable isotope-based dynamic metabolic profiling (SIDMAP) in drug resistance. Pohang University of Sciences and Technology Department of Chemistry Research Seminar, Pohang, Korea, May 20, 2005
70. Classic laws of physics and mass spectrometry: time of flight, quadrupole, ion trap instruments and their principles of operation. AP Physics student class, Carson High School, Carson, California, June 10, 2005
71. Stable Isotope Based Metabolic Profiling (SIDMAP) and its Applications. First Scientific Meeting of the Metabolomics Society, Tsuruoka City, Japan, June 23, 2005



72. Tracer substrate-based metabolomics: data handling, biomarkers and patient stratification. Metabolomics Standards Workshop, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, August 1-2, 2005
73. Why targeted drug therapies are doomed to fail: uncovering the mechanism of action using stable isotope-based dynamic metabolic profiling. Connective Tissue Research Institute, University City Science Center, Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA, October 18, 2005
74. Evolving metabolic tracer technologies and targeted drug resistance in cancer. Third International Conference on Tumor Cell Metabolism, Plenary Lecture, Louisville, KY, October 20, 2005
75. Predicting Clinical Resistance to Gleevec Treatment by *in vitro* Applied Stable Isotope-based Dynamic Metabolic Profiling. Advances in Metabolic Profiling, Pharmaceutical and Disease State Applications, London, UK, November 1, 2005
76. Metabolic effects of anti-psychotic treatments and the development of type 2 diabetes. Department of Pharmacology, University of Cambridge, United Kingdom, November 3, 2005
77. Ethanol-induced organ-specific lipotoxicity in the plasma, liver and pancreas: an *in vivo* tracer substrate-based metabolomics study. Center for Regulatory and Environmental Analytical Metabolomics (CREAM) at the University of Louisville, 1st CREAM Symposium, Louisville, KY, November 5 & 6, 2005
78. Identifying Patients Who are at Risk for Developing Resistance to Targeted Therapies. IBC Life Sciences Metabolic Profiling Using Metabolomics and Metabonomics Technology to Accelerate Drug Discovery and Development, Research Triangle Park, NC, November 14-15, 2005
79. Developing Metabolic Biomarkers by Measuring Isotopomer Ratios of Specific Metabolites: Metabolic Profiling and Analytical Methods, Orlando, Florida, December 7-8, 2005
80. Tumor cell metabolism. Basic Science Seminar, UCLA School of Medicine Department of Surgery, General Surgery Basic Science Seminar, Los Angeles, CA, December 21, 2005
81. Flexibility of the metabolic network and targeted drug failures. UCLA School of Medicine, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, April 18, 2006
82. Fermented Wheat Germ (Aveamar) Effect and Mechanism of Action as Determined by Stable Isotope-based Dynamic Metabolic Phenotyping. International Society for the Study of Xenobiotics (ISSX), Cheju Island, Korea, May 27, 2006
83. Tracer substrate-based metabolomics to unlock metabolic phenotypes. Buck Institute for Age Research, Novato, CA, July 21, 2006.
84. Metabolic targeted therapies during and after failed small molecule kinase inhibitors in cancer. Conference on Small Molecule Science, San Diego, CA, July 25, 2006
85. Tracer Substrate-based Metabolomics and the 2005 Nobel Prize award in Physiology & Medicine. Innovation in Life Science, Healthcare Research & Product Development, Bryn Mawr College, Philadelphia, USA, October 16-19, 2006
86. Clinical Genomics in Gastroenterology. Asian Pacific Digestive Disease Week, Lahug Cebu City, Philippines, November 20, 2006
87. Mass Isotopomer Markers of Drug Efficacy and Toxicity in Plasma and Urine. Global Technology Community's (GTCbio) 2nd Modern Drug Discovery and Development Summit, Philadelphia, PA, December 4-6, 2006



88. Clinical metabolic biomarkers of drug safety and efficacy using ^{13}C -labeled substrates. Division of Endocrinology & Metabolism Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 6, 2006. *AMA PRA Category 1 Credits™*. Institute for medical quality and the California Medical Association's continued medical association (CME) accreditation standards (IMQ/CMA)
89. [1,2- $^{13}\text{C}_2$]-D-glucose tolerance test in obesity. Keynote Lecture & Honorary Membership Recipient Presentation at the 49th International Meeting of the Hungarian Gastroenterological Association, Pancreatology Plenary Section, Tihany, Hungary, June 3, 2007
90. Stable ^{13}C isotope tracer substrate studies in drug target development, efficacy and safety testing. Research Seminar, Department of Pathophysiology and the Hungarian Academy of Sciences Szeged Regional Arm, Szeged, Hungary, June 9, 2007
91. Abnormal ^{13}C isotopomer production after acute and chronic antipsychotic treatment in mice. The Eight International Conference on Systems on Systems Biology; Systems Biology in Medicine, Long Beach, California, USA, October 5, 2007
92. Determination of New Biomarkers for Liver Toxicity in the form of Stable Isotope Labeled Metabolites. InnovationWell InterAction Meeting Session, Systems-based Biology & Toxicology, Bryn Mawr College, Philadelphia, PA, USA October 17, 2007
93. Use of metabolic pathway flux information in cancer drug design. Oncogenes meet metabolism – from deregulated genes to a broader understanding of tumor physiology, Berlin, Germany, November 14-16, 2007
94. Functional analysis of pancreatic cancer genes, signaling pathways and drugs using metabolomics. Fourth Hirshberg Symposium for Pancreatic Cancer Research, Los Angeles, California, USA, February 4, 2008
95. Metabolic pathway flux information and systems biology approaches in CNS disorders. 10th International Neuroscience Winter Conference, Sölden, Austria, April 5-10, 2008
96. Discovering markers of metabolic side effects from responses to drugs by altered synthesis and turnover of fatty acids and cholesterol. IBC's 13th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics (DDT), World Trade Center, Boston, MA, August 4-7, 2008
97. Individual variations of metabolism, diabetes and obesity markers, ^{13}C substrate based dynamic metabolic profiling (SiDMAP) and SiD-ELISA. United States Food and Drug Administration (FDA) National Center for Toxicological Research Science and Collaboration Seminar, Jefferson, Arkansas, August 27, 2008
98. Non-invasive methods of studying cancer cell metabolism, drug action and drug response. American College for the Advancement in Medicine (ACAM) – Integrative approaches in Oncology, Las Vegas, Nevada, October 19, 2008. The American College for Advancement in Medicine designates this educational activity for 1.00 *AMA PRA Category 1 Credit™*. Physicians can claim credit commensurate with the extent of their participation in the lecture.
99. Luteolin inhibits *in vitro* pancreatic cancer cell proliferation: a comparative tracer isotope study with a targeted fatty acid synthesis inhibitor compound (C75). UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, December 19, 2008
100. Stable (^{13}C) Isotope-labeled Metabolite Fragments' Isotopomer Regression Analysis (SIMFIRA) Studies in Cancer. Cancer Metabolism Workshop, Bethesda North Conference Center, Rockville, Maryland, July 9-10, 2009



101. Metabolic Flux and Nutritional Phenotypes. Nutritional Phenotype Database (dbNP) Workshop of the US Food and Drug Administration, Jefferson, Arkansas, January 21, 2010
102. Stable isotope tracer metabolite markers of failing kidney function. Department of Pathology Faculty Research Seminar, University of California at San Francisco, San Francisco, California, March 11, 2010
103. Intermediary metabolism and macromolecule synthesis in response to deuterium depletion in pancreatic, breast and lung cancer cell lines. 1st International Symposium on Deuterium Depletion, Budapest, Hungary, May 13-14, 2010
104. Tracer substrate-based metabolomics in renal cancer for target identification, reverse genomics and biomarker identification. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health – M. Linehan's Laboratory, Bethesda, Maryland, July 12, 2010
105. Tracer substrate-based metabolomics: a technological overview. Stanford Research Institute (SRI) International Biosciences Division Friday Seminars, Menlo Park, CA, July 30, 2010
106. Fructose alters glucose metabolism in adipocytes: FDA initiatives for stable isotope plasma markers of obesity, diabetes and cancer. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, October 12, 2010
107. Diverse substrate utilization by tumor cells: clinical implications. Pulmonary Clinical Conference, Greater Los Angeles Veterans Administration, Los Angeles, CA, December 21, 2010
108. Bioinformatics of Glucose-tracer Based Metabolomics. Seventh Hirshberg Symposium for Pancreatic Cancer Research, Los Angeles, California, USA, February 18, 2011
109. Metabolomics for Population and Drug Research: Peer Reviewed Methods and Program Initiatives. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, April 12, 2011
110. Metabolomic Studies of Cancer Using 13C Tracer Substrates and Model Fitting. Cancer Research UK, Cambridge, United Kingdom, June 2, 2011
111. Cornering tumor cells in hypoxia: ¹³C substrate guided tour of the metabolic network. Genentech Research Seminars, San Francisco, CA, USA, July 07, 2011
112. Research at academic institutions and pharmaceutical companies: from ideas to drugs. UCLA School of Medicine, Los Angeles Biomedical Research Institute - Career Pathways in Biological Sciences Student Fellowship Program, Torrance, CA, USA, August 02, 2011
113. Metabolomics and Drug Development in the Post-Genomic Era. Department of Pharmaceutical & Biomedical Sciences, College of Pharmacy at the University of Georgia, Athens, GA, February 29, 2012
114. Business and Science Perspectives for Stable Isotope Tracer-based Metabolomics in 2012. Institute for Veterinary Physiology and Biochemistry, Justus-Liebig-University, Giessen, Germany, July 02, 2012
115. Impact of growth signaling and the kinase inhibitor Glivec on tumor cell metabolism. Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ, August 29, 2012
116. Metformin, cholesterol, K-ras: Contextual synthetic inhibition of fatty acid synthase. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, November 02, 2012



117. ¹³C Substrate-based Metabolomics and Drug Development in the Post-Genomic Era. Discovery Biology, Rigel Pharmaceuticals, Inc., South San Francisco, CA, November 16, 2012
118. Targeted Tracer Fate Associations (TTFAS) in the ¹³C-labeled Metabolome. Preston Robert Tisch Brain Tumor Center at the Duke University Medical Center, Durham, NC, June 19, 2013 (Certified by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME credit (AMA PRA Category 1 Credit)[™])
119. Targeted ¹³C Tracer Fate Association Studies (TTFAS): Isotopolomics powered by SiDMAP. Johns Hopkins School of Medicine, Baltimore, MD, June 20, 2013.
120. Isocitrate dehydrogenase-1 (IDH-1) mutation and D-2-hydroxyglutarate deregulate mitochondrial function. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, August 07, 2013.
121. Serine oxidation and glycine cleavage SOGC-isobolome as the signature of malignancy and targeted drug resistance. United States Food & Drug Administration (FDA) National Center for Toxicological Research, Center Wide Biomarker Study Concept Seminar, Jefferson, Arkansas, November 15, 2013.
<http://harborped.org/news/dr-laszlo-boros-cancer-sog-pathway>
122. Failing molecular drug targets: how to overcome them using targeted metabolic tracer fate associations. Discovery Biology, Rigel Pharmaceuticals, Inc., South San Francisco, CA, November 18, 2013.
123. Deuterium depletion and mitochondrial NADPH production: the link for epigenetic control of oncogenesis. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, December 13, 2013. <http://youtu.be/GkYAjabGxJs> - doi: 10.12918/SCIENCEFRDEC132014LGB
124. Mitochondrial fumarate hydratase deficient metabolic network of tumor cells. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 20, 2014. (Hungarian) https://youtu.be/-rMQdOn_TR8
125. Metabolic control analysis (MCA) using targeted ¹³C tracer substrate fate associations. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 18, 2014 (English) <http://youtu.be/Pms6k9AQ3bQ>
126. Deuterium depletion controls oncogenesis via NADPH-dependent reductive synthesis via the pentose cycle. Celebrate Half a Century of Medical Innovations at LA BioMed, Torrance, CA, USA, April 24, 2014.
127. Targeted Deuterium Fate Association Study in Medicine Using Deuterobolomics (TDFAS). Patent Committee Business Development & Technology Management Faculty Presentation, Los Angeles BioMedical Research Institute at the Harbor-UCLA Medical Center [LAB0106], Torrance, CA, USA, November 14, 2014.
128. Partial deuteration of hydrogen bonded systems and their role in cancer development. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, November 21, 2014
129. Molecular Biology, Functional Biochemistry and Deuterobolomics in Scriptures. Department for the Study of Religions, Faculty of Arts, University of Szeged, Szeged, Hungary, European Union, December 4, 2014.
<http://youtu.be/a7PdYx0hHU4> - DOI: 10.13140/2.1.4907.5525
130. Stable isotope methods to trace metabolic channels. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 10, 2014 (English)



131. Metabolic and cytoplasmic water in hydrogen bonding networks of biomolecules. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 10, 2014 (English)
132. Metabolic and cytoplasmic water in hydrogen bonding networks of DNA. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, April 28, 2015
133. Anti-cancer properties of metformin via mitochondrial deuterium depletion. Endocrine Clinical Research Conference, UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA, July 29, 2015
134. Submolecular regulation of cell transformation by deuterium. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, November 25, 2015
135. Mitochondrial deuterium depletion as the central mechanism of anti-cancer drug action. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, December 02, 2015
136. How carbohydrates become oncometabolites when intracellular deuterium depletion fails. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, December 08, 2015
137. Stable isotope-based dynamic metabolic phenotyping. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 08, 2016
138. Oncogenes, oncometabolites, oncoisotopes and cell transformation. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 08, 2016
139. Deuterobolomics: Course Proposal for the Honor Collegium at UCLA UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, March 15, 2016
140. Nanoindentations of fast moving enzymes and their lubrication with deuterium depleted water in mitochondria: applications for hyperbaric oxygen and nutritional ketosis. Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, Hyperbaric Biomedical Research Laboratory, University of South Florida, Tampa, FL, USA, April 29, 2016
141. Nanoindentations of fast moving enzymes and their lubrication with deuterium depleted water: oncological applications for ATP synthase in the matrix of mitochondria. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, May 04, 2016
142. Biological Nanomechanics: ATP Synthesis and Deuterium Depletion. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, August 23, 2016 - <https://youtu.be/6P8ggB4zLGQ>
143. Metabolomics and Biomarkers for the Prevention of Cancer and other Degenerative Diseases. American College for the Advancement in Medicine (ACAM) – Preventive approaches in Oncology, Tucson, Arizona, September 16, 2016. Educational activity for 1.00 AMA PRA Category 1 Credit™.
144. Ketogenic Diet and Deuterium Depleted Water for the Prevention and Treatment of Cancer and Neurodegenerative Conditions. American College for the Advancement in Medicine (ACAM) – Preventive approaches in Oncology, Tucson, Arizona, September 16, 2016. Educational activity for 1.00 AMA PRA Category 1 Credit™.



145. Nanomechanics of ATP Synthesis and Deuterium Depletion. Biochemistry, Biophysics, Molecular and Cell Biology PhD Elective Course in 2016/2017 first semester - Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, October 12, 2016
146. The Effect of Deuterium Depletion on Cancer Cell Metabolism: Therapeutic Perspectives. 2nd International Conference for Cancer Metabolism and Therapy (CMT2017), First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China, October 15, 2017
147. In Memoriam: The Scientific Contributions of Dr. Wai-Nang Paul Lee. 3rd International Conference for Cancer Metabolism and Therapy (CMT2018), Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China, October 13, 2018
148. Deuterium Depleted Metabolic Water and Mitochondrial Health. China Academy Of Science & Technology Development, Shenzhen, China, March 23, 2019
149. Deutenomics, the inherent autonomic discrimination of deuterium by Nature: medical implications. Hirshberg Foundation Seed Grant Awardees Presentations, University of California Los Angeles School of Medicine UCLA Faculty Center Sequoia Room, September 20, 2019
150. Mitochondrial depletion (deuterium depletion) restrains prokaryote proliferation and virus hosting cellular events thus alleviates the use of biologics. New Frontiers of Biology, Biological Drugs - Precision Medicine and -omic Sciences: The Role of Biologists, Place Parco dei Principi, Rome, Italy, European Union, April 18, 2020
151. Metabolic profiling and deutenomics of mitochondrial diseases. Institute for Women's and Children's Health at The Lundquist Institute and the Harbor-UCLA Medical Center, Torrance, CA, USA, June 01, 2020
152. Fitness, cognitive functions and strength - group meeting on Deutenomics. Vrije University Amsterdam, The Netherlands, Nov 23, 2020
153. Deuterium distribution in tissues and nutrients as a guide to human health. Institute for Women's and Children's Health at The Lundquist Institute and the Harbor-UCLA Medical Center, Torrance, CA, USA, January 04, 2021
154. Deuterium Distribution in Disease and Health. The Body Electric Summit 2.0, Online Course Series, February 24, 2021 - <https://bodyelectric.byhealthmeans.com/>
155. Positioning Deutenomics Within Biochemistry And Translational Medicine. Deuterium Depletion Summit 2021, February 27, 2021 (Online) - <https://deuteriumdepletionsummit.com/>
156. The Role of Heavy Hydrogen (deuterium) in Translational Medicine. Silicon Valley Health Institute of California, April 27, 2021 (Online) - <http://www.svhi.com/>

Peer Review Panels

African Journal of Biotechnology (ISSN 1684-5315) (2014); *Analytical Biochemistry* (ISSN 0003-2697) (2003); *Anti-Cancer Drugs* (ISSN: 0959-4973) (2016); *Biochemical Pharmacology* (ISSN: 0006-2952) (2005); *Biochimica et Biophysica Acta - Molecular Basis of Disease* (ISSN: 0925-4439) (2015); *Biomarkers in Medicine* (ISSN 1752-0363) (2007); *BMC Cancer* (ISSN 1471-2407) (2017); *BMC Systems Biology* (ISSN 1752-0509) (2014); *British Journal of Cancer* (ISSN 0007-0920) (2008); *Cancer & Metabolism* (ISSN 2049-3002) (2013); *Cancer Cell International* (ISSN 1475-2867) (2011); *Cancer Epidemiology, Biomarkers & Prevention* (ISSN 1538-7755) (2017); *Cancer Investigation* (ISSN 1532-4192) (2010); *Cancer Letters* (ISSN 1872-7980) (2007); *Cancer Metabolomics* (ISSN 2299-1085) (2012); *Cancer Research* (ISSN 1538-7445)



(2011); *Cancers* (ISSN 2072-6694) (2014); *Carcinogenesis* (ISSN 1460-2180) (2009); *Cell Biology & Toxicology* (ISSN 1573-6822) (2007); *Cell Chemical Biology* (ISSN: 1074-5521) (2016); *Cell Death and Disease* (ISSN 2041-4889) (2021); *Cells* (ISSN 2073-4409) (2019); *Cellular Oncology* (ISSN 2211-3428) (2011); *Chemistry and Biodiversity* (ISSN 1612-1880) (2016); *Clinical and Translational Medicine* (ISSN 2001-1326) (2020); *Diagnostics* (ISSN 2075-4418) (2020); *Digestive Diseases & Sciences* (ISSN: 1573-2568) (2003); *Drug Design, Development and Therapy* (ISSN 1178-8881) (2013); *Dutch Cancer Society (Nederlandse Kankerbestrijding)* (2003); *European Journal of Pharmacology* (ISSN 0014-2999) (2006); *Evidence-Based Complementary and Alternative Medicine* (ISSN 1741-4288) (2013); *Federation of European Biochemical Societies (FEBS) Letters* (ISSN 0014-5793) (2005); *Free Radical Biology & Medicine* (ISSN 0891-5849) (2009); *French Recherche Médicale - Research pioneers programme CHEMISTRY FOR MEDICINE* (2018); *Frontiers in Endocrinology* (ISSN 1664-2392) (2019); *Genes & Nutrition* (ISSN: 1555-8932) (2019); *Harbor-UCLA Research and Education Institute (REI), Grants & Contracts* (2001 - 2004); *Hormone & Metabolic Research* (ISSN 0018-5043) (2000); *International Journal of Cancer* (ISSN 1097-0215) (2007); *International Journal of Molecular Sciences* (ISSN 1422-0067) (2019); *Israel Science Foundation* (2016); *Journal of Industrial and Engineering Chemistry* (ISSN: 1226-086X) (2017); *Journal of Theoretical Biology* (ISSN: 0022-5193) (2018); *Journal of Translational Medicine* (ISSN: 1479-5876) (2015); *Lipids in Health and Disease* (ISSN: 1476-511X) (2015); *Lung Cancer* (ISSN 0169-5002) (2010); *Marine Drugs* (ISSN 1660-3397) (2021); *Metabolic Engineering* (ISSN 1096-7176) (2012); *Metabolites* (ISSN 2218-1989) (2013); *Metabolomics* (ISSN 1573-3890) (2004); *Molecular Cancer Research* (ISSN: 1541-7786 (Print)) (2019); *Molecular Cancer Therapeutics* (ISSN: 1535-7163 (Print)) (2019); *Molecular Medicine Reports* (ISSN 1791-2997) (2017); *Molecules* (ISSN 1420-3049) (2013); *Natural Sciences & Engineering Research Council of Canada* (2000); *Nature Protocols* (ISSN 1754-2189) (2007); *NMR in Biomedicine* (ISSN 1099-1492 (Online)) (2018); *Nutrients* (ISSN 2072-6643) (2019); *Nutrition & Cancer* (ISSN 1532-7914) (2004); *Oncogene* (ISSN 0950-9232) (2004); *Oncotarget* (ISSN · 1949-2553) (2018); *Pancreatology* (ISSN: 1424-3903) (2016); *Pharmacology & Therapeutics* (ISSN 0163-7258) (2012); *Phytomedicine* (ISSN: 0944-7113) (2017); *Public Library of Science (PLoS) Computational Biology* (ISSN 1553-7374) (2018); *Scientific Reports – Nature Publishing Group* (ISSN: 2045-2322) (2018); *The European Foundation for Alcohol Research (ERAB)* (2017); *The Journal of Pediatrics* (ISSN 0022-3476) (2006); *University of Alabama at Birmingham Clinical Nutrition Research Center* (2004)

Support

Completed

1. HEPATOTOXICITY FLUX STUDY FOR REGORAFENIB

United States Food and Drug Administration, Jefferson, Arkansas, USA

P.I. – L. G. Boros

09/15/2016 – 09/01/2020

¹³C and ²H markers of Stivarga's Liver Toxicity

\$25,410 40%

This project will determine precise mitochondrial toxicity markers in the liver with a translational edge regarding regorafenib

2. DEUTEROBOLOMICS AND KETOBOLOMICS

Epigenix Foundation, El Segundo, CA, USA

P.I. – L. G. Boros

05/15/2016 - 05/15/2017

Continued Medical Education (CME) and College Course Development

\$75,000 30%

This grant is to develop biochemistry courses that train physicians and honors students for interpreting deuterium and hydrogen biochemistry in response to ketogenic dietary modifications which deplete deuterium with



applications in biology and medicine. The topic is for continued medical education (CME) credits and also considered for the UCLA Honors College.

3. **HUNTINGTON SOCIETY OF CANADA** - New Pathways Research Grant
Western Washington University, Bellingham, WA, USA
WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros) 01/01/2016 - 12/31/2016
Peripheral silencing of Htt^{Q111} in Huntington's disease \$18,000 15%

This grant is to establish whether peripheral silencing of Htt^{Q111} is associated with rescue of central metabolic dysregulation in Huntington's disease using U-¹³C-glucose to determine striatal ¹³C-lactate -, glutamate and – palmitate ¹³C labeling.

4. **RO1CA169919 US NIH/NCI**
University of Maryland and UCLA Liver Cancer Research Project
JHSM (P.I. – G. Girnun); UCLA SubK (Co-P.I. – L. Boros) 09/01/2012 - 08/31/2017
Metabolic control of hepatocellular carcinoma by PGC1-alpha \$337,000 5%

Stable isotope tracer substrate technology is used to reveal peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC1alpha) in liver carcinogenesis and its Systems' Biology and how it affecting the metabolic network.

Funding History

1. **MRDF 53656** (P.I. - Boros) 01/01/1995-12/31/1995
The Ohio State University Department of Surgery \$4,996
Tumor ribose synthesis pathways.
- This project allowed preliminary/feasibility investigations in the field of tumor specific nucleic acid ribose synthesis pathways from glucose as the precursor and source for nucleic acid backbone sugar synthesis.
2. **PO1 CA42710-12** (P.I. - Heber) 01/01/1998-12/31/1998
US NIH Clinical Nutrition Research Unit/UCLA (CNRU) \$15,000
Lipid and RNA ribose synthesis in tumor cells and the mechanism of soy protein action on pentose cycle activity using ¹³C labeled glucose or acetoacetate.
- This project provided preliminary/feasibility funding for studying specific inhibitors of pentose cycle enzymes in order to inhibit *in vitro* pancreatic tumor cell growth and transformation.
3. **Fulbright** (P.I. - Cascante) 01/07/1999-31/06/2000
Commission for Cultural, Educational and Scientific Exchange of Spain \$12,780
Travel grant for scientific exchange and visits between the US and Spain.
4. **Harbor-UCLA Inaugural Collegium** (P.I. - Boros) 2001
Harbor-UCLA Research and Education Institute \$12,000 N/A
Equipment purchase award for an atmospheric pressure chemical ionization (APCI) probe for the LCQ Deca ion trap mass spectroscopy instrument.
5. **MO1 RR00425-34** (P.I. - Anderson) 12/01/1977 - 09/30/2003
US DHHS/NIH/NCRR (Mass Spectroscopist - Boros)
General Clinical Research Center



This project provided continued support for an inpatient General Clinic Research Center (GCRC) unit, outpatient GCRC facilities, a Perinatal Clinical Research Center (PCRC) at Martin Luther King Drew Medical Center, and a Satellite GCRC at Cedars-Sinai Medical Center.

- | | | | |
|----|---|--|-----|
| 6. | MA 1760/2-1 & 1760/2-2; German Research Communications (Deutsche Forschungsgemeinschaft (DFG) (P.I. – Mazurek)
Habilitation and scientific exchange studies for Dr. Sybille Mazurek | 02/01/2001 - 01/31/2003
\$20,000.00 | N/A |
| 7. | Henry L. Guenther Core Metabolic Profiling Laboratory (P.I. – Lee)
Harbor-UCLA Research & Education Institute (Co-P.I. – Boros) | 08/01/2003
\$380,000.00 | |

This project provides funds for a one-time purchase of a time of flight (TOF) mass spectrometer (Applied Biosystems - Voyager), a Liquid Chromatograph Finnegan Deca Ion Trap mass spectrometer (LCQ-Deca) and their support peripheries.

- | | | | |
|----|---|-------------------------------------|--|
| 8. | Inflammatory Breast Cancer Research Foundation (P.I. - Boros)
Metabolic profile of inflammatory breast cancer cells.
N/A | 03/01/2003 - 02/28/2004
\$20,000 | |
|----|---|-------------------------------------|--|

This project provides funding to clarify inflammatory breast cancer metabolic characteristics and to develop new treatment strategies based on metabolic pathway inhibitors in this rapidly growing undifferentiated cancer on a renewable seed grant basis.

- | | | | |
|----|---|-------------------------------------|-----|
| 9. | RO1 HL66182-01A1 SUBK (P.I. - Neufeld)
US DHHS/NIH/NCI (P.I.-Boros; Operating Institution Project Director)
Pathophysiology of Thiamine-Responsive Anemia Syndrome | 10/01/2001 - 09/30/2006
\$20,050 | 14% |
|----|---|-------------------------------------|-----|

This project describes the biochemical defect involved in the thiamine responsive megaloblastic anemia syndrome using stable isotope based metabolic profiling *in vitro* and *in vivo*.

- | | | | |
|-----|---|-------------------------------------|----|
| 10. | PO1 CA42710-16 SUBK (P.I. Heber)
UCLA Subcontract (Mass Spectroscopist - Boros)
Clinical Nutrition Research Unit: Stable Isotope Core. | 05/01/1992 - 04/30/2007
\$19,637 | 5% |
|-----|---|-------------------------------------|----|

The major goal of this project is to develop chemo preventative approach to cancer through nutrition modification. To operate and co-direct the GC/MS core for CNRU approved projects.

- | | | | |
|-----|--|------------------------------------|-----|
| 11. | 6-FY2002-181 (P.I.-Torday)
March of Dimes (Boros-Co. I.)
The Role of Myofibroblasts in the Pathophysiology of Bronchopulmonary Dysplasia. | 06/01/2003 - 5/31/2007
\$68,182 | 10% |
|-----|--|------------------------------------|-----|

The aim of this project is to determine the mechanism of lipo-fibroblast transdifferentiation in newborns using combined genetic and metabolic profiling approaches.

- | | | | |
|-----|---|--------------------------------------|-----|
| 12. | RO1 HL66182-01A1 SUBK (P.I. – Eibl)
US NIH/NCI (Co-P.I. – Boros)
The Role of COX-2 and PPAR- γ in Pancreatic Cancer | 03/01/2004 - 31/12/2008
\$225,000 | 10% |
|-----|---|--------------------------------------|-----|

The proposed studies explicate the effect of COX-2 and PPAR gamma inhibitors in pancreatic cancer anti-proliferative treatment and metabolic phenotype.

- | | | | |
|-----|--|-------------------------|--|
| 13. | REI Project #: 200279-00-00 (Los Angeles Biomedical Research Institute) | 07/01/2004 - 06/30/2010 | |
|-----|--|-------------------------|--|



Hirshberg Foundation for Pancreatic Cancer Research (P.I. - Boros) \$25,000 14%
 Biochemistry of Pancreatic Cancer using Stable Isotope-based Metabolic Profiling

This project describes the biochemical defect involved in the development and progression of pancreatic cancer using stable isotope based metabolic profiling *in vitro* and *in vivo*.

14. **RO1CA140492 US NIH/NCI**

Johns Hopkins School of Medicine and UCLA Nrf2 Lung Cancer Research Project
 JHSM (P.I. – S. Biswal); UCLA SubK (Co-P.I. – L. Boros) 04/01/2010 - 03/31/2015
 Regulation of Tumorigenesis and Therapeutic Resistance by Nrf2 in Lung Cancer \$325,000 5%

Stable isotope tracer substrate technology is used to reveal therapeutic resistance in lung cancer using several Nrf2 gene constructs and their effect on the metabolic network.

15. **UCLA 20038-01 (Interim) - NIH NCI Chemical Biology Consortium**

Stanford Research Institute (SRI) and UCLA Applicant Organizations

SRI (P.I. – Sambucetti); UCLA-Metabolomics Core (P.I. – Boros) 05/01/2011 - 06/31/2012
 Project Consortium for new Cancer Drug Development \$108,877 25%

This project determines the effect of AMP-Kinase growth signaling in cancer cell energy metabolism *in vitro* and *in vivo*.

16. **1 P01 AT003960-01A1**

US NIH/NCI (P.I. – Go); Metabolomics Core (Co-P.I.s – Lee-Boros) 10/01/2007 - 09/30/2012
 UCLA Center for Excellence in Pancreatic Diseases \$125,000 5%

Stable isotope tracer substrate technology is used to reveal natural phytochemical and nutritional products and their preventive/therapeutic applications in pancreatic diseases, including inflammation and cancer.

17. **HUNTINGTON SOCIETY OF CANADA - New Pathways Research Grant**

Western Washington University, Bellingham, WA, USA
 WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros) 07/01/2013 - 06/31/2014
 Mapping hepatic dysfunction in Huntington's disease \$135863
 5%

This grant is to quantify metabolic flux from ¹³C-labeled glucose and palmitate in primary hepatocytes from Htt^{+/+} and Htt^{Q111/+} mice fed medium- and high-fat diets. Additional transcriptomic data sets from parallel cultures of purified hepatocytes are generated to refine existing genome-scale models of hepatic metabolism, in hopes of identifying key signaling nodes that could serve as targets for future therapeutic development.

18. **HUNTINGTON SOCIETY OF CANADA - New Pathways Research Grant**

Western Washington University, Bellingham, WA, USA
 WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros) 07/01/2015 - 06/30/2016
 Mapping hepatic dysfunction in Huntington's disease \$93,000
 15%

This grant is to quantify metabolic flux from ¹³C-labeled glucose, glutamine and palmitate tracers in primary hepatocytes isolated from Huntington's mice fed a normal diet across an allelic series of 6 different allele lengths using Huntington's gene constructs.

19. **Pilot 1506944155 - The University of Arizona Cancer Center**



National Cancer Institute-designated Comprehensive Cancer Center
 The UACC — Orange Grove Campus, Tucson, AZ, USA
 UACC (P.I. – H. Patel, MD); Harbor-UCLA Consortium (Co-P.I. – L. Boros) 07/01/2015 - 06/31/2016
Pilot project to study metabolic profile in patients with pancreatic adenocarcinoma \$140,000 15%

This grant is to determine targeted tracer fate association patterns (TTFAS) by metabolic products of [U-¹³C₆]-D-glucose in control subjects and in patients with pancreatic cancer. The study is designed to establish functional ¹³C-based plasma markers of mitochondrial deuterium depletion and oxygen saturation to enhance anti-cancer drug efficacy based on individual metabolic profiles.

Languages & Communications Skills

Fluent and literate in English and Hungarian, basic language skills in German, advanced computer skills, Microsoft-office, Word Perfect, Corel graphics, Mass Spectra analyses/processing using Excel macros and Visual Basic

Courses, Compliance and Certifications

Advanced Tools for Proteomics and Pharmaceutical Analysis – Dionex Corporation 2001 Spring Seminar Series for Laboratory Professionals, *Woodland Hills, CA, May 17th, 2001*

Data and Safety Monitoring Policy and Procedures for the General Clinical Research Centers (GCRCs) of the United States – Harbor-UCLA Medical Center, *Torrance, CA, March 28th, 2001*

LCQ Operations – ThermoQest Finnegan LCQ Classic, Duo, Deca and triple quadrupole (TSQ) basic instrument operations, including atmospheric pressure ionization (API) and ion trap theory, tuning, calibration, data collection, maintenance, qualitative and quantitative data analysis/processing using Xcalibur - *Riviera Beach, Florida, February 26- March 2, 2001*

Responsible Conduct of Research Curriculum – Harbor-UCLA Research and Education Institute General Clinical Research Center, *Torrance, CA, February 28th, 2001*

Protecting Study Volunteers in Research – Educational/Training Course Certification – Harbor-UCLA Research and Education Institute – *Torrance, CA, Sep 29th, 2000*

Laboratory Animal Care and Handling Course, guided by the Institutional Laboratory Animal Care and Use Committee (ILACUC) of the University of California at Los Angeles, *Torrance, CA, October, 1998*

Basic Life Support cognitive and skills evaluation certificate for healthcare providers, curriculum of the American Heart Association – Ohio Valley, Columbus State C.C. Training Center, *Columbus, OH, June 12th, 1998*

Laboratory Animal Care and Handling Course, guided by the Institutional Laboratory Animal Care and Use Committee (ILACUC) of the Ohio State University, *Columbus, Ohio, July, 1990*

The Impact of Colorful Fruits and Vegetables on Health, UCLA Center for Human Nutrition, *Los Angeles, CA, September 5, 2001*

Matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF) sample preparations, operations, data analysis. UCLA Department of Chemistry, *Los Angeles, CA, March 18, 2001*



Human Proteome Organization (HUPA) & Amersham Proteomics Tour 2002. University of California Faculty Center, Los Angeles, CA, September 19, 2002

Finnigan Technology Forum: Gel analysis by mass spectrometry, Protein quantitation and analysis of phosphoproteins. Thermo Finnigan Western Region, La Jolla, CA, November 21, 2002

Linear ion trap technology, high throughput quantitative analysis by liquid chromatography/mass spectrometry (LC/MS/MS), advanced structural characterization, and metabolite and impurity identification. Applied Biosystems Applications seminar, Buena Park, CA, November 22, 2002

Southern California Biomedical Council Presentation Preparation Course for Venture and Investment Opportunities. KPMG International, Los Angeles, CA, February 6, 2003

Preparative Screening Course for Academic Institutions, the Southern California Biomedical Council and Kaiser Permanente Management Ground (KPMG) International, Los Angeles, CA, February 13, 2003

Protected Health Information (PHI) Health Insurance Portability & Accountability Act Certificate of the Harbor-UCLA Research and Education Institute, Torrance, CA, May 30, 2003

Voyager-DE™ STR BioSpectrometry™ Workstation (Applied Biosystems MALDI-TOF) Training Course, Foster City, California, July 13-16, 2004

Research Services Training: Current Laboratory Animal Handling and Use. Los Angeles Biomedical Research Institute, Torrance, CA, June 06, 2005

Title 8, Section 5193 California Code of Regulations Bloodborne Pathogen and Disease Training Course. Los Angeles Biomedical Research Institute, Torrance, CA, June 13, 2005

Infectious Agents and Diagnostics Specimens Transportation Saf-T-Pack Training (Tested As Per 49CFR 172.700 / IATA 1.5). Los Angeles Biomedical Research Institute, Torrance, California, July 14, 2005

Integrated Medical Research Information System - iMedRIS Data Corporation on-site Training Course at the Los Angeles Biomedical Research Institute, Torrance, California, July 15, 2005

Sexual Harassment Prevention Training Course – State of California Code Training Course at the Los Angeles Biomedical Research Institute, Torrance, California, December 16, 2005

Mandated Section Test Los Angeles County Department of Health Services Harbor-UCLA Medical Center Re-orientation: Infection Control, Environment of Care, Family Violence, Cultural Diversity, HIPAA & Age Appropriate Care Considerations. Result: Pass; Torrance, California, July 10, 2006

Department of Health & Human Services – USA; Los Angeles County DHS Compliance Training Program, June 22, 2007

Mandatory Online Sexual Harassment Prevention Course for University of California (UC) Faculty. Sexual Harassment Prevention Training - required by California law (AB1825), October 11, 2007

Mandatory Compliance Briefing: University of California Ethical Values and Conduct. April 05, 2010

Mandatory Online Sexual Harassment Prevention Course for University of California (UC) Faculty Title VII of the Civil Rights Act of 1964 - Title IX of the Education Amendments of 1972, April 05, 2010



Basics of Drug Safety and Pharmacovigilance. Pharmacovigilance audit compliance course of global drug safety and pharmacovigilance regulations. FDA and EMA drug safety regulations. Park Avenue Presentations, Inc., webinar: Wednesday, December 8, 2010

California Medical Waste Management Act Inspection Mandatory Course. N-14 Board Room, LABiomed at the Harbor-UCLA Medical Center, Gil Armangué, CHMM, Safety Director, November 30, 2010

General Training - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. January 23, 2011

Interactions with Health Care Providers (HCPs): Payments, Meals and the Provision of Other Items - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. January 23, 2011

Federal Compliance and Process/Approval Mechanisms - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. January 23, 2011

The Health Insurance Portability and Accountability Act (HIPAA) LABiomed Online Educational Training Course - Protection of Research Subjects, February 09, 2011

Good Clinical Practices Properly Informed Investigator/Faculty Certificate – General Clinical Research Center at the Harbor-UCLA Medical Center, Torrance, CA, February 12, 2011

Association for the Accreditation of Human Research Protection Programs, Inc., From the Investigator's Point of View – LABioMed – UCLA Certification Update and Course, RB-2, Torrance, CA, October 27, 2011

Investigator Manual - accreditation updates for responsibilities of investigators and staff when conducting human research. LABioMed – UCLA Certification Update Course, RB-3, Torrance, CA, December 02, 2011

Human Research Protection Program Accreditation - Protocol and Consent Form Template (Unit 2, 2012). Research Building (RB)-2, Torrance, CA, March 19, 2012

Sexual Harassment Prevention Training Course (supervisory employees) – Unlawful Harassment and Non-Retaliation Policy Review, two-year mandatory re-certification – State of California Code Training Course at the Los Angeles Biomedical Research Institute, Torrance, California, April 20, 2012

Financial Conflict of Interest (FCOI) Training, Office of Research Administration Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, December 07, 2012

Financial Conflict of Interest (FCOI), National Institutes of Health Office of Extramural Research, Bethesda, Maryland, USA, December 11, 2012 - <http://grants.nih.gov/grants/policy/coi/tutorial2011/fcoi.htm>

Office of Continuing Medical Education, Duke School of Medicine, Conflict of Interest Disclosure For Presenters, May 29, 2013.

Workplace Safety, Hazardous Substances & Materials. Hazard Communication & GHS – What Employees Need to Know". Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, November 22, 2013



Workplace Safety, Hazardous Substances & Materials. Hazard Communication & GHS – What Supervisors Need to Know”. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, November 22, 2013.

Human Biomedical Research Basic Scientists - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515591, July 18, 2014. (Expire July 17, 2017)

Human Biomedical Research Staff - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515590, July 18, 2014. (Expire July 17, 2017)

Human Biomedical Research Investigators – FDA Regulated Research - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515593, July 18, 2014.

University of California Los Angeles (UCLA) Employee Safety Handbook material re-certified ehs.ucla.edu/SafetyHandbook.pdf, July 27, 2017

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) - University of California, Los Angeles (UCLA) (ID: 762) - PEDIATRICS-ENDOCRINOLOGY - UCLA HIPAA (ID:13861) June 29, 2015

Supervisor Anti-Harassment (CA) - 300: Intersections: LawRoom Inspired Employer Solutions course of the Los Angeles Biomedical Research Institute, Torrance, California, February 10, 2016

Accident Investigations - BUSINESS & LEGAL RESOURCES – The importance of accident investigation, how to talk to witnesses, what questions to ask when evaluating an accident scene, how to determine causal factors, and how to identify corrective actions – Pass: August 30, 2016

Americans with Disabilities Act – What Supervisors Need to Know - BUSINESS & LEGAL RESOURCES – To handle job interviews and post-offer discussions properly, deal appropriately with leaves of absence and reinstatement, and avoid discrimination based on disability – Pass: August 30, 2016

Basic First Aid for Medical Emergencies - BUSINESS & LEGAL RESOURCES – to recognize the benefits of obtaining first-aid and CPR certification; identify proper procedures for a variety of medical emergencies; assist in administering first aid when a co-worker is injured; and do no further harm – Pass: August 30, 2016

Fire prevention and extinguishers in California - BUSINESS & LEGAL RESOURCES – To understand the requirements enforced by the California Occupational Safety and Health Administration for both fire prevention and portable fire extinguishers – Pass: August 30, 2016

Hazard Communication and GHS - What Supervisors Need to Know - BUSINESS & LEGAL RESOURCES – To recognize the revised chemical labels and safety data sheets, or SDSs, and train employees to read and interpret GHS-compliant labels and SDSs – Pass: August 30, 2016

Laboratory Recordkeeping for Supervisors - BUSINESS & LEGAL RESOURCES – To cover all the basic laboratory safety records you have to maintain concerning the use of hazardous chemicals in the lab – Pass: August 30, 2016

Laboratory Safety- the Supervisor’s Role - BUSINESS & LEGAL RESOURCES – To gain a better understanding of your role as a supervisor in implementing and maintaining chemical hygiene and safety in the laboratory – Pass: August 30, 2016

Violence in Workplace- How to Prevent and Defuse for Supervisors - BUSINESS & LEGAL RESOURCES – To identify the causes of workplace violence, spot the signs of potential violence, follow required security procedures, respond effectively to violent acts, and recognize and respond to terrorist threats – Pass: August 30, 2016



COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute (LABIOMED) (ID: 2094) - PEDIATRICS – EXPORT COMPLIANCE (ID:16800) - Oct 06, 2016

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute (LABIOMED) (ID: 2094) - PEDIATRICS – CONFLICT OF INTEREST COURSE – Introduction (Cal-Basic) (ID: 15177) - Financial Conflicts of Interest: Overview, Investigator Responsibilities, and Cal Rules (Cal-Basic) (ID: 15070) - Institutional Responsibilities as They Affect Investigators (Cal-Basic) (ID: 15072) - Oct 06, 2016

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute (LABIOMED) (ID: 2094) - PEDIATRICS – STAGE-1 ANIMAL RESEARCH POST-APPROVAL MONITORING – June 19, 2018

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute (LABIOMED) (ID: 2094) - PEDIATRICS – ANIMAL WELFARE REFRESHER – June 26, 2018

SUPERVISORS [CALIFORNIA] - HARASSMENT PREVENTION FOR SUPERVISORS (AB1825 COMPLIANT) May 30, 2019

SCIENTIFIC REPORTS - NATURE - EDITORIAL BOARD MEMBER COURSE - [CERTIFICATE OF COMPLETION](#) - July 01, 2019

BIOMEDICAL RESEARCH – BASIC/REFRESHER – STAGE 2 (Curriculum/Course Learner Group) - (CITI PROGRAM) – EXPIRATION DATE: 24 SEP 2022 – RECORD ID: 33153483

HUMAN RESEARCH - BIOMEDICAL RESEARCHERS & STAFF (ID 38617) - COMPLETION DATE 10-FEB-2020, EXPIRATION DATE 09-FEB-2023, RECORD ID 33953071 - [HTTPS://WWW.CITIPROGRAM.ORG/VERIFY/?W61BEE093-26D8-4B72-9022-354E77238881-33953071](https://www.citiprogram.org/verify/?W61BEE093-26D8-4B72-9022-354E77238881-33953071)

Personal

Date and Place of Birth: June 12, 1962, Szolnok, Hungary

Marital status: Single (divorced)

Child: 1 Daughter (born March 26, 1988, Germany)

Native of Hungary and citizen of the European Union

Lawfully Admitted Permanent Resident of the United States of America: Professional holding an advanced degree and of exceptional ability" [#203 (b) a(A) of the Immigration and Nationality Act; category E26]" – May 04, 1993 – January 19, 2011

Citizen of the United States of America: January 19, 2011



CURRICULUM VITAE

Carole H. Browner, Ph.D., M.P.H.

PERSONAL HISTORY

Business Contact Information

Department of Anthropology
Box 951553 347 Haines Hall
Los Angeles, CA 90095-1553
Office Phone (310) 794-6299
Office Fax (310) 794-6297
E-mail browner@ucla.edu

Citizenship U.S.

EDUCATION

School	Date Graduated	Degrees
The New School for Social Research	1969	B.A.
University of California, Berkeley	1972	M.A.
University of California, Berkeley	1976	Ph.D.
University of California, Berkeley	1977	M.P.H.

LANGUAGE

Spanish: Speak fluently; read, write well.

PROFESSIONAL EXPERIENCE

Employer	Position	From	To
UCLA Los Angeles, CA	Distinguished Research Professor, Professor Emerita, Departments of Psychiatry, Anthropology, and Gender Studies	2013	present
UCLA Los Angeles, CA	Director, Lemelson Anthropological Fellows and Scholars Program Department of Anthropology	2010	2013
UCLA Los Angeles, CA	Chair Department of Anthropology	2010	2013
UCLA Los Angeles, CA	Professor Department of Women's Studies	2009	2013

Columbia University New York, NY	Visiting Professor Dept. of Sociomedical Sciences School of Public Health	2004	2005
Russell Sage Foundation New York, NY	Visiting Scholar	1998	1999
Universitat Rovira I Virgili Tarragona, Spain	Visiting Professor	1999	1999
UCLA Los Angeles, CA	Professor-in-Residence Departments of Psychiatry and Anthropology	1993	2013
UCLA Los Angeles, CA	Member, Intellectual and Developmental Disabilities Research Center	1983	2013
UCLA Los Angeles, CA	Associate Professor-in- Residence, Department of Psychiatry	1987	1993
UCLA Los Angeles, CA	Assistant Professor-in- Residence, Department of Psychiatry	1983	1987
Wayne State University Detroit, MI	Associate Professor Department of Anthropology	1983	1984
Wayne State University Detroit, MI	Assistant Professor and Coordinator of M.A. Program in Medical Anthropology, Department of Anthropology	1977	1983
UC-Berkeley Berkeley, CA	Research Anthropologist Department of Anthropology	1977	1977
UC-Berkeley Berkeley, CA	Research Assistant School of Public Health	1977	1977

FIELD RESEARCH

San Francisco, California. Analysis of ways staff mediates physician-patient interaction, 1970-71.

San Francisco, California. Factors which influence differential use of outpatient services, 1971.

San Francisco, California. Investigation of the assumption that the experience of induced abortion invariably constitutes a "life crisis." Analysis of the effects of network dissonance on individual perception of significant life events, 1972.

Cali, Colombia. Field research for Ph.D. dissertation *Poor Women's Fertility Decisions: Illegal Abortion in Cali, Colombia*. Concerns the social etiology of fertility decisions, especially the resolution of unwanted pregnancy and the decision to have an illegal abortion. The implications of differential family organization (particularly varying degrees of conjugal stability) for the major life decisions that women make, 1974-75.

Palo Alto, California. Co-director of four research projects on the impact of computerized office technology in the sales offices of a major American corporation, 1977.

Cali, Colombia. Further study of concepts of pregnancy and abortion, especially how women decide they are pregnant and actions they take once a decision is made, 1978.

Oaxaca, Mexico. Research into the use of medicinal plants by Chinantec speaking women for the management of reproduction and the treatment of reproductive health problems. Also examined the nature of gender-based power relations and the circumstances under which women in a male controlled society exercise reproductive and social autonomy, 1980-81.

Pomona, California. The use of social resources at work to reduce the impact of job stress on the health of nursing staff who care for the developmentally disabled, 1983-85.

Los Angeles and Orange Counties, California. Research on the considerations pregnant women of various ethnic groups and their male partners take into account when deciding whether to undergo prenatal diagnostic testing, 1989-99.

Southern California and South Texas. Field work on the culture and work practices of prenatal genetic service providers who provide prenatal genetic information and testing to pregnant Latinas, 1999-2003.

Southern California, Central Mexico. Field research on how neurologists, patients, and family members conceptualize and use genetic information, 2003-ongoing.

Baja California, Mexico. An investigation of the factors that promote long-term medical volunteerism, 2011-13.

Baja California, Mexico. Field and archival research on individual and systems-level barriers to care among Mexican children with congenital craniofacial defects, 2012-13.

PROFESSIONAL ASSOCIATIONS

- Fellow, American Anthropology Association
- Fellow, Society for Applied Anthropology
- American Ethnological Study
- Society for Medical Anthropology
- Latin American Studies Association
- Society for Latin American Anthropology
- Sigma Xi
- Southern California Applied Anthropology Network
- American Association on Mental Retardation.

SERVICE TO GOVERNMENTAL, EDUCATIONAL AND COMMUNITY AGENCIES

- Interviewer and Member of the Selections Committee. Health Sciences and Medical Education Program. University of California, Berkeley. CA, 1973-74.
- Consultant. Committee on Problems of Health and Community Development. Centro de Salud de Siloé. Cali, Colombia, 1975.
- Consultant. Dean's Committee to Redesign the Medical School Curriculum. Escuela de Medicina. Universidad del Valle, Cali, Colombia, 1975.
- Consultant to Tom Bates, California State Assembly. Environmental Pollution and Occupational Health, 1977.
- Consultant. Palo Alto Research Center. Xerox Corporation, 1977.
- Director of Research on Cultural Enrichment Programs for Methadone Maintenance Clients. Department of Health, Detroit, MI, 1979-80.
- Consultant. National Institute of Education. The Use of Ethnographic Techniques in the Study of Formal Institutions. Washington, D. C., 1979.
- Consultant. World Health Organization/Pan American Health Organization, 1980.
- Consultant. U.S. Department of Transportation & Highway Safety. Washington, D.C., 1981
- External evaluator of Doctoral Program in Medical Anthropology, School of Medicine, University of California, San Francisco, CA, 1989.
- External evaluator of Master's Degree Program in Medical Anthropology, School of Medicine, Universidad Nacional Autonoma de México, Mexico City, Mexico, 1989.
- Consultant. Dept. of Obstetrics and Gynecology, Olive View Medical Center, Sylmar, CA, 1993-.
- Founding Associate. Pacific Institute for Women's Health, Los Angeles, CA, 1993.
- Lead Anthropologist. "Ethnicity and Attitudes Towards Advance Care Directives." L. Blackhall, P. I., School of Medicine, University of Southern California, Los Angeles, CA.
- Member, Planning and Policy Committee. Pacific Institute for Women's Health, Los Angeles, CA. 1994-96.
- Consultant. "*Conceptualización social de la salud reproductiva y factores sociales que los determinan*" [Conceptualizing Reproductive Health and Social Factors Which Determine It], Norma Ojeda, P. I., Department of Gender Studies, Colegio de la Frontera, Tijuana, B. C., 1995-96.
- Consultant. "Institutional, Cultural and Psychosocial Factors Affecting Mexican-American Women's Follow-up Behaviors for Positive Pap Screening Tests," Linda M. Hunt, P. I., American Cancer Society, 1995-96, 1996-97.
- Consultant. "Patterns of Change in Reproductive Decision Making in Rural Mexico," Katherine Tolbert, Ph.D., P. I. The Population Council, Mexico City, Mexico, 1995-98.
- Member, Scientific Advisory Committee. California Birth Defects Monitoring Program, Department of Health Services, State of California, 1996-99.
- Member. International Forum for Social Sciences in Health 1996-.

- Consultant. California State Birth Defects Monitoring Program (CBDMP), 1996-.
- Consultant to the Transborder Consortium on Gender and Health on the U.S.-Mexican Border, Southwest Institute for Research on Women (SIROW), University of Arizona, Tucson, AZ, 1997-2000.
- Consultant and Member of Advisory Board. “Crossing Cultural Boundaries: An Ethnographic Study,” NIMH. Cheryl Mattingly, P.I. Department of Occupational Therapy, USC, Los Angeles, CA. 1996 - 2001.
- Consultant in gender and reproductive health. La Universidad de las Regiones Autónomas de la Costa Caribe Nicaragüense (URACCAN), Puerto Cabezas, Nicaragua, 1998.
- Advisory Board. “Ethnic Folk Medicine in Los Angeles,” National Endowment for the Humanities. Michael Owen Jones, P. I., Program in Folklore, UCLA, 2000-03.
- Advisory Board. “Boundary Crossings: An Ethnographic and Longitudinal Study,” NIMH. Mary Lawler and Cheryl Mattingly, Co-P.I.s. Department of Occupational Therapy, USC, Los Angeles, CA. 2000-05.
- Consultant. “Reducing Cultural Barriers to the Provision of Genetic Service in South Texas,” C. I. Kaye, M. C. Aguilar, and M. L. Urdaneta, Co-P.Is., University of Texas Health Science Center, San Antonio, 2000.
- Interviewer, Robert Wood Johnson Clinical Scholar Program, UCLA, 2001.
- Member, Multidisciplinary Sexual Health Curriculum Committee, Dept. of Urology, UCLA, 2001-2013.
- Member, Advisory Board, Foundation for Psycho-Cultural Research, Pacific Palisades, CA, 2000-present.
- Consultant to Russell Sage Foundation Program on Cultural Contact, 2001.
- Consultant, “Fixing Men: Negotiating Reproductive Health and Sexuality,” Matthew Gutmann, P. I., NEH, 2001-02.
- Steering Committee, Special Grants Program on Migration and Health, California Policy Research Center, Office of the President of the University of California, 2001-
- Advisor, Sexuality Research Fellowship Program, Social Science Research Council, 2002-.
- Consultant, “Barriers to Treatment for Children Born with *Spina Bifida* in Guatemala City, Guatemala,” Dr. Julio Lazaroff, Neurosurgery, ULCA, 2002, 2007.
- Consultant, “Assessment of the use of anthropological methods to study the adaptive behavior of the mentally retarded people at the Colonia Manuel Montes de Oca, Provincia de Buenos Aires, Argentina,” Silvia Balzano, P. I., Argentine National Council for Research on Science and Technology (CONICET).
- Consultant to UCLA Pharmacogenetics and Pharmacogenomics Research Group, 2004-
- Consultant and Member of Advisory Board. “Boundary Crossing: Re-situating Cultural Competence” NIMH. Cheryl Mattingly, P.I. Department of Occupational Therapy, USC, Los Angeles, CA. 2005-2008.
- Program Committee, FPR-UCLA 3rd Interdisciplinary Conference: Seven Dimensions of Emotion, 2006.
- Consultant, NIH National Center on Minority Health and Health Disparities Program, 2006.
- Program Committee, FPR-UCLA 4th Interdisciplinary Conference: Cultural and Biological Contexts of Psychiatric Disorder, 2008-09.
- Faculty Mentor, Washington State University NSF ADVANCE Program, 2011-12.
- Founder and Director, Lemelson Anthropological Scholars Program, UCLA, 2011-13.
- Steering Committee, Bixby Center for Population and Reproductive Health, UCLA.
- Program Committee, FPR-UCLA 5th Interdisciplinary Conference: The Emerging Neuroscience of Sex and Gender, 2013-15.

- *Socia*, Profesores del Grupo Ampliado en el Posgrado en Socio-Medicina de la Universidad de Guadalajara 2017-
- Committee Member, Facultad de Filosofía, Universidad Autónoma de Querétaro, Santiago de Querétaro, México, 2020.
- External Examiner, Department of Anthropology, The School of Graduate Studies, University of Toronto, 2021.

REVIEWER FOR FUNDING AGENCIES

- Review Panel for Behavioral and Neural Sciences (Social/Cultural Anthropology), National Science Foundation, 1987-89.
- Review Panel, U. S. Department of Education Talent Search Program, 1994.
- Occasional grant reviews for the National Science Foundation, the World Health Organization, the Wenner-Gren Foundation for Anthropological Research, March of Dimes, Social Sciences and Humanities Research Council of Canada, Russell Sage Foundation, Foundation for Psycho-Cultural Research, Israel Science Foundation.
- Review Panel, Ethical, Legal, and Social Issues, Center for Human Genome Research, NIH, 2002.
- *Ad hoc* Review Panel, NIH Challenge Grants for Health and Science Research, 2009.
- *Ad hoc* Review Panel, NIH Grants for Health and Science Research, 2010.
- Proposal Review Panel, The Center of Expertise in Women's Health and Empowerment, University of California, 2011.
- *Ad hoc* proposal reviewer, The Russell Sage Foundation, 2011.
- Member, NIH Study Section, Fellowships: Risk, Health, and Healthcare, 2012.
- External Evaluator, The Spinoza Prize, Netherlands Organization for Scientific Research, 2012.
- External Reviewer, South African National Research Foundation, 2015.
- External Reviewer for promotion and tenure, Northwestern University, 2015.
- External Reviewer, The Marsden Fund, Royal Society Te Apārangi, New Zealand, 2017.
- External Evaluator, South African National Research Foundation, 2017.

SERVICE TO PROFESSIONAL AND SCHOLARLY SOCIETIES

Editorial

- Editorial Board, *Women in International Development*, 1981-82.
- Editorial Board, *Medical Anthropology Quarterly*, 1992-94, 1999-02
- Editorial Board. *Encyclopedia of Medical Anthropology* (3 volumes), Melvin and Carol Ember, eds. Kluwer Academic/Plenum, 2000.
- Editorial Board, *Anthropology of Work Review*, 2002-
- Editor, Invited theme issue on "The Social Production of Health: Critical Contributions from Evolutionary, Biological, and Socio-cultural Anthropology," *Social Science and Medicine* 61(4):745-878, 2005.

Ad hoc manuscript reviews, periodicals

American Anthropologist, American Ethnologist, Anthropological Quarterly, Central Issues in Anthropology, Human Organization, Feminist Studies, Women in International Development, Social Science and Medicine, Ethos, Current Anthropology, Urban Anthropology, Medical Anthropology, Medical Anthropology Quarterly, Bulletin of Latin American Research, Gender and Society, Frontiers, Health Policy and Planning, Culture, Medicine, and Psychiatry, Journal of Ethnobiology, Food and

Foodways, Women and Health, American Behavioral Scientist, Daedalus, Community Genetics, Journal of Genetic Counseling, Atlantis: A Women's Studies Journal, Revu d'Etudes sur les femmes, Meridians: Feminism, Race, Transnationalism, American Journal of Medical Genetics, Hastings Center Report, Fertility and Sterility, New Genetics and Society, Transcultural Psychiatry, Body and Society, Latino Studies, Sexuality Research and Social Policy, Journal of Middle Eastern Women's Studies, Family Relations, Prenatal Diagnosis, Anthropology & Medicine, Culture, Health and Sexuality, Journal of JMEWS: Middle Eastern Women's Studies, BioSocieties, PLOS ONE, Einstein Journal of Biology and Medicine, Reproductive Health Matters, International Journal of Masculinity Studies, Reproductive Biomedicine and Society.

Ad hoc manuscript reviews, presses

University of Texas Press, University of Pennsylvania Press, Princeton University Press, SUNY Press, Routledge, Oxford University Press, Cambridge University Press, University of Minnesota Press, Sage Publishers, Rutgers University Press, Haworth Press, *El Colegio de la Frontera del Norte*, Greenwood Publishing Group, University of California Press, University of New Mexico Press, Alta Mira Press, Indiana University Press, University of Michigan Press, Duke University Press, Rowman & Littlefield, Yale University Press, Columbia University Press, Wiley-Blackwell, Left Coast Press, HarperCollins, Berghahn, Palgrave Macmillan, University of Alabama Press, Stanford University Press, Polity Press, Vanderbilt University Press.

Other Service (selected)

- Committee to Investigate the Feasibility of Certifying Master's Degree Programs in Applied Anthropology. Society for Applied Anthropology, 1979.
- Committee on the Status of Women in Anthropology. American Anthropological Association, 1980-83.
- Nominations Committee, Society for Medical Anthropology, 1986.
- Rivers Student Prize Committee, Society for Medical Anthropology, 1986.
- Elected to Nominations and Elections Committee, Society for Applied Anthropology, 1987-89.
- Program Committee, Annual Meeting of the Society for Applied Anthropology, Tampa, FL, 1987.
- Program Chair, 1988 Annual Meeting of the Society for Medical Anthropology, Phoenix, AZ, 1987.
- Elected to Executive Board, Society for Medical Anthropology, 1987-90.
- Chair, Nominations and Elections Committee, Society for Applied Anthropology, 1988-89.
- Elected to Executive Board, Society for Latin American Anthropology, 1988-91.
- Review Panel for *Practicing Anthropology*, Society for Applied Anthropology, 1989.
- Program Chair, Luncheon and Wine and Cheese Roundtable Discussions, Annual Meeting of the Society of Medical Anthropology, Washington, D.C., 1989.
- Chair, Nominations and Elections Committee, Society for Latin American Anthropology, 1989.
- Program Chair, Roundtable Wine and Cheese and Luncheon Discussions, Annual Meeting of the Society of Medical Anthropology, New Orleans, LA, 1990.
- Program Chair, Roundtable Luncheon Discussions, Annual Meeting of the Society of Latin American Anthropology, New Orleans, LA, 1990.
- Appointed to Executive Board, Society for Medical Anthropology, 1990-91.
- Program Committee, Annual Meeting of the Society for Applied Anthropology, Charleston, SC, 1991.
- Program Chair, 1992 Annual Meeting of the Society for Latin American Anthropology, Chicago, IL, 1991.

- Program Committee, 1992 American Ethnological Society, Chicago, IL, 1991.
- Chair, Publications Committee, Society for Medical Anthropology, 1991-92.
- Eileen Basker Award Committee, Society for Medical Anthropology, 1993.
- Program Committee, Annual Meeting of the American Ethnological Society, Santa Monica, CA, 1994.
- Eileen Basker Award Committee, Society for Medical Anthropology, 1994.
- Elected to Executive Board, Society for Applied Anthropology, 1994-97.
- President Elect, Society for Medical Anthropology, 1994-95.
- Chair, Membership Committee, Society for Medical Anthropology, 1995-98.
- Liaison, Interorganizational Committee, Society for Applied Anthropology and Society for Medical Anthropology, 1995-98.
- Chair, Nominations and Elections Committee, Society for Medical Anthropology, 1994.
- President, Society for Medical Anthropology, 1995-97.
- Executive Board, American Anthropological Association, 1995-96.
- Chair, Administrative Advisory Committee, American Anthropological Association, Search Committee, Executive Director of American Anthropological Association, 1996.
- Program Committee, Plenary Session for 1st Independent Meeting of the Society for Medical Anthropology, San Francisco, CA, 2000.
- Executive Program Committee, Annual Meeting of the American Anthropological Association, San Francisco, CA, 2000.
- External Reviewer for promotion and tenure, Simon Fraser University, 2004.
- External Reviewer for promotion, Brown University, 2004
- External Reviewer for promotion and tenure, University of California, San Francisco, 2005.
- External Reviewer for promotion, Wayne State University, 2005.
- External Reviewer for promotion, National Taiwan University, 2006.
- External Reviewer for promotion and tenure, University of California, Santa Barbara, 2006.
- External Reviewer for promotion and tenure, University of Haifa, 2006.
- External Reviewer for promotion and tenure, Ohio State University, 2006.
- External Reviewer for promotion, Rice University, 2008.
- External Reviewer for promotion and tenure, University of California, Riverside, 2011.
- New Millennium Book Award Committee, Society for Medical Anthropology, 2008, 2009, 2011, 2013.
- MASA Dissertation Award Committee, Society for Medical Anthropology, 2009.
- Chair, Search Committee for Editor-in-Chief, *Medical Anthropology Quarterly*, 2009.
- External Reviewer for promotion and tenure, Rutgers University, 2009
- External Reviewer for promotion and tenure, Bryn Mawr College, 2009.
- Organizing Committee, “Gender, Art, and Social Movements in the Middle East and Global South,” UCLA, November 28th, 2011.
- New Millennium Book Award Committee, Society for Medical Anthropology, 2011.
- Organizing Committee, Conference on Culture, Mind, and Brain: Emerging Concepts, Methods, Applications. Foundation for Psychocultural Research, UCLA, 2012.
- External Reviewer for promotion and tenure, Simon Fraser University, 2012.
- External Reviewer, Kagawa Singer M, Dressler WW, George SM, Elwood WN. *The Cultural Framework for Health: An Integrative Approach for Research, Program Design and Evaluation*.
- External Reviewer for promotion and tenure, Notre Dame University, 2013.
- External Reviewer for promotion to Distinguished Professor, The Graduate Center, CUNY, 2013.
- External Reviewer for promotion, University of Michigan, 2013.
- External Reviewer for promotion, University of Chicago, 2014.
- NIH Office of Behavioral and Social Science Research, 2015.
- External Reviewer for promotion, Notre Dame University, 2017.

- External Reviewer, Netherlands Institute for Advanced Study in the Humanities and Social Sciences, 2015.
- External Reviewer for promotion and tenure, Gonzaga University, Spokane, WA, 2019
- External Reviewer for promotion and tenure, Rutgers University, 2019.
- External Reviewer for promotion and tenure, Northwestern University, 2019.
- External Reviewer for promotion and tenure, University of Texas, El Paso, 2020.
- Nominations Committee (*ad hoc*), Society for Medical Anthropology, 2020.
- External Reviewer for promotion and tenure, Oregon State University, Portland, 2020.
- External Reviewer for promotion and tenure, University of Texas, El Paso, 2020.

HONORS AND AWARDS

- Outstanding Graduate Student Teaching Award, Dept. of Psychiatry and Biobehavioral Sciences, UCLA, 2001.
- Outstanding Research Mentor Award, Dept. of Psychiatry and Biobehavioral Sciences, UCLA, 2003.
- Medical Anthropology Student Association MASA Mentoring Award, Society for Medical Anthropology, 2009.
- Society for Medical Anthropology Eileen Basker Memorial Award for Studies in Gender and Health for Browner and Sargent, eds. *Reproduction, Globalization and the State: New Theoretical and Ethnographic Perspectives*, Duke University Press, 2012.
- Council for Anthropology and Reproduction Award for Most Significant Edited Collection for Browner and Sargent, eds. *Reproduction, Globalization and the State: New Theoretical and Ethnographic Perspectives*, Duke University Press, 2012.
- Distinguished Member, American Anthropological Association, 2019.
- Loyalty Society, American Anthropological Association, 2020.

MAJOR GRANT SUPPORT

- | | |
|---------|--|
| 1980-83 | Sociocultural and Pharmacological Dimensions of Women's Reproductive Medicine (NSF BNS80-16431), Carole H. Browner, Principal Investigator, \$51,520 direct costs. |
| 1988-94 | Decisions about the Use of Prenatal Diagnostic Testing by Mexican-American and Non-Hispanic White Women (NICHD ND11944), Carole H. Browner, Key Investigator, \$432,534 direct costs. |
| 1994-96 | The Context and Meaning of Reproductive Decision Making among Inner City Hispanic/Latino Couples (Contraceptive Research and Development Program, CONRAD/CDC), Carole H. Browner, Co-Principal Investigator, \$200,386 direct costs. |
| 1995-96 | Building Across Borders: A Proposal to Establish a Transborder Consortium for Research and Action on the Mexican-United States Border. (MacArthur and Ford Foundations), Carole H. Browner, Co-Investigator. \$125,226 direct costs. |
| 1995-98 | Use of Amniocentesis by Mexicans and Mexican-Americans, (NIH 1 RO1 HD31618-01), Carole H. Browner, Principal Investigator, \$431,790 direct costs. |

- 1995-98 Access to Care for Homeless Women of Reproductive Age, Carole H. Browner, Co-Principal Investigator (AHRP H508323-01), \$1,761,831 direct costs.
- 1999-2001 Partnering for Tobacco Control Research Among Deaf Youth (Tobacco-Related Diseases Research Program 8BT-1701), Carole H. Browner, Co-Principal Investigator, \$75,000 direct costs.
- 1999-2003 Genetic Counseling Strategies with Mexican-origin Women, (NIH 1 RO1 HG01384-04), Carole H. Browner, Principal Investigator, \$911,584 direct costs.
- 2001-2004 Community Consultation and Haplotype Mapping in Mexican Americans (NIH R03 HG02500-01-S01), Carole H. Browner, Co-Investigator, \$112,260 direct costs.
- 2003-2007 Use of Genetics in Neurologists' Clinical Practices (NIH 1 RO1 HG003228-01), Carole H. Browner, Principal Investigator, \$915,923 direct costs.
- 2013-2015 Establishing Infrastructure for Prevention of Familial Alzheimer Disease in Mexico (NIH Fogerty International Center R21 TW009787-01), Carole H. Browner, Co-Investigator, \$113,000 direct costs.

OTHER GRANT SUPPORT

- 1972-75 National Institute for General Medical Sciences Traineeship.
- 1974-76 Predoctoral Training Grant. International Center for Medical Research, Tulane University School of Medicine.
- 1977a Committee on Teaching Minigrant for Instructional Improvement. University of California, Berkeley.
- 1977b Committee on Teaching Minigrant for Instructional Improvement. University of California, Berkeley.
- 1978 Faculty Research Award, Wayne State University.
- 1980 American Philosophical Society Research Award.
- 1980-82 National Institute of Health Postdoctoral Training Fellowship to study population policy and demography (declined).
- 1980-82 Wenner-Gren Foundation for Anthropological Research.
- 1982 American Council of Learned Societies. Travel Grant.
- 1984-85 Committee on Research of the Academic Senate, UCLA. Research Award.
- 1985-86 UC-MEXUS. Research Award.
- 1987-88 UCLA Program on Mexico. Research Award.
- 1988-89 Committee on Research of the Academic Senate, UCLA. Research Award.
- 1988-89 Chicano Studies Research Center, UCLA. Research Award.
- 1994-95 UCLA Center for the Study of Women. Research Award.
- 1994-95 UC-MEXUS. Research Award.
- 1996-97 Committee on Research of the Academic Senate, UCLA. Research Award.
- 2006 Wenner-Gren Foundation for Anthropological Research.
- 2006 Rockefeller Foundation Bellagio Program.
- 2009 Committee on Research of the Academic Senate, UCLA, Research Award.
- 2011 UCLA Dental School Seed Grant.

LECTURES AND PRESENTATIONS

Selected Lectures

- Kresge College, University of California, Santa Cruz, California, 1975.
- Department of Anthropology, Cornell University, Ithaca, NY, 1976.
- Program in Medical Anthropology. University of California School of Medicine. San Francisco, CA, 1976.
- Department of Anthropology and Women's Studies Program, Indiana University, Bloomington, IN, 1977.
- Department of Anthropology, Memphis State University, Memphis, TN, 1977.
- Department of Anthropology, Southern Methodist University, Dallas, TX, 1979.
- Women's International Film Festival. Wayne State University, Detroit, MI, 1980.
- Center for Population Planning. School of Public Health. University of Michigan, Ann Arbor, MI, 1980.
- Department of Anthropology. Michigan State University, East Lansing, MI, 1981.
- *Servicios Coordinados de la Salud del Estado de Oaxaca* (Oaxacan Government Coordinated Health Services) District of Ixtlán, Oaxaca, Mexico, 1981.
- Department of Anthropology. University of Wisconsin, Kenosha, WI, 1983.
- Department of Anthropology. California State Polytechnic University, Pomona, CA, 1984.
- Program in Continuing Medical Education, Lanterman State, Hospital, Pomona, CA, 1985.
- School of Social Ecology, University of California, Irvine, CA, 1985.
- Women, Health and Healing Summer Institute, University of California, San Francisco, CA, 1985.
- Women's Studies Program and Department of Anthropology, Southern Methodist University, Dallas, TX, 1987.
- Mount Saint Mary's College, Los Angeles, CA, 1987.
- Department of Anthropology, University of Leiden, Leiden, The Netherlands, 1987.
- Program in Social Relations, University of California, Irvine, 1988.
- Department of Anthropology and Women's Studies Program, University of California, Irvine, CA, 1991.
- Departament de Geografia, Història i Filosofia, Universitat de Barcelona, Camp de Tarragona, Spain, 1992.
- Centre d'Investigació Històrica de la Dona, Universitat de Barcelona, Spain, 1992.
- Departament d'Antropologia de la Facultat de Geografia i Història, Universitat de Barcelona, Spain, 1992.
- Antigone: Institute for Feminist Psychology, Barcelona, Spain, 1992.
- Prolèg Feminist Cultural Institute, Barcelona, Spain, 1992.
- Department of Anthropology, UC-Irvine, Irvine, CA, 1993.
- California Medical Association, UCI Student Chapter, Irvine, CA, 1993.
- Anthropology Club, Southern Methodist University, Dallas, TX, 1994.
- Symposium on Gender Issues in Science, Technology, and Medicine. Program in the Cultural Studies of Medicine and Science, UCLA, 1994.
- Workshop on Qualitative Research Methods, Department of Gender Studies, Colegio de la Frontera, Tijuana, B. C., 1995, 1996.
- Dept. of Anthropology and College of Nursing, University of Colorado, Denver, CO 1997.
- Leadership Seminar, Annual Meeting of the Society for Applied Anthropology, Seattle, WA, 1997.
- Faculty Development Workshop in Ethnomedical Sciences. Drew Medical School, Los Angeles, CA, 1998.

- *I Jornadas Internacionales de Antropología Médica*, Universidad de Guadalajara, Guadalajara, Mexico, 1998.
- Russell Sage Foundation, New York, NY, 1999.
- Metropolitan Medical Anthropology Association, Graduate Center, CUNY, 1999.
- Latino Mental Health Research Group, UCLA, 2000.
- Dept. of Anthropology, University of Iowa, Iowa City, IA, 2000.
- Program in Demography, Colegio de la Frontera de Baja California, Tijuana, B. C., 2000.
- Workshop in Research Methods, Instituto de Programas de Estudios sobre Epidemiología Psiquiátrica (PEPSI), National Counsel for Research on Science and Technology (CONICET), Buenos Aires, Argentina, 2003.
- Dept. of Educational Psychology and Counseling, California State University, Northridge, CA, 2004.
- Dept. of Socio-medical Sciences, School of Public Health, Columbia University, New York, NY, 2004.
- Dept. of Anthropology and Program in Demography, Brown University, Providence, RI, 2004.
- Depts. of Anthropology and Women's Studies, Mt. Holyoke College, S. Hadley, MA, 2004.
- Reproductive Politics Study Group, Hampshire College, Amherst, MA, 2004.
- Series on "Science, Society 'n You," Occidental College, Los Angeles, CA, 2006
- Interdisciplinary Relationship Sciences Program, UCLA, 2008.
- MSTs (Medical Anthropology & Science and Technology Studies) Emergent Intersections, Unexpected Syntheses, University of California, Irvine, 2010.
- Going the Anthropological Mile: What Dedicated Mentors Have to Say to Students of Anthropology. Invited Roundtable, Society for Medical Anthropology, Annual Meeting of the American Anthropological Association, New Orleans, LA, 2010.
- Dept. of Anthropology, Vanderbilt University, Nashville, TN, 2011.
- Mind, Medicine and Culture, Department of Anthropology, UCLA, 2012.
- Institute for Society and Genetics, UCLA, 2012.
- Unidad en Medicina Social y Servicios de Salud, Escuela de Medicina, Universidad de Guadalajara, Guadalajara, MX, 2014.
- Unidad en Medicina Social y Servicios de Salud, Escuela de Medicina, Universidad de Guadalajara, Guadalajara, MX, 2017.
- Unidad en Medicina Social y Servicios de Salud, Escuela de Medicina, Universidad de Guadalajara, Guadalajara, MX, 2021.

Presentations

- 1974 Abortion as a Life Crisis. *Annual Meeting of the American Anthropological Association*. New Orleans, LA.
- 1976 The Failure of Reform: Community Development and the Limits of Technical Assistance. *Annual Meeting of the Southwestern Anthropology Association*. San Francisco, CA.
- 1976 Female Masochism Reconsidered: The Virgin Mary as Economic Woman, CHB and E. Lewin). Invited paper presented in symposium "Social Structure, Ideology, and Women's Choices." *Annual Meeting of the American Anthropological Association*. Washington, D.C.
- 1977 Folk Concepts of Pregnancy and Abortion in Cali, Colombia. *Joint Annual Meetings of the Society for Applied Anthropology, Southwestern Anthropology Association*. San Diego, CA.

- 1978 Perspectives and New Directions for Corporation Anthropology, (CHB and M. Chibnik). Presented in symposium "Innocents at Home: American Anthropologists Study American Institutions." *Annual Meeting of the American Anthropological Association*. Los Angeles.
- 1978 White Collar Anthropology: Field Research in Corporate America, (CHB and M. Chibnik). *Annual Meeting of the Society for Applied Anthropology*. Merida, Yucatan, Mexico.
- 1979 Couvade in the City: Evidence for Male Pregnancy in Cali, Colombia. *Annual Meeting of the American Anthropological Association*. Cincinnati, OH.
- 1979 Traditional and Modern Techniques for Diagnosis, Treatment and Control of Fertility in Cali, Colombia. Invited paper presented in symposium "Traditional Medicine as an Alternative in Latin America." *43rd International Congress of Americanists*. Vancouver, B.C.
- 1980 Riding the Corporate Roller Coaster: Management Strategies to Control Office Productivity. Invited paper presented at an interdisciplinary conference on "The Exercise of Power in Complex Organizations." *Wenner-Gren Foundation for Anthropological Research*. Burg Warstein, Austria.
- 1980 Machismo, Sympathetic Pregnancy and Changing Men's Roles in Urban Colombia. Invited paper presented to the *Annual Meeting of the Michigan Academy of Science, Arts and Letters*. Detroit, MI.
- 1980 Gender Role Ambiguity in the Mexican Fotonovela, (J. Hill and CHB). *Annual Meeting of the Popular Culture Association*. Detroit, MI.
- 1982 Medicinal Plant Use in a Highland Oaxaca Village, (G. Martin and CHB). *Fifth Annual Ethnobiology Conference*. San Diego, CA.
- 1982 The Personal as Political: Women's Role in the Incorporation of an Indigenous Community into Mexican National Society. Invited paper presented in symposium "Pressure and Counter Pressure: Interaction between State and Local Levels in Highland Mexico." *44th International Congress of Americanists*. Manchester, England.
- 1982 Women's Understandings about Reproductive Physiology and their Choice of Herbal Medicines in Cali, Colombia. *Women, Health, and International Development*. M. Aguwa, organizer. Michigan State University, E. Lansing.
- 1983 Herbal Emmenagogues Used by Women in Mexico and Colombia, (CHB and B. Ortiz de Montellano). Invited paper presented at the *Annual Meeting of the Michigan Academy of Science, Arts and Letters*. Ypsilanti, MI.
- 1983 The Sexual Politics of Reproduction in a Mexican Village. Invited paper presented in symposium "Reproduction and the Cultural Construction of Gender." *Annual Meeting of the American Anthropological Association*. Chicago, IL.
- 1983 Remedies for Reproductive Health and Their Implications for Humoral Medicine, (CHB and B. Ortiz de Montellano). Invited paper in symposium "Recent Anthropological Advances in Health and Ethnomedicine among Hispanics." *Annual Meeting of the American Anthro. Assn.* Chicago, IL.

- 1985 Women, Household, and Health. Invited paper presented at Social Science Research Council Conference on *The Political Economy of Health and Disease*, Toluca, Mexico
- 1985 Issues in the Study of Household Health. Invited paper presented in symposium on "The Political Economy of Health in Latin America." *XIII International Conference of the Latin American Studies Association*. Albuquerque, NM.
- 1985 Social and Cultural Aspects of the Childbearing Decision. Invited paper presented at conference on *Childbearing: Tradition and Decision*. The Oklahoma Council on the Humanities and the Planned Parenthood Federation of Tulsa.
- 1985 Enseñanzas que derivan del uso de yerbas medicinales en Oaxaca, in symposium "What Biomedicine can learn from Traditional Medicine." Mexico (CHB and B. Ortiz de Montellano). Invited paper presented at *45th International Congress of Americanists*. Bogotá, Colombia.
- 1985 Women's Secrets: Knowledge of Plants for Reproduction in Oaxaca, Mexico (CHB and S. Perdue). Invited paper presented in symposium "Cross-Cultural Perspectives on Women in Health Care." *Annual Meeting of the American Anthropological Association*. Washington, D.C.
- 1986 The Management of Reproduction in an Egalitarian Society. Invited paper presented in symposium, "Knowledge and Power in the Management of Reproduction." *Joint Meeting of the American Ethnological Society, the Southern Anthropological Society and the Society for Medical Anthropology*. Wrightsville Beach, NC.
- 1986 A New Methodology for Medical Anthropology (CHB, B. Ortiz de Montellano and A. J. Rubel). Invited discussion paper presented in invited symposium on "Latin American Medical Anthropology" sponsored by the Society for Medical Anthropology and the Society for Latin American Anthropology. *Annual Meeting of the American Anthropological Association*. Philadelphia, PA.
- 1987 Production, Reproduction and Women's Health: A Case Study from Oaxaca, Mexico. Invited paper presented in symposium "Health in Mexico." *Annual Meeting of the Society for Applied Anthropology*. Oaxaca, Mexico.
- 1987 Work and Women's Health: The Role of Job-Based Social Support. Paper presented at conference on Women at Work, UCLA, Los Angeles, CA.
- 1988 Prenatal Care for Latino Women. Invited paper presented at conference on Clinical and Cultural Dimensions in Health Care Delivery to Chicano/Latino Patients. International Chicano Studies Program. University of California, Irvine, CA.
- 1988 Hypoglycemia: Portrait of a Popular Diagnosis in Use (L. M. Hunt and CHB). Paper presented at *Annual Meeting of American Anthropological Association*. Phoenix, AZ.
- 1988 Knowledge, Power, and Reproduction: A Study of Economic and Social Change in Rural Mexico. Invited paper presented in symposium "Gender Hierarchy and Economic Change in Mexico." *Annual Meeting of the American Anthropological Association*. Phoenix, AZ.

- 1989 American Women and the Medicalization of Childbirth. Invited paper presented in special AES invited symposium "Author Meets Critics: Emily Martin and Cultural Construction of Scientific Knowledge." *Annual Meeting of the American Anthropological Association*. Washington, D.C.
- 1990 Medical Anthropological Perspectives on Prenatal Care for California Hispanics. Invited paper presented at *Annual Meeting of the California Medical Association*. Anaheim, CA.
- 1990 Women's Economic Roles in a Highland Chinantec Community. Invited paper presented at Meeting of the Society for Women Geographers, Los Angeles, CA.
- 1990 Crisis in Prenatal Care for Poor Latinas: A Medical Anthropological Perspective. Invited paper presented in symposium "Medical Anthropological Research in the Southwest." *Annual Meeting of the Southwest Anthropology Association*. Long Beach, CA.
- 1990 Women's Therapeutic Herbal Knowledge: Key to Development? Invitational Conference on Tropical Ethnomedicine. The Esalen Institute, Big Sur, CA.
- 1990 Intracultural Variation in Therapeutic Knowledge. Paper presented at *Annual Meeting of the American Anthropological Association*. New Orleans, LA.
- 1990 The Politics of Disclosure in Prenatal Diagnostic Testing (N. Press and CHB). Invited paper presented in invited symposium on "The Human Body and the Body Politic: Exploring the Role of Western Medicine in the Maintenance of Social Control." *Annual Meeting of the American Anthropological Association*. New Orleans, LA.
- 1991 The Normalization of Prenatal Screening: Women's Acquiescence to the Alpha Feto-Protein Blood Test, (CHB and N. Press). Invited paper presented at conference on "The Politics of Reproduction." *Wenner-Gren Foundation for Anthropological Research*, Teresópolis, Brazil.
- 1991 "Collective Fictions": Similarities in Reasons for Accepting MSAFP Screening Among Women of Diverse Ethnic and Social Class Backgrounds (N. Press and CHB). Invited paper presented at the *National Institutes of Health Working Group "Reproductive Genetic Testing: Impact on Women."* Bethesda, MD.
- 1992 "It's Just a Simple Blood Test": What Women's Acceptance of MSAFP-Testing Can Tell Us About the Human Genome Project (N. Press and CHB). Invited paper presented at the Hastings Center Genetics Project Meeting, Northridge.
- 1992 *La salud prenatal: un enfoque metodológico*. Invited presentation at *Reunión Internacional Sobre la Antropología de la Salud*. Tarragona, Spain.
- 1992 Policy Issues in Maternal Serum Alpha-Feto Protein Screening: The View from California (N. Press and CHB). Invited paper for Meeting on Assessing Genetic Risks, Institute of Medicine, National Academy of Sciences, Irvine, CA.
- 1992 Patient Culture, Provider Culture, Biomedical Culture: Patterns of Informed Consent for Prenatal Testing in a Multicultural Setting (N. Press and CHB). Invited paper presented at *Annual Meeting of the International Society of Nurses in Genetics*. San Francisco, CA.

- 1992 Population Screening for Genetic Diseases (N. Press and CHB). Invited paper presented at *Human Genetics and Genome Analysis Workshop*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- 1993 Cultural Factors in Communicating Genetic Risk. Invited plenary address at *Joint Annual Meeting of the Great Lakes Regional Genetics Group, the Great Plains Regional Genetics Society and the Great Plains Genetics Service Network*. Minneapolis, MN.
- 1993 Cultural Issues in the Use of Genetic Information (N. Press and CHB). Paper presented at conference "Charting the Genome: Implications of Genetic Technology for Health Care Practitioners in the 1990s." Pacific Center for Health Policy and Ethics, Los Angeles, CA.
- 1993 Genetic Screening to Identify Affected Fetuses. Paper presented at conference "Charting the Genome: Implications of Genetic Technology for Health Care Practitioners in the 1990s." Pacific Center for Health Policy and Ethics, Los Angeles, CA.
- 1993 Informed Consent for Prenatal Testing (N. Press and CHB). Invited paper presented in the symposium "Women's and Consumers' Issues in Teratology and Genetics." *Annual Meeting of the Teratology Society*. Tucson, AZ.
- 1993 The Medicalization of Pregnancy and Women's Resistance to It. Invited paper presented at "The Intersections of Science, Gender and Ethnicity." Swarthmore College, Swarthmore, PA.
- 1993 The Production of Authoritative Knowledge in Prenatal Care (CHB and N. Press). Invited paper presented in invited symposium "Rationality in the Real World: Varieties of Medical Reasoning in Medical Anthropology." *Annual Meeting of the American Anthropological Association*. Washington, D. C.
- 1993 How Prenatal Diagnostic Testing for Disability of Transforming the Foundational Meanings of Reproduction in America (N. Press, CHB, and B. C. LeMaster). Invited paper presented in invited symposium on "Reproducing Reproduction." *Annual Meetings of the American Anthropological Association*. Washington, D. C.
- 1994 The Role of American Women in Medicalization and the Circumstances of their Resistance (CHB and E. K. Abel). Invited paper presented in invited symposium on "Women and Biopower: What Constitutes Resistance?" *Annual Meeting of the American Ethnological Society*. Santa Monica, CA.
- 1994 Research Contributions by Medical Anthropologists to Oaxacan Studies (A. J. Rubel and CHB). Invited paper presented at Workshop and Symposium on "Advances in Oaxacan Anthropology." Welte Institute for Anthropology, Oaxaca, Mexico.
- 1994 What Meanings Do Prenatal Technologies Hold for Pregnant American Women (N. A. Press and CHB). Invited paper presented in panel on the "Cultural Constructions of Abortion, Contraception, Prenatal, and Postnatal Care." *Annual Meeting of the Society for the Social Studies of Science, the History of Science Society and the Philosophy of Science Association*. New Orleans, LA.

- 1994 Cultural Models and Individual Choices: Why Some Pregnant Women Refuse the Offer of Medical Information (N. A. Press and CHB). Invited paper presented in symposium on "Models in Cultural Anthropology." *Annual Meeting of the American Anthropology Association*. Atlanta, GA.
- 1994 Gender Politics and Reproduction. Department of Anthropology Colloquium, UCLA, Los Angeles, CA.
- 1995 Prenatal Diagnosis: Women's Visions and Medical Images (CHB and N. A. Press). Paper presented in workshop sponsored by the UCLA Center for Cultural Studies of Science, Technology and Medicine. Los Angeles, CA.
- 1995 When Pregnant Women Follow Medical Advice and When They Don't. Symposium on "Putting Health in Its Place." Department of Geography, University of Southern California, Los Angeles, CA.
- 1995 Women's Selective Compliance with Biomedical Authority and the Uses of Subjugated Knowledge (E K. Abel and CHB). Feminist Research Seminar, Center for the Study of Women, UCLA.
- 1995 The Context and Meaning of Reproductive Decision-Making among Inner City Latino Couples (M. Harvey, L. Beckman, CHB, S. Balzano). Behavioral Research and Evaluation Program Targeting Communities of Color (BREPTCC) Conference, CDC, Atlanta, GA.
- 1995 Preserving Ethnic Identity in Collaborative Community Research (M. Harvey, L. Beckman, CHB, S. Balzano). *Annual Meeting of the Society for Applied Anthropology*. Albuquerque, NM.
- 1995 Reproductive Decision-Making in Latino Couples: Issues in Community-Based Research (M. Harvey, L. Beckman, CHB, S. Balzano). Psychosocial Workshop at *Annual Meeting of the Population Association of America*. San Francisco, CA.
- 1995 A Community-Based Study of Latino Couples' Decisions about Use of Condoms. (L. Beckman, M. Harvey, CHB, S. Balzano) Paper presented at *Annual Meeting of the American Psychological Association*. New York, NY.
- 1995 Heterosexual Relationships and Reproductive-Decision-Making Among Inner-City Latino Couples (M. Harvey, L. Beckman, CHB, S. Balzano). Presented at *Annual Meeting of American Public Health Association*. San Diego, CA.
- 1995 Mexican Couples' Experiences with Prenatal Diagnosis (CHB and H. M. Preloran). Invited paper presented at University of California Conference to Highlight Research and Policy Initiatives in Chicano/Latino Topics, University of California, Riverside, Riverside, CA.
- 1995 Feeding the Fetus: The Dietary Practices of Pregnant Women and the Politics of "Fetal Personhood," (S. Markens, CHB, N. Press). Invited paper presented in symposium on "Feminist Perspectives on Food and Body in Reproduction." *Annual Meeting of the American Anthropological Association*. Washington, D.C.

- 1995 Women's Roles, Gender Ideologies, and Health. Southwest Institute for Research on Women, University of Arizona, Tucson, AZ.
- 1996 The Effect of Domestic Politics on Reproductive Decisions. Invited paper presented at conference on Social Dimensions of Mexican Health. University of California Institute for Mexico and the United States, Riverside, CA.
- 1996 "Eating for Two": The Construction of Maternal-Fetal Conflict as Seen Through the Dietary Practices of Pregnant American Women (S. Markens, CHB, N. Press). *Annual Meeting of the Pacific Sociological Association*. Seattle, WA.
- 1996 Mexican Immigrant Couples' and Amniocentesis (CHB and H. M. Preloran). Invited paper presented in workshop on Dorothy Meets the Wizard: Discourses of Technology and Childbirth. Program in Cultural Studies in Science, Technology, and Medicine and the Center for the Study of Women, UCLA, 1996.
- 1996 "Sneaking in the Junk": Eating Strategies of Pregnant Women in the U.S. (S. Markens, CHB, N. Press). *Annual Meeting of the American Sociological Association*. New York, NY.
- 1996 "Vivir con la espina?" Tolerancia de la incertidumbre asociada a diagnósticos prenatales (H. M. Preloran and CHB). Invited paper presented in workshop "Tomas de decision." El Museo Nacional Hernández, La Universidad de Buenos Aires, Buenos Aires, Argentina.
- 1996 *Decisiones sobre aceptar o rechazar pruebas prenatales* (H. M. Preloran and CHB). Invited paper presented in workshop "Definición-Evaluación de Situaciones: estudios de proyectos comunitarios referidos a la salud y la educación. Universidad de Buenos Aires, Argentina.
- 1996 The Effects of Conjugal Politics on Women's Reproductive Reproductive Decisions. Public Symposium on Women's Health in International Perspective. University of Wisconsin-Madison, Madison, WI.
- 1996 A Look Backward at the History and Founding of the Society for Medical Anthropology. President's Address. *Annual Meeting of the Society for Medical Anthropology*. San Francisco, CA.
- 1996 *Para sacarse la espina: Mexican Immigrant Women and Amniocentesis* (CHB and H.M. Preloran). Invited paper for symposium on "Deforming Bodies Forming Subjects." *Annual Meeting of the American Anthropological Association*, San Francisco, CA.
- 1996 Household Politics and Reproductive Decisions. Invited paper presented in symposium "New Directions in Latin American Medical Anthropology." *Annual Meeting of the American Anthropological Association*, San Francisco. CA.
- 1997 Decisions about Fetal Diagnosis: A Cross-Cultural Perspective. Grand Rounds, Department of Psychiatry and Biobehavioral Sciences, UCLA.

- 1997 Micro-Communications, Macro-Implications: Conjugal Politics and Reproduction in Latino Communities. Program in Development Communication, Annenberg Center for Communication, University of Southern California and the Pacific Institute for Women's Health, L.A., CA.
- 1997 Women, Men, and Reproduction in Latino Communities. Public Symposium on Ecological Perspectives on Women's Health. University of Colorado, Denver, CO.
- 1997 The Anthropology of Health in Oaxaca (A. J. Rubel and CHB). *49th International Congress of Americanists*, Quito, Ecuador.
- 1997 The Impact of Male Partners' Presence on Mexican Immigrant Women's Decisions about Fetal Diagnosis (CHB and H. M. Preloran). *49th International Congress of Americanists*, Quito, Ecuador.
- 1997 On the Medicalization of Medical Anthropology. President's Address. *Annual Meeting of the Society for Medical Anthropology*, Washington, D.C.
- 1997 Modeling Latinas' Reproductive Behavior. Program in Medical Anthropology. University of California, San Francisco, San Francisco, CA.
- 1997 *El uso de la narrativa en los Ciencias Sociales* (H.M. Preloran and CHB). Invited paper presented in workshop on Arte y Humanidades. Patronat Municipal de Seveis Comunitaris, Cultura, Educació, Juventut I Serveis Socials, Ajuntament de Gavà, Barcelona, Spain
- 1998 International Migration and the Changing Social Ecology of Reproduction, Reproductive Health and Sexuality: Perspectives from a Chinantec Community in Oaxaca, Mexico (K.A. Morris, K. Tolbert, A.T. Cortes, CHB). *Annual Meeting of the Population Association of America*. Chicago, IL.
- 1998 Risky Business: Accounting for Pregnant Women Who Decline a Routine Prenatal Testing (S. Markens, CHB, N. Press), *Annual Meeting of the American Sociological Association*, San Francisco, CA.
- 1998 *Texto y contexto en el analisis de las narrativas* (H.M. Preloran and CHB). Invited paper presented in symposium on *Historias de vida, narrativas, y el rol asignado al etrevistador*. Centro Argentino de Etnología Americana (CAEA), Consejo Nacional de Investigaciones Cientificas y Técnicas. Buenos Aires.
- 1998 Latinas, Amniocentesis, and the Discourse of Choice (CHB and H. M. Preloran). Invited paper presented in Executive Program Committee Invited session "Questing for Perfection: The New Eugenics?" *Annual Meeting of the American Anthropological Association*, Philadelphia, PA.
- 1999 Analyzing Latinas' Narrative Accounts of their Acquiescence to Amniocentesis. Invited paper presented in 10th Annual Occupational Science Symposium on The Embodied Self, organized by Cheryl Mattingly and Mary Lawler, Dept. of Occupational Sciences, University of Southern California, Los Angeles, CA.

- 1999 "It Was Pretty Much My Decision...But Of Course He Also Has a Say": Latino Men and Amniocentesis Decisions (S. Markens, CHB, H. M. Preloran). Paper presented at *Annual Meeting of the Society for the Social Studies of Science*, San Diego, CA.
- 1999 Fatalism or Hope? Interpreting Latinas' Decisions to Refuse Amniocentesis (CHB and H. M. Preloran). Invited paper presented in symposium Performing "Race" and Ethnicity in the Crisis of the Medical Moment, organized by Linda M. Hunt and Cheryl Mattingly. *Annual Meeting of the American Anthropological Association*, Chicago, IL.
- 1999 Abortion Attitudes and Embodied vs. Authoritative Knowledge in Latinas' Decisions about Amniocentesis (S. Markens, CHB, H. M. Preloran). Paper presented at *Annual Meeting of the American Anthropological Association*, Chicago, IL.
- 2000 "It's Our Baby, But It's Her Body": Latino Couples, Gender Rationales, and Amniocentesis Decisions (S. Markens, CHB, H.M. Preloran), Paper presented at the *Annual Meeting of the American Sociological Association*, Washington, D. C.
- 2000 Religion, Education, Economics and Domestic Politics in Mexican-Origin Couples' Amniocentesis Decision (H. M. Preloran and CHB). Genetics Unit, Morris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
- 2000 *Análisis de historias de vida en situaciones médicas* (H. Mabel Preloran and CHB). Obradoiro: Baixo o Signo do Real: O Humano & Biográfico, Universidad Internacional Menéndez Pelayo. Pontevedra, Spain.
- 2001 Latinas' Amniocentesis Decisions in Cultural Perspective. A Decade of ELSI Research, Natcher Conference Center, Bethesda, MD.
- 2001 "I'm Not the One They're Sticking the Needle Into: Latino Couples and Amniocentesis (S. Markens and CHB). A Decade of ELSI Research, Natcher Conference Center, Bethesda, MD.
- 2001 "I'm Not A Doctor But I Know How I Feel": The Interaction of Embodied and Authoritative Knowledge In Amniocentesis Decisions (S. Markens, CHB, M. Preloran), *Annual Meeting of the American Sociological Association*, Anaheim, CA.
- 2001 Some Consequences of Miscommunication between Prenatal Genetic Service Providers and Latina Clients (CHB and H. M. Preloran). *Annual Meeting of the American Anthropological Association*, Washington, D. C.
- 2002 Sex in the City: Homeless Women's Needs for and Use of Reproductive Health Care (CHB, E. Lejano, L. Gelberg). *The Anthropology of Los Angeles*, Los Angeles, CA.
- 2002 Communicating Genetic Risk and Other Unwelcome Information (CHB and H. M. Preloran). Prepared for symposium Culture as Context in Clinical Communication, L. M. Hunt and C. H. Browner, organizers. *Annual Meeting of the American Anthropological Association*, New Orleans, LA.

- 2002 The Consequences of Competing Client and Clinician Agendas in Prenatal Care. Communication Processes in Social Groups (H. M. Preloran, CHB, and S. Balzano). Social Science Workshop, Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET), Buenos Aires, Argentina.
- 2002 The Risks of Knowing and Not Knowing for Managing Ambivalence in a Situation of Medical Uncertainty. Communication Processes in Social Groups (S. Balzano, H. M. Preloran, and CHB). Social Science Workshop, Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET), Buenos Aires, Argentina.
- 2002 The Social Impact of the Proliferation of Medical Technologies (CHB and H. M. Preloran). Instituto de Programas de Estudios sobre Epidemiologia Psiquiatrica (PEPSI). Buenos Aires, Argentina.
- 2003 *Decisiones medicas a traves de la emocion y la razon. 51st International Congress of Americanists*, Santiago, Chile.
- 2004 Gender Politics and the Distribution of Knowledge about Plants for Reproductive Health in Jamaica (C. F. Sargent and CHB). *International Society of Ethnobiology Ninth International Congress and Society for Economic Botany 45th Annual Meeting*, Canterbury, England.
- 2004 *Comunicación medico-paciente: El papel de los intermediarios* (H. M. Preloran and CHB). Panel de Comunicaciones: Seminario de Comunicación Oral. Sub-Secretaria de Educación, Provincia de Córdoba, Argentina, 2004.
- 2004 *Filtro: Comunicación de segunda mano*. Panel de Comunicaciones: Seminario de Jornadas de Nararativas y Oralidad. (CHB y H. M. Preloran). Programas de Investigaciones sobre Epidemiologia Psiquiatrica, Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Buenos Aires, Argentina.
- 2004 Does “Gender Equality” in Reproductive Policies and Programs Unintentionally Reinforce Male Authority? Prepared for symposium Sexuality, Equality, and Reproductive Health: The Case of Mexico, K. E. Bliss and M. C. Gutmann, organizers. *Meeting of the Latin American Studies Association*, Las Vegas, NV.
- 2004 Impact of Translators' Approach on Latinas' Use of Amniocentesis (CHB, H. M. Preloran, and E. Lieber). *The Challenge Ahead: Implications of Genomics for Health Behavior and Health Education*, School of Public Health, University of Michigan, Ann Arbor, MI.
- 2005 Unexpected and Unwanted Consequences of "Gender Equity" in Reproductive Health Programs and Policies. *Reproductive Disruptions: Childlessness, Adoption, and Other Reproductive Complexities*, Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI.
- 2005 Ethical Implications of Reproductive Genetic Technologies. *Science and Technology in New York City*. CUNY Honors College Seminar, New York, NY.

- 2005 Risk Communication: Cultural Issues. *National Society of Genetic Counselors Short Course*. Los Angeles, CA.
- 2005 Bossed in Translation: The Impact of Translator's Approach on Latinas' Amniocentesis Decisions. Beyond the Patient-Doctor Dyad, M. C. Hay and C. H. Browner, organizers. *Annual Meeting of the American Anthropological Association*, San Francisco, CA.
- 2006 Does Gender "Equity" in Genetic Screening Unintentionally Reinforce Male Authority? Reproductive Disruptions: Gender, Technology, and Ethics in the New Millennium. SMA Plenary Session, M. Inhorn, organizer. Joint Meetings of the *Societies for Applied and Medical Anthropology*, Vancouver, B. C.
- 2006 Opportunities and Future Directions for Medical Anthropologists. Meet the SMA Presidents Panel. *Society for Medical Anthropology and Medical Anthropology Students Association*, Vancouver, B. C.
- 2006 *Clínica Neurológica: comunicación médico-paciente y su efecto en el uso de la tecnología genética* (H. Mabel Preloran y CHB). Organización de los Servicios Médicos y su influencia en la salud de los usuarios, Coordinador: Dr. Marcelo Britos. Departamento de Salud Mental, Ciencias Sociales y Humanidades de la Facultad de Medicina de la Universidad Nacional de Tucuman, Argentina.
- 2006 *Recolección de datos: instrumentos para su documentación y análisis* (H. Mabel Preloran y CHB). Metodología para la realización de estudios de usuarios de servicios médicos" Coodinadora: Dra. Marta Martinez, Departamento de Programática de la Facultad de Medicina de la Universidad Nacional de Tucuman, Argentina.
- 2006 When Cultures Collide – or At Best, Work at Cross Purposes: Lessons from California on Implementation of State-Mandated Fetal Diagnosis. Reproduction, Globalization, and the State, C. H. Browner and C. F. Sargent, organizers. Rockefeller Foundation Bellagio Study and Conference Center, Lake Como, Italy.
- 2006 Timing and the Meaning of a Genetic Diagnosis. The Experience of Patients with Neurodegenerative Symptoms, (Pascale Hess & CHB). Paper presented in panel on Temporality, Suffering and Experience, Jill Mitchell and Jason Throop, organizers, *Annual Meeting of the American Anthropological Association*, San Jose, CA.
- 2007 Storm Clouds Ahead: The Impact of a Genetic Diagnosis on Siblings Suffering Neurodegenerative Disease. (CHB & H. Mabel Preloran). Paper presented in panel on Families in Pain: Illness, Suffering, and (Inter)subjectivity, Mara Buchbinder and Ignasci Clementi, organizers, *Biennial Meeting of the Society for Psychological Anthropology*, Manhattan Beach, CA.
- 2007 Information Exchange between Patients and Doctors (H. Mabel Preloran & CHB). Panel on Medical Anthropology Past, Present, and Future. Universidad Nacional de la Pampa. Santa Rosa, Argentina.

- 2007 What Does the Concept of “Genetic Responsibility” Add to Understanding Carework? The Case of Individuals with Neurodegenerative Disorders (J. Musto & CHB). Paper presented in panel on Ethic of Care. *The Fifth Carework Conference, “Is a Caring Society Possible? Mobilizing for Change,”* CUNY Graduate Center, New York, New York.
- 2008 Dark Prophecies: Neurodegenerative Patients’ Search for a Genetic Diagnosis. Paper presented at conference, Translating “ELSI:” The Ethical, Legal, and Social Implications of Genomics. Case Western Reserve University, Cleveland, OH.
- 2008 Interrogating the Dynamics between Power, Knowledge and Pregnant Bodies in Amniocentesis Decision-Making (S. Markens, CHB, H. Mabel Preloran). Paper presented at *Annual Meeting of the American Sociological Association*, Boston, MA.
- 2009 The Meaning of Diagnostic Testing for Neurologists and Their Patients. Paper presented in symposium on Creating and Crossing Medical Fields of Practice, Bill McKellin and Sylvie Fortin, organizers, *Joint Annual Meetings of the Canadian Association of Social and Cultural Anthropology and the American Ethnological Association*, Vancouver, B.C.
- 2009 Family Communication of BRCA Genetic Testing Among Latina Women: A Qualitative Study (N. Santiago Neal, C. Ricker, C. Palmer, T. Geva & CHB). Poster presented at *National Society of Genetic Counselors 28th Annual Education Conference*, Atlanta, GA.
- 2009 Keynote Speaker, Inauguration of “On the Same Map,” Sponsored by the UCLA School of Public Health, UCLA Chapter of FACE AIDS, UCLA Global Summit Reading Program, and UCLA American Medical Student Association Global Health Action Committee, UCLA, Los Angeles.
- 2009 *Salud: lo ultimo en perder es la esperanza*. (H. Preloran & CHB) Paper presented at La Fundación del Cine, Programa del Ciencias Sociales, Manuel Antín, coordinator, Buenos Aires.
- 2010 The Promise and Reality of Genetic Testing in Clinical Neurology. Paper presented at UCLA Center for Society and Genetics Colloquium. Los Angeles, CA.
- 2010 Keynote Speaker, Inauguration of “Gender, Sexuality, and Health International Program,” Washington University, St. Louis, MO.
- 2011 Genetic Testing for Fatal Neurological Diseases: A Dead End? Paper presented at UCLA Biological Anthropology Society. Los Angeles, CA.
- 2011 A Legacy of Michael Kearney: Global and Transnational Approaches to the Anthropology of Reproduction and Reproductive Rights. Inaugural Keynote Kearney Lecture in Responsible Anthropology. *Annual Meeting of the Society for Latin American and Caribbean Anthropology and the Society for Applied Anthropology*, Seattle, WA.
- 2011 The Interplay of Hope and Expectation for Genetic Testing in Clinical Neurology. Cedars-Sinai Ethics Noon Conference, Los Angeles, CA, 2011.
- 2112 But Is It Disclosure? Rethinking Retellings Tellings of Genetic Diagnoses (D. Flaherty and CHB). Workshop on Disclosing Subjects: Bodies, Selves, Intimacies, Politics. Thomas Coram Research Unit, University of London.

- 2012 The Promise and Reality of Genetic Testing in Clinical Neurology. *Beyond the Headlines*, UCLA Extension Series in Humanities and Sciences.
- 2012 How Family Dynamics Can Shape Disclosure Patterns and Processes In Patients Newly Diagnosed with Huntington's Disease, Paper presented at *Annual Meeting of the Annual Meeting of the American Anthropological Association*, San Francisco, CA.
- 2013 Utilization of Genetic Testing Prior to Subspecialist Referral for Cerebellar Ataxia (B. Fogel, B. Vickrey and CHB). Poster presentation at Annual Meeting of the American Neurological Association's Annual Meeting New Orleans, LA.
- 2015 The Politics of Reproduction: Evolutionary Perspectives, Contemporary Realities. *A Critical Moment: Sex/Gender Research at the Intersections of Culture, Brain, & Behavior*. 6th UCLA/FPR Conference. Los Angeles, CA.
- 2017 *Metos metodológicas del siglo XXI en investigaciones antropológica medica*. Unidad en Medicina Social y Servicios de Salud, Escuela de Medicine, Universidad de Guadalajara, Guadalajara, MX.

SYMPOSIA ORGANIZED AND/OR CHAIRED; DISCUSSANT

1. Co-organizer of symposium on Women in Culture and Society. *Annual Meeting of the Southwestern Anthropological Association*. San Francisco, CA, 1973.
2. Organizer of symposium on Research and Directions in Medical Anthropology. *Annual Meeting of the Kroeber Anthropological Society*. Berkeley, CA, 1974.
3. Co-organizer of symposium on Social Structure, Ideology and Women's Choices. *Annual Meeting of the American Anthropological Association*. Washington, D.C., 1976.
4. Organizer of symposium on Innocents at Home: American Anthropologists Study American Institutions. *Annual Meeting of the American Anthropological Association*. Los Angeles, CA, 1978.
5. Co-organizer and Chair of special COSWA symposium on Women Anthropologists in the Public and Private Sectors: Non-academic Career Advancement. *Annual Meeting of the American Anthropological Association*. Los Angeles, CA, 1981.
6. Organizer and Coordinator of Round Table Discussion on Women's Reproductive Health. *Annual Meeting of the American Anthropological Association*. Los Angeles, CA, 1981.
7. Co-organizer of two-part special invited symposium on Pressure and Counter Pressure: Interaction Between State and Local Levels in Highland Mexico. *44th International Congress of Americanisms*. Manchester, England, 1982.
8. Organizer of Round table Discussion on Power and Medical Monopolies. *Annual Meeting of the American Anthropological Association*. Washington, D.C., 1982.

9. Organizer of Round table Discussion on The Interface Between Traditional and Modern Medicine in Latin America. *Annual Meeting of the Latin American Studies Association*. Mexico City, Mexico, 1983.
10. Co-organizer of symposium on Reproduction and the Cultural Construction of Gender. *Annual Meeting of the American Anthropological Association*. Chicago, IL, 1983.
11. Organizer and Coordinator of Round table Discussion on the Determinants of Household Health in Developing Countries. *Annual Meeting of the American Anthropological Association*. Washington, D.C., 1985
11. Discussant. Constructing Reproduction: Female Bodies and a Feminist Critique of Science. Symposium presented at the *Annual Meeting of the American Anthropological Association*. Washington, D.C., 1985.
12. Coordinator of Round table Discussion on Gender and Interaction. Second Southern California Forum on Cognition, Interaction, and Communication. Irvine, CA, 1985.
14. Co-organizer and Chair of invited symposium on Knowledge and Power in the Management of Reproduction. *Joint Meetings of the American Ethnological Society, Southern Anthropological Society and the Society for Medical Anthropology*. Wrightsville Beach, NC, 1986.
15. Co-organizer and Chair of panel discussion on Women and Immigration. Conference of Women: Culture, Conflict and Consensus. Center for the Study of Women, UCLA, 1987.
16. Discussant. Health, Education and Social Welfare in South America. Conference on South American Culture and Development. Latin American Studies Center, UCLA, 1987.
17. Discussant. Huntington Library Women's Studies Seminar on "Attitudes Toward the Female Body in Medieval Religion." San Marino, CA, 1988.
18. Chair and Discussant. Can California be Competitive in Caring? Institute for Industrial Relations, UCLA, 1988.
19. Organizer and Chair. Anthropology and Mental Retardation. Invited Symposium presented at *Annual Meeting of the Society for Applied Anthropology*, Tampa, FL, 1988.
20. Discussant. Gender Hierarchy and Economic Change in Mexico. *Annual Meeting of the American Anthropological Association*. Phoenix, AZ, 1988.
21. Coordinator of Roundtable Discussion on Women, Work, and Health in Latin America. *Annual Meeting of the American Anthropological Association*. Washington, D.C., 1989.
22. Discussant. Body Image and Social Meaning: The Interplay of Symbol and Action, *Annual Meeting of the American Anthropological Association*, Washington, D.C. 1989.
23. Moderator and Discussant. Primary Health Care for Women: International Examples. Women's Health Care and Empowerment in the Third World. University of California, San Francisco, 1990.

24. Discussant. Conference of Women and Health in the Middle East. The von Grunebaum Center for Near Eastern Studies, UCLA, 1990.
25. Chair. Panel on Adaptation of Aging People with Mental Retardation in the Community. UCLA Mental Retardation Research Center Annual Retreat. Lake Arrowhead, CA, 1990.
26. Discussant. The Medicalization of Natural Processes and Conditions. *Annual Meeting of the American Anthropological Association*. New Orleans, LA, 1990.
27. Chair. Ethnomedicine and Meaning in the Study of Illness. *Annual Meeting of the American Anthropological Association*. New Orleans, LA, 1990.
28. Co-organizer and Co-chair of The Human Body and the Body Politic: Exploring the Role of Western Medicine in the Maintenance of Social Control. Invited symposium sponsored by the Society for Medical Anthropology. *Annual Meeting of the American Anthropological Association*. New Orleans, LA, 1990.
29. Discussant. The Control of Reproduction. International Conference on the Construction of Gender and Sexuality in East and Southeast Asia. Center for Pacific Rim Studies, UCLA, 1990.
30. Chair. Household Strategies and National Policies in Latin America and South Asia. *Annual Meeting of the Society for Applied Anthropology*. Charleston, SC, 1991.
31. Discussant. Agrarian Transformations and Health. *Annual Meeting of the Society for Applied Anthropology*, Charleston, SC, 1991.
32. Discussant. Birth in Twelve Cultures: Papers in Honor of Brigitte Jordan. Invited symposium sponsored by the Society for Medical Anthropology. *Annual Meeting of the American Anthropological Association*. San Francisco, CA, 1992.
33. Chair. Mothers and Children. Graduate Student Research Conference on Women and Gender. Center for the Study of Women. UCLA, 1993.
34. Organizer and Chair. Women and Biopower: What Constitutes Resistance? *Annual Meeting of the American Ethnological Society*. Santa Monica, CA, 1994.
35. Chair. Panel on Cultural Constructions of Abortion, Contraception, Prenatal and Postnatal Care. *Society for the Social Studies of Science*. New Orleans, LA, 1994.
36. Discussant. "On the Terror of Aging in a Low-Budget Horror Film," Feminist Research Seminar, Center for the Study of Women, UCLA, 1994.
37. Chair. Panel on Reproductive Technologies. Forum on Gender Issues in Science, Technology, and Medicine. UCLA, 1994.
38. Chair and Discussant. Panel on Reproductive Issues in Conference "Thinking Gender" UCLA/USC Fifth Annual Graduate Student Research Conference. Center for the Study of Women, UCLA, 1995.

39. Discussant. "Of Pregnancy, Illicit Drugs, and Punishment: Lawmakers, Prosecutors and the Politics of a Social Problem." Feminist Research Seminar, Center for the Study of Women, UCLA, 1995.
40. Chair and Discussant. Panel on Nationalism and the Politics of Reproduction. UCLA/USC Sixth Annual Graduate Student Research Conference. Center for the Study of Women, UCLA, 1996.
41. Commentator. New Leadership Training Workshop. Annual Meeting of the Society for Applied Anthropology, Baltimore, MD, 1996.
42. Co-organizer. Dorothy Meets the Wizard: Discourses of Technology and Childbirth. Sponsored by Program in Cultural Studies in Science, Technology, and Medicine and the Center for the Study of Women, UCLA, 1996.
43. Discussant. Human Capital and Economic Development in Latin America: A UCLA Doctoral Student Research Conference. UCLA Center for Latin American Studies, Ventura, CA, 1997.
44. Chair and Discussant. Panel Women's on Health and Health Care. UCLA/USC Eighth Annual Graduate Student Research Conference. Center for the Study of Women. UCLA, 1998.
45. Co-organizer and Discussant. The Gendered Politics of Reproduction. Symposium invited by the Society for Feminist Anthropology, *Annual Meeting of the American Anthropological Association*, Philadelphia, PA, 1998.
46. Co-organizer and Chair. Struggling for Health in the Face of Disease and Danger: Analytic and Policy Perspectives. Invited Presidential Symposium. *Annual Meeting of the American Anthropological Association*, San Francisco, CA, 2000.
47. Facilitator, Dissertation Improvement Workshop. Spencer Foundation, Los Angeles, CA, 2001.
48. Facilitator, Workshop on Mind, Brain, and Culture Interactions, Foundation for Psychocultural Research, Ojai, CA, 2001.
49. Co-organizer and Co-Chair. Culture as Context in Clinical Communication, Annual Meeting of the American Anthropological Association, New Orleans, LA, 2002.
50. Moderator, Interdisciplinary Panel on Trauma and Early Relational Experiences, Social Contexts, and Developmental Trajectories, Third Annual Symposium on Brain, Mind, and Culture, La Jolla, California, 2003.
51. Discussant, Rethinking Pragmatism: Medicalization, Reproduction, and Social Constraint. *Annual Meeting of the American Anthropological Association*, Chicago, IL, 2003.
52. Discussant, Panel on Gender Issues in Ethnobotanical and Ethnobiological Research and Related Development Practice. *International Society of Ethnobiology Ninth International Congress and Society for Economic Botany 45th Annual Meeting*, Canterbury, England, 2004.

53. Co-organizer and Co-chair. Beyond the Patient-Doctor Dyad: Health and Communication in Clinical Settings. *Annual Meeting of the American Anthropological Association*, Washington, D.C., 2005.
54. Organizer and Co-chair. Reproduction, Globalization, and the State. Rockefeller Foundation Bellagio Study and Conference Center, Lake Como, Italy, 2006.
55. Discussant, Foundation for Psychocultural Research-UCLA 3rd Interdisciplinary Conference: Seven Dimensions of Emotion, UCLA, Los Angeles, CA. 2007.
56. Discussant, Responsible Reproduction: Technologies of Risk in Maternal and Child Health, *Annual Meeting of the American Anthropological Association*, San Francisco, CA, 2008.
57. Keynote Speaker, "On the Same Map." Sponsored by the UCLA School of Public Health, UCLA Chapter of FACE AIDS, UCLA Global Summit Reading Program, and UCLA American Medical Student Association Global Health Action Committee, UCLA, Los Angeles, 2009.
58. Co-organizer, Invited Panel: Founders' Perspectives on the Origins of the SMA. *Meeting of the Society for Medical Anthropology*, Yale University, New Haven, CT, 2009.
59. Welcome Address. *Meeting of the Society for Medical Anthropology*, Yale University, New Haven, CT, 2009.
60. Discussant, Symposium on Gender, Health, and the Politics of Reproduction. *Annual Meetings of the American Anthropological Association*, Philadelphia, PA, 2009.
61. Chair, Panel on Cultural and Biological Contexts of Autism. 4th Interdisciplinary The Cultural and Biological Contexts of Psychiatric Disorder: Implications for Diagnosis and Treatment. UCLA. Foundation for Psychocultural Research-UCLA Los Angeles, CA, 2010.
62. Commentary on "Cultural and Biological Contexts of Bipolar Disorder, Schizophrenia, and Anxiety-Related Conditions. The Cultural and Biological Contexts of Psychiatric Disorder: Implications for Diagnosis and Treatment. UCLA. Foundation for Psychocultural Research-UCLA Los Angeles, CA, 2010.
63. Chair and Moderator, Panel on State Terrorism and Resistance: *Esclabones*, a new volume of stories, poetry, and short stories from the Former Political Prisoners of Córdoba, Argentina. Latin American Institute, UCLA, Los Angeles, CA, 2010.
64. Invited Roundtable: Stealing a Moment: Individual Follow-Up with Award Winning Mentors, Society for Medical Anthropology, *Annual Meeting of the American Anthropological Association*, New Orleans, LA, 2010.
65. Introduction, Gender, Art and Social Movements in the Middle East and Global South: Conference in Honor of Professor Sondra Hale's Retirement. UCLA Center for Near Eastern Studies, 2011.
66. Chair, Panel on Disclosure and Health Psychology: A Critical Interrogation. Workshop on Disclosing Subjects: Bodies, Selves, Intimacies, Politics, University of London, 2012.

67. Co-organizer and Chair, Disclosure: On Secrets and Tellings, *Annual Meeting of the American Anthropological Association*, San Francisco, 2012.
68. Remembering John G. Kennedy: A Tribute to His Life and Work. *Annual Meeting of the American Anthropological Association*, San Francisco, CA, 2012.
69. Discussant, Resistance, Resilience and Reproductive Governance in Latin America. Centering Reproductive Politics in Imaginative Transformation. *Annual Meeting of the American Anthropological Association*, San Jose, CA, 2018.
70. Discussant, Seeing Men Where They Already Are: Ethnographies of Men and Pregnancy/Childbirth. *Joint Meeting of the American Anthropological Association and the Canadian Anthropology Society*. Vancouver, B.C. 2019.

BIBLIOGRAPHY

RESEARCH PAPERS

A. RESEARCH PAPERS - PEER REVIEWED

1. Browner, C. H. 1975. Abortion as a Life Crisis. *Kroeber Anthropological Society Papers* 47:86-115.
2. Browner, C. H. and Chibnik, M. 1979. Anthropological Research for a Computer Manufacturing Company. *Central Issues in Anthropology* 1(2):63-76.
3. Browner, C. H. 1979. Abortion Decision Making: Some Findings from Colombia. *Studies in Family Planning* 10(3):96-106.

Translated and reprinted in *Estudios de Población IV* (1-6):16-29, 1979.
4. Browner, C. H. 1980. The Management of Early Pregnancy: Colombian Folk Concepts of Fertility Control. *Social Science and Medicine* 14B:25-32.
5. Browner, C. H. and Lewin E. 1982. Female Altruism Reconsidered: The Virgin Mary as Economic Woman. *American Ethnologist* 9(1):61-75.
6. Hill, J. and Browner, C. H. 1982. Gender Ambiguity and Class Stereotyping in the Mexican Fotonovela. *Studies in Latin American Popular Culture* 1(1):43-64.
7. Browner, C. H. 1983. Male Pregnancy Symptoms in Urban Colombia. *American Ethnologist* 10(3):494-510. Profiled in A. McElroy and P. Townsend, eds. *Medical Anthropology in Ecological Perspective*, pp. 270-275. N. Scituate, MA: Duxbury Press, 1989.

Profiled in 1st-4th editions, Westview, 4th edition: 2004.
8. Browner, C. H. 1983. The Outpatient Department as Social System: Structure, Ideology & Behavior. *Kroeber Anthropological Society Papers* 61 & 62:52-68.
9. Browner, C. H. 1985. Criteria for Selecting Herbal Remedies. *Ethnology* 24(1):13-32.
10. Ortiz de Montellano, B. R. and C. H. Browner 1985. Chemical Bases for Medicinal Plant Use in Oaxaca, Mexico. *Journal of Ethnopharmacology* 13:57-88.
11. Browner, C. H. 1985. Plants Used for Reproductive Health in Oaxaca, Mexico. *Economic Botany* 39(4):482-504.
12. Browner, C. H. 1986. Gender Roles and Social Change: A Mexican Case Study. *Ethnology* 25(2):89-106.

13. Browner, C. H. 1986. The Politics of Reproduction in a Mexican Village. *Signs: Journal of Women in Culture and Society* 11(4):710-24.

Reprinted all editions of C. Brettell and C. Sargent, eds. *Gender in Cross-Cultural Perspective*, pp. 385-96. Englewood Cliffs, NJ: Prentice-Hall, 2001.

Reprinted B. Miller, ed. *Sociocultural Anthropology: Critical and Primary Sources*, Vol 2-11. pp. 181-192. New York: Routledge, 2020.

14. Browner, C. H., Ellis, K. A., Ford, T., Silsby, J., Tampoya, J., Yee, C. 1987. Stress, Social Support, and Health of Psychiatric Technicians in a State Facility. *Mental Retardation* 25(1):31-38.
15. Browner, C. H. 1987. Job Stress and Health: The Role of Social Support at Work. *Research in Nursing and Health* 10(2):93-100.
16. Browner, C. H. and Perdue, S. T. 1988. Women's Secrets: Bases for Reproductive and Social Autonomy in a Mexican Community. *American Ethnologist* 15(1):84-97.
17. Browner, C. H., Ortiz de Montellano, B. R., Rubel, A. J. 1988. A Methodology for Cross-Cultural Ethnomedical Research. *Current Anthropology* 29(5):681-701.
18. Browner, C. H. 1989. Women, Household and Health in Latin America. *Social Science and Medicine* 28(5):461-73.
19. Hunt, L. M., Jordan, B., Irwin, S., Browner, C. H. 1989. Compliance and the Patient's Perspective: Controlling Symptoms in Everyday Life. *Culture, Medicine and Psychiatry* 13(3):315-34.
20. Browner, C. H. 1989. *La producción, la reproducción, y la salud de la mujer: Un estudio de un caso de Oaxaca, Mexico*. *Anales de Antropología* 26:319-329.
21. Hunt, L. M., Browner, C. H., Jordan, B. 1990. Hypoglycemia: Portrait of an Illness Construct in Everyday Use. *Medical Anthropology Quarterly*, new series 4(2):191-210.
22. Browner, C. H. and Kubarski, K. 1991. The Paradoxical Control of American Clerks. *Organization Studies* 12(2):233-50.
23. Browner, C. H. 1991. Gender Politics in the Distribution of Therapeutic Herbal Knowledge. *Medical Anthropology Quarterly*, new series, 5(2):99-132.
24. Browner, C. H. 1991. Women and Economic Change in Rural Mexico. *Peasant Studies* 19(1):5-20.
25. Press, N. and Browner, C. H. 1992. Policy Issues in Maternal Serum Alpha Feto-Protein Screening: The View from California. In *Proceedings of the Committee on Assessing Genetic Risks: Issues and Implications for Health*. Institute of Medicine, National Academy of Sciences, Washington, D. C.: National Academy Press.

26. Browner, C. H. 1993. New Feminist Scholarship on Reproduction and Women's Health. *Signs: Journal of Women in Culture and Society* 18(3):698-703.
27. Press, N. and Browner, C. H. 1993. "Collective Fictions": Similarities in Reasons for Accepting MSAFP Screening Among Women of Diverse Ethnic and Social Class Backgrounds. *Fetal Diagnosis and Therapy* 8 (suppl 1):97-106.
28. Browner, C. H. 1994. Margaret Clark's Enduring Contribution to Latino Studies in Medical Anthropology. *Medical Anthropology Quarterly*, 8(4):468-475.
29. Press, N. and Browner, C.H. 1995. Risk, Autonomy, and Responsibility: Informed Consent for Prenatal Testing. Special Supplement. *Hastings Center Report* 25(3):S9-12.
30. Browner, C. H. and Press, N. 1996. The Production of Authoritative Knowledge in American Prenatal Care. *Medical Anthropology Quarterly* 10(2):141-156.
- Reprinted** in R. Davis-Floyd and C. Sargent, eds. *Childbirth and Authoritative Knowledge: Cross-Cultural Perspectives*, pp. 113-131. Berkeley: University of California Press, 1997.
31. Browner, C. H., Preloran, H. M., and Press, N. 1996. The Effects of Ethnicity, Education, and an Informational Video on Pregnant Women's Knowledge and Decisions about a Prenatal Diagnostic Screening Test. *Patient Education and Counseling* 27(2):135-142.
32. Markens, S., Browner, C. H., and Press, N. 1997. Feeding the Fetus: On Interrogating The Notion of Maternal-Fetal Conflict. *Feminist Studies* 23(2):351-72.
33. Press, N. and Browner, C. H. 1997. Why Women Say Yes to Prenatal Testing. *Social Science and Medicine* 45(7):979-989.
34. Preloran, H. M. and Browner, C. H. 1997. *Rol de la tradición en la prácticas del embarazo: efectos de la información genética entre Mexicanas residentes en los Estados Unidos*. *Revista de Investigaciones Folklóricas* 12: 67-75.
35. Press, N.A. and Browner, C.H. 1998. Characteristics of Women Who Refuse an Offer of Prenatal Diagnosis: Data from the California MSAFP Experience. *American Journal of Medical Genetics* 78:433-445.
36. Hunt, L.M., de Voogd, K.B., Akana, L.L., and Browner, C.H. 1998. Abnormal Pap Screening among Mexican-American Women: Impediments to Receiving and Reporting Follow-up Care. *Nursing Oncology Forum* 25(10):1743-1749.
37. Browner, C.H. 1999. On the Medicalization of Medical Anthropology. *Medical Anthropology Quarterly* 13(2): 135-40.
38. Browner, C.H. and Preloran, H.M. 1999. Male Partners' Role in Latinas' Amniocentesis Decisions. *Journal of Genetic Counseling* 8(2): 85-108.

39. Markens, S., Browner, C. H., and Press, N. 1999. "Because of the Risks": How U. S. Pregnant Women Account for Refusing Prenatal Screening. *Social Science and Medicine* 49(3):359-69.
40. Rubel, A. J. and Browner, C. H. 1999. *La antropología de salud en Oaxaca. Alternidades*, año 9, núm. 17:85-94.
41. Preloran, H. M., Browner, C. H., and Balzano, S. 1998/99. *Texto y contexto en el análisis de la narrativa: Renegociación de roles en situaciones médicas con peligro de vida. Scripta Ethnológica*, 20:23-36. Buenos Aires: Centro Argentino de Ethnologia Americana).
42. Browner, C. H., Preloran, H. M., and Cox, S. J. 1999. Ethnicity, Bioethics, and Prenatal Diagnosis: the Amniocentesis Decisions of Mexican-origin Women and their Partners. *American Journal of Public Health* 89(11):1658-66.
43. Browner, C. H. and Preloran, H. M. 2000. Latinas, Amniocentesis and the Discourse of Choice. *Culture, Medicine, and Psychiatry*, 24(3):353-75.
44. Browner, C. H. and Preloran, H. M. 2000. Interpreting Low-Income Latinas' Amniocentesis Refusals. *Hispanic Journal of Behavioral Sciences* 22(3):346-68.
45. Browner, C. H. 2000. Situating Women's Reproductive Activities. *American Anthropologist* 102(4):773-88.
46. Root, R. and Browner, C. H. 2001. Practices of the Pregnant Self: Compliance with and Resistance to Biomedical Prenatal Norms. *Culture, Medicine, and Psychiatry* 25 (2):195-223.
47. Preloran, H. M., Browner, C. H. and Lieber, E. 2001. Strategies for Motivating Latino Couples' Participation in Qualitative Health Research. *American Journal of Public Health* 91(11): 1832-41.
48. Gelberg, L., Leake, B.D., Lu, M. C., Andersen, R.M., Wenzel, S. L., Morgenstern, H., Koegel, P. Browner, C. H. 2001. Use of Contraceptive Methods among Homeless Women for Protection against Unwanted Pregnancies and STDs: Prior Use and Willingness to Use in the Future. *Contraception* 63:277-81.
49. Frank, G., Blackhall, L.J., Murphy, S. T., Michel, V., Azen, S. P., Preloran, H.P. and Browner, C. H. 2002. Ambiguity and Hope: Disclosure Preferences of Less Acculturated Elderly Mexican Americans Concerning Terminal Cancer: A Case Story. *Cambridge Quarterly of Healthcare Ethics* 11:117-126.
50. Gelberg, L., Leake, B., Lu, M.C., Andersen, R., Nyamathi, A. M., Morgenstern, H. and Browner, C. H. 2002. Chronically Homeless Women's Perceived Deterrents to Contraception. *Perspectives on Sexual and Reproductive Health* 34:278-285.
51. Harvey, S. M., Beckman, L. J., Browner, C. H. and Sherman, C. A. 2002. Relationship Power, Decision-Making and Sexual Relations: An Exploratory Study with Couples of Mexican Origin. *The Journal of Sex Research* 39(4): 284-291.

52. Balzano, S., Preloran, M. and Browner, C. H. 2002. *El protocolo medico como una forma de performance cultural: La neutralidad profesional y su efecto en la vida de los Pacientes y sus Familias* (The consequences of competing client and clinician agendas in prenatal care) *Revista de Investigaciones Folclóricas* 17:145-155.
53. Browner, C. H., Preloran, H. M., Casado, M. C., Bass, H., and Walker, A. 2003. Genetic Counseling Gone Awry: Some Consequences of Miscommunication between Prenatal Genetic Service Providers and Latina Clients. *Social Science and Medicine* 56(9): 1933-1946.
54. Markens, S., Browner, C. H. and Preloran, H. M. 2003. "I'm Not the One They're Sticking the Needle Into": Latino Couples, Fetal Diagnosis, and the Discourse of Reproductive Rights. *Gender & Society* 17(3):462-481.
55. Preloran, H. M. Balzano, S. and Browner, C. H. 2003. The Roles of Trust and Cross-Cultural Miscommunication in Clinical Decision-Making. 2003. *Californian Journal of Health Promotion* 1(2):198-207.
56. Browner, C. H. and Preloran, H.M. 2004. Expectations, Emotions, and Medical Decision Making: A Case Study on the Use of Amniocentesis. *Transcultural Psychiatry* 41(4): 427-444.
57. Preloran, H. M, Balzano, S. and Browner, C. H., 2004. *Globalizacion y salud: El impacto de un protocolo medico sin fronteras* (Globalization and health: the impact of a medical protocol without borders). *Realidad Revista del Cono Sur de Psicología Social y Política* (Buenos Aires: Universidad Argentina John F. Kennedy). 2/3:287-304.
58. Gelberg, L., Browner, C. H., Lejano, E. and Arangua, L. 2004. Access to Women's Health Care: A Qualitative Study of Barriers Perceived by Homeless Women. *Women and Health* 40(2):87-100.
59. Preloran, H. M., Browner, C. H., and Acebo Ibañes, E. 2004/05 *Una mirada antropologica a la relacion entre concientizacion, percepcion del ambiente y el uso de tecnologia genetica*. *Realidad Revista del Cono Sur de Psicología Social y Política* (Buenos Aires: Universidad Argentina John F. Kennedy) 4/5: 485-498.
60. Levin, B. W., Browner, C. H. 2005. The Social Production of Health: Critical Contributions from Evolutionary, Biological, and Cultural Anthropology. *Social Science and Medicine* 61(4):745-50.
61. Browner, C. H. Some Unexpected Consequences of Implementing Gender "Neutral" Reproductive Programs and Policies. 2005. *Women in International Development Publication Series*, #284.
62. Preloran, H. M., Browner, C. H., and Lieber, E. 2005. Impact of Interpreters' Approach on Latinas' Use of Amniocentesis. *Health Education & Behavior* 32(5): 599-612.
63. Preloran, H. M., Browner, C. H., and Lieber, E. 2005. Filtro: El efecto de la comunicación mediada a través de traductores en el uso de las pruebas genéticas. *Revista de Investigaciones Folclóricas*, 20: 46-75.

64. Hess, P., Preloran, H. M., and Browner, C. H. 2009 Diagnostic Genetic Testing for a Fatal Illness: The Experience of Patients with Movement Disorders. *New Genetics and Society* 28(1): 3-18.
65. Browner, C. H., Preloran, H. M., Balzano, S. 2006. Anomie and Identity Management in an At-Risk Medical Situation. *Realidad Revista del Cono Sur de Psicología Social y Política* (Buenos Aires: Universidad Argentina John F. Kennedy) 6(1):7-22.
66. Markens, S., Browner, C. H. and Preloran, H. M. 2010 Interrogating the Dynamics between Power, Knowledge and Pregnant Bodies in Amniocentesis Decision-Making. *Sociology of Health and Illness* 32(1): 37-56.
67. Withers, M. and Browner, C.H. 2011. The changing contexts of fertility outcomes: Case studies from a remote village in Bali, Indonesia. *Culture, Health and Sexuality* 13(10):1-14.
68. David, S., Browner, C., and Singh, R.R. 2011. Is Autoimmunity a Sign of Our Times: Stress, Lupus, and Late Capitalism. [abstract] *Clinical and Experimental Rheumatology* 29(1): 210.
69. Withers, M., Browner, C.H. and Aghaloo, T. 2013. Promoting Volunteerism in Global Health: Lessons from a Medical Mission in Northern Mexico, *Journal of Community Health* 38 (2): 374-384.
70. Fogel, B., Vickrey, B., Walton-Wetzel, J., Lieber, E. and Browner, C.H. 2013. Utilization of Genetic Testing Prior to Subspecialist Referral for Cerebellar Ataxia, *Genetic Testing and Molecular Biomarkers*. 17 (8): 588-594.

B. RESEARCH PAPERS - NON-PEER REVIEWED

1. Browner, C. H. 1977. An Evaluation of Anthropology 190, "Analytic Methods in Anthropology." Prepared for the Committee on Teaching for Undergraduate Instructional Improvement, University of California., Berkeley, CA.
2. Browner, C. H., Chibnik, M., Crawley, C., Newman, K. and Sonafrank, A. 1978. A Behavioral View of Office Work. Palo Alto Research Center, Xerox Corp., Palo Alto, CA.
3. Browner, C. H. and Chibnik, M. 1980. Anthropologists and Industry. *Practicing Anthropology* 4(2):4, 18-19.
4. Hunt L. M. and Browner, C. H. 1980. An Ethnographic Report on the Cultural Enrichment Programs at Two Detroit Department of Health Methadone Clinics. Department of Health, Detroit, MI.
5. Browner, C. H., Ellis, K. A., Ford, T., Silsby, J., Tampoya, J., Yee, C. 1985. Work Stress and Health of Nursing Staff for the Mentally Retarded. Working Paper #31. Socio-Behavioral Group, Mental Retardation Research Center, UCLA, Los Angeles, CA.
6. Browner, C. H. 1985. Workers' Use of Peer Relations to Deal With Stress at Work. Working Paper #96. Institute for Industrial Relations, UCLA, Los Angeles, CA.

7. Browner, C. H. 1986. Clerical Workers' Responses to Management Control of Office Productivity. Working Paper# 115. Institute for Industrial Relations, UCLA
8. Browner, C. H. 1987. Work and Women's Health: The Role of Job-Based Social Support. ISSR Working Papers in the Social Sciences, Vol 3(12).
9. Browner, C. H. and Press, N. 1991. Prenatal Diagnostic Testing: How Do Women Decide? UCLA Center for the Study of Women Newsletter, Los Angeles, CA.
10. Harvey, S. M., Beckman, L. J., Browner, C., Rodriguez-Trias, H., Balzano, S., Doty, M. and Satre, S. 1997. The Context and Meaning of Reproductive Decision-Making among Mexican Immigrant Couples. Final report to CONRAD/CDC, Subcontract Agreement CSA 94-155.

C. BOOKS and BOOK CHAPTERS

BOOKS

1. Browner, C. H. and H. M. Preloran *Neurogenetic Diagnoses: The Power of Hope and the Limits of Today's Medicine*, Oxon: Routledge, 2010.
2. Browner C. H. and Sargent, C. F. eds. 2011 *Reproduction, Globalization, and the State: New Theoretical and Ethnographic Perspectives*. Durham, NC: Duke University Press.

2012 Elaine Basker Memorial Prize for Studies in Gender and Health, Society for Medical Anthropology.

2012 Most Significant Edited Collection Prize, Council on Anthropology and Reproduction.

Excerpt reprinted in 2014. Bookshelf, *Reproductive Health Matters: An International Journal of Reproductive and Sexual Rights* 21(43).

CHAPTERS

3. Browner, C. H. 1982. "Induced Abortion: The Risks and The Myths." In, G. C. Hongladarom, R. McCorkle, and N. F. Woods, eds. *The Complete Book of Women's Health*, pp. 208-20. Englewood Cliffs, NJ: Prentice-Hall, Inc.
4. Browner, C. H. 1983. "Women's Understandings about Reproductive Physiology and Their Choice of Herbal Medicines in Cali, Colombia." In, M. Aguwa, ed. *Women, Health and International Development*, pp. 91-103. East Lansing: Michigan State University Press.
5. Browner, C. H. and Rubel, A. J. 1984. "Pressure and Counter-Pressure: Interaction Between Local and State Levels in Highland Mexico." In, J. Lynch, ed. *Past and Present in the Americas. A Compendium of Recent Studies*, pp. 222-25. Manchester: Manchester University Press.

6. Browner, C. H. 1985. "Traditional Techniques for Diagnosis, Treatment and Control of Pregnancy in Cali, Colombia." In, L. Newman, ed. *Women's Medicine: Cross-Cultural Studies of Indigenous Fertility Regulation*, pp. 100-23. New Brunswick, NJ: Rutgers University Press.
7. Browner, C. H. and Ortiz de Montellano, B. R. 1986. "Herbal Emmenagogues Used by Women in Colombia and Mexico." In, N. Etkin, ed. *Plants in Indigenous Medicine & Diet: Biobehavioral Approaches*, pp. 32-47. Bedford Hills, NY: Redgrave.
8. Browner, C. H. and Ortiz de Montellano, B. R. 1988. "*Enseñanzas que derivan del uso de yerbas medicinales en Oaxaca, México.*" In, E. Reichel Dolmatoff, ed. *Patrones Cognitivos: Rituales y Fiestas de las Americas*. pp. 358-67. Bogota: Editorial Presencia, Ltda.
9. Browner, C. H. 1989. "The Management of Reproduction in an Egalitarian Society." In, C. McClain, ed. *Women as Healers: Cross-Cultural Perspectives*, pp. 58-71. New Brunswick, NJ: Rutgers University Press.
10. Lundgren, R. and Browner, C. H. 1990. "Caring for the Institutionalized Mentally Retarded: Work Culture and Work-Based Social Support." In, E. K. Abel and M. K. Nelson, eds. *Circles of Care: Work and Identity in Women's Lives*, pp. 150-72. Albany: SUNY Press.
11. Browner, C. H. and Sargent, C. F. 1990. "Anthropology and Human Reproduction." In, T. Johnson and C. F. Sargent, eds. *Medical Anthropology: A Handbook of Theory & Research*, pp. 215-29. Westport, CT: Greenwood Press.
12. Browner, C. H., Ortiz de Montellano, B. R., Rubel, A. J. 1992. "*El analisis comparativo de los sistemas médicos.*" In, P. Sesia, ed. *Medicina tradicional, herbolaria y salud comunitaria en Oaxaca, México*, pp. 223-263. Oaxaca, Mexico: CIESAS y Gobierno del Estado de Oaxaca.
13. Press, N. and Browner, C. H. 1994. "Collective Silences and Collective Fictions: How Prenatal Diagnostic Testing Became Part of Routine Prenatal Care." In, K. H. Rothenberg and E. J. Thomson, eds. *Women & Prenatal Testing: Facing The Challenges of Genetic Technology*, pp. 201-218. Columbus: Ohio State University Press.
14. Browner, C. H. and Press, N. 1995. "The Normalization of Prenatal Diagnostic Screening." In, F. Ginsburg and R. Rapp, eds. *Conceiving the New World Order: The Global Politics of Reproduction*, pp. 307-322. Berkeley: University of California Press.
15. Browner, C. H. and Rubel, A. J. 1995. "The Chinantec." In, D. Levinson, ed. *Encyclopedia of World Cultures*, Vol. 8, pp. 52-55. Boston: G. K. Hall & Co.
16. Browner, C. H. and Leslie, J. 1995. "Women, Work, and Household Health in the Context of Development." In, C. Sargent and C. Brettell, eds. *Gender and Health*, pp. 260-277. Englewood Cliffs, NJ: Prentice Hall.

17. Browner, C. H. and Sargent, C. F. 1996. "Anthropology and Studies of Human Reproduction." In, C. F. Sargent and T. Johnson, eds. *Medical Anthropology: Contemporary Theory & Method*, revised edition, pp.219-234. Westport, CT: Greenwood Press.
18. Press, N., Browner, C. H., Tran, D., Morton, C., and LeMaster, B. 1998. "Provisional Normalcy and 'Perfect Babies': Pregnant Women's Attitudes Toward Disability in the Context of Prenatal Testing." In, S. Franklin and H. Ragoné, eds. *Reproducing Reproduction*, pp. 46-65. Philadelphia: University of Pennsylvania Press.
19. Abel, E. K. and Browner, C. H. 1998. "Selective Compliance with Biomedical Authority and the Uses of Experiential Knowledge." In, M. Lock and P. Kaufert, eds. *Pragmatic Women and Body Politics*. pp. 310-326. Cambridge: Cambridge University Press.
20. Browner, C. H. and Preloran, H. M. 2000. *Para sacarse la espina* (To Get Rid of the Doubt): Mexican Immigrant Women's Amniocentesis Decisions. In, Ann R. Sætnan, Nelly Oudshoorn, and Marta Kirejczyk, eds. *Bodies of Technology: Women's Involvement with Reproductive Medicine*, pp. 368-383. Columbus: Ohio State University Press.
21. Rubel, A. J. and Browner, C. H. 2001. Chinantec. In, *Oxford Encyclopedia of Mesoamerican Cultures: The Civilizations of Mexico and Central America, Vol. 1*, pp 201-02. New York: Oxford University Press.
22. Rubel, A. J. and Browner, C. H. 2001. Curing and Healing. In, *Oxford Encyclopedia of Mesoamerican Cultures: The Civilizations of Mexico and Central America, Vol. 1*, pp 300-04. New York: Oxford University Press.
23. Browner, C. H. and Sargent, C. F. 2005. "Donner un genre à l'anthropologie médicale (Engendering Medical Anthropology)". In, Francine Saillant and Serge Genest, eds. *Anthropologie médicale: Ancrages locaux, défis globaux*, pp 358-81. Quebec: Les Presses de l'Université Laval.
24. Browner, C. H. and Preloran, H. M. 2006. "Culture and Communication in the Realm of Fetal Diagnosis. Unique Considerations for Latino Patients." In, Neil F. Sharpe and Ronald F. Carter, eds. *Genetic Testing: Current Practices, Ethical Concerns, Legal Considerations*, pp. 31-44. NY: John Wiley & Sons.
25. Browner, C. H. and Preloran, H. M. 2006. "Entering the Field: Recruiting Latinos for Ethnographic Work." In, Dick Hobbs and Richard Wright, ed. *Handbook of Fieldwork*, pp. 93-106. London: Sage.
26. Browner, C. H. and Sargent, C. F. 2007. "Engendering Medical Anthropology." In, Serge Genest and Francine Saillant, eds. *Medical Anthropology: Regional Perspectives and Shared Concerns*, pp. 233-51. Oxford: Blackwell Publishing. Ltd. (English translation of #23 above).

27. Browner, C. H. 2007. Does ‘Gender Equity’ in Reproductive Programs and Policies Unintentionally Reinforce Male Authority?’ In, Marcia Inhorn, ed. *Reproductive Disruption: Gender, Technology and Biopolitics in the New Millenium*, pp. 147-64. Oxford: Berghahn. (revised and expanded version of #60 above).
28. Root, R. and Browner, C. H. 2008. Cultural Contexts of Reproductive Health, In, H. Kris Heggenhougen and Stella Quah, eds. *International Encyclopedia of Public Health Vol. 2*, pp. 44-48, San Diego: Academic Press.
29. Root, R. and Browner, C. H. 2011. Cultural Contexts of Reproductive Health, In, Paul F.A. Van Look, H. Kristian Heggenhougen and Stella R. Quah, eds. *Sexual and Reproductive Health: A Public Health Perspective Vol. 4*, pp. 314-318. Reprint of #28 above. (revised and updated 12/14)
30. Browner, C. H. and Sargent, C. F. 2011. Introduction. In, C. H. Browner and C. F. Sargent, eds. *Reproduction, Globalization, and the State: New Theoretical and Ethnographic Perspectives*, pp. 1-17. Durham: Duke University Press.
31. Browner, C. H. 2011. Lost In Translation: Lessons from California on the Implementation of State-Mandated Fetal Diagnosis in the Context of Globalization. In, C. H. Browner and C. F. Sargent, eds. *Reproduction, Globalization, and the State: New Theoretical and Ethnographic Perspectives*, pp. 204-23. Durham: Duke University Press.
32. Browner, C. H. and Sargent, C. F. 2012. Dando um Genero a Antropologia Médica. In, Francine Saillant e Serge Genest, *Antropologia Médica: Ancoagens Locais, Desafios Globais*, pp. 351-74. Rio de Janeiro: Editora Fiocruz. (Portuguese translation of #21 above.)
33. Flaherty, D., Preloran, H. M. and Browner. C. H. 2014. Is It “Disclosure?” Rethinking Tellings of Genetic Diagnoses. In, M. Davis and L. Manderson, eds. *Disclosure in Health and Illness*, pp. 89-103. London: Routledge.
34. Browner, C.H. and Withers, M. 2015. Reproduction. In, P. Whelehan and A. Bolin, eds. *International Encyclopedia of Human Sexuality*, First Edition. Boston: Wiley and Company.
35. Browner, C.H. and Root, R. 2015. Cultural Contexts of Reproductive Health. In, *Elsevier Reference in Biomedical Sciences*. (Revised and updated of #28 above.)
36. Browner, C.H. 2016. Reproduction: From Rights to Justice. In, L.J. Disch and M. Hawkesworth, eds. *Oxford Handbook of Feminist Theory*, pp. 803- 831. Oxford: Oxford University Press.
37. Browner, C.H. and Root, R. 2017. Cultural Contexts of Reproductive Health. *International Encyclopedia of Public Health*, Second Edition, 2: 87–190. Oxford: Academic Press. (Revised and updated of #35.)
38. Withers, M., Browner, C. H. and Adinata, I.N.A. 2018. The Role of Balinese Culture in Explaining Inconsistencies Between Fertility Intentions and Reproductive Outcomes. In, S. Choudhury, J. T. Erausquin, and M. Withers, eds. *Global Perspectives on Women’s Sexual and Reproductive Health Across the Lifecourse*, pp. 127-140. Cham, Switzerland: Springer International.

39. Browner, C.H. and Sargent, C. F. forthcoming. Reproduction and the State. In, S. Han and C. Tomori, eds. *The Routledge Handbook of Anthropology and Reproduction*. New York: Routledge.

D. LETTERS TO THE EDITOR

1. Lewin, E. and Browner, C. H. 1990. Letter to the Editor on review of Faye Ginsberg's *Contested Lives*. *Women's Review of Books* 7(6): 6.
2. Morgan, L. M. and Browner, C. H. 1995. Letter to the Editor on editorial by G. Gillett, "Why Worry About Embryos?" *Social Science and Medicine* 40(7): 1015.
3. Rubel, A. J. and Browner, C.H. 1998. More than a Single Approach. (Letter to the Editor). *Anthropology Newsletter* 39(3): 6.
4. Browner, C.H. 2009. A Payoff Out of Poverty? *The New York Times Magazine* January 4, p. 6.

E. REVIEWS and REVIEW ARTICLES

1. Browner, C. H. 1974. Review of *The Abortion Controversy* by B. Sarvis and H. Rodman. *Social Science and Medicine* 8:162.
2. Browner, C. H. 1982. Review of *Latin American Urbanization* by D. Butterworth and J. Chance. *American Anthropologist* 84:681-82.
3. Browner, C. H. 1982. The Social Formation of Childbirth: A Review of Recent Research. *Medical Anthropology Newsletter* 14:1, 6-13.
4. Browner, C. H. 1990. Review of *From Menarche to Menopause: Reproductive Lives of Peasant Women in Two Cultures* by Y. Beyene. *American Ethnologist* 17(3):569-70.
5. Browner, C. H. 1990. Review of *Contested Lives: The Abortion Debate in an American Community* by F. D. Ginsburg. *American Anthropologist* 92(3):767-68. Reprinted in UCLA Center for the Study of Women Newsletter, Winter, 1991.
6. Browner, C. H. 1990. Review of *Healers of the Andes* by J. Bastien. *The Latin American Anthropology Review* 2(1):21-22.
7. Browner, C. H. 1994. Review of *The Health of Women: A Global Perspective* edited by Marge Koblinsky, Judith Timyan and Jill Gay. *Medical Anthropology Quarterly* 8(1):125-27.
8. Browner, C. H. 1994. Review of *Feminism and Disability* by Barbara Hillyer. *Women and Health* 22(2):71-73.
9. Browner, C. H. 1994. Review of *The Health of Women: A Global Perspective* edited by Marge Koblinsky, Judith Timyan and Jill Gay. *Women and Health* 22(2):74-77 (revised version of #15).

10. Browner, C. H. 1995. Review of *Women in Pain: Gender and Morbidity in Mexico* by Kaya Finkler. *American Anthropologist* 97(2):387-88.
11. Browner C. H. and Shapira, J. 2001. Review of *Testing Women, Testing the Fetus: The Social Construction of Amniocentesis in America* by Rayna Rapp. *Social Science and Medicine*. (53)1:148-49.
12. Browner, C. H. 2010. Review of *Biosocialities, Genetics, and the Social Sciences: Making Biologies and Identities* edited by Sahra Gibbon and Carlos Novas, *Transcultural Psychiatry* 47(1):193-96.
13. Browner, C. H. 2010 Review of *Matters of Choice: Puerto Rican Women's Struggle for Reproductive Freedom* by Iris López. *Medical Anthropology Quarterly* 24(1): 127-129.
14. Browner, C. H. 2013 Review of *God's Laboratory: Assisted Reproduction in the Andes* by Elizabeth F. S. Roberts. *American Ethnologist* 40(2): 414-15.
15. Browner, C. H. 2019. Moving Beyond Neoliberal Models of Health Care. Review essay *Health Care Under the Knife Waitzkin: Moving Beyond Capitalism for Our Health*. H. and the Working Group on Health Beyond Capitalism. *Medical Anthropology* 38(5): 455-458.
16. Browner, C. H. 2019. Review of *The Logics of Gender Justice: State Action on Women's Rights Around the World* by Mala Htun and S. Laurel Weldon. *Politics & Gender* 15(2): 11-14 doi:10.1017/S1743923X19000175, e10.
17. Browner, C. H. 2019. Review of *The Anthropology of the Fetus: Biology, Culture, and Society*. Sallie Han, Tracy K. Betsinger & Amy B. Scott, eds. *Journal of the Royal Anthropology Institute (JRAI)* (N.S.) 25 (4): 830-831.
18. Browner. C. H. 2020. Review of *Caring for the People of the Clouds: Aging and Dementia in Oaxaca* by Jonathan Yahalom. *The Journal of Latin American and Caribbean Anthropology* <https://doi.org/10.1111/jlca.12467>, 20 March.

F. EDITED VOLUMES

1. Browner, C. H. 1983. Women Practicing Anthropology: Perspectives Across the Discipline. Special Section *Practicing Anthropology* 6(1):4-10.
2. Browner, C. H. and King, D. L. 1989. Cross-Cultural Perspectives on Women and Immigration. *Women's Studies* 17(1):49-69.

Reprinted in E. K. Abel and M. L. Pearson, eds. *Across Cultures: The Spectrum of Women's Lives*, pp. 49-69. New York: Gordon and Breach, 1989.
3. Browner, C. H. and Levin, B. W., eds. 2005. The Social Production of Health: Critical Contributions from Evolutionary, Biological, and Cultural Anthropology. Papers in Memory of Arthur J. Rubel. Invited theme issue for *Social Science and Medicine* 61(4):745-878.

G. INTRODUCTIONS AND FOREWORDS

1. Browner, C. H. 1983. Introduction. Women Practicing Anthropology: Perspectives Across the Discipline. Special Section. *Practicing Anthropology* 6:4 and 7.
2. Browner, C. H. and King, D. L. 1989. Introduction to "Cross-Cultural Perspectives on Women and Immigration." *Women's Studies* 17(1):49-51.

Reprinted in E. K. Abel and M. L. Pearson, eds. *Across Cultures: The Spectrum of Women's Lives*, pp. 49-51. New York: Gordon and Breach, 1989.

3. Browner, C. H. 2004. Foreword to *Healing by Hand: Manual Medicine and Bonesetting in Global Perspective*. K. Oths and S. Z. Hinojosa, eds. Walnut Creek, CA: Altamira Press.
4. Browner, C. H. 2012. Foreword to *Risk, Reproduction, and Narratives of Experience*, pp. ix-xiii. L. Fordyce and A. Maraesa, eds. Nashville: Vanderbilt University Press.

H. COMMENTARIES

1. Browner, C. H. 1980. Invited Commentary on Nag, M. How Modernization Can Also Increase Fertility. *Current Anthropology* 21(5):581.
2. Hunt, L. M. and Browner, C. H. 1984. Invited Commentary on Bolton, R. The Hypoglycemia-Aggression Hypothesis: Debate Versus Research. *Current Anthropology* 25(1):32-33.
3. Browner, C. H., Ortiz de Montellano, B. R., Rubel, A. J. 1989. Reply to Fabrega, H. On Research Methodology for Ethnomedicine. *Current Anthropology* 30(3):347-48.
4. Browner, C. H. 1989. Invited Commentary on B. Jordan's Cosmopolitical Obstetrics: Some Insights from the Training of Traditional Midwives. *Social Science and Medicine* 28(9):937-38.
5. Browner, C. H. 1997. Commentary: Looking Backward at the Creation of the Society for Medical Anthropology. *Anthropology Newsletter* 38(6): 62-3.
6. Browner, C.H. 1998. Commentary on Varieties of Reasoning in Medical Anthropology. *Medical Anthropology Quarterly* 12(3):356-58.
7. Browner, C. H. and Sargent, C. F. 1999. The Gendered Politics of Reproduction: Session Report. *Council on Anthropology and Reproduction Newsletter* 6(2): 6-7.
8. Browner, C. H. and Sargent, C. F. 1999. Browner, Sargent Summarize *Politics of Reproduction*. *Anthropology Newsletter* 40(3): 43-44.
9. Browner, C. H. and Rosenthal, R. M. 2004. Death notice: Duane Metzger. *Anthropology News* 45(6): 42-43.
10. Browner, C. H. 2005. Invited commentary on "Conscientious Autonomy: Displacing Decisions in Health Care," by Rebecca Kulka, *Hastings Center Report* 35(5):4-5.

11. Sargent, C. F. and Browner, C. H. 2005. Globalization Raises New Questions about the Politics of Reproduction. *Anthropology News* 46(3): 5-7.
12. Browner, C.H. and Low, S.M. 2015. In Memoriam: Remembering Lucile Newman. *Anthropology News* January 7.

Updated July 21, 2021

CURRICULUM VITAE

NAME Aditi Bhargava, PhD
Professor
Department of Obstetrics and Gynecology, Center for Reproductive Sciences

ADDRESS Health Sciences East Rm 1645,
University of California, San Francisco,
513 Parnassus Avenue,
San Francisco, CA 94143-0556, USA

CONTACT Office: (415) 502-8453
Lab: (415) 476-3336
Fax: (415) 502-7866
Email: aditi.bhargava@ucsf.edu
<http://bms.ucsf.edu/directory/faculty/aditi-bhargava-phd>
https://cancer.ucsf.edu/people/profiles/bhargava_aditi.7449

EDUCATION

B.Sc. 1986 Zoology (Honors), University of Rajasthan, Jaipur, India
M.Sc. 1988 Zoology (Specialization: Molecular Biology), University of Pune, India
Ph.D. 1995 Zoology (Area: Molecular Biology), University of Pune, India

ACADEMIC POSITION

07/2016 – Present Professor, Department of Ob-Gyn, Center for Reproductive Sciences, UCSF
10/2014 – 2020 The Osher Center of Integrative Medicine, UCSF.
02/2015 – 06/2016 Associate Professor, Department of Ob-Gyn, CRS, UCSF
12/2010 – 01/2015 Associate Professor, Department of Surgery, UCSF.
8/2004 – 12/2010: Assistant Professor, Department of Surgery, UCSF.
8/2003 – 8/2004: Assistant Research Physiologist, Department of Surgery & Physiology, University of California, San Francisco.
2000 - 2003: Post Graduate Researcher, Departments of Medicine & Physiology, University of California, San Francisco.
1996 - 1999: Postdoctoral Fellow, Departments of Medicine, University of California, San Francisco.
1995 - 1996: Postdoctoral Fellow, Department of Pathology, New York Medical College, Valhalla, NY.
1990 – 1995 Graduate student (PhD), Department of Zoology, University of Pune, Poona, India.
1988 - 1990: Junior Research Fellow, Department of Virology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

ACADEMIC HONORS AND AWARDS

1986 Certificate of Merit (IX Position), BSc Honors, University of Rajasthan, Jaipur
1988-1993 Graduate Research Fellowship (awarded to top 2% students), CSIR, India
1992 UNESCO/TWAS Human Genome Fellowship, Department of Biochemistry, Sir EM Southern's lab, University of Oxford, Oxford, UK
1994 – 1995 Senior Research Fellowship, Department of Biotechnology, India
1994 Senior Research Fellowship, Indian Council for Medical Research (ICMR), India (declined due to conflict with DBT award).
2003 Quest Diagnostic Young Investigator Award, Endocrine Society

2004	Young Investigator Travel Award, GIRI Conference, Canada
2005	Editorial Board, Journal of Molecular and Genetic Medicine, Library Publishing Media, Oxford, UK.
2006-09	Member, Minority Affairs Committee, The Endocrine Society.
2006	Bavaria California Technology Award (BaCaTe).
2007	Hellman Award.
2009-12	Member, Minority Affairs Committee (MAC), The Endocrine Society.
2010	New Investigator Award, American Physiological Society (Gastrointestinal & Liver Physiology section), Experimental Biology.
2010	FASEB MARC Mentor Travel Award, June 19-22, Endo 2010, San Diego.
2011	NIH/NIAAA Peer Review Committee, ad-hoc member (ZAA1 GG).
2011	T1 Translational Catalyst Award from CTSI, UCSF.
2012	Inducted Fellow of the American Gastroenterological Association (AGAF).
2012	NIH/NIDDK Member Study Section (CIMG), Temporary member.
2012	Organized Health Disparities in Endocrinology Summit, The Endocrine Society.
	Member, Research Affairs Core Committee (RACC), The Endocrine Society.
2012-2019	Member, Breakthroughs in Bioscience Subcommittee, FASEB
2013-2016	Nominated for the “2014 Ernest Oppenheimer Laureate Award”.
2013	Member, CSR IAM Study section ZRG1 IFCN-Z (02)
2013	Nominated for the “2015 Weitzman Award”, The Endocrine Society.
2014	Member, NIH/CSR DKUS Special Emphasis Panel
2014	Organized and Moderated, “Inaugural Translational Research Workshop” at ICE/ENDO 2014.
2014	
2015	Chaired and Organized, “Translational Research Workshop” at ICE/ENDO
2015	Member, NIH/ CSR Study section ZRG1 IFCN-Z (02)
2015	Member, NIH/CSR Study Section ZRG1 IFCN- B-04M (October)
2016	NIH/CSR Study Section 05 ZRG1 IFCN-Z (02) M (February), Member
2016	NIH/CSR Study Section 05 ZRG1 BBBP-X (45) P (April), Member
2016	NIH CIMG Study Section (October), Temporary Member
2017	NIH Digestive Sciences Small Business Activities [SBIR/STTR] SEP [DKUS]
2017	NIH SEP 2017/05 ZRG1 BCMB-A (51) R
2017-21	NIH CIMG Study Section, Member
2018	NIH ZRG1 EMNR Study Section, Member
2019	NIH SEP ZRG1 DKUS-D (90) S
2020	NIH SEP ZRG1 DKUS-A (90)
2017-21	AJP (GI & Liver) Editorial Board
2018-22	Cells, Editorial Board
2020-2023	Endocrinology, Editorial Board
2021-2024	Chair, Scientific Statement Committee, The Endocrine Society
2021-2022	FEBS OpenBio, Editorial Advisory Board

PROFESSIONAL SOCIETY MEMBERSHIPS

- American Society for Cell Biology
- The Endocrine Society
- American Physiological Society
- American Gastroenterological Association

- American Pancreatic Association
- European Pancreatic Club

PROFESSIONAL DEVELOPMENT ACTIVITIES

- Mid-career women in Medicine, AAMC, Austin, TX, December 2016.

RESEARCH PUBLICATIONS

1. P. Shankar, N. Manjunath, R. Lakshmi, **Bhargava Aditi**, P. Seth and Shriniwas. (1990). Identification of *Mycobacterium tuberculosis* by polymerase chain reaction. *The Lancet*. **335**: 432.
2. Manjunath N, Shankar P, Rajan L, **Bhargava A**, Saluja S and Shriniwas. (1991). Evaluation of a polymerase chain reaction for the diagnosis of tuberculosis. *Tubercle*. **72**:21-27
3. **Bhargava A**, Deobagkar DN, and Deobagkar DD. (1991). Identification and Characterization of Oncogene *yes* homologous genomic clones from *Drosophila melanogaster*. *J. Genetics*. **70**: 181-88.
4. **Bhargava A**, Kumar A, Yuan N, Gewitz MH and Mathew R. (1999). Monocrotalin induces Interleukin-6 mRNA expression in Rat Lungs. *Heart Disease*: **1**: 126-132.
5. **Bhargava**[†] **A**, Chen[†] S-Y, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone G, Verrey, F, and Pearce D. (1999) Epithelial sodium channel regulated by aldosterone-induced protein sgk. *Proc. Natl. Acad. Sci.*, **96**: 2514-2519. (†: equal contribution by two authors). PMC26816
6. Pearce D, Verry F, Chen S-Y, Mastroberardino L, Meijer OC, Wang J, and **Bhargava A**. (2000) Role of SGK in mineralocorticoid-regulated sodium transport. *Kidney International*, **57**(4): 1283-1289.
7. **Bhargava A**, Meijer OC, Dallman MF, and Pearce D. (2000) Plasma Membrane Calcium Pump Isoform 1 Gene Expression is Repressed by Corticosterone and Stress in Rat Hippocampus. *J. Neuroscience*. **20**(9):3129-3138.
8. Wang J, Barbry P, Maiyar A, Rozansky DJ, **Bhargava A**, Leong M, Firestone GL, and Pearce D (2001). SGK integrates insulin and mineralocorticoid regulation of epithelial sodium transport. *Am. J. Physiology (Renal)*, **280** (2): F303-F313.
9. **Bhargava A**, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D and Cole TJ (2001). The serum- and glucocorticoid-induced kinase is a physiological aldosterone target in rat kidney and colon. *Endocrinology*, **142**(4): 1587-94.
10. Rozansky DJ, Wang J, Doan N, Purdy TM, **Bhargava A**, Dawson K and Pearce D (2002). Hypotonic induction of SGK1 and Na⁺ transport in A6 cells. *Am J Physiol Renal Physiol*. **283**(1):F105-13).
11. Bell ME, **Bhargava A**, Soriano L, Laugero K, Akana SF, Dallman MF (2002). Sucrose and corticosterone interact with cold to modulate behaviour, energy balance, autonomic outflow and neuroendocrine responses during chronic stress. *J Neuroendocrinology*, **14**(4): 330-42.
12. **Bhargava A**, Mathias RM, McCormick JA, Dallman MF and Pearce D. (2002). Glucocorticoids prolong Ca(2⁺) transients in hippocampal-derived H19-7 neurons by repressing the plasma membrane Ca(2⁺)-ATPase-1. *Mol Endocrinol*, **16**(7): 1629-37. PMID: 12089356
13. Pearce D, **Bhargava A** and Cole T. (2003). Aldosterone: Its Receptor, Target genes and Actions. *Vitamins and Hormone*, **66**:29-76.
14. Houshyar H, Gomez F, Manalo S, **Bhargava A** and Dallman MF. (2003). Intermittent morphine administration induces dependence and is a chronic stressor in rats. *Neuropsychopharmacology*, **28**(11):1960-72.
15. Adams M, Meijer OC, Wang J, **Bhargava A**, Pearce D. (2003). Homodimerization of the Glucocorticoid Receptor is not Essential for Response Element Binding: Activation of the Phenylethanolamine N-Methyltransferase Gene by Dimerization-Defective Mutants. *Mol Endocrinol*. **17**: 2583-92.
16. Pecoraro N, Reyes F, Gomez F, **Bhargava A**, Dallman MF. (2004). Chronic stress promotes palatable feeding, which reduces signs of stress: Feedforward and feedback effects of chronic stress. *Endocrinology*. **145** (8): 3754-62.

17. **Bhargava A** and Pearce D. (2004). Mechanisms of mineralocorticoid action: determinants of receptor specificity and actions of regulated gene products. *Trends Endocrinol Metab.* 15 (4): 147-53.
18. **Bhargava A**, Wang J and Pearce D. (2004). Regulation of epithelial ion transport by aldosterone through changes in gene expression. *Mol. Cell. Endocrinol.* 217 (1-2): 189-96.
19. **Bhargava A**, Dallman MF, Pearce D and Choi SJ. (2004). Long double-stranded RNA mediated interference as a tool to achieve site-specific silencing of hypothalamic neuropeptides. *Brain Res Protoc.* 13 (2): 115-25.
20. la Fleur SF, Wick EC, Idumalla PS, Grady EF and **Bhargava A**. (2005). Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. *Proc Natl Acad Sci.* 102 (21): 7647-7652. PMC1140406
Comment in: *Proc Natl Acad Sci U S A.* 2005 May 24;102(21):7409-10.
21. Ni XP, **Bhargava A**, Pearce D, and Humphreys MH. (2006). Modulation by Dietary Sodium Intake of Melanocortin 3 Receptor mRNA and Protein Abundance in the Rat Kidney. *Am J Physiol Regul Integr Comp Physiol.* 290(3):R560-7.
22. James P. Warne, Hart F. Horneman, Elizabeth C. Wick, **Aditi Bhargava**, Norman C. Pecoraro, Abigail B. Ginsberg, Susan F. Akana and Mary F. Dallman. (2006). Comparison of Jugular versus Superior Mesenteric Venous Infusions of Insulin in Streptozotocin-Diabetic Rats on the Choice of Caloric Intake, Body Weight and Fat Stores. *Endocrinology.* 147(11): 5443-5451.
23. Pecoraro N, Dallman MF, Warne JP, Ginsberg AB, Laugero KD, la Fleur SE, Houshyar H, Gomez F, **Bhargava A**, Akana SF. (2006). From Malthus to motive: How the HPA axis engineers the phenotype, yoking needs to wants. *Prog Neurobiol.* 79(5-6):247-340.
24. Vit JP, Jasmin L, **Bhargava A**, Ohara PT. (2006). Satellite glial cells in the trigeminal ganglion as a determinant of orofacial neuropathic pain. *Neuron Glia Biol.* 2(4):247-257. PMCID: PMC2435170.
25. Clifton MS, Hoy JJ, Chang J, Idumalla PS, Fakhruddin H, Grady EF, Dada S, Corvera CU, and **Bhargava A**. (2007). The Role of Clacitonin Receptor-Like Receptor in Colonic Motility and Inflammation. *Am J Physiol Gastrointestinal and Liver Physiology.* 293(1): G36-44.
26. Chang J, Hoy JJ, Idumalla PS, Clifton MS, Pecoraro N, and **Bhargava A**. (2007). Urocortin2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis. *Peptides.* 28(7): 1453-60. PMCID: PMC3718314
27. **Bhargava A***, Jean Philippe V*, Ohara PT*, Kanwar K, Jasmin L. (2008). Silencing the Kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. *J. Neuroscience.* 28(16): 4161-4171. *: co-first authors. PMCID: PMC2533133
28. Gavrilu AM, Robinson B, Hoy JJ, Stewart J, **Bhargava A**, Amir S. (2008). Double-stranded RNA-mediated suppression of PER2 expression in the suprachiasmatic nucleus disrupts circadian locomotor activity in rats. *Neuroscience.* 154(2):409-14.
29. Ohara PT, Vit JP, **Bhargava A**, Jasmin L. (2008). Evidence for a role of connexin 43 in trigeminal pain using RNA interference in vivo. *J Neurophysiol.* 100(6):3064-73. PMCID: PMC2604845
30. Ohara PT, Vit JP, **Bhargava A**, Romero M, Sundberg C, Charles AC, Jasmin L. (2009). Gliopathic pain: when satellite glial cells go bad. *Neuroscientist.* 15(5):450-63. PMCID: PMC2852320
31. Cureton EL, Ereso AQ, Victorino G, Poole PD, Liao M, Currian B, Harken AH and **Bhargava A**. Local Secretion of Urocortin 1 Promotes Microvascular Permeability During Lipopolysaccharide-induced Inflammation (2009). *Endocrinology.* 150(12):5428-37. PMCID: PMC2795720
Comment in: *Endocrinology.* 2009 Dec; 150(12):5205-7.
32. Jasmin L, Vit JP, **Bhargava A**, Ohara PT. Can satellite glial cells be therapeutic targets for pain control? *Neuron Glia Biol.* 2010 Feb;6(1):63-71. PMCID: PMC3139431
33. Samak G, Suzuki T, **Bhargava A**, Rao RK. c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium. *Am J Physiol Gastrointest Liver Physiol.* 2010 Sep; 299(3):G572-84. PMCID: PMC3774214

34. **Bhargava A***, Pao A*, Di Sole F, Quigley R, Shao X, Wang J, Thomas S, Zhang J, Shi M, Funder JW, Moe O, and Pearce D. Expression and Role of Serum and Glucocorticoid Regulated Kinase 2 in the Regulation of Na⁺/H⁺ Exchanger 3 in Mammalian Kidney" by *Am J Physiol Renal Physiol*. 2010 Dec; 299(6):F1496-506. *: co-first authors. PMID: PMC3006302
35. Aggarwal S, Suzuki T, Taylor WL, **Bhargava A**, Rao RK. Contrasting Effects of ERK on Tight Junction Integrity in Differentiated and Under-Differentiated Caco-2 Cell Monolayers. *Biochemical Journal*. 2010 Dec15; 433(1):51-63. PMID: PMC4438673
36. Chang J, Adams MR, Clifton MS, Liao M, Brooks JH, Hasdemir B, and **Bhargava A**. Urocortin 1 Modulates Immunosignaling in a Rat Model of Colitis via Corticotropin-Releasing Factor Receptor 2. *Am J Physiol Gastrointest Liver Physiol*. 2011 Feb 17; 300:G884-G894. PMID: PMC3094137
37. **Bhargava A**. CRF and Urocortins: A Challenging Interaction Between Family Members. *Gastroenterology*. 2011 May; 140(5):1391-4. Exempt
38. Liu LS, Qian Li, Sapolsky R, Liao M, Mehta K, **Bhargava A**, Pasricha PJ. 2011. Transient gastric irritation in the neonatal rats leads to changes in the hypothalamic CRF expression, depression- and anxiety-like behavior as adults. *PLoS ONE*. 12;6(5):e19498. PMID: PMC3093391
39. Hasdemir B, Mahajan S, Bunnett NW, Liao M, **Bhargava A**. 2012. Endothelin-Converting Enzyme-1 Actions Determine Differential Trafficking and Signaling of Corticotropin-Releasing Factor Receptor 1 at High Agonist Concentrations. *Mol Endocrinol*. 26(4):681-95. PMID: PMC3327357
40. Cottrell GS, Alemi F, Kirkland JG, Grady EF, Corvera CU, **Bhargava A**. 2012. Localization of Calcitonin Receptor-like Receptor (CLR) and Receptor Activity Modifying Protein 1 (RAMP1) in Human Gastrointestinal Tract. *Peptides*. 35(2):202-11. PMID: PMC3356482
41. Kim HJ, Prasad V, Hyung S-W, Lee ZH, Lee S-W, **Bhargava A**, Pearce D, Lee Y, Kim H-H. 2012. Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival. *Journal of Cell Biology*. 2012 Dec 24;199(7):1145-58. PMID: PMC3529522
42. **Bhargava A**, Clifton MS, Mhaske P, Liao M, Pothoulakis C, Leeman SE, Grady EF. 2013. Local injection of dsRNA targeting Calcitonin receptor-like receptor (CLR) ameliorates *Clostridium difficile* Toxin A-induced ileitis. *Proc Natl Acad Sci*. 2013 Jan 8;110(2):731-6. PMID: PMC3545755
43. Kubat E, Mahajan S, Liao M, Ackerman L, Ohara P, Grady E, **Bhargava A**. 2013. Corticotropin Releasing Factor Receptor 2 Mediates Sex-specific Cellular Stress Responses. *Molecular Medicine*. 2013 Jul 24;19:212-22. Selected as "Featured Article". PMID: PMC3745594
44. Kung L-H, Gong K, Adedoyin M, Ng J, **Bhargava A**, Ohara PT, Jasmin L. 2013. Evidence for glutamate as a neuronal transmitter with sensory ganglia. *PloS One*; Jul 2;8(7):e68312. PMID: PMC3699553
45. Mahajan S, Liao M, Barkan, P, Takahashi K, **Bhargava A**. 2014. Urocortin 3 expression at baseline and during inflammation in the colon: Corticotropin releasing factor receptors cross-talk. *Peptides*; 2014 Apr;54:58-66. PMID: PMC4006935
46. Kido M, Buddenkotte J, Kempkes C, Ikoma A, Cevikbas F, Akiyama T, Nunes F, Seeliger S, Hasdemir B, Mess C, Buhl T, Sulk M, Ulrich F, Metze D, Bunnett NW, **Bhargava A**, Carstens E, Furue M, Steinhoff M. 2014. Neural peptidase endothelin-converting enzyme 1 regulates endothelin-1-induced pruritis. *Journal of Clinical Investigation*; 2014; 124(6):2683-95. PMID: PMC4038561
47. Gong K, Kung L-H, Magni G, **Bhargava A**, Jasmin L. 2014. Increased response to glutamate in small diameter dorsal root ganglion neurons after sciatic nerve injury. *PloS One*; 2014. Apr 18;9(4):e95491. PMID: PMC3991716
48. Gong K, **Bhargava A**, Jasmin L. 2015. GluN2B NMDA receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after seven days of morphine administration in rats: implication for opiate-induced hyperalgesia. *Pain*. 2016 Jan;157(1):147-58. PMID: PMC4957526
49. Liu S, Chang J, Long N, Beckwith K, Talhouarne G, Brooks JJ, Qu M-H, Ren W, Wood JD, Cooper S, **Bhargava A**. 2015. Endogenous CRF in rat large intestine mediates motor and secretory responses to stress. *Neurogastroenterology and Motility*. 2016 Feb;28(2):281-91 PMID: PMC4727995

50. Hasdemir B, Mhaske P, Paruthiyil S, Garnett EA, Heyman MB, Matloubian M, **Bhargava A**. 2016. Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation. *Am J Physiol Regul Integr Comp Physiol*. 2016 Jun 1;310(11):R1244-57. PMID: PMC4935495
51. Gao MH, Giamouridis D, N. Chin Lai, Walenta E, Paschoal VA, Kim YC, Miyanohara A, Guo T, Liao M, Liu L, Tan Z, Ciaraldi TP, Schenk S, **Bhargava A**, Oh DA, Hammond HK. 2016. One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. *JCI Insight*. 201; 1 (15):e88322. PMID: PMC5033760
52. Gurfein BT*, Hasdemir B*, Milush JM, Touma C, Palme R, Nixon DF, Hecht FM, **Bhargava A**. Enriched environment and stress exposure influence splenic B lymphocyte composition. *PLoS One*. 2017 Jul 12;12(7). (*) co-first authors. PMID: 28704473.
53. Hasdemir B, Mahajan S, Oses-Prieto J, Chand S, Woolley M, Burlingame A, Grammatopoulos DK, **Bhargava A**. Actin Cytoskeleton-Dependent Regulation of Corticotropin-releasing Factor Receptor Heteromers. *Mol Biol Cell*. 2017 Jul 12. pii: mbc.E16-11-0778. PMID: 28701349
54. Liu S, Hagiwara SI, **Bhargava A**. Early life adversity, epigenetics, and visceral hypersensitivity. *Neurogastroenterology and Motility*. 2017. Feb;28(2):281-91 PMID: PMC4727995.
55. Strumwasser A, **Bhargava A**, Victorino GP. Attenuation of Endothelial Phosphatidylserine Exposure Decreases Ischemia-reperfusion INDUCED Changes in Microvascular Permeability. *J Trauma Acute Care Surg*. 2018 Mar 12. PMID: 29538229. PMID: PMC5970025.
56. Hagiwara S-I, Kaushal E, Paruthiyil S, Pasricha PJ, Hasdemir B, **Bhargava A**. Gastric corticotropin-releasing factor influences mast cell infiltration in a rat model of functional dyspepsia. *PLoS One*. 2018 Sep 7;13(9):e0203704. PMID: 30192883.
57. D'Costa S, Ayyadurai S, Gibson A, Mackey E, Sommerville L, Li Y, Kumar A, Subramanian H, Kubat E, **Bhargava A**, and Moeser A. Corticotropin Releasing Factor Subtype 2 Receptor Signaling Constrains Mast Cell Degranulation and Limits Pathophysiology Induced by Immunological and Psychological Stress. *The Journal of allergy and clinical immunology*. 2018. Nov 12. pii: S0091-6749(18)31586-0. doi: 10.1016/j.jaci.2018.08.053. PMID: 30439403.
58. Paruthiyil S, Hagiwara SI, Kundassery K, **Bhargava A**. Sexually dimorphic metabolic responses mediated by CRF2 receptor during nutritional stress in mice. *Biol Sex Differ*. 2018 Nov 6;9(1):49. doi: 10.1186/s13293-018-0208-4. PMID: 30400826.
59. Hagiwara SI, Hasdemir B, Heyman MB, Chang L, **Bhargava A**. Plasma Corticotropin-Releasing Factor Receptors and B7-2⁺ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. *Cells*. 2019 Jan 30;8(2). pii: E101. doi: 10.3390/cells8020101. PMID: 30704133.
60. Qu J, Ko C-W, Tso P, **Bhargava A**. (2019) Apolipoprotein A-IV: A Multifunctional Protein Involved in Protection against Atherosclerosis and Diabetes. *Cells*. Cells. 2019 Apr 5;8(4). pii: E319. doi: 10.3390/cells8040319. PMID: 30959835.
61. Yuan J, Hasdemir B, Tan T, Chheda C, Rivier J, Pandol SJ, **Bhargava A**. Protective effects of urocortin 2 against caerulein-induced acute pancreatitis. *PLoS One*. 2019 May 17;14(5):e0217065. doi: 10.1371/journal.pone.0217065. eCollection 2019. PMID: 31100090.
62. Vuppalahadham L, Ehsan C, Akkati M, and **Bhargava A**. Corticotropin-Releasing Factor Family: A Stress Hormone-Receptor System's Emerging Role in Mediating Sex-Specific Signaling. 2020. *Cells*. Mar 31;9(4):E839. doi: 10.3390/cells9040839. PMID: 32244319.
63. Liu S, Karo A, Agterberg S, Hua H, **Bhargava A**. 2021. Effects of stress-related peptides on chloride secretion in the mouse proximal colon. *Neurogastroenterology and Motility*. 2021 Apr;33(4):e14021. doi: 10.1111/nmo.14021. Epub 2020 Oct 28. PMID: 33118282.
64. Vuppalahadham L*, Lager J*, Fiehn O, Weiss S, Chesney M, Hasdemir B, and **Bhargava A**. Human Placenta Buffers the Fetus from Adverse Effects of Perceived Maternal Stress. *Cells*. 2021 Feb 12;10(2):379. doi: 10.3390/cells10020379.
65. **Bhargava A**, Arnold AP, Bangasser DA, Denton KM, Gupta A, Hilliard Krause LM, Mayer EA, McCarthy M, Miller WL, Raznahan A Verma R. Considering Sex as a Biological Variable in Basic and Clinical Studies: An Endocrine Society Scientific Statement. *Endocr Rev*. 2021 Mar 11;bnaa034. doi: 10.1210/edrev/bnaa034.

66. Wang M, Gorelick F, **Bhargava A**. 2021. Sex differences in the exocrine pancreas and associated diseases. *Cell Mol Gastroenterol Hepatol*. 2021 Apr 22;12(2):427-441. doi: 10.1016/j.jcmgh.2021.04.005. PMID: 33895424
67. Corder Z, Li Q, Liu L, Tamashiro KL, **Bhargava A**, Moran TH, Pasricha PJ. 2021. Vagal gut-brain signaling mediates amygdaloid plasticity, affect, and pain in a functional dyspepsia model. *JCI Insight*. 2021 Mar 22;6(6):144046. doi: 10.1172/jci.insight.144046. PMID: 33591956
68. Qu J, Fourman S, Fitzgerald M, Liu M, Nair S, Oses-Prieto J, Burlingame A, Morris JH, Davidson WS, Tso P, **Bhargava A**. Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue. *Sci Rep*. 2021 Jun 24;11(1):13289. doi: 10.1038/s41598-021-92711-0. PMID: 34168225
69. Bell RL, Withers GS, Kuypers FA, Stehr W, **Bhargava A**. Stress and corticotropin releasing factor (CRF) promote necrotizing enterocolitis in a formula-fed neonatal rat model. *PLoS One*. 2021 Jun 10;16(6):e0246412. doi: 10.1371/journal.pone.0246412. eCollection 2021. PMID: 34111125
70. Murray I, Bhanot G, **Bhargava A**. Neuron-Glia-Immune Triad and Cortico-Limbic System in Pathology of Pain. *Cells*. 2021 Jun 19;10(6):1553. doi: 10.3390/cells10061553. PMID: 34205372
71. **Bhargava A**, Fan S, Lujan C, Fiehn O, Neylan TC, Inslicht SS. Chemical set enrichment analysis: novel insights into sex-specific alterations in primary metabolites in posttraumatic stress and disturbed sleep. *Clinical and Translational Medicine*. 2021. In Production. DOI: 10.1002/ctm2.511

BOOK CHAPTERS

1. Heat Shock Proteins (HSP) in stress-related inflammatory diseases. Burcu Hasdemir, Dina Shakran, Sreenivasan Paruthiyil, **Aditi Bhargava (2019)**. Book Title: Heat Shock Proteins in Signaling Pathways. Series Title: Heat Shock Proteins. Series Volume: 17, edition 1. Series ISSN: 1877-1246. Publisher: Springer International Publishing AG. Editor(s) name(s): Prof. Dr. Alexzander A. A. Asea and Dr. Punit Kaur.
2. Probing the Interactome of Corticotropin-Releasing Factor Receptor Heteromers using Mass Spectrometry. Burcu Hasdemir, Juan Oses-Prieto, Alma Burlingame, and **Aditi Bhargava**. (2019) *Methods Mol Biol*. 2019;1947:269-285. doi: 10.1007/978-1-4939-9121-1_15. PMID: 30969422. Book Title: G-Protein-Coupled Receptor Signaling: Methods and Protocols. Part IV, Chapter 15, Exploring GPCR Signaling Properties. Series Title: MiMB. Publisher: Springer Science+Business Media, LLC, New York. Editor(s) name(s): Mario Tiberi, PhD.
3. Heat Shock Proteins in Human Reproductive System in Health and Disease. (2021) **Aditi Bhargava**, Joshua F. Robinson, Unurzul Jigmeddagva and Sahar Houshdaran. Book Title: "Heat Shock Proteins in Inflammatory Diseases". Series Title: Heat Shock Proteins. Series Volume: 22. Publisher: Springer International Publishing AG. Editor(s) name(s): Prof. Dr. Alexzander A. A. Asea and Dr. Punit Kaur.

MEDIA COVERAGE AND BLOGS

- 1) <https://www.cnn.com/2021/05/14/health/sex-biological-variable-research-science-drugs-scn/index.html>
- 2) <https://www.healio.com/news/endocrinology/20210311/endocrine-society-consider-sex-differences-in-biomedical-research>
- 3) <https://aditibhargava-sfo.medium.com/>

INVITED PRESENTATIONS

- West Virginia University, Department of Biochemistry, School of Medicine, September 8, 2020
- University of Concordia, Montreal, Canada, October 2019
- European Pancreatic Club (EPC) Meeting, Bergen, Norway, June 2019
- Fondazione Ettore Majorana e Centro di Cultura Scientifica, Workshop on Sex differences, dimorphisms, divergences: impact on brain and behavior in health and disease, Trapani, Italy, May 2019
- University of Cincinnati, Mouse Metabolic Phenotyping Center Seminar Series, Ohio, September 2018

- Dipartimento Materno-Infantile (DAIMI), Azienda Ospedaliera Universitaria Careggi (AOUC), Firenze (Florence), Italy, July 2018
- Visiting Professor, Division of Gastroenterology, Mayo Clinic, Rochester, MN, April 2018
- Department of Molecular and Cell Biology, Boston University, MA, March 2018
- Department of Gastroenterology, All India Institute of Medical Sciences (AIIMS), New Delhi, India, March 2018
- Cedar Sinai Medical Center, Los Angeles, CA, February 2018
- University of Chicago, Department of Medicine, IL, 2017
- University of Miami, Miller School of Medicine, Miami, FL, 2017
- European Pancreatic Club, Liverpool, UK, 2016
- Career Development Workshop, Endocrine Society, Boston, 2016
- Future Leaders Advancing Research in Endocrinology (FLARE) Workshop, Los Angeles, 2016
- Comparative Biomedical Sciences, Royal Veterinary College, London, UK, 2016
- European Pancreatic Club (EPC) Meeting, Liverpool, UK, 2016
- The Integrative Neuroscience Research Center at Marquette University, Milwaukee, 2014
- Future Leaders Advancing Research in Endocrinology (FLARE) Workshop, Atlanta, 2015
- Penn State College of Medicine, Department of Behavioral Neuroscience, Hershey, PA, 2013
- Division of Gastroenterology, Department of Medicine, University of Texas Medical Branch, June 2012
- ENDO 2012 Minority Student and Trainee Day, Invited speaker.
- Departments of Bioinformatics and Zoology, University of Pune, India, 2012
- Center for Cellular and Molecular Biology, Hyderabad, India, 2012
- Asian Institute of Gastroenterology, Hyderabad, India, 2012
- Department of Physiology, University of Tennessee, Memphis, March 2011
- ENDO 2011 Minority Student and Trainee Day, Invited speaker.
- Marquette University, Biomedical Sciences, 2010
- University of Concordia, Montreal, Canada, April 2007
- American Pain Society, May 2007, invited speaker for symposium entitled “All you want to know about RNAi”
- University of Pune, Poona, India, July 2007
- University Erlangen-Nürnberg, Germany, October 2006
- AstraZeneca lecture, University of California, Los Angeles, August 2004
- The Endocrine Society, June 2003 (session co-chair)

REGIONAL AND OTHER INVITED PRESENTATIONS

- San Mateo Public Library, San Mateo, CA, October 28, 2020.
- Women’s Cancer Resource Center, Berkeley, CA, February 19, 2020.
- Center for Reproductive Sciences, UCSF, 2018.
- Biomedical Science Graduate Student’s retreat UCSF-BMS, Granlibakken, 2017.
- Endocrine Grand Rounds, UCSF, 2016
- Biomedical Science (BMS) Graduate Student’s Blitz, UCSF, 2016

- The Center for Reproductive Sciences, UCSF, 2015
- Mental Illness Research, Education, and Clinical Center, San Francisco VA, 2015
- The Diabetes Center, UCSF, 2014
- The Osher Center, UCSF, 2014
- Biomedical Sciences (BMS) Faculty Seminar Series, 2014.
- The Endocrine Society Meeting, San Francisco, 2013
- Division of Gastroenterology and Nutrition, UCSF, 2013
- American Gastroenterological Association (oral) DDW, San Diego, 2012
- Surgery Grand Rounds, Department of Surgery, UCSF 2012
- American Gastroenterological Association (oral) DDW, San Diego, 2008
- Surgery Grand Rounds, Department of Surgery, UCSF, 2007
- The Endocrine Society Meeting (oral presentation), San Diego, 2005
- American Gastroenterological Association (oral) DDW, Chicago, 2005
- Medicine Grand Rounds, School of Medicine, UCSF, 2004
- The Endocrine Society Meeting (oral), Philadelphia, 2003
- Society for Neuroscience (oral), San Diego, 2001
- The Experimental Biology Meeting (FASEB), Washington DC, 1996
- Indian Congress of Medical Microbiologist, India, 1989.

ABSTRACTS AND POSTERS

- Abstracts and Posters Presentation at National and International Meetings not included in the CV.
- Several awards, including President's award, travel awards, and featured poster awarded to my trainees at the DDW/AGA meetings, Endocrine Society meeting, and the FASEB meetings over the last several years.

AWARDS TO TRAINEES

- Burcu Hasdemir, PhD, Postdoc Slam Finalist, UCSF 2016
- Burcu Hasdemir, PhD, RAP Postdoctoral Fellow Grant, UCSF, 2016
- Burcu Hasdemir, PhD, ASBMB Postdoctoral Fellow Travel Award, 2016
- Shilpi Mahajan, PhD, ASBMB Postdoctoral Fellow Travel Award, 2014
- Shilpi Mahajan, PhD, Presidential Poster Award Finalist, ICE/Endo, 2014
- Robert Bell, MD, First Place Winner (Best Abstract), Surgery Resident Research Symposium, UCSF, 2013.
- Paris Barkan, BS, Undergraduate Summer Research Award from Endocrine Society, 2013
- Eric Kubat, MD, Runner Up, Surgery Resident Research Symposium, UCSF, 2012.
- Eric Kubat, MD, Excellence in Research Award (category of Alimentary Tract), American College of Surgeons Annual Meeting, 2011
- Eric Kubat, MD, Kenneth P. Warren/Pancreas Club Award for an Outstanding Resident Research Presentation, AGA, 2011
- Alexander Ereso, MD, Presidential Poster Award Winner, Endocrine Society, 2008

RESEARCH FUNDING

CURRENT FUNDING

W81XWH-19-PRMRP-DA (Inslicht)

05/01/20 - 04/30/22

PRMRP Women's Health

Elucidating the potential relationship between post-traumatic stress disorder and women's heart disease

The primary goals of this project are to identify sex-specific, PTSD-related lipid alterations that are linked with CVD risk using a metabolomics approach.

Role. Co-Investigator

RECENTLY COMPLETED (LAST 3 YEARS)

5R01DK097518-03 (Bhargava MPI)

05/01/14 - 04/30/18

NIH/NIDDK

Neuroplasticity of the gut-brain axis in functional dyspepsia

The major goal of this multi PI proposal is to test the hypothesis that signals originating in the gut influence neuronal plasticity.

W81XWH-15-PRMRP-DA (Inslicht)

9/30/16-3/31/18

PRMRP

Metabolomics: A window for understanding long-term physical consequences of disturbed sleep and hypothalamic-pituitary-adrenal function in posttraumatic stress

The primary goal of this project is to evaluate biochemical pathways underlying complex clinical presentation of posttraumatic stress (PTS) and comorbid conditions. We will do this by evaluating the metabolomics of previously collected blood samples in a cohort of patients with PTS and matched trauma-exposed controls.

RB 20140520 (Bhargava)

11/17/14 - 8/28/17

AbbVie Inc.

Local Delivery of Biologics in IBD

The major goal of this proposal is to test local delivery of potentially therapeutic biologics in animal models of IBD.

2R56DK080787-06A1 (Bhargava)

9/1/15 - 8/31/17

NIH/NIDDK

Regulation and Function of Urocortins and their Receptor

The major goals of this project are to evaluate the role of urocortins and their receptor in irritable bowel syndrome and associated changes in gut permeability.

NIH/NCATS UL1 TR001872 (Bhargava)

12/16/16-5/31/17

NIH-NCATS

Delivery Challenges in Developing New Treatments for Inflammatory Bowel Disease (IBD)

The major goal of this study is to determine stability of CQ-encapsulated drugs and small molecules as well as to determine presence of CTB receptors in human gut.

1R01DK080787 (Bhargava)

04/01/09 - 03/31/17

NIH/NIDDK

Regulation and Function of Urocortins and their Receptor

The major goals of this project are to define the role of the CRF system in the genesis of inflammatory bowel disease.

PREVIOUS FUNDING

Agency: National Institutes of Health/CTSI

Role: Principal Investigator (Bhargava)

Title: Delivery Challenges in Developing New Treatments for IBD

Grant type: Pilot and Catalyst Award

Funding period: Feb 2014-June 2015

Agency: National Institutes of Health/NINDS

Role: Co-PI (PI: Jasmin L, MD)

Title: Satellite Glial Cells

Grant type: R01

Funding period: 2009-2014

Agency: National Institutes of Health/NINDS

Role: Co-PI (PI: Jasmin L, MD)

Title: Glutamatergic transmission within the sensory ganglion

Grant type: R21
Funding period: 2013-2015

Agency: National Institutes of Health/NIDDK
Role: Principal Investigator
Title: Regulation and Function of Urocortins and their Receptors in Pancreatitis
Grant type: R01 re-entry supplement for Eileen Grady DK080787-02S1
Funding period: 2010-2012

Agency: UCSF T1 Translational Catalyst Award
Role: Principal Investigator
Title: Targeted delivery of RNA molecules for neuronal pathophysiologies
Grant type: Pilot Award
Funding period: 2011-2012

Agency: National Institutes of Health/NINDS
Role: Co-PI (PI: Jasmin L, MD)
Title: Gene Therapy for Nerve Injury
Grant type: R01
Funding period: 2006-2011

Agency: National Institutes of Health/NINDS
Role: Co-PI (PI: Ohara PT, PhD)
Title: Neuronal/Glial Interactions in Neuropathic Pain
Grant type: R21
Funding period: 2007-2010

Source: UCSF Bridge Funds
Role: Principal Investigator
Funding period: 2009

Source: Hellman Family Foundation
Role: Principal Investigator
Title: Stress and Altered Intestinal Permeability: Role of Corticotropin Releasing Factor
Funding period: 2007-2009

Source: REAC/UCSF
Role: Principal Investigator
Title: Role of Urocortins in Colonic Inflammation
Funding period: 2006-2007

Source: Bavarian California Technology (BaCaTe)
Role: Principal Investigator along with Korbamacher C, MD/PhD (Germany)
Title: Regulatory role of α -Actinin-1 for the epithelial sodium channel (ENaC)
Funding period: 2006

Source: Merck Inc.
Role: Principal Investigator
Funding period: 2004-2006

Agency: National Institutes of Health/NIMH
Role: Principal Investigator

Title: Site-specific Gene Silencing by RNA Interference

Grant type: R21

Funding period: 2003-2006

PRIVATE DONATIONS AND GIFTS

Ms. Dorothy Seacrest
Molecular Neurobiology Funds
The Painless Foundation
The Zarrow Family Foundation

PATENT(S) FILED

- Targeted delivery Platform for RNAi 506

INTERACTIONS WITH INDUSTRY

- Merck, Inc.
- RW Johnson
- Abbott

PEER REVIEW

MEETING ABSTRACTS

- The Broad Foundation (*Ad hoc* reviewer)
- FASEB
- The Endocrine Society
- American Gastroenterological Association (DDW)
- The Australian-American Foundation (2018, 2019)

MANUSCRIPTS

- *Ad hoc* reviewer for American Journal of Physiology, British Journal of Pharmacology, Biology of Sex Differences, Cells, Cell Physiology, Current Drug Targets, Endocrinology, European Journal of Pain, FEBSJ, Frontiers in Neuroscience, Gastroenterology, Genomics, JASN, Journal of Clinical Investigation (JCI), Journal of Molecular Medicine, Journal of Neurochemistry, Journal of Neuroscience, Mediators of Inflammation, Molecular Endocrinology, MDPI journals, Peptides, PLoS One, Scientific Reports,.

CONFERENCE & SYMPOSIA ORGANIZATION

- Co-organizer and Instructor for a Department of Biotechnology (DBT), India-sponsored short course on “*In situ* hybridization techniques in *Drosophila* and invertebrates”, 1994, University of Pune, Pune, India.
- Co-proposed a symposium topic for the 2007 annual meeting for the American Pain Society entitled “All you want to know about RNAi”. The organizers accepted this symposium topic.
- Member, Organizing Committee for the Health Disparities in Endocrinology, 2013 sponsored by the Endocrine Society.
- Organizer, Chair and Moderator, “Translational Research Workshop” at ICE/ENDO 2014 & 2015.

TEACHING AND EDUCATION

FORMAL TEACHING

Molecular Biology: Theory and lab to MSc Biotechnology Students, University of Pune, India.

Physiology 121: Cardiovascular (the human electrocardiogram) and Respiration (spirometry, lung volumes and capacities) lab.

Physiology 122: Gastrointestinal Physiology I-IV.

Core Inquiry Curriculum (CIC to Medical Students): 2017-2020

2017-2018

- Ground School Block
- Airways, Blood, and Circulation
- Health and the Individual
- The REGulationN Block - Renal, Endocrine, GI, and Nutrition

2018-2019

- The Health & Society Block
- The Pathogens & Host Defense Block – PHD
- The REGulationN Block - Renal, Endocrine, GI, and Nutrition

2019-2020

- Airways, Blood, and Circulation
- Life Stages- Complications of Pregnancy

Biomedical Sciences (Graduate Program)

- **Conflict of Interest (Grad214):** Responsible Conduct of Research Course (2015, 2017, 2018, 2019).
- **BMS 260 Cell Biology** (2014, 2015, 2016, 2018)

RESIDENT EDUCATION

As the director of laboratory research at the Osher Center for Integrative Medicine, UCSF, I am charged with providing wet-lab training to pre- and post-doctoral fellows, an opportunity that did not exist before.

As a member of the Research Committee, Department of Surgery, I was involved in issues pertaining to surgery residents. Activities include ensuring that residents make optimum progress with their research training and that their funding needs are being met by guiding them to funding sources, advise residents if they have any questions or issues. I am also involved in reading and selecting abstracts that can be presented at annual meetings. Additionally, I have trained surgical residents research in the Department of Surgery since my I was first recruited in 2003. A number of residents have devoted 2 years of full time research training without clinical responsibilities in my laboratory. All residents have presented their research work at National and International meetings, and published in high-impact peer reviewed journals (average of 2 manuscripts/resident).

- Resident Alex Ereso's poster was judged as a poster of distinction at the 2008 Endocrine meeting in San Francisco, and he was awarded a cash prize for this distinction. **Role:** Mentor
- Resident Eric Kubat was awarded the Kenneth P. Warren/ Pancreas Club Award for an Outstanding Resident Research Presentation at the American Gastroenterology Association meeting in May 2011. **Role:** Mentor
- Eric Kubat received the Excellence in Research Award by the American College of Surgeons for the category of Alimentary Tract at the 2011 Surgical Forum held in October in San Francisco. **Role:** Mentor
- Eric Kubat awarded the "Runner Up" award at the 2012 Resident's Research Day Symposium organized by the Department of Surgery, UCSF. **Role:** Mentor
- Resident Robert Bell awarded the "2013 Best Presentation" award at the 2013 Resident's Research Day Symposium organized by the Department of Surgery, UCSF. **Role:** Collaborator and co-mentor

- Postdoctoral Fellow Shilpi Mahajan was awarded the ASBMB 2014 Travel Award to present her work at the Annual EB/FASEB Meeting. **Role:** Mentor
- Postdoctoral Fellow Burcu Hasdemir's poster was short listed in the "Presidential Poster" Section at the Annual Endocrine Society's Meeting in 2015. **Role:** Mentor
- Postdoctoral Fellow Burcu Hasdemir's poster was the finalist for the 1st UCSF "Postdoc Slam" held in 2016. **Role:** Mentor
- Postdoctoral Fellow Shinichiro Hagiwara's poster was selected as a "Poster of Distinction" at the Annual AGA/DDW Meeting in 2017. **Role:** Mentor
- Postdoctoral Fellow Shinichiro Hagiwara's poster was selected as a "Poster of Distinction" at the Annual AGA/DDW Meeting in 2018. **Role:** Mentor

BIOMEDICAL SCIENCES GRADUATE (BMS) PROGRAM

As a faculty member of the BMS program at UCSF, graduate students can do their rotation in my laboratory. I am also involved in coaching with journal club presentations. Our lab participates in annual BMS retreat where students, postdoctoral fellows and faculty get to interact and learn about activities of all other students.

HIGH SCHOOL AND UNDERGRADUATE STUDENTS

- Mentored high school students that are part of the Science & Health Education Partnership (SEP) at UCSF.
- FASEB/Minority Access Program Students
- Obtained FASEB/ENDO Summer Fellowship (2013) for Paris Barkan, a Medical Student.

FORMER AND CURRENT TRAINEES

The following table provides the names of former and current trainees and includes their current positions when known.

Name	Years in Laboratory	Current Position (if known)
<i>Medical Students</i>		
Victoria Lyo	2010	Surgery Resident, UCSF
Paris Barkan	2013	4 th year student, Jefferson Medical College, PA
<i>UCSF Residents</i>		
Alan Pao, MD	2002-2003	Associate Professor, Department of Medicine, Stanford, CA
Elizabeth Wick, MD	2003-2005	Associate Professor, Department of Surgery, UCSF
Matthew Clifton, MD	2004-2006	Associate Professor, Emory University
Jen Chang, MD	2005-2007	Anesthesia Fellow, Cincinnati Hospital, OH
Alexander Ereso, MD	2007-2008	Plastic Surgeon, El Camino and Sequoia Hospitals
Elizabeth Cureton, MD	2007-2009	Breast Surgeon, Kaiser Permanente, San Francisco
Eric Kubat, MD	2010-2012	Surgeon, Mills Peninsula Hospital, Burlingame,
Robert Bell, MD	2013	Surgery Resident, East Bay Program, UCSF
<i>Postdoctoral Fellows</i>		
Kevin Dawson, MD	2000-2002	Chief Information Officer, Howard University Hospital, Washington DC
Srividya Sundaresan, PhD	2008	Scientific writer, Stanford University
Mary Adedoyin, PhD	2010-2011	Researcher, UCSD

Timothy Kaan, PhD	2010-2011	Medical Science Liaison, Janssen Pharma, Toronto, Canada
Shilpi Mahajan, PhD	2010-2014	
Kerui Gong, MD, PhD	2013-2016	Scientist, Genentech, CA.
Esha Kaushal, PhD	2016-2017	
Shinichiro Hagiwara, MD	2016- 2018	Assistant Professor, Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Medical Center and Research Institute for Maternal and Child Health,
Burcu Hasdemir, PhD	2014- 2018	Scientist, Twist Biosciences
Current Trainees		
Other Trainees (FASEB-MAP- minority access program and FLARE)		
Stanley Andrisse, PhD	2014-2016	Assistant Professor, Howard University
Antentor O. Hinton, Jr.	2014-2015	Postdoctoral Fellow, University of Iowa
Mentor for Faculty		
SuJean Choi, PhD	2001-2006	Professor, Marquette University
Gregory Victorino, MD	2007-2009	Chair & Professor of Surgery, UCSF-East Bay
Alan Pao, MD	2009-2011	Associate Professor, Stanford
Eileen F Grady, PhD	2010- 2012	Retired, Associate Professor, UCSF
Blake Gurfein, PhD	2013- 2015	Chief Scientific Officer, Tivic Health
Sumei Liu, PhD	2017 (4-month sabbatical)	Professor, University of Wisconsin-La Crosse, WI
Junior & mid-career faculty	2017-current	
Summer Students/ International Graduate Students		
Sirisha Idumalla, MS	2003	
Humera Fakhruddin, MS	2004	Teacher, Peel District School, Canada.
Masako Le	2009	Medical Student, Poland
Giovanni Villa	2010	Researcher in Pharmaceutical company, Italy.
Giulia Magni	2013	Postdoctoral fellow, Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy.
Kanokporn Sathitsamphan	2015	Undergraduate Student, UC Berkeley Extn.
High school and Undergraduate Students		
Julia Hoy-Brooks	2005-2008	Dentist, APLA Health & Wellness
Shivali Mathur	2010	Software Engineer, Life360
Tammy Ying	2012	
Helen Chen	2012	Science & Health Education Partnership (SEP) at UCSF; Junior, Thurgood Marshall Academic High School, San Francisco
Keshav Kundassery	2016	Senior, Mission San Jose High School, Fremont, CA. (Sophomore at Vanderbilt University).
Dina Shakran	2017-2018	Applying to Medical School
Alyssa Cho	2018	Sophomore, Wellesley College
Lahari Vuppaladhiam	2019-2021	Freshman, Washington University, St. Louis
Cameron Eshan	2019	Senior, University High school, San Francisco
Meghana Akkati	2019	Junior, Irvington High School, Fremont
Adithi Gandhi	2021	Senior, Northwestern University, Illinois

UNIVERSITY AND PUBLIC SERVICE

SYSTEM-WIDE

UCSF representative on Committee on Planning and Budget, 2018-2019

INSTITUTIONAL/SCIENTIFIC SOCIETIES

- **Vice Chair, Institutional Animal Care and Use Committee (IACUC), UCSF, (2020-22, Member since 2012):** Members of this committee are responsible for the entire animal welfare and research program at UCSF. Members meet every two weeks and Vice Chair also runs the policy meeting in addition.
- **Vice Chair (2018-2019), Academic Planning and Budget Committee, UCSF, 2017-2019.** Members of APB are charged with interfacing with senior administration to assess campus-wide planning and budgetary decisions impacting the academic mission of UCSF. Members confer with and advise the Senate, the Chancellor and administrative officers. Members meet once a month.
- **Co-Chair, IACUC: Animal Numbers Justification Task Force:** December 2017-Present. The main goal is to improve and streamline numbers justification in animal protocols.
- **Member, UCSF Dean's Difference Matters Initiative, Action Group 1 (2016-2018).** This action group is charged with developing an informed and committed leadership, educated to oversee a culture of inclusion and to achieve greater diversity.
- **Chair, Scientific Statement Subcommittee (2021-2023).** The committee was established to position the Endocrine Society as a thought leader on critical public health and emerging scientific issues and to raise awareness of the central role of endocrinology in science and medicine. The members develop and recommend potential statement topics for the Council to review.
- **Member, Breakthroughs in Biosciences Subcommittee (2013-19),** Federation of American Societies for Experimental Biology (FASEB). This committee is charged with choosing timely topics that demonstrate the critical link between basic research in the biomedical sciences and the improvement in the quality of medical care available to our citizens. <http://www.faseb.org/Policy-and-Government-Affairs/Publications/Breakthroughs-and-Horizons-in-Bioscience/Breakthroughs-and-Horizons-Subcommittee.aspx#sthash.QEGa7tDp.dpbs>
- **Member, Health Disparities Inter-Committee Work Group and Health Disparities Summit Planning Committee,** The Endo Society. A summit was planned and held in March 2013 on "Reducing Health Disparities and Improving Care".
- **Member, Research Affairs Core Committee (RACC), The Endocrine Society, 2012-2016.** Members of this committee are charged with promoting, supporting and participating in the Society's advocacy efforts for increasing funding in biomedical research and other issues important to basic and clinical scientists. In addition, the members are charged with recommending strategic partnerships to the Council that will increase the Society's profile in the broader scientific community.
- **Ad-hoc Member, Institutional Animal Care and Use Committee (IACUC), UCSF, 2007-2008.** This ad-hoc committee was responsible for coming up with strategies to improve and expedite the annual and bi-annual review process for animal protocols, and improve online application process in RIO by providing more drop-down options for standardized protocols.
- **Member, Minority Affairs Committee, The Endocrine Society, 2006-2012.** This committee is involved in developing strategies to increase presence of minorities in the area of Endocrine research. Along with FASEB, this committee administers summer training at various Universities for minority students (FASEB-MARC Program). I am involved in organizing student's day programs at the annual meetings and poster judging. I also review their summer applications for FASEB/MARC and NIGMS-funded MAP programs.
- **Member, Resident Research Committee, Department of Surgery, UCSF, 2003 – 2014.**

GABRIEL VOROBIOF, MB BCh.
CURRICULUM VITAE
Last updated: April 2021

PERSONAL HISTORY:

650 Charles E. Young Dr. South,
A2-237 CHS
Los Angeles, CA 90095

EDUCATION:

1997	MBBCh, (Bachelor of Medicine and Bachelor of Surgery) University of the Witwatersrand, Johannesburg, South Africa
01/98-12/98	Intern in Medicine and Surgery, Baragwanath Hospital, University of the Witwatersrand
01/99-12/99	Senior House Officer in Medicine & Pediatrics, Groote Schuur Hospital, University of Cape Town
2001-2002	Intern in Internal Medicine, Mount Sinai School of Medicine, Maimonides Medical Center, Brooklyn, NY
2002-2004	Resident in Internal Medicine, Columbia University College of Physicians & Surgeons, St. Luke's Roosevelt Hospital Center, New York, NY
2004-2007	Fellow in Cardiovascular Medicine, University of Rochester Medical Center, University of Rochester School of Medicine, Rochester, NY
2007-2008	Clinical Fellow in Advanced Multi-modality Cardiovascular Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

LICENSURE

2004-2007	New York State Registered Physician
2007-2008	Massachusetts Registered Physician
2008-2009	Connecticut Registered Physician
2009-present	California Registered Physician

BOARD CERTIFICATION

2004	Board Certified in Internal Medicine (ABIM)
2007	Board Certified in Cardiovascular Medicine (ABIM)
2007	Vascular Ultrasound COCATS level II, certified
2007	Echocardiography - COCATS Level III
2008	Board Certified in Echocardiography (NBE)
2008	Board Certified Nuclear Cardiology (CBNC)
2008	Cardiac MRI - COCATS Level III
2008	Myocardial Perfusion Imaging SPECT & PET - COCATS Level III
2008	Coronary CTA - COCATS Level III
2008	Vascular CTA & MRA - COCATS Level
2009-present	Advanced Cardiac Life Support (ACLS)
2020	Recertification Board Certified in Cardiovascular Medicine (ABIM)
2020	Recertification Board Certified Nuclear Cardiology (CBNC)

PROFESSIONAL EXPERIENCE

2016-present	Health Sciences Associate Clinical Professor of Medicine, (Cardiology), David Geffen School of Medicine at UCLA
2012-present	Director, Non-Invasive Cardiology Laboratories, Ronald Reagan UCLA Medical Center, UCLA Health
2012-2016	Health Sciences Assistant Clinical Professor of Medicine (Cardiology), David Geffen School of Medicine at UCLA
2009-2012	Director, Non-Invasive Cardiology and Cardiac Imaging, Memorial Heart & Vascular Institute
2009-2012	Health Sciences Assistant Clinical Professor of Medicine (Cardiology), University of California Irvine, Irvine, CA
2009-2012	Staff Cardiologist, Departments of Cardiology & Radiology, Long Beach Memorial Medical Center, Long Beach, CA
2008-2009	Assistant Professor of Medicine (Cardiology) & Diagnostic Radiology, Yale University School of Medicine, New Haven, CT
07/07-06/08	Cardiology Adjunct Faculty, Brockton Hospital, Brockton, MA
07/04-06/07	Hospitalist in Internal Medicine, Geneva General Hospital, Geneva, NY

- 07/04-06/07 Instructor, University of Rochester Medical Center, University of Rochester School of Medicine, Rochester, NY
- 07/02-06/04 Instructor, Columbia University College of Physicians & Surgeons, New York, NY

PROFESSIONAL ACTIVITIES

Major Committee Assignments:

LOCAL

- 2009-2012 Member, Advisory Board, Memorial Heart & Vascular Institute
- 2009-2012 Clinical Research Committee, Memorial Heart & Vascular Institute
- 2011-2012 Chairman, Executive Committee, Memorial Heart & Vascular Institute
- 2012-present Board of Directors, Los Angeles Society of Echocardiography

REGIONAL

- 2004-2007 International Medical Graduate Committee, Medical Society of the State of New York

NATIONAL

- 2005-2007 Founding Member, ACC Fellows in Training Committee, American College of Cardiology
- 2005-2007 AHA Fellows' Society of Greater New York, American Heart Association

Professional Societies:

- 2001-2004 American College of Physicians, Member
- 2001-2007 American Medical Association, Member
- 2004-2007 American Heart Association, Member
- 2004-2007 American College of Cardiology, Member
- 2007-present Society of Cardiovascular Magnetic Resonance, Member
- 2008-present Society of Cardiovascular Computed Tomography, Member
- 2008-present American Society of Echocardiography, Licensed Member
- 2012-present Los Angeles Society of Echocardiography

Community Service Related to Professional Work:

- 1999-2000 Senior House Officer - Community Service, Groote Schuur Hospital, University of Cape Town, South Africa

Community Service:

10/1/13 – 2018 Advisory Board Member, Ilan Ramon Day School, Agoura CA
2014 – Present Chabad Mench Club President

Activities in Scholarly And Professional Societies:

2013 – Present American College of Cardiology: Cardiovascular Imaging in 2020
Committee

Editorial Boards:

2007-present Reviewer, Clinical Cardiology
2007-present Reviewer, International Journal of Cardiology
2007-present Reviewer, International Journal of Cardiovascular Imaging
2007-present Reviewer, Echocardiography
2008-present Reviewer, American Journal of Cardiology
2010-present Section Editor, iReviews, Journal of the American College of
Cardiology (JACC) Imaging

Other Professional Activities:

2013 – 2018 Co-Founder and Chief Medical Officer, PadInMotion.

Consulting:

2009 – Present Lantheus Medical Imaging - consultant
2011 – 2018 Maximus Federal Services - medical insurance reviews

HONORS & SPECIAL AWARDS

2004 Henry I. Russek Award, New York Cardiovascular Symposium,
American College of Cardiology
2005 Second place, H.J.C. Swan Memorial Prize for Medical Writing,
Cardiology Journal, Basel, Switzerland
2006 Winner, Sable Foundation Grant for Cardiovascular Research, U. Of
Rochester School of Medicine and Dentistry
2006 Scripps Clinic Interventional Cardiology Fellowship Award,
Scripps Clinic, Sand Diego, CA
2006 Finalist, Northwestern University Young Cardiovascular Forum,
Northwestern U. Medical School
2006 Finalist, Duke Clinical Research Institute Abstract Contest, Duke
University

2006-2007	Chief Fellow in Cardiovascular Medicine, U. Of Rochester School of Medicine and Dentistry
2007	ACCF Bristol-Myers Squibb Research Award, American College of Cardiology Foundation
2007	Star Award of Excellence, U. Of Rochester School Of Medicine And Dentistry
2012-2013	UCLA Faculty Award – Recognition of Outstanding Accomplishments in Fellow Teaching

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED

1. Sable Foundation Award, “Tissue Factor, Aspirin and Clopidogrel Resistance in Acute Stent Thrombosis”, \$25,000, 2006-2007, PI: Vorobiof, G.
2. Gilead Sciences, Inc. “Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy.” \$209,350. 2011-2012. PI: Vorobiof, G.

(Non-Funded) Activities:

2004-2007	Co-Principal Investigator. Comparative follow-up study for patients with Cordis Symmetry Aortic Connector Device in Coronary Artery Bypass Grafting Surgery
2005-2007	Investigator. Inhibiting BARK function in vivo to ameliorate cardiac dysfunction
2006-2007	Investigator, University of Rochester. DORADO Trial (Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension)
2006-2007	Co-Principal Investigator. Strain Rate Imaging Predicts Subclinical Cardiac Dysfunction in Patients Receiving CHOP Chemotherapy
2007-2010	Co-Principal Investigator. Comparison of Plaque Morphology in ST elevation Myocardial Infarction and Stable Coronary Disease by Virtual Histology Intravascular Ultrasound (VH-IVUS)
2009-2011	Principal Investigator, DETERMINE Trial (DEfibrillators To REduce Risk by Magnetic ResoNance Imaging Evaluation)
2009-2012	Principal Investigator, COMPASS Trial (Coronary Obstruction Detection by Personalized Gene Expression)

2009-2014	Principal Investigator, PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain)
2011-2012	Three-Dimensional Echocardiographic Comparison of Mitral Valve Ring Geometry Before and After Annuloplasty: Predictors of Durability and Stability
2011-2012	Low-Dose Radiation Pulmonary CT Angiography Model Using Prospective ECG or Peripheral Pulse Triggering
2011-2012	Comprehensive Right Heart and Pulmonary Artery Imaging Using a Modified Dual Injection Computed Tomography Pulmonary Angiography Technique
2011-2012	A Novel Model for Cardiac Segmentation in Cardiac Imaging: The 12LV + 3RV Mercator Plot to Quantify Regional Myocardial Ischemia and Infarction
2011-2013	Early Evaluation of Clinical and Hemodynamic Performance of the Trifecta Aortic Valve Tissue Prosthesis
2014-2018	Site Principal Investigator for national ISCHEMIA Trial, funded by National Heart, Lung & Blood Institute (NHLBI), NIH.

LECTURES AND PRESENTATIONS

1. Acute Myocarditis by Cardiac MRI; Brigham & Women's
Boston, MA 5/21/08
2. Physiology of the Endothelium; Bridgeport Hospital
Bridgeport, CT 10/23/08
3. Imaging of Non-Ischemic Cardiomyopathy; St. Mary's Hospital
Waterbury, CT 10/31/08
4. How to Integrate Cardiac MRI into Practice; St. Mary's Hospital
Waterbury, CT 11/4/08
5. Using Cardiac MRI for Electrophysiology I; Yale University
New Haven, CT 12/10/08
6. Multimodality Cardiac Imaging; Yale University
New Haven, CT 1/16/09
7. Cardiac MRI in Myocardial Rejection; Yale University
New Haven, CT 1/23/09
8. Using Cardiac MRI for Electrophysiology II; Yale University
New Haven, CT 2/5/09
9. Delayed Myocardial Enhancement; Yale University
New Haven, CT 2/9/09
10. When Should I be Using Cardiac CT?; St. Mary's Hospital
Waterbury, CT 2/11/09

11. Cardiac CT & MRI Cases; Yale University
New Haven, CT 2/12/09
12. Cardiac CT and MRI Clinical Cases; Yale University
New Haven, CT 3/5/09
13. Intro to Cardiac Imaging for Med Students; Yale University
New Haven, CT 3/9/09
14. 3 Dimensional Echocardiography; Norwalk Hospital
Norwalk, CT 3/11/09
15. Radiology Cardiac Case Conference; Yale University
New Haven, CT 4/6/09
16. Using T2W Imaging post Cardiac Transplant; Yale University
New Haven, CT 4/17/09
17. Cardiac Masses; Yale University
New Haven, CT 4/27/09
18. Cardiac CTA in Clinical Diagnosis of CAD; Yale University
New Haven, CT 5/26/09
19. Recent Cardiac CT & MRI Cases; Yale University
New Haven, CT 6/1/09
20. Introduction to CMR Protocols; Yale University
New Haven, CT 6/16/09
21. Non-Ischemic Cardiomyopathies by CMR; Yale University
New Haven, CT 6/23/09
22. Stress Cardiac MRI Perfusion ; Yale University
New Haven, CT 6/23/09
23. Coronary CTA for the Interventionalist; Yale University
New Haven, CT 6/24/09
24. Basics of Cardiac CTA; Yale University
New Haven, CT 7/10/09
25. Cardiac CT & MRI for the Radiologist I; Bridgeport Hospital
Bridgeport, CT 8/5/09
26. Introduction to Cardiac MRI for Fellows; Yale University
New Haven, CT 8/13/09
27. Cardiac CT & MRI for the Radiologist II; Bridgeport Hospital
Bridgeport, CT 8/21/09
28. Cardiac CT for UCI Fellows; UC Irvine
Irvine, CA 9/22/09
29. Multimodality Cardiovascular Imaging; Long Beach Memorial
Long Beach, CA 10/28/09
30. Cardiac CT: Current Role & Future Potential; UC Irvine
Irvine, CA 2/16/10
31. Cardiac CT in the Emergency Room; Long Beach Memorial
Long Beach, CA 3/10/10
32. Cardiac CT Artifacts; Long Beach Memorial
Long Beach, CA 5/19/10
33. Cardiac CT for Valvular Disease; Long Beach Memorial
Long Beach, CA 6/9/10

34. Multimodality Cardiac Imaging; Morningside Hospital
Johannesburg, SA 6/30/10
35. Cardiac Imaging in the USA; Johannesburg General
Johannesburg, SA 7/1/10
36. Cardiac MRI Fellows Bootcamp; UC Irvine
Irvine, CA 8/10/10
37. Contrast Echocardiography; Long Beach Memorial
Long Beach, CA 12/16/10
38. Preventive Cardiology; Temple Aliyah
West Hills, CA 2/1/11
39. Using Contrast Echocardiography; UC Irvine
Irvine, CA 3/29/11
40. Using CMR for Valvular Disease; Cedars Sinai
Beverly Hills, CA 5/16/11
41. Echocardiography vs CT/MRI for Valves; American Society of Echo
Montreal, QC 6/11/11
42. Advanced Imaging in Valvular Disease; San Pablo Institute
Lima, Peru 8/17/11
43. Applying Echo Guidelines in Valvular Dis; San Pablo Institute
Lima, Peru 8/18/11
44. Using Echo Contrast in Clinical Practice; Kaiser Riverside
Riverside, CA 8/30/11
45. Transesophageal Echocardiography; UC Irvine
Irvine, CA 10/9/11
46. Contrast Stress Echocardiography; Orange Coast Memorial
Fountain Valley, CA 10/12/11
47. Imaging for Ischemic Heart Disease; UCLA Monthly CCU
Los Angeles, CA 2012-2015
48. Interesting Clinical Cases; LA Society of Echo
VA Hospital 6/13/12
49. Introduction to Stress ECG; Dept. Nuclear Medicine
Los Angeles, CA 7/5/12
50. Using Cardiac MRI for Valve Assessment; Community Dinner Program
Beverly Hills, CA 8/7/12
51. Advances in Transcatheter Aortic Valve Rx; Dept. Medicine Grand Rounds
Los Angeles, CA 8/14/12
52. Introduction to TEE; Cardiothoracic Surgery
Los Angeles, CA 8/15/12
53. New SPECT Hardware including D-SPECT; Dept. Nuclear Medicine
Los Angeles, CA 9/21/12
54. Nuclear Cardiology Journal Club; Monthly
Los Angeles, CA 2012-2016
55. Assorted Cardiovascular Imaging topics; Monthly imaging conference
Los Angeles, CA 2012-2016
56. Methods for Assessing LVEF Poor Quality; Quarterly Echo Lab Meeting
Los Angeles, CA 4/6/13

57. Introduction to Echo Contrast ; Cardiology Fellows Conference
Los Angeles, CA 4/15/13
58. Cardiovascular CT for Fellows; UCLA
Los Angeles, CA 8/5/13
59. Cardiac MRI For Fellows; UCLA
Los Angeles, CA 9/9/13
60. Aortic Stenosis Paradoxus; Cardiology Grand Rounds
Los Angeles, CA 9/13/13
61. Strategies for Nuclear Cardiologists; Astellas Advisory Board
San Francisco, CA 10/11/13
62. Low Gradient Severe Aortic Stenosis; LA Society of Echo
Los Angeles, CA 10/17/13
63. Nuclear Cardiology Journal Club; Dept. Nuclear Medicine
Los Angeles, CA 12/5/13
64. TAVR: A New Era for AS; Community Memorial Hospital
Ventura, CA 12/6/13
65. Echocardiology IAC Lab Meeting Monthly
Los Angeles, CA 2013-2016
66. Detection of Ischemia 31P MR Spectroscopy; Community Dinner Meeting
Beverly Hills, CA 2/11/14
67. Cardiac Amyloidosis; Cardiology Case Conference
Los Angeles, CA 3/2/14
68. Dr. Anthony Koppula ; Fellows Graduation
Los Angeles, CA 6/4/14
69. Moderate to Severe Myocardial Ischemia; Cardiology Fellows Conference
Los Angeles, CA 6/25/14
70. ISCHEMIA Trial Introduction; Santa Monica Conference
Santa Monica, CA 7/31/14
71. Introduction to Mitral Valve Disease; Cardiology Fellows Conference
Los Angeles, CA 8/28/14
72. Acute Coronary Syndromes by CT/MRI; National Peruvian Cardiology
Lima, Peru 9/18/14
73. Lead aVR in Clinical Cardiology; National Peruvian Cardiology
Lima, Peru 9/18/14
74. Viability Testing: An Update ; National Peruvian Cardiology
Lima, Peru 9/19/14
75. Intermediate Coronary Assessment of Lesions; National Peruvian Cardiology
Lima, Peru 9/19/14
76. Aortic Stenosis Paradoxus; National Peruvian Cardiology
Lima, Peru 9/20/14
77. Chest Pain in Acute Aortic Syndromes; Aortic Center Symposium
Los Angeles, CA 11/7/14
78. Cardiac Tamponade; Internal Medicine Case Conference
Los Angeles 11/13/14
79. Introduction to Transesophageal Echo; Cardiology Fellows Conference
Los Angeles, CA 1/8/15

80. An Update on Mitral Regurgitation; LA Society of Echo
Los Angeles, CA 1/20/15
81. Detection & Management of Ischemia; Cardiology Grand Rounds
Los Angeles, CA 4/24/15
82. 3D Echocardiography: Uses & Directions; Cardiology Fellows Conference
Los Angeles, CA 4/29/15
83. Dr. Houman Khakpour; Cardiology Fellows Graduation
Los Angeles, CA 6/8/15
84. Myocardial Deformation & Strain; Cardiology Fellows Conference
Los Angeles, CA 6/26/15
85. Introduction to Cardiac MRI; Cardiology Fellows Conference
Los Angeles, CA 7/29/15
86. Dr. John Dinkler; Cardiology Fellows Graduation
Los Angeles, CA 6/16/16
87. Introduction to Cardiac MRI; Cardiology Fellows Conference
Los Angeles, CA - 7/28/16
88. Introduction to Nuclear Cardiology; Cardiology Fellows Conference
Los Angeles, CA - 8/11/16
89. Aortic stenosis paradoxus; LASE Lecture
Los Angeles, CA - 8/17/16
90. Nuclear cardiology journal discussion; Nuclear Cardiology Journal Club
Los Angeles, CA 1/5/17
91. Introduction to Nuclear Cardiology; Cardiology Fellows Conference
Los Angeles, CA 8/10/17
92. Introduction to Cardiac CT; Cardiology Fellows Conference
Los Angeles, CA 8/17/17
93. Introduction to Cardiac MR; Cardiology Fellows Conference;
Los Angeles, CA 8/24/17
94. Introduction to Cardiac MR; Cardiology Fellows Conference;
Los Angeles, CA 7/31/18
95. Introduction to Cardiac CT; Cardiology Fellows Conference
Los Angeles, CA 8/24/18
96. Introduction to Cardiac CT; Cardiology Fellows Conference
Los Angeles, CA 8/11/19
97. Introduction to Cardiac MR; Cardiology Fellows Conference;
Los Angeles, CA 8/18/19
98. Prosthetic Valve Assessment by Echo; Cardiology Fellows Conference;
Los Angeles, CA 1/16/20
99. Introduction to Cardiac CT; Cardiology Fellows Conference
Los Angeles, CA 8/25/20
100. Introduction to Cardiac MR; Cardiology Fellows Conference;
Los Angeles, CA 9/1/20
101. Prosthetic Valve Assessment by Echo; Cardiology Fellows Conference;
Los Angeles, CA 2/8/20
102. Interactive Echo Reading; Cardiology Fellows Conference
Los Angeles, CA 3/19/21

103. Interactive Echo Reading; Cardiology Fellows Conference
Los Angeles, CA 4/23/21
104. Introduction to Cardiac CT; Cardiology Fellows Conference
Los Angeles, CA 8/4/21
105. Introduction to Cardiac MR; Cardiology Fellows Conference;
Los Angeles, CA 8/11/21

PUBLICATIONS/BIBLIOGRAPHY

RESEARCH PAPERS

RESEARCH PAPERS (PEER REVIEWED)

A. RESEARCH PAPERS - PEER REVIEWED

1. Vorobiof DA, Sitas F, **Vorobiof G**. Breast cancer incidence in South Africa. *J Clin Oncol*. 2001;19(18 Suppl):125S-127S.
2. **Vorobiof G**, Hariparsad G, Freinkel W, Said H, Vorobiof DA. Primary osteosarcoma of the breast: a case report. *Breast J*. 2003;9(3):231-3.
3. Hall B, Jeevanantham V, Simon R, Filippone J, **Vorobiof G**, Daubert J. Variation in left atrial transmural wall thickness at sites commonly targeted for ablation of atrial fibrillation. *J Interv Card Electrophysiol*. 2006;17(2):127-32.
4. **Vorobiof G**, Goldenberg I, Moss AJ, Zareba W, McNitt S. Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). *Am J Cardiol*. 2006; 98(10):1383-6.
5. **Vorobiof G**, Kroening D, Hall B, Brugada R, Huang D. Brugada Syndrome with Marked Conduction Disease - Dual Implications of a Novel SCN5A Mutation. *Pacing & Clinical Electrophysiology*. 2008;31(5):630-4.
6. Rybicki FJ, Otero HJ, Steigner ML, **Vorobiof G**, Nallamshetty L, Mitsouras D, Ersoy H, Mather RT, Judy PF, Cai T, Coyner K, Schultz K, Whitmore AG, Di Carli MF. Initial evaluation of coronary images from 320-detector row computed tomography. *The International Journal of Cardiovascular Imaging*. 2008;24(5):535-46.
7. Kwong RY, Sattar H, Wu H, **Vorobiof G**, Gandla V, Steel K, Siu S, Brown KA. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. *Circulation*. 2008;118(10):1011-20.
8. Casey L; Nwakanma F; **Vorobiof G**; Dunaevsky O; Smrcka AV; Blaxall BC. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. *Circ Res*. 2010 Aug 20;107(4):532-9.
9. Odigie E, Okon E, Dodson J, **Vorobiof G**. Stress-induced Cardiomyopathy Complicating Severe Babesiosis. *Cardiol J*. 2011;18(1):83-6.
10. Saremi F, **Vorobiof G**. Aberrant Penetrating Posterior Descending Artery From Proximal Right Coronary Artery. *Clinical Anatomy* 2011 Nov;24(8):956-8

11. Suh WM, Berdjis F, Rizi HR, **Vorobiof G**. Multimodality evaluation and transcatheter closure of a muscular ventricular septal defect. *J Am Coll Cardiol*. 2011 Nov 1;58(19):e35.
12. Saremi F, **Vorobiof G**. Coronary Artery Ostial Atresia: Diagnosis and Evaluation of the Conotruncal Anastomotic Collateral Rings Using MDCT. *JACC Imaging* 2011;4;1320-1323.
13. Barseghian A, Bethencourt DM, **Vorobiof G**. Dual anterior and posterior mitral valve clefts evaluated by 3-dimensional echocardiography with robot-assisted surgical correction. *J Thorac Cardiovasc Surg*. 2012 Feb;143(2):503-4.
14. Buttan A, **Vorobiof G**. Multi-modality Imaging in the Diagnosis of Coexisting Left Atrial Myxoma and Aortic Valve Papillary Fibroelastoma. *Circulation*. 2012 Jun 12;125(23):e1003-5.
15. Saremi F, Vojdani E, **Vorobiof G**, Shavelle D, Wilcox A, Madanipour S, Lundquist R. Right to left shunting through communications between the left superior intercostal vein tributaries and the left atrium: A potential cause of paradoxical embolism. *Int J Cardiol*. 2012 Aug 7.
16. Catton K, Blurton D, **Vorobiof G**, Setty SP. Bilateral superior vena cavae with anomalous criss-cross atrial drainage. *Pediatr Cardiol*. 2013 Mar;34(3):769-70.
17. Bhutani S, Tobis J, Gevorgyan R, Sinha A, Suh W, Honda HM, **Vorobiof G**, Packard RR, Steadman R, Wray C, Busuttill R, Tseng CH. Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. *Am J Cardiol*. 2013 Apr 1;111(7):1057-61.
18. Suh WM, **Vorobiof G**, Shemin RJ, Kwon MH, Fusari M, Tobis JM. Treating aortic stenosis and mitral regurgitation with 1 transcatheter heart valve: 2 birds with 1 stone. *J Am Coll Cardiol*. 2013 Jun 18;61(24):e349.
19. Yadlapati A, Diep J, Barnes M, Grogan T, Bethencourt DM, **Vorobiof G**. Comprehensive hemodynamic comparison and frequency of patient-prosthesis mismatch between the St. Jude Medical Trifecta and Epic Bioprosthetic aortic valves. *J Am Soc Echocardiogr*. 2014 Jun;27(6):581-9.
20. Yadlapati A, Diep J, Barnes MB, Grogan T, Bethencourt DM, **Vorobiof G**. Comprehensive Hemodynamic Performance and Frequency of Patient Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve. *Journal of Heart Valve Disease* 2014 Jul;23(4):516.
21. Yadlapati A, Diep J, Barnes MJ, Grogan T, Bethencourt DM, **Vorobiof G**. Comprehensive hemodynamic performance and frequency of patient-prosthesis mismatch

- of the St. Jude Medical Trifecta bioprosthetic aortic valve. *J Heart Valve Dis.* 2014 Jul; 23(4):516-23.
22. Milin AC, **Vorobiof G**, Aksoy O, Ardehali R. Insights into aortic sclerosis and its relationship with coronary artery disease. *J Am Heart Assoc.* 2014 Sep 5;3(5):e001111.
 23. Lluri G, Aboulhosn JA, Moriarty JM, Finn JP, Ruehm SG, Budoff MJ, **Vorobiof G**, Yang EH. Applications of cardiac CT in the tetralogy of Fallot patient. *JACC Cardiovasc Imaging.* 2014 Dec;7(12):1276-9.
 24. Xia VW, Worapot A, Huang S, Dhillon A, Gudzenko V, Backon A, Agopian VG, Aksoy O, **Vorobiof G**, Busuttil RW, Steadman RH. Postoperative atrial fibrillation in liver transplantation. *Am J Transplant.* 2015 Mar;15(3):687-94.
 25. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL; PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. **Vorobiof G** (listed as official collaborator). *N Engl J Med.* 2015 Apr 2; 372(14):1291-300.
 26. Moriarty J, Harris TJ, **Vorobiof G**, Kwon M, Aboulhosn J. Direct Percutaneous Repair of Left Ventricular Pseudoaneurysm via Transthoracic Deployment of a Ventricular Septal Defect Closure Device. *Tex Heart Inst J.* 2015 Aug 1;42(4):362-6.
 27. Ajijola OA, Romero J, **Vorobiof G**, Suh WM, Shivkumar K, Tung R. Hyper-response to cardiac resynchronization with permanent His bundle pacing: Is parahisian pacing sufficient? *HeartRhythm Case Rep.* 2015 Nov;1(6):429-433.
 28. Garg, V, Ho JK, **Vorobiof G**. Changes in myocardial deformation after transcatheter and surgical aortic valve replacement. *Echocardiography.* 2017 Apr;34(4):603-613. doi: 10.1111/echo.13485. Epub 2017 Mar 23.
 29. Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, **Vorobiof G**. Cardiac Amyloidosis: Diagnosis and Treatment Strategies. *Curr Oncol Rep.* 2017 Jul;19(7):46. doi: 10.1007/s11912-017-0607-4.
 30. Fischer M, Salehi A, Sopher MJ, **Vorobiof G**, Shemin RJ. Ruptured Papillary Muscles After Chordae-Preserving Bioprosthetic Mitral Valve Replacement. *Ann Thorac Surg.* 2017 Sep;104(3):e243-e245. doi: 10.1016/j.athoracsur.2017.03.007.
 31. Lluri G, Renella P, Finn JP, **Vorobiof G**, Aboulhosn J, Deb A. Prognostic Significance of Left Ventricular Fibrosis in Patients With Congenital Bicuspid Aortic Valve. *Am J Cardiol.* 2017 Oct 1;120(7):1176-1179. doi: 10.1016/j.amjcard.2017.06.060. Epub 2017 Jul 14.

32. Asthana N, Mantha A, Yang EH, Suh W, Aksoy O, Shemin RJ, **Vorobiof G**, Benharash P. Myocardial functional changes in transfemoral versus transapical aortic valve replacement. *J Surg Res.* 2018 Jan;221:304-310. doi: 10.1016/j.jss.2017.08.036. Epub 2017 Oct 7.
33. Ershoff BD, Gordin JS, **Vorobiof G**, Elashoff D, Steadman RH, Scovotti JC, Wray CL. Improving the Prediction of Mortality in the High Model for End-Stage Liver Disease Score Liver Transplant Recipient: A Role for the Left Atrial Volume Index. *Transplant Proc.* 2018 Jun;50(5):1407-1412. doi: 10.1016/j.transproceed.2018.03.017.
34. Gordin, J., Eyvazian, V., Agopian, V., Honda, H., Aksoy, O., Busuttil, R., **Vorobiof, G.** Incidence, Predictors, and Outcomes of New-Onset Left Ventricular Systolic Dysfunction After Orthotopic Liver Transplantation. *J Card Fail.* 2019 Mar;25(3):166-172. doi: 10.1016/j.cardfail.2018.10.013. Epub 2018 Nov 6.
35. West BH, Low CG, Bista BB, Yang EH, **Vorobiof G**, Busuttil RW, Budoff MJ, Elashoff D, Tobis JM, Honda HM. Significance of Coronary Artery Calcium Found on Non-Electrocardiogram-Gated Computed Tomography During Preoperative Evaluation for Liver Transplant. *Am J Cardiol.* 2019 Jul 15;124(2):278-284. doi: 10.1016/j.amjcard.2019.04.025. Epub 2019 Apr 23.
36. Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE Jr, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB; **ISCHEMIA Research Group.** Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. *N Engl J Med.* 2020 Apr 9;382(15):1408-1419.
37. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; **ISCHEMIA Research Group.** Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med.* 2020 Apr 9;382(15):1395-1407.

B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS)

None

C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)

None

RESEARCH PAPERS (NON-PEER REVIEWED)

D. RESEARCH PAPERS - NON-PEER REVIEWED

1. **Vorobiof G.** Introducing the Online Fellows in Training Forum. ACC Cardiology Newsletter. 2006.2.

E. RESEARCH PAPERS - NON-PEER REVIEWED (IN PRESS)

None

F. RESEARCH PAPERS - NON-PEER REVIEWED (SUBMITTED)

None

CHAPTERS

1. Conrad Fischer, **Gabriel Vorobiof** (Contributor). Conrad Fischer's Internal Medicine Question Book. International Medical publishing; 2005.
2. **Vorobiof G**, Di Carli MF. Hybrid PET/CT and SPECT/CT Imaging - Cardiac Applications. Hybrid PET/CT and SPECT/CT Imaging (Editors: Dominique Delbeke and Ora Israel). 2008
3. Tzemos N, **Vorobiof G**, Kwong RY. Non-Ischemic Cardiomyopathy. In: Braunwald's Atlas of Cardiovascular Medicine- Cardiac Magnetic Resonance. 2009.
4. **Vorobiof G**, Akhondi A. 3 Dimensional Echocardiography. In: Tips & Tricks for the Echo Board Exam. 2013.
5. **Vorobiof G**, Lepor NE, Doyle M, Kim HW, Pohost GM. Cardiovascular Magnetic Resonance and Multidetector Computed Tomography. C. Rosendorff (ed.), *Essential Cardiology*, Springer Science+Business Media New York. 2013.
6. **Vorobiof G**. 3 Dimensional Tranthoracic and Transesophageal Echocardiography for the Boards. Editor: Vincent Sorrell, University of Kentucky. Lippincott Williams & Wilkins. E1 Edition. June 26, 2014.

LETTERS TO THE EDITOR

1. **Vorobiof G**, Kadiev S. Evaluation of right ventricular size on computed tomography: unreliable at best. American Journal of Medicine. 2008;121(8):e15.
2. **Vorobiof G**. Do conflicts of interest really matter or does no one read the fine print anyway? Journal of the American College of Cardiology. 2008;51(19):1911.
3. **Vorobiof G**. Coronary Angiography by 64-row CT. N Engl J Med. 2009;360(19):2028-9.
4. **Vorobiof G**, Vorobiof DA. Apologising for Nazi Medicine: Too little too late. Lancet. 2012 Oct 27;380(9852):1472.

REVIEWS

1. **Vorobiof G.** An evidence based review of popular diets. ACC Cardiology Newsletter. 2005;1(5).
2. **Vorobiof G,** Blaxall BC, Bisognano JD. The Future of Endothelin Receptor Antagonism as Treatment for Systemic Hypertension. Current Hypertension Reports. 2006;8(1):35-44.
3. **Vorobiof G,** Achenbach S, Narula J. Minimizing Radiation Dose for Coronary CT angiography. Cardiol Clin. 2012 Feb;30(1):9-17.
4. **Vorobiof G,** Silverstein C. Imaging for Cardiotoxicity in cancer patients-early detection and follow up. South African Heart Journal 2012.
5. Evaluation of valvular disease by cardiac computed tomography assessment. Buttan AK, Yang EH, Budoff MJ, **Vorobiof G.** J Cardiovasc Comput Tomogr. 2012 Nov-Dec;6(6):381-92.
6. Insights into aortic sclerosis and its relationship with coronary artery disease. Milin AC, **Vorobiof G,** Aksoy O, Ardehali R. J Am Heart Assoc. 2014 Sep 5;3(5):e001111.
7. Lee E, Ha E, Yang EH, **Vorobiof G.** Diagnosis and Management of Valvular Heart Disease. Hosp Med Clin (2014) e305–e333.
8. Wickramasinghe CD, Nguyen KL, Watson KE, **Vorobiof G,** Yang EH. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncol. 2016 Mar;12(6):855-70.
9. Garg V, **Vorobiof G.** Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure. Curr Oncol Rep. 2016 Aug;18(8):52.
10. Garg V, Ho JK, **Vorobiof G.** Changes in myocardial deformation after transcatheter and surgical aortic valve replacement. Echocardiography. 2017 Apr;34(4):603-613.
11. Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, **Vorobiof G.** Cardiac Amyloidosis: Diagnosis and Treatment Strategies. Curr Oncol Rep. 2017 Jul;19(7):46.

EDITORIALS

1. **Vorobiof G,** Rocco T. The questions remains: Is it more beneficial for patients with AF to undergo rate control or rhythm control? Cardiology Journal. 2006;13(4):272-4.

2. **Vorobiof G**, Schwartz RG. Encouragement to optimize medical therapy for coronary heart disease. *Cardiology Journal*. 2007;14(3):217-9.
3. **Vorobiof G**, Ellestad M. Lead aVR: Dead or Simply Forgotten? *JACC Cardiovasc Imaging*. 2011 Feb;4(2):187-90.
4. **Vorobiof G**, Chandrashekhar Y, Narula J. Intermediate lesions: Retrieving black from shades of gray. *JACC Cardiovasc Interv*. 2011 Feb;4(2):209-12.

PAPERS IN PREPARATION (RESEARCH COMPLETED)

None

ABSTRACTS

1. Vorobiof DA, Ostria DE, **Vorobiof G**, Chasen MR. Outcome of high risk melanoma patients treated with low dose interferon alpha 2b. 1999.
2. Vorobiof DA, Chasen MR, **Vorobiof G**, Rosengarten A. Long term outcome of malignant melanoma patients treated with low dose adjuvant interferon alpha 2b . 2001.
3. **Vorobiof G**, Greenberg H. Hyperthyroid Induced Coronary Vasospasm. American College of Physicians. 2004.
4. **Vorobiof G**, Goldenberg I, Moss AJ, Ryan D, McNitt S, Eberly SW, Zareba W. A Common Apolipoprotein A1 Polymorphism Predicts Racial Differences in Cardiovascular Outcomes. *Circulation*. 2006;114(II):56.
5. **Vorobiof G**, Goldenberg I, Moss AJM, Zareba W, McNitt S. Racial Differences in the Effectiveness of the Implantable Cardioverter Defibrillator in MADIT-II. American College of Cardiology_s Fellow_s Clinical Research Conference 2006. 2006.
6. Yoder SR, Hong J, **Vorobiof G**, Kudes MA, Anolik J, Schwartz RG. Do Patients with Systemic Lupus Erythematosus have Higher Risk ECG-Gated Myocardial Perfusion and Function Scintigraphic Scans? American Society Of Nuclear Cardiology 2006, Montreal, Canada . 2006.
7. **Vorobiof G**, Minor S, Aktas MK, McNitt S, Rocco TA, Hall B, Huang DT, Wyse DG, Waldo AL, Daubert JP. Analysis of Outcomes Based on Left Ventricular Ejection Fraction in the AFFIRM Study . *Circulation*. 2007;116(II):438.
8. Liam Casey; Frances Nwakanma; **Gabriel Vorobiof**; Olga Dunaevsky; Alan V Smrcka; Burns C Blaxall. Small Molecule Targeting Of g_ Reduces _-adrenergic

Receptor Desensitization And Normalizes Cardiac Dysfunction In An Acute Heart Failure Model. *Circulation*. 2007;116(II):258.

9. **Vorobiof G**, Aktas MK, Minor S, Ling FS. In Vivo Virtual-Histology Intravascular Ultrasound Characteristics in Patients with Acute ST-Elevation Myocardial Infarction and Stable Coronary Artery Disease. *American Journal of Cardiology*. 2007;100(Suppl 8A):139L.
10. Akram K, Thomas D, Nallamshetty K, **Vorobiof G**, Di Carli M, Dorbala S. Comparison of Inter- reader Reproducibility between Myocardial Perfusion Imaging with PET/CT and SPECT. *American Society of Nuclear Cardiology Annual Scientific Sessions*. 2008.
11. **Vorobiof G**, Pedulla A, Minor S, Cove CJ. Long Term Clinical Outcomes of the Symmetry Aortic Connector Anastomotic Device in Coronary Artery Bypass Surgery. *Journal of the American College of Cardiology*. 2008.
12. Srivastava AV, El Fakhri G, Abi Hatem N, Mitiku T, Khanna P, Levine E, Liu Yi-Hwa, **Vorobiof G**, Lee F, Sinusas A. Quantification of Myocardial Blood Flow Reserve in Cardiac Transplant Rejection Using 82-Rb Positron Emission Tomography. *International Conference of Nuclear Cardiology, Paris 2009*.
13. Srivastava AV, Levine E, **Vorobiof G**, Sinusas A. Comparison of Myocardial Blood Flow Reserve Between Calcineurin and Non-Calcineurin Inhibitor-Based Immunosuppressive Regimens in Cardiac Transplant Recipients — Assessment by 82Rb Dynamic PET. *American Society of Nuclear Cardiology, Minneapolis 2009*.
14. **Vorobiof G**, Vojdani E, Jalali P, Lundquist R, Shavelle D, Suh WM, Saremi S. A New Cause of Paradoxical Embolism and Cryptogenic Stroke: Right to Left Shunting Between Superior Intercostal Veins and the Left Atrium. *American College of Cardiology Annual 2012, Chicago, Illinois*.
15. **Vorobiof G**, Diep J, Bethencourt DM. Comparison and Comprehensive Hemodynamic Evaluation of the Trifecta Aortic Valve Tissue Prosthesis Performance. *New York Heart Valve Summit 2012. New York, NY*.
16. **Vorobiof G**, Diep J, Bethencourt DM. Comparison and Comprehensive Hemodynamic Evaluation of the Trifecta Aortic Valve Tissue Prosthesis with the Epic and Magna Valves. *American Society of Echocardiography Annual Scientific Sessions 2012. Baltimore, MD*.
17. Yadlapati A, Diep J, Barnes MJ, Bethencourt DM, **Vorobiof G**. Comprehensive Hemodynamic Comparison and Frequency of Patient Prosthesis Mismatch between the St. Jude Epic and Trifecta Bioprosthetic Aortic Valves. *American College of Cardiology Annual Scientific Sessions 2013*.

18. Kolaitis NA, **Vorobiof G**, Ha E. Restricted Cardiomyopathy Leads to Restricted Options. American College of Physicians 2014 National Conference. 2014.
19. Guerrero M, Dvir D, Himbert D, Urena M, Mahadevan VS, Eleid M, O'Hair D, Martinez-Clark P, Witkowski A, Wendler O, Rodes-Cabau J, Dumonteil N, Ferrari E, Ciaburri D, Suh WM, **Vorobiof G**, Greenbaum A, Wang DD, Paone G, Sinning JM, Dager AE, Linke A, Kornowski R, Nickenig G, Cribier AG, Bapat V, Rihal C, Vahanian A, Webb J, O'Neill WW. Transcatheter mitral valve replacement with balloon expandable valves in native mitral valve disease due to severe mitral annular calcification: Results from the first global registry. TCT Conference 2015.
20. Asthana NK, Mantha A, Yang EH, Benharash P, **Vorobiof G**. The Effect of Transcatheter Aortic Valve Replacement on Subclinical Cardiac Function Using Speckle Tracking Echocardiography. UCLA Cardiovascular Symposium 2016.
21. Mantha A, Asthana N, **Vorobiof G**, Benharash P. Impact of Prior Myocardial Infarction on Myocardial Recovery after Transcatheter Aortic Valve Replacement. 2016 Academic Surgical Conference. 2016.
22. Mantha A, Asthana N, **Vorobiof G**, Benharash P. Functional Recovery in Transfemoral Versus Transapical Transcatheter Aortic Valve Replacement. 2016 Academic Surgical Conference. 2016.
23. Eyvazian V, Gordin J, Agopian V, Honda H, Aksoy O, Busuttil R, **Vorobiof G**. Incidence and Factors Associated with New-onset Cardiomyopathies following Liver Transplantation. 2017 American College of Cardiology Scientific Sessions.
24. Asthana NK, Mantha A, Yang EH, Benharash P, **Vorobiof G**. The Effect of Transcatheter Aortic Valve Replacement on Subclinical Cardiac Function Using Speckle Tracking Echocardiography. 2017 American College of Cardiology Scientific Sessions.
25. Garg V, Bostani M, **Vorobiof G**, Cagnon C, Demroff S, Calfon-Press M, Suh M, Aksoy O, Aboulhosn J, Lin L, Lluri G, Yang EH. Implementation of a Radiation Protection Cabin to Minimize Ionizing Radiation Exposure to the Echocardiographer during Structural Interventions. 2017 American Heart Association Scientific Sessions.
26. Nguyen HL, Calfon-Press M, **Vorobiof G**, Yang EH. Assessment of Right Ventricular Systolic Function 1 Month After Percutaneous Mitral Valve Repair with the MitraClip System. 2017 American Heart Association Scientific Sessions.
27. Nguyen HL, Tehrani D, Chertboonmuang P, Yang EH, **Vorobiof G**, Nsair A, Aksoy O, Calfon Press M, Parikh RV. Impact Of Change In Pulmonary Artery Pulsatility Index On All-Cause Mortality After Percutaneous Mitral Valve Repair. 2020 American College of Cardiology Scientific Sessions.

28. Tehrani DT, Nguyen HL, Chertboonmuang P, Yang EH, **Vorobiof G**, Nsair A, Aksoy O, Calfon Press M Parikh RV. Change in Invasively Measured Mean Pulmonary Artery Pressure After Transcatheter Mitral Valve Repair is Associated with Clinical Outcomes. 2021 American College of Cardiology Scientific Sessions.